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Community acquired pneumonia (CAP) accounts for 5-12% of lower respiratory tract 
infections presenting to primary care in the UK. Of patients who present to their GP with 
suspected CAP, 22- 42% are referred to hospital for further management in the UK. The 
majority of patients (  ̴90%) admitted for CAP survive to hospital discharge. However, 
little is known about the morbidity related to recovery from pneumonia.  
 
Methods 
Three studies in this thesis used large-scale hospitalisation data from Hospital Episode 
Statistics (HES, England), linked to the Clinical Practice Research Datalink (CPRD), and 
death registration data from Office for National Statistics (ONS). These studies aim to 
improve our understanding on the morbidity after CAP and the objectives were: 
(1) to describe the primary care consultations after pneumonia and the reasons for 
these consultations 
(2) to determine the incidence of, and risk factors for developing cardiac 
complications 
(3) to determine the incidence of recurrent hospitalisation for pneumonia and the 
association of tobacco smoking. 
In addition, published literature on cardiac complications, a major morbidity following 
CAP and tobacco smoking and passive smoke exposure as a risk factor for developing CAP 
were systematically summarised.  
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Finally, a multicentre retrospective study was conducted during the first wave of COVID-
19 pandemic to determine the proportion of laboratory proven co-infection in critically ill 
adults with COVID-19 infection in England. 
 
Results 
This thesis found a previously unrecognised large burden of morbidity during recovery 
from pneumonia; 56% of patients consulted primary care within 30 days of discharge. 
The highest rate of consultation occurred early, within the first 7 days (4.7 per 100 
person-days). Nearly 40% of consultations were for a respiratory disorder and 30% of 
patients consulting received further antibiotics within 30 days of discharge.  
 
The systematic review (n=47 studies) found in-hospital incidence of cardiac complications 
of between 3-8%. Patients who developed cardiac complications were more likely to die 
both in-hospital (odds ratio (OR) 3.45, 95% CI 2.38-4.99) and within 30 days (OR 2.65, 
95% CI 1.24-5.68) of admission than those who did not. Data from the population-based 
study showed that those with pneumonia were significantly at higher risk of developing 
all cardiac complications compared to those without pneumonia. The highest risk was 
observed for developing arrhythmia at 30 days after discharge (subhazard ratio (sHR) 
9.51, 95% CI 8.35-10.83).  
 
The systematic review (n=27 studies) found that current and ex-smokers were both 
significantly at higher risk of developing CAP whilst passive tobacco smoke exposure had 
a significant effect only in those aged ≥ 65. A dose-response trend with higher risk of CAP 
amongst current smokers who smoke higher amounts of tobacco was noted.  From the 
population-based study, 9% of patients hospitalised with index pneumonia developed 
recurrent pneumonia within a year of follow-up. Current tobacco smoking status at index 
ix 
 
hospitalisation for pneumonia was independently associated with a higher risk of 
recurrent pneumonia.  
 
Finally, bacterial co-infection within 48 hours of hospital admission for COVID-19 
infection in adults was uncommon; 1.6% on admission and 5.5% within 48 hours. Patients 
with co-infections were more likely to die in ICU (crude OR 1.78, 95% CI 1.03-3.08) 
compared to those without co-infections.  
 
Conclusion 
In conclusion, this thesis highlights that patients experience a significant morbidity during 
recovery from pneumonia. A better understanding of the morbidity after CAP is 
necessary to develop and implement appropriate interventions to improve the long-term 
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This introductory chapter provides an overview of community acquired pneumonia (CAP), 
the incidence, economic burden, aetiology, risk factors, as well as associated morbidity 
and mortality. Detailed objectives of the thesis are summarised at the end of the chapter. 
 
1.1 Definition of pneumonia  
Clinical features of CAP include fever (>38°C), cough, dyspnoea, sputum production, 
pleuritic chest pain, and non-specific features in the elderly such as ‘off legs’ and 
confusion, in the absence of fever.1 Physical examination signs that suggest pneumonia 
include raised respiratory rate, tachycardia, and new and localizing signs on chest 
examination such as reduced chest expansion on the affected side, with signs consistent 
with consolidation (dull percussion note, reduced air entry with bronchial breathing, 
increased vocal resonance) and crackles. The diagnosis of CAP is unlikely if the chest 
examination is normal. 
 
The British Thoracic Society (BTS)2 defined CAP in hospital as: 
• symptoms and signs consistent with an acute lower respiratory tract infection 
associated with new radiographic shadowing for which there is no other 
explanation (e.g., not pulmonary oedema or infarction), and 
• the illness is the primary reason for hospital admission and is managed as 
pneumonia 
 
Community acquired pneumonia accounts for 5- 12% of non-pneumonic lower 
respiratory tract infections (LRTIs) presenting to general practitioners (GP).2,3 As a result, 
the recognition and diagnosis of suspected CAP in the community may be more 
challenging as it is based on clinical features alone, without the benefit of the gold 
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standard chest radiograph. Although there is a high sensitivity (91%-95%), clinical 
diagnosis without radiographic evidence has a low specificity of 40%-56%.4,5 
 
1.2 Incidence  
In 2013, Torres et al. summarised the incidence of CAP from 16 studies from the UK, Italy, 
Spain, France, Germany and Denmark; the overall annual incidence of CAP in adults 
ranged from 1.07-1.2/1000 person-years and 1.54-1.7/1000 population.6 Of patients who 
present to their GP with suspected CAP, 22- 42% are referred to hospital for further 
management in the UK.3 Data from Hospital Episode Statistics (HES) Admitted Patient 
Care activity 2019/2020 reported over 288,000 patients admitted to hospital had a 
primary diagnosis of pneumonia (ICD-10 J12-J18) and 6% of admissions had pneumonia 
recorded in any diagnostic field.7  
 
The most recent incidence of CAP requiring hospitalization in the UK was 0.80/1000 
adults (95% CI 0.77– 0.83) between 2008-2013 using a prospective cohort study design.8 
This incidence was comparable to that reported by a Spanish study with similar design, 
0.90/1000 (95% CI 0.77- 1.00).9 An increasing trend of CAP incidence rate was observed 
by Quan et al. in their 16-year study using coded data in the UK; 4.2%/ year (95% CI 3.6-
4.8) increase from 1998-2008, and subsequently 8.8%/ year (95% CI 7.8-9.7) increase 
from 2009- 2014.10 A similar trend was observed in those over 65 years; Millett et al. 
reported the average predicted probability of hospitalisation for CAP markedly rose by 
29% between 1998-2010.11 Of note, higher incidence rate amongst males and older 





1.3 Economic burden 
CAP carries a significant burden of cost to the NHS. The average cost for managing 
pneumonia in the community was estimated at £100 per episode compared to 
hospitalisation cost of £1700–5100.12 In 1992/93, the annual cost was estimated at £441 
million, mostly (87%) associated with inpatient care cost.12 In this analysis, there were 
261,000 annual episodes of CAP, with approximately 83,153 annual cases of CAP (32% of 
all episodes) which required hospital admission. The average length of stay is 7.8 days for 
patients who are 65 and above, and shorter at 5.8 days for younger patients.13 Following 
an episode of hospitalised CAP, adults with underlying comorbidities were found to have 
subsequent higher healthcare resource utilisation with higher hospital admission costs 
during a 3-year follow-up period compared to matched controls who did not have an 
episode of CAP.14 In addition, sickness absence in general is estimated to cost the UK 
economy approximately £15 billion annually.15 With rising incidence and admissions for 
CAP, it is likely that the economic burden of CAP in the UK will continue to rise. 
 
The economic burden of both direct and indirect costs of CAP globally will need to take 
into account the type of healthcare system, admission criteria, average length of hospital 
stay and functional impairment after hospitalisation including return to work, job loss and 
loss of independence or short-term disability. In the US, the national direct and indirect 
costs of CAP in the working-age adults was estimated at $8.5 billion and $2.1 billion 
respectively.16 The costs of healthcare, sick time and short-term disability increased with 
advancing age and higher risk status (based on underlying co-morbidities) in working-age 
adults.17 The indirect costs resulting from sick time and short-term disability were 
substantially higher in an employee with CAP compared to an employee without CAP; 
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mean annual costs of $1129 vs $853 for sick time and $1016 vs $322 for short-term 
disability.   
 
1.4 Aetiology 
Where an aetiology is found, a single pathogen is identified in 85% of patients, though 
the true frequency of polymicrobial CAP is not known.2 Streptococcus pneumoniae is the 
commonest pathogen identified globally. Welte et al. extensively analysed the aetiology 
of CAP in European adults.18 In addition to S. pneumoniae, other bacterial pathogens 
identified in decreasing frequency were H. influenzae, Legionella spp, Chlamydophila spp, 
Mycoplasma pneumoniae, Staphylococcus spp, Gram-negative bacilli, Moraxella 
catarrhalis and Coxiella burnetti.  For patients managed on the ICU, Legionella spp and S. 
aureus were identified more frequently.  
 
Meta-analysis of 31 studies which mostly obtained polymerase chain reaction (PCR) via 
nasopharyngeal or oropharyngeal swab, found a high proportion of viral infection in 
patients with CAP; 24.5% (95% CI 21.5-27.5).19 The proportion was higher in studies 
which obtained lower respiratory samples; 44.2% (95% CI 35.1-53.3). The most 
commonly identified viruses were influenza, rhinovirus, respiratory syncytial virus and 
coronavirus. 
 
Community-acquired pneumonia is a result of the interplay between the host, microbes 
and environmental factors. Hendley et al. found that adults with preschool children in the 
family (18%) had higher Streptococcus pneumoniae carriage rates than adults without 
preschool children in the family (2-9%).20 In a large observational study of 2221 patients, 
Daniel et al. found adults admitted to hospital with a diagnosis of CAP during school 
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holiday periods were significantly more likely to report child contact prior to hospital 
admission (35.3% vs 26.7%; aOR 1.38, 95% CI 1.11–1.72, p=0.004) and were significantly 
more likely to have pneumococcal infection compared to those admitted during term 
time (42.0% vs 33.7%, OR 1.43, 95% CI 1.00–2.03, p=0.046).21 Various studies have shown 
that transmission of S. pneumoniae occur by close contact with a carrier (especially young 
children), large-droplet secretions or via fomites and intercurrent viral respiratory tract 
infection.22–25  
 
1.5 Risk factors 
A systematic review by Almirall et al. in 2017 identified several risk factors for developing 
CAP from 29 observational studies.26 The authors divided the risk factors into three 
categories, namely ‘clear risk factor’, ‘no effect’ and when the evidence was 
‘inconclusive’.  




Clear risk factor Sociodemographic and lifestyle Factors 
• older age  
• smoking 
• environmental exposures to different substances 
(home, occupational and environment)  
Comorbidities/ clinical conditions  
• COPD 
• asthma  
• malnutrition 
• previous CAP  
• functional impairment 
• poor dental health  
Medications  
• immunosuppressive therapy 
• oral steroids 
• gastric acid-suppressive drugs 
No effect Sociodemographic and lifestyle Factors 
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• raised BMI 
• passive smoking  
Comorbidities/ clinical conditions  
• chronic renal disease  
Medications  
• use of antibiotics before CAP 
• influenza vaccine 
Inconclusive Sociodemographic and lifestyle Factors 
• male gender 
• alcohol use 
• passive smoking in the older age subgroup 
Comorbidities/ clinical conditions  
• heart disease 
• dysphagia 
• cancer 
• chronic liver disease 
• diabetes  
Medications  
• inhalers 
• pneumococcal vaccine 
  
1.6 Mortality 
Lower respiratory tract infections (LRTIs), including CAP were reported as the ‘most 
deadly communicable disease’ worldwide in 2016, causing 3.0 million deaths.27 The 
Global Burden of Disease Study 2019 reported LRTIs were the fourth leading cause of 
worldwide deaths in 2019 with an age standardised death rate of 34.3/100,000 (95% CI 
31.1-37.9/100,000), outranked by ischaemic heart disease, stroke and chronic obstructive 
pulmonary disease.28 Meta-analysis by Fine et al. in 1995 reported mortality rate of 
13.6% in hospitalised patients (n=25,629, n=84 studies), with a significant rise to 36.5% 
for those admitted to intensive care units (ICUs) (n=788, n=13 studies).29 In 2012, Welte 
et al. reviewed published European studies and reported a case fatality range of 5.6-43% 
for hospitalised patients, with 22-48% for those requiring admission to ICU.18 The latest 
BTS National CAP Audit 2018/19 reported the lowest 30-day mortality in the past decade 
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at 10.4%.30 Prior to this audit cycle, there was a steady decline in inpatient mortality from 
20.2% to 17.7% between 2009/10-2014/15.  
 
Factors associated with increased 30-day mortality include older age, ICU admission, 
presence of comorbidities (including neoplastic disease, chronic pulmonary disease, 
congestive heart failure, coronary artery disease, neurological disease, liver disease, renal 
disease, dementia and diabetes), bacteraemia, pneumococcal aetiology disease, lifestyle 
factors (smoking and alcohol abuse), admission from nursing home, multilobar 
involvement, and the development of incident cardiac complications (myocardial 
infarction, new or worsening heart failure, and new or worsening arrhythmia).31–37 
 
Mortality rate appear to be the highest within the first few days after hospitalisation, 
irrespective of disease severity.31 Two studies have reported early deaths in 30.3%- 38.6% 
at two and three days of admission respectively.38,39 Independent predictors of early 
death in these studies include increased age, altered mental status, multilobar 
pneumonia, shock on admission, mechanical ventilation on admission, pneumococcal 
bacteraemia and discordant antibiotic therapy. Patients admitted with CAP have also 
been shown to have decreased long-term survival. In a Dutch study, patients hospitalised 
with CAP had a significantly higher long-term mortality than age and sex-matched 
controls (RR 3.6, p<0.001) with the highest annual mortality observed within the first 3 
years of follow-up.40 Similar increased long-term mortality was seen compared to 
patients admitted for another reason in 2 further studies at 5 and 7 years of follow-up in 
US and this effect remained significant after adjustment for age and comorbidities; OR 
5.6, 95% CI 2.8-11.2 and HR 1.4, 95% CI 1.2-1.5 respectively.41,42 Late deaths are more 
likely to be related to comorbid illness such as malignancy, COPD, or cardiovascular 
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disease compared to early deaths which are due to infectious conditions (pneumonia, 
sepsis or bacteraemia), respiratory failure, and cardiac complications.43–45 
 
A higher mortality was observed in patients with dual bacterial and viral infection, 
compared with those without dual infection; OR 2.1, 95% CI 1.32-3.31.19 
 
1.7 Morbidity  
The majority of patients (  ̴90%) admitted for community-acquired pneumonia survive to 
hospital discharge.30 However, little is known about the morbidity related to recovery 
from pneumonia. Readmission to hospital after an episode of CAP is common. An 
unpublished meta-analysis of 60 studies estimated the pooled 30-day readmission rate to 
be 10% with 31% of readmissions due to pneumonia-related reasons.46 The BTS National 
CAP Audit 2018/19 reported the 30-day readmission following CAP has increased from 
10.5% in 2009 to 14.6% in 2018 in the UK.30  Whilst it is recognised that patients consult 
healthcare providers following an admission for CAP, the full scale of the problem is 
unknown, especially with minimal data on primary care utilisation. A small study of 108 
working age adults found 59.2% consulted primary care and 12% attended emergency 
department within 4 weeks; persistence of respiratory symptoms accounted for majority 
of these consultations.47  
 
Previous studies on LRTI consultations not requiring hospital admission found that a prior 
consulting behaviour was a strong predictor of further consultation.48,49 The patient 
cohorts in these primary care studies are mostly different compared to patients 
hospitalised with CAP, often involving adults with self-limiting RTIs in whom the challenge 
is the avoidance of overuse of antibiotics and managing patient expectation. Taking this 
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into consideration, the reasons for prior consulting behaviour emerging as a strong 
predictor of further consultation were speculated to be due to unrealistic expectations of 
the resolution of symptoms and a heightened consulting habit. 49 
 
Patients are believed to have achieved ‘clinical cure’ or recovered from pneumonia when 
there is resolution of signs and symptoms related to pneumonia without recurrence.50 
Radiographic clearance of CAP varies between 35.1% at 3 weeks (in patients >70 years) to 
66.7% at 4 weeks.51,52 Bruns et al. reported physician-based clinical cure in 88.9% at 28 
days after hospitalisation for mild to moderate CAP, though radiological resolution was 
seen in 68.4% and symptoms were completely resolved in only 41.7%, highlighting the 
discordance between physician rated clinical cure, radiographic resolution and patient 
reported symptoms.53  
In a systematic literature review of patient reported outcome measures in CAP, Pick et al. 
found that up to 70% of patients continue to report at least one symptom 4 weeks post-
discharge; the commonest symptom being fatigue, followed by cough and dyspnoea.54 
Functional impairment was reported in 18-51% of patients at four weeks post-discharge 
with a median time to return to normal activities of 15-28 days. One study found 16.3% 
of survivors at 6 weeks after hospitalisation for CAP required a change of residence on 
discharge, indicating a greater level of dependency.55  These studies suggest that the full 
long-term burden of adverse health outcomes after CAP is likely to be higher than 
measures of symptoms resolution alone.56 It is important to note that an episode of 
pneumonia may be a marker for frailty or increased susceptibility to illness from non-
pneumonia related factors.57 
 
1.8 Thesis objectives 
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In summary, a better understanding of the morbidity after CAP is necessary to develop 
and implement appropriate interventions to improve the long-term outcomes of patients 
hospitalised with CAP. In this thesis, there are three main research aims to improve our 
understanding on the morbidity after CAP: 
1) To describe the primary care consultations after CAP and the reasons for these 
consultations 
2) To determine the incidence of, and risk factors for developing cardiac 
complications 




1.9 Outline of chapters 
The following is a brief overview of subsequent chapters in this thesis: 
Chapter 2: Methods for studies using Clinical Practice Research Datalink (CPRD), linked to 
Hospital Episode Statistics (HES) 
This chapter gives an overview of the databases used for three studies in this thesis, the 
study population and how the variables that are used across studies are defined.  
 
Chapter 3: Primary care consultations following hospitalisation for pneumonia 
This study addresses the gap in knowledge about the burden on primary care following 
hospitalisation for pneumonia with specific objectives of: 
• determining the rate and predictors of consultation 
• exploring reasons for primary care consultations and hospital readmissions  
• investigating further antibiotic prescription at consultation. 
 
Chapter 4: Cardiac complications following community acquired pneumonia: A 
systematic review and meta-analysis 
This chapter summarises the available evidence on cardiac complications, a major 
morbidity following CAP. Key objectives were to determine the: 
• short- (<30 days), medium- (90 days) and long-term (>1 year) effect of CAP on 
developing incident cardiac complications 
• risk factors and biomarkers associated with developing cardiac complications 
• mortality  
 




Using the background information from Chapter 4, the aims of this study were to 
determine the incidence of cardiac complications after hospitalisation for pneumonia at 
30 days, 90 days and 1 year, and the associated risk factors, when compared to the 
general population in a matched cohort study. 
 
Chapter 6: Effect of tobacco smoking on the risk of developing community acquired 
pneumonia: A systematic review and meta-analysis 
This chapter summarises the available evidence on tobacco smoking and passive smoke 
exposure as a risk factor for developing CAP. Key objectives were to:   
• determine the effect of tobacco smoking and passive smoke exposure on the risk 
of developing CAP in adults 
• determine the strength of the association 
• to examine whether there is a ‘dose-response’ association between amount of 
tobacco smoked and the risk of developing CAP. 
 
Chapter 7: Tobacco smoking is an important modifiable risk factor for recurrent 
hospitalisation with pneumonia 
The primary objective of this study was to determine incidence of recurrent 
hospitalisation with pneumonia in England, another major morbidity associated with CAP. 
Using the background information from Chapter 6, this chapter explores the association 
of tobacco smoking as a potentially modifiable risk factor for recurrent hospitalisation 
with pneumonia was explored and determines the proportion of current smokers 





Chapter 8: Co-infection in critically ill patients with COVID-19: A retrospective multicentre 
cohort study from England 
This chapter describes a study conducted during the first-wave of COVID-19 pandemic. 
The primary objective was to determine the proportion of laboratory proven co-infection 
in critically ill adults with COVID-19 infection in England. Secondary objectives were to: 
• to describe the organisms 
• the characteristics of patients with co-infection 
• the antibiotic susceptibilities of identified bacteria. 
 
Chapter 9: Conclusions and future research 
This chapter summarises the main findings of this thesis and describes the implications to 










Chapter 2 Methods for studies using 
Clinical Practice Research Datalink 
(CPRD), linked to Hospital Episode 
Statistics (HES)  
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This chapter describes the data sources, in addition to the definitions of exposures, 
outcomes and covariates used in the studies in this thesis. It also provides an overview of 
the study designs and methods used in each study. Detailed methods for individual 
studies are described in subsequent chapters. 
 
2.1 Ethical approval 
Ethical approval was provided by the Medicines and Healthcare products Regulatory 
Agency (MHRA) Independent Scientific Advisory Committee (ISAC); study protocol 
number: 18_178A (Appendix 1). 
 
2.2 Data sources 
Anonymised data were used from four sources: primary care, and linked data to 
secondary care, death registration data and deprivation data. 
 
2.2.1 Primary care data         
The Clinical Practice Research Datalink (CPRD) is a real-world UK government research 
service which collects anonymous patient data from a network of general practices across 
the England, Scotland, Wales and Northern Ireland. It is now one of the world’s largest 
databases of longitudinal primary care electronic health records (EHRs). CPRD is jointly 
funded by the MHRA and the National Institute for Health Research (NIHR), as part of the 
Department of Health and Social Care. CPRD collects fully-coded patient EHR from 
practices using Vision® (CPRD GOLD) or EMIS Web® (CPRD Aurum) software systems with 
some differences in the structure and clinical coding in these two systems. Following 
ethical approval by MHRA Independent Scientific Advisory Committee (ISAC) (study 
17 
 
protocol number: 18_178A), access to the CPRD GOLD July 2018 file was provided. This 
file contained 15.5 million patients (including those who transferred out of practice and 
deceased), who were broadly representative of the UK population with respect to age, 
sex and region. Of these, 2.3 million patients were actively contributing data; this covered 
3.6% of the total UK population. Data were available from 738 practices; 272 actively 
contributing practices. All patients registered with a participating practice are included in 
the dataset, with the exception of those who have opted-out of data sharing.  
 
2.2.1.1 Data quality 
Primary care data quality is variable as data are entered during routine consultations, not 
for the purpose of research. Therefore, comprehensive data quality checks were 
undertaken before conducting the studies in this thesis. In order to select research-
quality patients and periods of quality data recording, there are two measures which are 
recommended to be used by the CPRD: acceptability for patients and up to standard 
(UTS) time for practices. The former is based on registration status, recording of events in 
the patient record, and valid age and gender; patients are labelled as ‘acceptable’ for use 
in research by a process that identifies and excludes patients with non-continuous follow 
up or patients with poor data recording that raises suspicion of the validity of the 
patients’ record. The latter, UTS date is the date at which data in the practice is 
considered to have continuous high-quality data fit for use in research. This date is 
calculated for each participating practice, based on the continuity of data recording and 
the number of recorded deaths. 
 
2.2.1.2 Data supplied by CPRD 
CPRD provides data to researchers in several file types which separates information into 
different categories. The file types used in this thesis include patient, practice, 
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consultation, clinical, additional clinical details and therapy (Table 2-1). Patients are 
assigned a unique identifier which enables their records to be linked across the files and a 
consultation identifier which allows events from the same consultation to be linked. 
Table 2-1: Data files supplied by CPRD and used in this thesis 
File type Information Example of contents 
Patient Demographics and registration 
status of patients 
Patient identifier, month and year of birth, 
registration date with the practice, death date, 
transfer out of practice date 
Practice Practice administrative data Practice identifier, geographical region, date 
practice became 'Up to standard' (UTS) i.e. 
when data from practice were deemed to be of 
research quality, last data collection date 
Consultation Administrative information 
about the consultation 
Date of clinical event, date of data entry, type 
of consultation (e.g. clinic, follow-up visit, 
emergency consultation, telephone 
consultation, discharge details, administration) 
and duration of consultation 
Clinical Clinical data regarding medical 
history including diagnoses, 
signs and symptoms 
Date of clinical event, date of data entry, the 
CPRD medical code for the chosen Read code, 
additional details identifier*, entity type 
Additional clinical 
details  
Specific data about a clinical 
event 
Type of information held (e.g. smoking status, 
alcohol consumption), called an 'entity', specific 
clinical details relating to that entity 
Therapy Information about therapies 
including medications and 
appliances 
The CPRD product code for the medication, 
British National Formulary code, quantity of 
product, dose, pack size, number of days 
prescribed 
Adapted from Herrett et al.58  
*Allows a link to be made between a Read code in the 'clinical file' to additional details held in the 
'additional clinical details' file. 
 
2.2.2 Data linkage 
English practices contributing to CPRD data can be linked to other established non-
primary care data such as hospitalisation data from Hospital Episode Statistics (HES), 
death registration data from Office for National Statistics (ONS) and deprivation data 
(Table 2-2). These linkages were available for approximately 50% of contributing CPRD 
GOLD practices in the UK. Data linkages are not available for CPRD practices in the rest of 
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the UK due to different operating systems similar to HES in England; The Scottish 
Morbidity Record, The Patient Episode Database for Wales and The Northern Ireland 
Hospital Statistics Dataset.  
 
HES Admitted Patient Care (HES APC) data contain details of all admissions to NHS 
hospitals in England.59 Hospitalisations, also known as ‘spells’ in HES refer to the total 
period of inpatients hospital stay from admission to discharge, therefore includes 
information on the admission and discharge dates. Each spell may contain several 
‘episodes’, a time-period which corresponds to when a patient is in the continuous care 
of a consultant and for each episode, there may be up to 20 diagnoses recorded. The 
primary diagnosis i.e. the first diagnosis recorded during the first episode of the patient 
care was used as the reason for the patients’ admission in this thesis. Diagnostic data 
recorded in HES are coded using International Classification of Diseases, Tenth Revision 
(ICD-10). 
 
Death registration data contains data from the Office for National Statistics (ONS) and 
includes information on the date of death and causes of death coded using ICD-10. 
 
The Index of Multiple Deprivation (IMD) is one the most commonly used measures of 
deprivation and data are provided in quintiles; score of 1 (least deprived) -5 (most 
deprived). A composite index is calculated by combining a number of indicators covering 
seven domains of material deprivation: housing, employment, income, access to services, 
education and skills, crime and living environment.60 The 2015 English IMD (Set 17) was 
used in this thesis and data were linked to CPRD primary care data through the practice 
postcode.  The practice postcode is mapped to Lower Super Output Areas (LSOA), small-
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level geographic regions based on census geography with a minimum size of 1,000 
residents and 300 households, and an average of 1,600 residents.61 
Table 2-2: Data sources linked to CPRD primary care records used in this thesis. 
Linkage HES APC Death Registration Deprivation 
Type of resource Hospitalisation data 
for inpatients 
Date and cause of 
death register 
Socioeconomic status 
Who is included? Patients with 
hospitalisations for 
any cause 
People who die in 
England and Wales 
Lower super output 
area levels 
Geographic regions 
covered by linkage 
England England and Wales England, Wales, 
Scotland and Northern 
Ireland 
Period of linkage for 
this thesis 
01/04/97 – 30/11/18 02/01/98– 14/01/19 - 
Examples of data 








Index of Multiple 
Deprivation (IMD) 
 
2.2.3 Generalisability and validity of data 
CPRD data are broadly representative of the UK population with respect to age, sex and 
ethnicity.58 CPRD has been widely used for epidemiological research for a range of 
conditions. A systematic review of 212 publications investigating the validation of 183 
diagnoses recorded in the database found a high data validity; median proportion of 
cases with a confirmed diagnosis by either internal (e.g. manual review of records 
including free-text or diagnostic algorithm using symptoms/signs, prescriptions for 
disease-specific drugs and/or confirmatory test results) or external validation (e.g. by 
requesting additional information from GP comparison of rates with a non-CPRD, UK-
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based data source) of 89% overall and 88% for respiratory system diagnoses in 
particular.62  
 
An important external influence that could have a potential impact on the data quality in 
CPRD is the introduction of the Quality and Outcomes Framework (QOF) in 2004. The 
QOF is a voluntary annual reward and incentive programme for all GP surgeries in the UK, 
which financially rewards GPs for providing high quality care to their patients.63 The QOF 
has resulted in considerable improvement in the recording of key lifestyle variables 
particularly smoking status and offering cessation advice.64,65  
 
HES APC has universal coverage, providing an unselected sample of hospital admissions. 
In comparison to CPRD, HES is less extensively validated. Clinical coders rely on the 
quality and detail of completed discharge summaries to enter data consistently using ICD-
10 codes.66 Since the introduction of Payment by Results in 2003/04, an initiative to 
direct health-care funding based on coding data, there has been an increase in the 
number of diagnostic codes used and improvement in diagnostic accuracy.67 The average 
inaccurate diagnosis and procedure coding has reduced from 16.5% in 2007/08 to 11.3% 
in 2009/10.68 Roughly a third of ICD-10 coded cases of pneumonia within HES lack 
radiographic evidence of pneumonia and would strictly be considered cases of non-
pneumonic LRTI.30 The vast majority of these patients are nevertheless treated clinically 







2.3 Study population 
Adults aged ≥18 years with the first episode of hospitalisation for pneumonia (index date) 
recorded in HES between 1 July 2002 and 30 June 2017 were included. Patients were 
excluded if they a) did not have data that met the minimum quality criteria for use in 
research b) had less than a year of time registered to practice before admission or c) 
were admitted for at least a day in the 10 days preceding the index admission (hospital-
acquired pneumonia identified from HES). 
 
2.4 Building the dataset: Definition of key variables 
This section describes the key variables used throughout the research. Other variables 
used in the three studies will be described in the individual chapters. 
 
2.4.1 Definition of pneumonia 
The focus of this research was on pneumonia. Pneumonia was defined based on J12- J18 
ICD-10 codes recorded as the primary code for the first episode of hospitalisation in the 
HES dataset (Table 2-3). The ‘epidemiological year’ definition of July- June was used as 
the unit of time in order to avoid the winter peak of pneumonia traversing two calendar 
years. 
Table 2-3: ICD-10 codes for pneumonia 
ICD-10 code Description 
J12 Viral pneumonia, not elsewhere classified 
J13 Pneumonia due to Streptococcus pneumoniae 
J14 Pneumonia due to Haemophilus influenzae 
J15 Bacterial pneumonia, not elsewhere classified 
J16 




J17 Pneumonia in diseases classified elsewhere 
J18 Pneumonia, unspecified organism 
 
2.4.2 Definition of covariates in CPRD  
Age 
Age was calculated as year of admission – year of birth. Age was categorised into five 
categories; 18-49, 50-64, 65-74, 75-84, ≥85 
 
Gender 
Patients were included in the analyses if they were coded as male or female. Three 






Smoking status were divided into three categories; never smokers, ex-smokers and 
current smokers. If patients had more than one record for smoking status, the most 
recent record of smoking status was used. Never smokers were reclassified to ex-smokers 
if they had any record of smoking recorded in their entire clinical record entered on CPRD 
prior to study entry. Read code lists for smoking status were developed using validated 
medical Read codes (Appendix 2).69,70 
 
Alcohol consumption 
Alcohol consumption was divided into five categories; non-drinkers, former drinkers, 
occasional drinkers, current moderate drinkers (≤14 units/ weekly) and current heavy 
drinkers (>14 units/ weekly). Similar to smoking status, the most recent record of alcohol 
consumption was used if there were more than one record available. Non-drinkers were 
reclassified to former drinkers if they had any record of drinking recorded in their entire 
clinical record entered on CPRD prior to study entry. Read code lists for alcohol 
consumption were developed using validated medical Read codes (Appendix 2).70,71 
 
Charlson Comorbidity Index score 
The Charlson Comorbidity Index (CCI) is a weighted index which takes into account the 
number and seriousness of comorbid disease. Charlson et al. developed this index in a 
cohort of 559 hospitalised patients and the 1-year mortality rates for the different scores 
were determined.72 The index was validated in a second cohort of 685 patients, where 
the ability to predict risk of death from comorbid disease during a 10-year follow up was 
tested. With every rise in the CCI score, there was a stepwise increase in the cumulative 
mortality attributable to comorbid disease. The CCI is calculated using 15 conditions 
including myocardial infarction (MI), congestive cardiac failure (CCF), peripheral vascular 
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disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue 
disease, ulcer disease, liver disease, diabetes, hemiplegia, renal disease, any tumours, 
haematological malignancy and acquired immune deficiency syndrome (AIDS). Each of 
these comorbidities is assigned a weighted score and the sum of the scores is an indicator 
of the overall disease burden. Read code lists for CCI were developed using validated 
medical Read codes (Appendix 2).70,73 
 
Comorbid conditions of interest 
In addition to CCI, Read codes lists were developed for specific comorbid conditions of 
interest including chronic obstructive lung disease (COPD), asthma, cardiac diseases 
excluding CCF and MI (e.g. hypertension, arrhythmias, valvular heart disease, conduction 












Chapter 3 Primary care consultations 
following hospitalisation for pneumonia  
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3.1 Introduction  
The majority of patients (>85%) admitted for community-acquired pneumonia survive to 
hospital discharge.30 However, little is known about the morbidity related to recovery 
from pneumonia. A systematic literature review of patient reported outcome measures 
in CAP found limited research suggesting that up to 70% of patients continue to report at 
least one symptom four weeks post-discharge; the commonest symptom being fatigue, 
followed by cough and dyspnoea. Functional impairment is reported in 18-51% of 
patients at four weeks post-discharge with a median time to return to normal activities of 
15-28 days.54 
 
Readmission to hospital is also common.  A meta-analysis (n=60 studies) estimated the 
pooled 30-day readmission rate to be 10% with 31% of readmissions due to pneumonia-
related reasons.46 In the UK, 30-day readmission following CAP has increased from 10.5% 
in 2009 to 14.6% in 2018.30  In contrast, the impact on primary care is much less well 
understood. In a small exploratory study (n=108) of working age adults (<65 years old) 
discharged from hospital following admission for CAP, 59% consulted primary care within 
28 days of discharge, suggesting a potentially important burden to the NHS that is 
currently unrecognised.47  
 
The aim of this study was to address the gap in knowledge about the burden on primary 
care following hospitalisation for pneumonia with specific objectives of (1) determining 
the rate and predictors of consultation, (2) exploring reasons for primary care 
consultations and hospital readmissions, and (3) investigating further antibiotic 




3.2 Methods  
3.2.1 Study population and follow-up  
Adults aged ≥18 years with the first episode of hospitalisation for pneumonia (index date) 
recorded in HES (data from NHS hospitals in England) between 1 July 2002 and 30 June 
2017 were included. The ‘epidemiological year’ definition of July- June was used as the 
unit of time in order to avoid the winter peak of pneumonia traversing two calendar 
years. Pneumonia was defined based on J12- J18 ICD-10 codes recorded as the primary 
code for the first episode of hospitalisation. Patients were excluded if they a) did not 
have data that met the minimum quality criteria for use in research b) had less than a 
year of time registered to practice before admission or c) were admitted for at least a day 
in the 10 days preceding the index admission (identified from HES). Patients were 
followed up from day one after the date of discharge from hospital to either the first 
primary care consultation, end of data collection (30 days), date of transfer out of 
practice, date of last data collection for the practice or date of death, whichever came 
first. 
 
3.2.2 Definitions  
Primary care consultation was considered to have occurred if medical Read codes were 
recorded after the date of discharge from hospital; administration-related codes were 
excluded to capture face-to-face consultations.74,75 If there were multiple Read codes 
recorded in a day per patient, this was counted as a single episode of consultation. 
Validated codelists were used for pneumonia, smoking status, alcohol consumption, 
Charlson Comorbidity Index and specific co-morbidities of interest.70,76,77 In addition to 
the common reasons for consultations, namely respiratory, digestive, genitourinary and 
cardiac disorders, constitutional symptoms and cognitive disorder were categorised 
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according to Read codes. These category codes were developed for this study by a 
specialist trainee in respiratory medicine, a consultant in respiratory medicine, a 
geriatrician and an epidemiologist, and reviewed by an academic general practitioner. 
Within the ‘respiratory’ category, a subset of ‘only pneumonia Read codes’ was 
developed to determine the proportion of patients who consulted directly due to 
pneumonia. Read codes for antibiotics were categorised according to the British National 
Formulary (BNF) listing in Section 5.1 (Antibacterial drugs), excluding anti-tuberculosis 
and anti-leprotic drugs. 
 
3.2.3 Patient involvement 
The study concept and design were discussed with members of the Nottingham Lung 
Infection PPI group from inception. The group, comprising of patients previously treated 
for CAP, actively contributed towards identifying the issue of primary care consultation 
after hospitalisation for pneumonia as important and the need to develop the research 
question and relevant outcome measures; including “Who are more likely to consult?”, 
“Why do they consult” and “Are additional antibiotics prescribed at consultation?”. The 
group received regular updates on the progression of the research protocol 
development, ethics review and study conduct via regular PPI meetings. Findings of the 
study were discussed with PPI members and the authors have disseminated pre-
publication study results via conference abstract presentations. 
 
3.2.4 Statistical analysis 
Age was fitted as a categorical variable following likelihood ratio test (age categories:  18-
49, 50-64, 65-74, 75-84, ≥85). The 2015 English Index of Multiple Deprivation (IMD) was 
used as composite measure of material deprivation at the patient level.78 ‘Time to 
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consultation’ was measured from day one after discharge from hospital to the first 
consultation at primary care. Based on the first episode of consultation per patient, rates 
of consultation per 100 person-days for ≤7 days and ≤30 days were determined. 
Characteristics of adults who consulted were compared to those who did not consult. A 
predictive modelling approach was used where important predictors of consultations 
were determined from published literature on consultations for acute lower respiratory 
tract infection (LRTI) based on a postulated similarity between pneumonia and non-
pneumonic acute LRTI in this regard.49 There were missing data in smoking status (2.9%), 
alcohol consumption (15.1%) and IMD score (0.1%). The pattern of missing data for 
smoking status and alcohol consumption are shown in Table 3-1.  




Smoking status Alcohol status 
85% 1 1 
13% 1 0 
2% 0 0 
<1% 0 1 
100%   
Legend: 0 Missing data, 1 Non-missing data 
 
Multiple imputation using chained equations was performed with 10 imputed datasets 
for smoking status and alcohol consumption respectively, under a missing at random 
(MAR) assumption in line with previous published studies using CPRD data and are 
reported as per the suggested guidelines by Sterne et al.79–83 
 
Univariate and multivariate competing-risks regression analyses were used with death 
and readmission as competing events. Univariate analyses were conducted to investigate 
the association between primary care consultation and each variable (age, gender, 
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smoking status (never smoked, ex-smokers, current smokers), alcohol consumption (non-
drinker, former drinker, occasional drinker, moderate drinker (≤14 units/week), heavy 
drinker (>14 units/week)), length of hospital stay (≤3, 4-7, >7 days), previous primary care 
consultations in the past year prior to admission for pneumonia (<5, 5-15, >15 
consultations), IMD quintile (score of 1 (least deprived) -5 (most deprived), unknown), 
practice region (West Midlands, North West, Yorkshire and the Humber, East Midlands, 
North East, East of England, South West, South Central, London, South East Coast; West 
Midlands was selected as the reference region for analyses as it was a region 
representative of England by population size, age and gender84), presence of 
comorbidities (measured using Charlson Comorbidity Index and specific comorbidities of 
interest: chronic pulmonary obstructive disease (COPD), asthma, chronic lung disease 
(excluding COPD and asthma) congestive cardiac failure (CCF), myocardial infarction (MI), 
other cardiac diseases (excluding CCF and IHD), malignancy, chronic renal disease, 
cognitive impairment, cerebrovascular disease, diabetes mellitus, liver disease). Variables 
that were considered associated in the univariate analyses (p<0.05) were included in a 
multivariable backward logistic regression model with imputed data; age and sex were a 
priori variables. Charlson Comorbidity Index and specific comorbidities of interest were 
included in separate multivariate models. Sensitivity analysis was performed excluding 
previous consulting behaviour. 
 
The proportions for reasons of consultations were calculated for all patients who 
consulted, with sub-analyses for those who consulted before readmission or death. The 
top 20 reasons for hospital readmission were also determined. In addition, the number of 
antibiotic prescriptions, frequency of antibiotic courses (multiple antibiotics prescribed at 
a single consultation were counted as a single ‘course’) and the type of antibiotics 
prescribed at primary care consultation were also examined. Univariate and multivariate 
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logistic regression analyses were performed to investigate predictors of antibiotic 
prescription at consultation. Statistical analyses were performed using StataMP/ 15.1. 
 
3.3 Results 
Over the 15-year study period, there were 215,828 patients admitted to hospital with 
ICD-10 codes for pneumonia (Fig 3-1) of whom 17,928 had hospital acquired pneumonia 
and 37,442 (20.6%) died in hospital. After excluding remaining patients who did not have 
data that met the minimum quality criteria for use in research and patients who did not 
have at least a year of time registered to practice (n=87,773), the study cohort comprised 
56,396 patients.  





Table 3-2 shows the characteristics of the study population. Median age of the study 
cohort was 75 years (range 18-108 years; interquartile range (IQR): 61-84 years) and 
49.7% were male. During the 30-day follow-up, 16% (n=9,051) were readmitted to 
hospital and 6.1% (n=3,446) died after discharge from hospital. 
Table 3-2: Characteristics of the overall study population  
 Overall study population 
  n (%) 
Number of patients 56,396 
Age     
18-49 8208 (14.6) 
50-64 8830 (15.7) 
65-74 10499 (18.6) 
75-84 15317 (27.2) 
≥85 13542 (24.0) 
Gender     
Male 28002 (49.7) 
Female 28394 (50.4) 
IMD (patient-level)     
1 (least deprived) 10596 (18.8) 
2 11407 (20.2) 
3 11909 (21.1) 
4 11263 (20.0) 
5 (most deprived) 11171 (19.8) 
Unknown 50 (0.1) 
Practice region     
West Midlands 6990 (12.4) 
North West 9855 (17.5) 
Yorkshire & The Humber 1926 (3.4) 
East Midlands 1294 (2.3) 
North East 1454 (2.6) 
East of England 5589 (9.9) 
South West 7541 (13.4) 
South Central 7031 (12.5) 
London 7114 (12.6) 
South East Coast 7602 (13.5) 
Charlson Index    
0 13636 (24.2) 
1 12290 (21.8) 
2 9912 (17.6) 
3 7777 (13.8) 
4 5096 (9.0) 
≥5 7685 (13.6) 
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Primary care consultation occurred in 27.7% (n=15,626 patients) and in 55.9% (n=31,542 
patients) within 7 days and 30 days of discharge respectively (Fig 3-2).  
Fig 3-2: Kaplan- Meier plot of time to first consultation 
 
Legend: Vertical line A- 7 days, B- 14 days and C- 30 days. 
The highest consultation occurred within 7 days (27.7%), after which there was a decline in 
consultation (14 days: 41.4%, 30 days: 55.9%)  
 
The 30-day consultation proportion gradually increased from 54.2% in 2002/03 to a peak 
of 58.9% in 2006/07. This remained relatively stable until 2013/14 (56.6%) after which 
there was a steady fall to 47.3% in 2016/17 (Fig 3-3). The rate of first consultation was 
highest within 7 days of hospital discharge at 4.7 per 100 person-days and declined to 3.3 
per 100 person-days within 30 days of hospital discharge.  Of those who consulted within 
30 days, 47.7% (n=15,056) consulted two or more times. 
A B C 
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Fig 3-3: Trend of primary care consultation over the 15-year study period 
 
 
3.3.1 Factors associated with consultation 
The strongest predictor of consultation was previous consultation behaviour; specifically 
having consulted >15 times in the year prior to the index admission for pneumonia 
(adjusted sHR 8.98, 95% CI 6.42 to 12.55) (Table 3-3). Other factors independently 
associated with a higher probability of consultation were age 50-74 years compared to 
18-49 years, current and ex-smoking status compared to never smokers, length of 
hospital stay of between 4-7 days compared to ≤3 days, Charlson Comorbidity Index 
score ≥3 and pre-existing comorbid diseases; COPD, asthma, congestive cardiac failure, 
myocardial infarction, other cardiac diseases and diabetes mellitus. Geographical 
variation was observed with the lowest probability of consultation in the South East 
Coast compared to West Midlands. Over the course of the 15-year study period, lower 
probability of consultation was noted from 2009/10 onwards compared to 2002/03-
2004/05. Other important factors independently associated with lower probability of 
consultation were age ≥85 years and patients who are more deprived.  Gender and 
alcohol consumption were not independently associated with consultation.  
54.2 54.1







































Table 3-3: Univariate and multivariate competing-risks regression analyses investigating the predictors of primary care consultation after 
hospitalisation for pneumonia in the first 30 days after discharge. 
  




Univariate CRR  
sHR (95% CI) 
Multivariate CRR 
sHR (95% CI) 
p value 
Number of patients 24854 31542      
Age                
18-49 4017 (48.9) 4191 (51.1) 1.00 Reference 1.00 Reference   
50-64 3755 (42.5) 5075 (57.5) 1.18 (1.13-1.23) 1.08 (1.04-1.13) *<0.001 
65-74 4277 (40.7) 6222 (59.3) 1.24 (1.19-1.28) 1.08 (1.03-1.12) *<0.001 
75-84 6459 (42.2) 8858 (57.8) 1.21 (1.16-1.25) 1.03 (0.99-1.07) 0.161 
≥85 6346 (46.9) 7196 (53.1) 1.10 (1.06-1.14) 0.95 (0.91-0.99) *0.018 
Gender                
Male 12277 (43.8) 15725 (56.2) 1.00 Reference 1.00 Reference   
Female 12577 (44.3) 15817 (55.7) 0.99 (0.96-1.01) 0.99 (0.97-1.01) 0.32 
Smoking status                   
Never 8036 (45.5) 9634 (54.5) 1.00 Reference 1.00 Reference   
Ex 5970 (42.3) 8149 (57.7) 1.08 (1.05-1.11) 1.03 (1.00-1.06) *0.03 
Current 9897 (43.1) 13061 (56.9) 1.06 (1.03-1.09) 1.03 (1.00-1.06) *0.027 
Unknown 951 (57.7) 698 (42.3) -         
Alcohol status                 
Non-drinker 5559 (44.2) 7016 (55.8) 1.00 Reference      
Former drinker 1164 (41.1) 1667 (58.9) 1.08 (1.03-1.14)      
Occasional drinker 3276 (42.4) 4454 (57.6) 1.04 (1.00-1.08)      
Moderate drinker 7717 (42.4) 10499 (57.6) 1.03 (1.00-1.06)      
Heavy drinker 2896 (44.2) 3663 (55.8) 0.98 (0.94-1.02)      
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Unknown 4242 (50.0) 4243 (50.0) -         
CAP admission year                   
2002/03-2004/05 3296 (44.6) 4094 (55.4) 1.00 Reference 1.00 Reference   
2005/06-2006/07 2650 (41.3) 3764 (58.7) 1.09 (1.05-1.14) 1.03 (0.99-1.08) 0.144 
2007/08-2008/09 3387 (42.5) 4576 (57.5) 1.05 (1.01-1.09) 0.98 (0.94-1.02) 0.256 
2009/10-2010/11 4157 (43.7) 5357 (56.3) 1.03 (0.98-1.07) 0.95 (0.91-0.99) *0.008 
2011/12-2012/13 4416 (43.6) 5717 (56.4) 1.04 (1.00-1.08) 0.95 (0.91-0.99) *0.014 
2013/14-2014/15 3984 (44.1) 5042 (55.9) 1.04 (1.00-1.08) 0.95 (0.91-0.99) *0.015 
2015/16-2016/17 2964 (49.8) 2992 (50.2) 0.88 (0.84-0.93) 0.82 (0.79-0.87) *<0.001 
Length of stay                 
≤3 7694 (44.9) 9455 (55.1) 1.00 Reference 1.00 Reference   
4-7 6351 (42.1) 8743 (57.9) 1.07 (1.04-1.10) 1.04 (1.01-1.07) *0.019 
>7 10809 (44.8) 13344 (55.2) 1.03 (1.01-1.06) 1.00 (0.97-1.02) 0.852 
Primary care 
consultations in the 
previous year                   
0 358 (91.1) 35 (8.9) 1.00 Reference 1.00 Reference   
<5 1108 (61.3) 700 (38.7) 5.31 (3.77-7.48) 5.11 (3.63-7.21) *<0.001 
5-15 4039 (50.7) 3931 (49.3) 7.27 (5.20-10.16) 7.05 (5.04-9.87) *<0.001 
>15 19349 (41.9) 26876 (58.1) 9.30 (6.66-12.99) 8.98 (6.42-12.55) *<0.001 
IMD (patient level)                 
1 (least deprived) 4617 (43.6) 5979 (56.4) 1.00 Reference 1.00 Reference   
2 5038 (44.2) 6369 (55.8) 0.98 (0.94-1.01) 0.96 (0.93-0.99) *0.019 
3 5116 (43.0) 6793 (57.0) 1.01 (0.98-1.04) 0.99 (0.96-1.03) 0.585 
4 5053 (44.9) 6210 (55.1) 0.95 (0.92-0.99) 0.93 (0.90-0.96) *<0.001 
5 (most deprived) 5002 (44.8) 6169 (55.2) 0.96 (0.93-0.99) 0.91 (0.88-0.94) *<0.001 
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Unknown 28 (56.0) 22 (44.0) 0.73 (0.48-1.10) 0.78 (0.51-1.18) 0.237 
Practice region                   
West Midlands 2878 (41.2) 4112 (58.8) 1.00 Reference 1.00 Reference   
North West 4160 (42.2) 5695 (57.8) 0.97 (0.93-1.01) 0.98 (0.94-1.02) 0.245 
Yorkshire & The Humber 857 (44.5) 1069 (55.5) 0.89 (0.84-0.95) 0.89 (0.83-0.95) *<0.001 
East Midlands 533 (41.2) 761 (58.8) 1.00 (0.92-1.07) 1.01 (0.93-1.09) 0.846 
North East 568 (39.1) 886 (60.9) 1.05 (0.98-1.12) 1.05 (0.98-1.13) 0.154 
East of England 2246 (40.2) 3343 (59.8) 1.03 (0.99-1.08) 1.04 (0.99-1.08) 0.12 
South West 3268 (43.3) 4273 (56.7) 0.93 (0.89-0.97) 0.92 (0.89-0.96) *<0.001 
South Central 3116 (44.3) 3915 (55.7) 0.91 (0.87-0.95) 0.90 (0.86-0.94) *<0.001 
London 3492 (49.1) 3622 (50.9) 0.80 (0.77-0.84) 0.83 (0.79-0.86) *<0.001 
South East Coast 3736 (49.1) 3866 (50.9) 0.80 (0.77-0.84) 0.81 (0.77-0.85) *<0.001 
§ Charlson Comorbidity 
Index                   
0 6590 (48.3) 7046 (51.7) 1.00 Reference 1.00 Reference   
1 5488 (44.7) 6802 (55.3) 1.10 (1.06-1.13) 0.99 (0.96-1.02) 0.562 
2 4387 (44.3) 5525 (55.7) 1.11 (1.07-1.15) 0.98 (0.95-1.02) 0.42 
3 3279 (42.2) 4498 (57.8) 1.18 (1.14-1.23) 1.04 (1.00-1.08) *0.047 
4 2078 (40.8) 3018 (59.2) 1.23 (1.18-1.28) 1.08 (1.03-1.13) *0.001 
≥5 3032 (39.5) 4653 (60.5) 1.28 (1.24-1.33) 1.14 (1.09-1.18) *<0.001 
                    
Co-morbidities                   
COPD 4666 (39.5) 7132 (60.5) 1.14 (1.12-1.17) 1.05 (1.01-1.08) *0.003 
Asthma 5351 (40.1) 7996 (59.9) 1.12 (1.09-1.15) 1.06 (1.03-1.08) *<0.001 
¥Chronic lung disease 391 (43.6) 505 (56.4) 1.00 (0.92-1.09)      




Myocardial infarction 2125 (40.3) 3143 (59.7) 1.12 (1.08-1.17) 1.10 (1.06-1.15) *<0.001 
#Other cardiac diseases 9755 (41.8) 13571 (58.2) 1.11 (1.08-1.13) 1.11 (1.09-1.14) *<0.001 
Malignancy 5231 (42.2) 7166 (57.8) 1.07 (1.04-1.10)      
Chronic renal disease 4624 (42.1) 6350 (57.9) 1.08 (1.06-1.11)      
Cerebrovascular disease 3806 (40.5) 5584 (59.5) 1.12 (1.09-1.15)      
Diabetes mellitus 2701 (42.4) 3676 (57.6) 1.07 (1.03-1.11) 1.04 (1.01-1.07) *0.009 
Cognitive impairment 2725 (46.7) 3109 (53.3) 0.97 (0.94-1.01)      
Liver disease 213 (40.1) 318 (59.9) 1.09 (0.98-1.21)       
* signify a p value of <0.05 
¥ Chronic lung disease excluding COPD and asthma 
# Other cardiac diseases excluding CCF and MI (e.g. hypertension, arrhythmias, valvular heart disease, conduction disorder of the heart, pericarditis, 
myocarditis) 




In a sensitivity analysis excluding previous consulting behaviour in primary care as a 
factor, multivariate analysis showed a higher probability of consultation in patients aged 
50-84 years, length of hospital stay of between 4-7 days, Charlson Comorbidity Index 
score ≥1 and pre-existing comorbid diseases; COPD, asthma, congestive cardiac failure, 
myocardial infarction, other cardiac diseases, cancer, chronic renal disease and diabetes 
mellitus. Lower probability of consultation were seen in 2015/16- 2016/17 (Table 3-4). 
Geographical variation of consultation was again noted, however smoking status was no 
longer independently associated with consultation. 
Table 3-4: Sensitivity analysis excluding primary care consultation in the previous year 
  
Multivariate CRR 
sHR (95% CI) 
p value 
Number of patients       
Age      
18-49 1.00 Reference   
50-64 1.14 (1.09-1.18) *<0.001 
65-74 1.15 (1.10-1.20) *<0.001 
75-84 1.10 (1.06-1.15) *<0.001 
≥85 1.01 (0.97-1.05) 0.633 
Gender      
Male 1.00 Reference   
Female 1.00 (0.98-1.03) 0.671 
CAP admission year       
2002/03-2004/05 1.00 Reference   
2005/06-2006/07 1.08 (1.04-1.13) *<0.001 
2007/08-2008/09 1.03 (0.99-1.08) 0.146 
2009/10-2010/11 1.01 (0.97-1.05) 0.788 
2011/12-2012/13 1.02 (0.98-1.06) 0.423 
2013/14-2014/15 1.02 (0.98-1.06) 0.327 
2015/16-2016/17 0.89 (0.84-0.93) *<0.001 
Length of stay       
≤3 1.00 Reference   
4-7 1.04 (1.01-1.07) 0.005 
>7 1.00 (0.97-1.03) 0.921 
IMD (patient level)       
1 (least deprived) 1.00 Reference   
2 0.96 (0.93-1.00) 0.043 
3 0.99 (0.96-1.03) 0.7 
4 0.93 (0.90-0.97) *<0.001 
41 
 
5 (most deprived) 0.92 (0.88-0.95) *<0.001 
Unknown 0.74 (0.49-1.11) 0.143 
Practice region       
West Midlands 1.00 Reference   
North West 0.98 (0.94-1.02) 0.247 
Yorkshire & The Humber 0.90 (0.84-0.96) 0.001 
East Midlands 1.00 (0.93-1.08) 0.963 
North East 1.06 (0.99-1.14) 0.106 
East of England 1.03 (0.99-1.08) 0.139 
South West 0.93 (0.89-0.97) 0.001 
South Central 0.90 (0.86-0.94) *<0.001 
London 0.82 (0.78-0.85) *<0.001 
South East Coast 0.81 (0.77-0.84) *<0.001 
§ Charlson Comorbidity 
Index       
0 1.00 Reference   
1 1.08 (1.04-1.11) *<0.001 
2 1.09 (1.05-1.13) *<0.001 
3 1.17 (1.12-1.21) *<0.001 
4 1.21 (1.16-1.27) *<0.001 
≥5 1.28 (1.23-1.33) *<0.001 
        
Co-morbidities       
COPD 1.07 (1.04-1.10) *<0.001 
Asthma 1.08 (1.05-1.11) *<0.001 
Chronic lung disease      
Congestive cardiac failure 1.17 (1.13-1.22) *<0.001 
Myocardial infarction 1.14 (1.10-1.19) *<0.001 
Other cardiac diseases 1.16 (1.13-1.19) *<0.001 
Malignancy 1.05 (1.03-1.08) *<0.001 
Chronic renal disease 1.04 (1.01-1.07) 0.013 
Cerebrovascular disease      
Diabetes mellitus 1.06 (1.03-1.10) *<0.001 
Cognitive impairment      
Liver disease       
* signify a p value of <0.05 
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3.3.2 Reasons for consultations and readmissions 
The commonest reason for consultation within 30 days was for a respiratory disorder (40.7%) with 11.8% consulting for pneumonia specifically 
(Table 3-5). A small proportion of patients consulted for constitutional symptoms, such as fever, fatigue, loss of appetite or general malaise. 
Reasons for consultation within 7 days were similar. 
Table 3-5: Reasons for GP consultation after hospital discharge  
 
All patients  
who consulted 
Patients who consulted 
 before readmissiona 
Patients who consulted 
before deathb 
Reason for consultation 


















Respiratory  6155 (39.4) 12840 (40.7) 253 (39.0) 1350 (39.0) 158 (25.0) 741 (35.7) 
specifically pneumonia  2470 (15.8) 3730 (11.8) 71 (11.0) 293 (8.5) 87 (13.7) 312 (15.0) 
Constitutional symptoms 379 (2.4) 1240 (3.9) 16 (2.5) 162 (4.7) 15 (2.4) 84 (4.0) 
Digestive  1196 (7.7) 3316 (10.5) 60 (9.3) 439 (12.7) 27 (4.3) 183 (8.8) 
Cardiac  1139 (7.3) 2732 (8.7) 50 (7.7) 274 (7.9) 58 (9.2) 209 (10.1) 
Genitourinary 466 (3.0) 1629 (5.2) 26 (4.0) 179 (5.2) 16 (2.5) 76 (3.7) 
Cognitive 191 (1.2) 558 (1.8) 12 (1.9) 53 (1.5) 16 (2.5) 78 (3.8) 
* only Read codes referring to acute symptoms and disorders were included, such as acute cough, acute atrial fibrillation or worsening cognitive impairment; excluding routine reviews for 
chronic conditions, or routine post-discharge consultations 
a Readmission within 30 days of discharge 
b Death within 30 days of discharge 
Note: The same patient could fall into multiple categories for ‘Reason for consultation’ 
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Of patients readmitted within 30 days of discharge, 38.2% (n=3,459 of 9,051) consulted 
primary care before readmission. These patients had similar reasons for consulting when 
compared to all patients. The commonest reason for readmission was pneumonia; 34.6% 
(n=1,255 of 3,625) and 26.9% (n=2,431 of 9,051) within 7 and 30 days respectively (Table 
3-6). A large proportion of patients who died within 30 days of discharge consulted 
primary care before death (60.3%, n=2,077). Of these, 413 of 2077 (19.9%) were for 
reasons of palliative care or terminal illness (n=230), or cancers (n=183). 








J12-J18 Pneumonia  1255 (34.6) 2431 (26.9) 
J44 Other chronic obstructive pulmonary disease 194 (5.4) 583 (6.4) 
J22 Unspecified acute lower respiratory tract infection 149 (4.1) 400 (4.4) 
I50 Heart failure 130 (3.6) 298 (3.3) 
N39 Other disorders of urinary system 87 (2.4) 275 (3.0) 
R07 Pain in throat and chest 71 (2.0) 224 (2.5) 
J69 Pneumonitis due to solids and liquids 58 (1.6) 119 (1.3) 
C34 Malignant neoplasm of bronchus and lung 55 (1.5) 170 (1.9) 
R06 Abnormalities of breathing 51 (1.4) 142 (1.6) 
I26 Pulmonary embolism 47 (1.3) 114 (1.3) 
A41 Other sepsis 41 (1.1) 120 (1.3) 
J90 Pleural effusion 40 (1.1) 138 (1.5) 
K52 Other and unspecified non-infective gastroenteritis 
and colitis 39 (1.1) 87 (1.0) 
I48 Atrial fibrillation and flutter 31 (0.9) 104 (1.1) 
I21 Acute myocardial infarction 31 (0.9) 0 (0.0) 
R69 Illness, unspecified 29 (0.8) 75 (0.8) 
N17 Acute kidney injury 28 (0.8) 80 (0.9) 
R41 Other symptoms and signs involving cognitive 
functions and awareness 27 (0.7) 0 0 
K92 Other diseases of digestive system 25 (0.7) 68 (0.8) 
R29 Other symptoms and signs involving the nervous and 
musculoskeletal systems 25 (0.7) 0 0 




3.3.3 Antibiotic prescription at consultation 
Antibiotics were prescribed in fewer than 20% of those who consulted within 7 days of 
discharge compared to 31.1% of those who consulted within 30 days (Table 3-7). At 
consultations within 7 and 30 days of discharge, antibiotics were prescribed for 
respiratory disorders in 56.4% and 48.9% respectively.  
Table 3-7: Antibiotic prescription at consultation 
  
≤ 7 days 
n (%) 
≤ 30 days 
n (%) 
Frequency of antibiotic courses      
None 12919 (82.7) 21719 (68.9) 
One course 2582 (16.5) 7587 (24.0) 
Two or more courses 125 (0.8) 2236 (7.1) 
Total # 15626 (100.0) 31542 (100.0) 
Type of antibiotics         
Penicillin 1352 (41.9) 5753 (41.6) 
Macrolide 830 (25.7) 3029 (21.9) 
Tetracycline 352 (10.9) 1467 (10.6) 
Quinolones 220 (6.8) 875 (6.3) 
Others 474 (14.7) 2705 (19.6) 
Total* 3228 (100.0) 13829 (100.0) 
 # counted by number of people  
* counted by number of antibiotic courses  
The total for ‘Type of antibiotics’ do not match one or more courses of antibiotics prescribed due to 
difference in the way the count was done as listed above. 
 
There was an overall rise of about 9% in antibiotic prescribing from 25.2% in 2002/03 to 
34.1% in 2012/13, followed by a declining trend to 32.0% in 2016/17 (Fig 3-4). Of those 
who received antibiotics at consultation, 22.8% received two or more courses of 









Factors independently associated with a higher odds of antibiotic prescription in the first 
week after discharge were; year of pneumonia hospitalisation and pre-existing COPD or 
asthma. Factors independently associated with a lower odds of antibiotic prescription 
were; age ≥65 years, hospital stay ≥4 days, and practice region (East of England and 
London) (Table 3-8). 
Table 3-8: Univariate and multivariate logistic regression analyses investigating the 
important predictors of antibiotic prescription in patients who consulted within the first 
week of discharge. 
Predictors 
Univariate LR  
Crude OR (95% CI) 
Multivariate LR 
Adjusted OR (95% CI) 
p value 
Age          
18-49 1.00 Reference 1.00 Reference   
50-64 0.86 (0.74-1.00) 0.90 (0.78-1.05) 0.169 
65-74 0.78 (0.68-0.90) 0.81 (0.70-0.94) *0.005 
75-84 0.76 (0.67-0.87) 0.82 (0.72-0.95) *0.007 
≥85 0.73 (0.64-0.84) 0.84 (0.73-0.98) *0.023 
Gender          
Male 1.00 Reference 1.00 Reference   
Female 1.07 (0.98-1.16) 1.08 (0.99-1.17) 0.092 
CAP admission year           
2002/03-2004/05 1.00 Reference 1.00 Reference   
2005/06-2006/07 1.19 (1.00-1.41) 1.16 (0.97-1.37) 0.098 























































2009/10-2010/11 1.19 (1.02-1.40) 1.17 (1.00-1.37) 0.057 
2011/12-2012/13 1.26 (1.08-1.47) 1.25 (1.07-1.46) *0.005 
2013/14-2014/15 1.29 (1.10-1.51) 1.27 (1.08-1.49) *0.003 
2015/16-2016/17 1.23 (1.03-1.48) 1.21 (1.00-1.45) *0.047 
Length of stay           
≤3 1.00 Reference 1.00 Reference   
4-7 0.74 (0.67-0.82) 0.75 (0.67-0.84) *<0.001 
>7 0.63 (0.57-0.69) 0.65 (0.59-0.72) *<0.001 
Practice region           
West Midlands 1.00 Reference 1.00 Reference   
North West 0.97 (0.84-1.12) 0.94 (0.82-1.09) 0.435 
Yorkshire & The Humber 0.96 (0.75-1.24) 0.98 (0.76-1.27) 0.892 
East Midlands 0.91 (0.69-1.21) 0.93 (0.70-1.24) 0.616 
North East 0.86 (0.66-1.13) 0.85 (0.65-1.12) 0.252 
East of England 0.82 (0.70-0.97) 0.83 (0.70-0.98) *0.03 
South West 0.88 (0.76-1.04) 0.90 (0.77-1.05) 0.181 
South Central 0.99 (0.84-1.16) 0.98 (0.84-1.16) 0.853 
London 0.68 (0.57-0.81) 0.67 (0.56-0.80) *<0.001 
South East Coast 0.91 (0.78-1.08) 0.91 (0.77-1.07) 0.257 
Co-morbidities           
COPD 1.14 (1.04-1.26) 1.13 (1.01-1.26) *0.036 
Asthma 1.31 (1.19-1.44) 1.25 (1.13-1.38) *<0.001 
¥Chronic lung disease 1.18 (0.85-1.62)      
Congestive cardiac failure 0.98 (0.86-1.12)      
Myocardial infarction 0.88 (0.77-1.02)      
#Other cardiac diseases 0.88 (0.81-0.95)      
Malignancy 0.89 (0.81-0.99)      
Chronic renal disease 0.96 (0.87-1.07)      
Cerebrovascular disease 0.94 (0.83-1.07)      
Diabetes mellitus 0.95 (0.85-1.06)      
Cognitive impairment 1.09 (0.95-1.24)      
Liver disease 0.80 (0.51-1.26)       
* signify a p value of <0.05 
In addition to the variables listed in the table, univariate logistic regression showed no association between 
antibiotic prescription at consultation and smoking status, alcohol consumption, IMD score, primary care 
consultation in the previous year and Charlson Comorbidity Index.  
¥ Chronic lung disease excluding COPD and asthma 
# Other cardiac diseases excluding CCF and MI (e.g. hypertension, arrhythmias, valvular heart disease, 




3.4 Discussion  
3.4.1 Principal findings 
To our knowledge, this is the first study to describe the impact on primary care following 
discharge of adults hospitalised for pneumonia across England. We found a previously 
unrecognised large burden of care with almost 56% of patients consulting primary care 
within 30 days of hospital discharge, the highest rate of consultation occurring within 7 
days. Nearly 40% of consultations were for a respiratory disorder, with 12% consulting for 
pneumonia specifically and 30% of patients consulting received further antibiotics. 
Previous consultation behaviour at primary care was the strongest predictor of 
consultation.  
 
3.4.2 Strengths & Weakness of the study 
A major strength of this study is the large, nationally representative study cohort of over 
56,000 patients obtained through linkage between the CPRD and HES, two large validated 
medical record databases.58 This dataset reflects the real-world practice of pneumonia in 
NHS England covering a span of 15 years. In order to avoid measuring non-medically 
relevant consultation and ensure face-to-face consultations were captured, 
administration-related Read codes were judiciously excluded. Compared to relying on 
CPRD coding alone, the HES-CPRD linkage enabled patients hospitalised with pneumonia 
to be more accurately identified and allowed confident exclusion of patients with hospital 
acquired pneumonia. The 15-year study period also enabled an examination of time-
trends in relation to the outcomes of interest. 
 
A weakness of this study is that although CPRD contains data from all of the UK, these 
data are predominantly from England and linked datasets including HES are only available 
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for English practices. Therefore, the results from this study may not be generalisable to 
the rest of the UK. Secondly, a large number of patients (n=87,773) were excluded 
because their data did not meet the minimum research quality checks or their first 
practice registration date to date of admission was less than a year. These patients were 
younger than those included (median 71 vs 75 years, p<0.0001) and there was a higher 
proportion of females (51.5% vs 50.4%). Those discharged to a care facility outside the 
catchment area of their previous primary care practice would also have been excluded 
from the analysis. Excluded patients may have different patterns of consultation 
behaviour compared to the study cohort. Thirdly, we relied on ICD-10 coding for the 
identification of patients with pneumonia. Information bias from possible 
miscategorisation of pneumonia is a recognised limitation of reliance on HES coding. 
Roughly a third of ICD-10 coded cases of pneumonia within HES lack radiographic 
evidence of pneumonia and would strictly be considered cases of non-pneumonic LRTI.30 
The vast majority of these patients are nevertheless treated clinically as having 
pneumonia and inclusion of these patients in the analysis reflects real-world practice. 
Fourthly, although considerable efforts were made to ensure data quality, we cannot 
fully exclude the possibility of miscategorisation of outcomes arising from miscoding 
consultations after discharge.  
 
3.4.3 Comparison with other studies 
Very few studies have examined the impact on primary care following hospital discharge 
for an episode of pneumonia. A Dutch study using electronic health records observed 
that after hospitalisation for CAP, only 8% of adults consulted primary care within 30 
days.85 Their study comprised patients a) who were younger (mean age range per year 
from 2002- 2009; 57 years (SD 27.9) to 61 years (SD 24.8), compared to a median age of 
76 years (IQR 60-85) for our study cohort and b) with lower pneumonia severity, as 
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reflected in their combined mortality (in-hospital and within 30 days of discharge) of 7%, 
compared to 26.7% in our study.  Differences in healthcare systems and help-seeking 
behaviour may also have contributed. Two Spanish studies (a prospective cohort study at 
a tertiary hospital (n=934) and a multicentre clinical trial (n=207)) observed consultation 
proportions of 18-20%.86,87 A small 3-centre UK study by Daniel et al. (n=108) of adults 
aged <65 years found primary care consultation occurred in 59%.47  
 
We found a lower proportion of consultation due to respiratory symptoms compared to 
Daniel et al. and Adamuz et al. (69% and 75% respectively). Direct comparison between 
these studies is not possible due to the use of different methodologies for measuring and 
categorising reasons for consultation.47,87 Antibiotic use at consultation in our study 
(30.8%) was similar to that reported by Daniel et al. (34.4%).47 
 
Other studies have investigated the burden of reconsultations after initial management 
at primary care of patients with lower respiratory tract infections (RTIs) or acute 
bronchitis.49,88–90 The patient cohorts in these primary care studies are mostly different, 
often involving adults with self-limiting RTIs in whom the challenge is the avoidance of 
overuse of antibiotics and managing patient expectation. In these patient groups, 
reconsultations were observed in 20 - 33%. Similar to other research in lower RTI 
consultations not requiring hospital admission, we found that a prior history of 
consultation was a strong predictor of further consultation.48,49 Strategies such as the 
provision of patient information leaflets, or delayed prescriptions, for previously well 
adults presenting with RTIs have been tested and found to reduce reconsultation 
rate.48,91,92 Such strategies may be relevant in managing patients’ expectations on 
discharge from hospital as well. In addition, existing integrated care pathways between 
primary and secondary care for the post-discharge management of patients may provide 
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applicable approaches to improving the quality of care and patients’ experiences 
following pneumonia.93,94   
 
Patients with a shorter length of hospital stay might be expected to have a reduced 
likelihood of further antibiotic prescription at consultation. We observed the opposite 
effect. In those who consulted primary care, patients with shorter hospital stays (<4 days) 
were more likely to receive antibiotics compared to those with longer hospital stays. 
Further studies are required to determine the reasons for antibiotic prescription at these 
consultations and their appropriateness. 
 
3.4.4 Possible explanations & implications for clinicians & 
policymakers 
Consultation following hospitalisation for pneumonia may serve as a means of safety-
netting, providing an opportunity for clinicians to identify deteriorating patients who 
need further medical intervention or sometimes readmission. However, patients often 
continue to report persistence of symptoms, including fatigue, cough and dyspnoea, 
associated with functional impairment for several weeks after discharge from hospital.54 
Results from two qualitative studies in this group of patients reveal that at the time of 
hospital discharge, patients lack a clear understanding about the short and long-term 
consequences of CAP, or the natural course of their symptoms.95,96 Many patients 
describe a sense of isolation when their experiences of relatively slow recovery do not 
match the expectations of relatives, carers and even physicians.95,96 Such ongoing 
unaddressed patient needs may contribute towards the high level of consultation 




At a strategic level, lack of recognition of the burden of morbidity during recovery from 
pneumonia has thus far meant that evidence-based interventions to meet patients’ 
needs have not been adequately developed. The health economic costs of primary care 
consultations are considerable. Annually, over 100,000 patients are admitted to hospital 
in England with CAP.97 Assuming a cost of £30 for each primary care consultation, we 
estimate post-pneumonia consultations alone to cost the NHS approximately £2 million a 
year.98 These figures do not take into account any additional NHS and ecological costs 
from antibiotic prescribing nor the impacts from ‘long-COVID’ consequent on SARS-CoV2 
infection specifically.99–102  
 
Education of patients, the public, clinicians and policy makers regarding the sometimes 
prolonged morbidity associated with hospitalisation with pneumonia is important to 
create the understanding and space necessary to support patient recovery. One clinical 
trial demonstrated that having a dedicated nurse provide individualised patient 
education over two sessions between 24-72 hours before discharge reduced 
consultations in primary care and hospital readmissions.86   
 
The observation that previous consultation behaviour is strongly associated with post-
pneumonia discharge consultation raises the question of whether the index pneumonia 
admission is a precipitating event leading to further health consequences, or whether it is 
only a marker of on-going health needs. It is likely that both these explanations play some 
part.  Further studies are required to better understand the relative contributions of 
these factors and to inform where to direct health improvement efforts. 
 
A significant trend toward lower levels of post-discharge consultations was observed over 
the 15 years of the study (2002 to 2017). Over that period, concerted efforts were made 
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nationally to improve the care of patients with CAP including major updates of national 
CAP Guidelines (from the British Thoracic Society in 2009, and NICE in 2014).2,3 A 
corresponding decrease in mortality from CAP over a ten-year period (2009 to 2019) was 
also observed.30 These initiatives may have contributed to the observed decrease in post-
discharge consultations and supports continued efforts in this direction through the NHS 







Chapter 4 Cardiac complications 
following community-acquired 






Community-acquired pneumonia (CAP) and cardiac disease are the leading causes of 
morbidity and mortality worldwide. Twenty-five studies from the past decade alone have 
shown that there is a strong link between CAP and cardiac complications including acute 
coronary syndrome (ACS), heart failure and arrhythmias. Patients hospitalised with CAP 
have substantial mortality ranging from 5.1% to 47% depending on the age, severity, 
pneumonia aetiology and co-morbidities.29,97,103 The additional burden of cardiac 
complications will undoubtedly worsen their prognosis, highlighting the need to focus on 
this important global issue. 
 
Cardiovascular disease is a broad terminology that covers a group of disorders of the 
heart and blood vessels including hypertension, coronary heart disease, heart failure, 
cerebrovascular disease, vascular dementia and peripheral vascular disease.104,105 In 
contrast, cardiac disease refers to disorders specifically related to the heart. To date, 
three reviews have covered CAP and cardiac or cardiovascular complications. The first 
meta-analysis by Fine et al. in 1996 reported a pooled incidence rate of 8.6% (95% CI 6.4-
12.3) for heart failure (n=4 studies) following CAP.106 Corrales-Medina et al. in 2011 
included 25 studies in their systematic review. Although the objective of their study was 
to examine cardiac complications, studies with cardiovascular complications were also 
included.107 The pooled incidence rates of ACS, heart failure and arrhythmias within 30 
days of CAP diagnosis (either as inpatient or outpatient) were 5.3%, 14.1% and 4.7% 
respectively. Likewise, an updated systematic review by Tralhao et al. also included 
cardiovascular studies from both inpatient and outpatient settings, however a key point 
was not taken into account during analysis. No distinction was made between the 
included studies for the time at which the outcome i.e. cardiac or cardiovascular 




The aim of this systematic review was to focus on the incident cardiac complications 
following hospitalisation for community-acquired pneumonia (CAP), with particular 
attention to the temporal relationship of these complications in relation to CAP, which 
may affect development of management strategies. We have also summarised the 
available evidence regarding the mortality, risk factors as well as biomarkers associated 
with developing these incident cardiac complications.  
 
4.2 Methods 
This systematic review was conducted using a predefined protocol which was registered 
with PROSPERO database (CRD42019123996, Appendix 3) and reported in accordance 
with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
statement. 
 
4.2.1 Search strategy and study selection 
The search strategy which was designed to find published studies included subject 
headings and keywords related to CAP and cardiac complications such as acute coronary 
syndromes, heart failure and arrhythmias. Comprehensive searches of MEDLINE and 
Embase from inception to December 2018 were conducted. Details of the search strategy 
are found in Appendix 4. The reference list of all included studies and previously 
published relevant reviews were screened for inclusion.  
 
This review included observational studies. Studies published in all languages were 
considered and no date restrictions were placed on searches. Studies comprising adults 
aged 18 years and above with a clinical and radiological diagnosis of CAP were included. 




active pulmonary tuberculosis (TB) and post-obstructive pneumonia secondary to 
thoracic malignancy were excluded. 
 
Two reviewers (VB and TM) independently screened titles and abstracts using Rayyan 
software109 and subsequently reviewed full-texts of retrieved studies for eligibility. 
Disagreement was resolved by discussion and consensus, involving a third reviewer where 
necessary. 
 
4.2.2 Data extraction and assessment of methodological quality 
Two reviewers (VB, HL, DA, SQ or TM) independently extracted data for all studies using a 
standardised form created for this study (Appendix 5). Any disagreements that arose 
between reviewers were resolved through discussion, or with a third reviewer (TM) when 
required. The following information were collected: study population, study design, 
exposure of interest (CAP) and outcomes including i) incidence of cardiac complications 
(i.e. acute coronary syndrome including myocardial infarction (MI) and unstable angina, 
new or worsening heart failure and new or worsening arrhythmia), ii) mortality 
associated with cardiac complications, iii) risk factors for developing cardiac 
complications, and iv) biomarkers which are associated with cardiac complications. 
Methodological quality and risk of bias was assessed using the modified Newcastle-
Ottawa Quality Assessment Scale (Appendix 5) for either cohort or case-control studies 
depending on individual study design. This scale is based on three broad categories; (1) 
selection of the study sample, (2) comparability of the sample groups (for studies that 
adjust for confounders, age was a priori confounder) and (3) ascertainment of exposure 
and outcome. Thus, studies were scored out of either a total of five, seven or nine points 
depending on the study type. Scores were chosen a priori to indicate different levels of 




4.2.3 Data synthesis & Statistical analysis 
Where possible, the pooled incidence of ACS, heart failure and arrhythmia were 
determined using a random effects model (DerSimonian Laird weights methods), 
stabilising the variances using the Freeman-Tukey double arcsine transformation so that 
studies with proportions close to 0% or 100% were approximately estimated, with 
computation of exact binomial 95% confidence intervals at different time-points (e.g. on 
admission, in-hospital, 30 days, 90 days and 1 year).110 Studies with pooled ORs for the 
risk factors of developing incident cardiac complications and associated mortality were 
summarised with 95% confidence intervals. Measures of effect adjusted for confounders 
(age was an a priori confounder) were used in preference to crude measures of effect. 
One study reported MI and unstable angina separately, hence they were included 
separately.111 The I2 statistic was used to assist with assessment of heterogeneity 
between studies. As we anticipated a high level of heterogeneity for the pooled incidence 
of incident cardiac complications, an a priori decision was made not to abandon the 
meta-analyses due to high heterogeneity.  
 
Publication bias was not assessed in this review as the utility of standard publication bias 
tests for proportional meta-analyses has been questioned, with funnel plots and 
statistical tests potentially yielding misleading and inaccurate results.112 Although 
publication bias may cause inflated estimates in meta-analyses of studies of treatment 
effect, this is unlikely in the context of studies reporting the proportion of patients with 






Out of 10,631 studies identified, 109 full-text articles (including five non-English studies; 
one Spanish, one Russian, one Hungarian and two Chinese studies) were reviewed (Fig 
4-1). Forty-seven English studies with 134,966 participants were included in the 
systematic review from 1984- 2019 (Table 4-1). The most common reason for exclusion 
was lack of documented relevant outcome data (n= 46/63). 






4.3.1 Characteristics on included studies 
Of 47 included studies for the systematic review, there were 43 cohort studies, one case-
control study and three case series. All studies included both genders, however the study 
population for five studies were predominantly male (98%). The definition of CAP was 
based on radiological confirmation in 42 studies and diagnostic coding (International 
Classification of Diseases, ICD coding) in five studies. All studies included patients who 
were admitted to hospital for CAP and five studies included patients admitted to the 




Table 4-1: Characteristics of 47 included studies for systematic review; ordered by year. 
First Author  
Publication  
year 
Study design Country 
Study 
period 
Inclusion criteria Exclusion criteria N 




Esposito113 1984 Single-centre 
prospective 
cohort 
US Dec 1980- 
April 1983 
Adults ≥65 years 
Mean age: 61 
Male: 39.5% 
Follow-up: Hospitalisation, 
LOS 15.7 days 










Mean age: 39 
Male: 72.1% 
Follow-up: Hospitalisation 
• Refused inpatient treatment 
• pulmonary TB 
• lung abscess 
• empyema 
• bronchitis 
502   ✓  
Marrie115 1989 Single-centre 
prospective 
cohort 




Mean age: 63.2 
Male: 61.3% 
Follow-up: Hospitalisation, 
mean LOS 17.4 days 
• HAP 
• patients with other causes for their 












Mean age: 57.5 (21) 
Male: 57% 
Follow-up: 6 weeks 
• HAP 
• a prior episode of pneumonia within 6 
weeks of presentation 
• radiographic abnormalities attributed 
solely to CCF, carcinoma or pulmonary 
embolus 
• known positive test for antibodies to HIV or 
a clinical diagnosis of AIDS 















UK Nov 1987- 
May 1988 
Adults aged ≥65 
Median age: 79 (range 65-97) 
Male: 52% 
Follow-up: 6 weeks 




Leroy118 1992 Single-centre 
retrospective 
cohort 
France Jan 1987- 
Dec 1991 
Adults >16 
Mean age: 63.9 (17.6) 
Male: 63% 
Follow-up: ICU stay 
• HAP 
• AIDS 
• radiographic abnormalities solely 
attributed to either carcinoma, CCF, 





   
Woodhead119  1992 Multicentre 
retrospective 
cohort 
UK Jan- Dec 
1987 
Adults >15 years admitted to 
ICU 
Mean age: 54 
Male: 57% 
Follow-up: Mean 669 days 
(range 473-866) 
• immunosuppressed  
• CAP secondary to bronchial obstruction by 












Adults with pneumococcal 
pneumonia 
Mean age: 61.5 (range 38-91) 
Male: 98% 
Follow-up: 90 days 
• microscopic examination of the Gram-
stained sputum failed to show a clear 
predominance of forms typical for 
pneumococcus in areas that contained ≥20 
WBC per epithelial cell 
• culture of the sputum revealed other 
potential infecting organism(s) 
•  lack clinical or laboratory findings 
suggestive of an acute bacterial pneumonia 
• blood cultures were negative, but they had 















Adults ≥16 years 
Mean age: 65.2 
Male: 69.9% 
Follow-up: 30 days 
• severely immunosuppressed 












Adults >65 years 
Mean age: 75.5 (6.2) 
Male: 44% 
Follow-up: Hospitalisation, 
mean LOS 8.4 days (SD 5.9) 
• HAP 
• CAP was not the main cause of 
hospitalization 
91 ✓ 
   






Mean age: 68 (range 16-98) 
Male: 66.9% 
Follow-up: 30 days 
• HAP 
• immunosuppressed 
• leukopenia/ neutropenia unless 
attributable to pneumonia 
• died within the first 48 hours after 
admission 
1,424 ✓ 






Spain Jan 2000 – 
Sept 2003 
Adults >18 years 
Mean age: 70.5 
Male: 70.8% 
Follow-up: 30 days 
• HAP 
• neutropenia due to chemotherapy 
• haematological neoplasms 










Adults (>15 years) admitted 
to ITU during the first 24 
hours after admission 
Mean age: 73 (15) 
Male: 58.4 
Follow-up: 30 days 
• immunosuppressed 
• solid or hematologic tumours in 
chemotherapy 
• neutropenia (white blood cell count <1,000 
/ mm3)   













Adults with CAP 
Mean age: 43.6 (14.8) 
Male: 48.8 
Follow-up: Hospitalisation, 
mean LOS 7.4 days (SD 11.1) 
• direct admission from ED to the ICU 
• aspiration pneumonia, but were included in 
second year 
• TB 
• cystic fibrosis 
• pregnant and nursing mothers  






O'Meara *127 2005 Multicentre 
prospective 
cohort 
US 1989-2001 Adults ≥65 years 
Mean age: 75 
Male: 49% 
Follow-up: 10.7 years 
• institutionalised 
• not ambulatory at home 
• under hospice care 
• receiving radiation or chemotherapy for 
cancer 
• not expected to remain in the area for ≥ 3 
years 
• unable to be interviewed. 
582 
   
✓ 






Mean age: 76.6 (12.2) 
Male: 50.4% 
Follow-up: Hospitalisation 
• lack of evidence on chest radiograph of 
pneumonia 
• lack of serum glucose measurement within 
24 h of admission active cancer 




✓ ✓ ✓ 




Adults with pneumococcal 
pneumonia 
Follow-up: Hospitalisation 
• terminal arrhythmias 170 
 
✓ ✓ ✓ 
Aliberti130 2008 Single-centre 
retrospective 
cohort 
US June 2001- 
March 
2006 
Adults ≥18 years 
Mean age: 69.4 (12.3) 
Male: 97.8% 
Follow-up: 28 days 
- 500 
 










Mean age: 84.7 (6.5) 
Male: 59% 




• pneumonia as a terminal event  
117 
 
✓ ✓ ✓ 
Ramirez132 2008 Single-centre 
prospective 
cohort 
US June 2001- 
March 
2006 
Elderly adults in ICU 
Mean age: 69.3 (12.4) 
Male: 98% 
Follow-up: 30 days 
• patients with elevated troponin levels and 
a concomitant diagnosis of severe sepsis 
were excluded from the group of patients 
with AMI 
500 










Mean age: 68 (12.8) 
Follow-up: 15 days 
• immunosuppressed 
• excluded as controls if their reason for 
hospital admission was an elective or 
therapeutic procedure, or their diagnosis of 
admission was either pneumonia or ACS. 
601 
   
✓ 
Mandal *134 2011 Multicentre 
retrospective 
cohort  
Scotland 2005-2007 Adults ≥18 years 
Median age: 73 (IQR 52-82) 
Male: 48% 
Follow-up: 90 days 
• HAP  
• admission or transfer from a health-care 
facility 





Perry *111 2011 Multicentre 
retrospective 
cohort 
US Oct 2001- 
Sept 2007 
• ≥65 yrs old 
• ≥ 1 year of VA outpatient 
care before admission; were 
hospitalized for at least 24 
hours; and had received at 
least 1 dose of antibiotics 
within 48 hours of admission. 
Mean age: 77.5 (6.7) 
Male: 98% 
Follow-up: 90 days 
- 50,119 
 










Oct 2009 – 
Dec 2010 
Adults ≥18 years with CAP & 
HCAP 
Mean age: 73 (16) 
Male: 56% 
Follow-up: 30 days 
• HAP 
• unstable psychiatric or psychological 
condition rendering the subject unlikely to 










US, Canada Oct 1991 – 
March 
1994 
Adults ≥18 years 
Mean age: 56.2 (10.8) 
Male: 50% 
Follow-up: 30 days 
• HAP 
• radiographic findings were considered to 
represent a pre-existing infiltrate or if they 
were consistent with an alternative diagnosis 
(e.g. lung carcinoma, pulmonary oedema or 
pulmonary embolus) 
• HIV infection 
• previous enrolment in the study 
2,287 
 
✓ ✓ ✓ 
Griffin137 2013 Multicentre 
retrospective 
cohort 
13 countries June 2011 
– Nov 
2012 
Adults ≥ 16 years 
Median age: Cardiac events 
78 (IQR 21), 
Without cardiac events 64 
(IQR 33) 
Male: 58% 
Follow-up: 28 days 
• HAP 3,068 
 
✓ ✓ ✓ 
Viasus138 2013 Single-centre 
prospective 
cohort  
Spain Feb 1995- 
Dec 2010 
Mean age: 66.3 (17) 
Male: 68% 
Follow-up: 30 days 
- 3,921 
 




Cangemi139 2014 Multicentre 
prospective 
cohort 
Italy Oct 2011 – 
April 2013 
Adults ≥18 years 
Mean age: 70 (15.7) 
Male: 60.3% 
Follow-up: Hospitalisation, 
mean LOS 10 days 
• HCAP 
• radiographic evidence of pre-existing 
infiltrates 
• severe sepsis  
• immunosuppression 
• presence of malignancy 
• pregnancy or breastfeeding  
• allergy to antibiotics 
278 









US, Canada Feb 1998 - 
March 
1999 
Age ≥18 years 
Mean age: 68.5 (17.1) 
Male: 46% 
Follow-up: 30 days 
• HAP 
• cystic fibrosis, active pulmonary TB, 
immunosuppression or HIV infection 
• current illicit drug use or alcohol abuse 
with documented end-organ damage 
• palliative care only 
• homelessness 
• hospital stay less than 2 days 
• a culture positive for methicillin-resistant S. 
aureus infection within 24 hours of 
presentation or current treatment for this 
infection 
• unresolved or incompletely treated 
pneumonia or empyema diagnosed within 
the 30 days preceding presentation 
• previous enrolment in the study 
608 
 
✓ ✓ ✓ 
Dutt141  2014 Single-centre 
retrospective 
cohort 
India Jan 2011- 
Jan 2012 
Adults with ACE after 48-72 
hours of hospital stay 
Mean age: 53 (range 30-75) 
Male: 61.9% 
Follow-up: 72 hours 
• HAP 
• severe sepsis with a concomitant elevated 
troponin level  
105 




Tang *142  2014 Multicentre 
retrospective 
cohort 
US Oct 2001- 
Sept 2007 
Adults ≥ 65 years with ≥ 1 
Veteran Affairs (VA) 
outpatient clinic visit in the 
preceding year and ≥ 1 active 
and filled outpatient 
medication from a VA 
pharmacy within 90 days of 
admission  
Mean age: 77 (6.5) 
Male: 98% 
Follow-up: 30 days 
• patients who died during the initial 
hospitalisation 
• admitted to hospitals with <25 reported 
hospitalisations during study period 
45,134 
 
✓ ✓ ✓ 











Median age (AMI): 79 (IQR 
72-85) 
Male: 58.3% 
Follow-up: 30 days 
• HAP  905 
 
✓ ✓ ✓ 
Bello144  2015 Single-centre 
prospective 
cohort 
Spain Apr 2008- 
Nov 2011 
Adults (>18 years) with CAP 
within 24 hours of arrival.  
Mean age: 69 (15) 
Male: 63% 
Follow-up: 1018 days (SD 
539) 
• HAP 
• immunosuppression  
• leukopenia/ neutropenia/ and/or 
chemotherapy in the previous year 
• pulmonary abscess (radiological cavitation), 
aspiration pneumonia and obstructive 
pneumonia;  
• presence of malignancy 
265 ✓ 




Cangemi145 2015 Single-centre 
prospective 
cohort 
Italy Jan 2011- 
Dec 2014 
Adults ≥18 years 
Mean age: 71.8 (15.7) 
Male: 62.1% 
Follow-up: Median 17.4 
months 
• HAP & HCAP 
• radiographic evidence of a pre-existing 
infiltrates 
• immunosuppression  
• presence of malignancy 
• pregnancy or breast feeding 
• allergy to antibiotics 




Chen146 2015 Single-centre 
retrospective 
cohort 
Taiwan June 2007- 
Aug 2012 
Adults 




• patients with concurrent infections 
• use of steroids 
• hypoglycaemia   
203 
   
✓ 
Shebl147 2015 Single 
prospective 
cohort 
Egypt July 2012- 
Sept 2014 
Adults 
Mean age: 59 (19.3) 
Male: 52.3% 
Follow-up: Hospitalisation; 
mean LOS 12.2 days (7.6) 
• presence of an alternative diagnosis that 
likely explained the pulmonary symptoms 
and X-ray infiltrate (e.g. lung carcinoma, 
pulmonary oedema, or pulmonary embolus) 
130 
 
✓ ✓ ✓ 
Vannuchi148 2015 Prospective 
single-centre 
cohort 
Italy Jan 2013- 
July 2014 
Elderly patients with CAP 





Violi149 2015 Multicentre 
prospective 
cohort  
Italy Oct 2011 – 
June 2014 
Adults ≥18 years 
Mean age: 70.5 (15.5) 
Male: 62.5% 
Follow-up: Hospitalisation, 
mean LOS 10 days 
• HAP 
• pre-existing permanent or persistent AF 
• severe sepsis  
• immunosuppression  
• presence of malignancy 








Aliberti150 2016 Multicentre 
prospective 
case-control 
Italy Sept 2011- 
Jan 2013 
Adults with CAP & HCAP 




median LOS 9 days (7-14) 
• HAP  
• absence of sinus rhythm on ECG at hospital 
admission 
• pacemaker rhythm on ECG at hospital 
admission 
• undergoing mechanical ventilation  
• on chronic treatment with inhaled long 




✓ ✓ ✓ 





China Jan 2012- 
Dec 2014 
Adults ≥18 years 
Mean age: 57.9 (17.5) 
Male: 48.6% 
Follow-up:  
• Cohort: Mean 12.8 months 
• Self-controlled case 
analysis: 745 days  
• TB 
• the presence of an alternative diagnosis 
that likely explained the pulmonary 
symptoms and X-ray infiltrate (e.g. lung 
cancer, non-infectious interstitial lung 
diseases, pulmonary oedema, atelectasis, 
pulmonary embolism, pulmonary eosinophil 
infiltration and pulmonary vasculitis) 
• CCF, with liver or renal function failure 
• ACS 













Adults >17 years 
Mean age: 55 (20) 
Male: 53.1% 
Follow-up: Median 9.9 years 
(IQR 5.9-10.6) 
• TB 
• cystic fibrosis 






Violi153 2017 Prospective 
multi-centre 
cohort 
Canada Oct 2011- 
Jan 2016 
Adults ≥18 years 
Mean age: 73.1 (14.1) 
Male: 41% 
Follow-up: 30 days 
• HAP 
• radiographic evidence of pre-existing 
infiltrates 
• immunosuppression  
• presence of malignancy 
• pregnancy or breastfeeding 
• severe allergy to antibiotics 
1,182 
 
✓ ✓ ✓ 
Frencken154 2017 Multicentre 
prospective 
cohort 
Netherlands Jan 2011- 
May 2015 
Adults admitted to ICU 
Mean age: 63.9 
Male: 63.1% 
Follow-up: 30 days 
• HAP 
• cardiopulmonary resuscitation before ICU 
admission 
• not meeting criteria for organ failure  
• transferred from other hospitals. 
179 





Cilli155 2018 Multicentre 
retrospective 
cohort 
Turkey Jan 2009- 
Dec 2015 
Adults admitted to ICU 
Mean age: 68 (16) 
Male: 61.4% 
Follow-up: ICU stay 
• HAP 
• immunosuppression 
• presence of malignancy 
• the presence of an alternative diagnosis 
that likely explained the pulmonary 
symptoms and x-ray infiltrate (e.g. lung 




✓ ✓ ✓ 
Cangemi156 2019 Single-centre 
prospective 
cohort 
Italy Oct 2011- 
Oct 2018 
Adults ≥18 years 
Mean age: 70.4 (16.8) 
Male: 62.9% 
Follow-up: Hospitalisation, 
median LOS 11 days (IQR 9-
15) 
• pre-existing permanent or persistent AF 
• severe sepsis  
• immunosuppression 
• presence of malignancy 
• pregnancy, or breastfeeding. 
472   ✓  
Pieralli157 2019 Multicentre 
prospective 
cohort 
Italy Nov 2013- 
July 2016 
Adults ≥18 years, sinus 
rhythm confirmed by ECG on 
admission, no previous 
documented episodes of AF 
Mean age: 75.5 (14.4) 
Male: 48% 
Follow-up: Hospitalisation, 
mean LOS 9.5 (SD 5.1) 
• HAP 
• immunocompromised 








4.3.2 Risk of bias 
Based on the chosen a priori scores, 33 studies were of high-quality and 14 studies were 
of low to moderate quality (Table 4-2). In the risk of bias assessment for study selection 
domain, 20 of 47 studies (42.3%) were judged to have an element of selection bias; 17 
studies had patients who may not have been truly representative of patients with CAP 
and cardiac complications due to a combination of selected group of certain age, 
predominantly male population and from ICU cohort, and in eight studies, there was no 
explicit statement that the cardiac complication was not present at the start of the study. 
For studies that adjust for confounders, in the comparability of the sample groups 
domain, three of 18 studies (16.7%) did not control for the a priori confounder, age. As 
for the ascertainment of outcome domain, 20 of 47 studies (42.6%) were at some risk of 
bias, generally attributable to lack of description of the assessment of confirmation of the 
cardiac complications (n=18 studies). In the remaining two studies, one did not describe 





Table 4-2: Risk of bias for included studies (using Newcastle Ottawa Scale) 
Cohort studies, maximum score= 5 




  Selection Outcome 
Total 
(max=5) 
Esposito 1984 1 1 2 
Allen 1984 1 0 1 
Marrie 1989 2 1 3 
Fine 1990 3 1 4 
Venkatesan 1990 3 1 4 
Leroy 1992 1 1 2 
Woodhead 1992 2 1 3 
Musher 2000 2 1 3 
Fernande-Sabe 2003 3 1 4 
Martinez-Moragon 2004 2 1 3 
Menendez 2004 2 1 3 
Querol-Ribelles 2004 2 1 3 
Diaz 2005 2 1 3 
O'Meara 2005 2 2 4 
Marrie 2005 2 1 3 
Becker 2007 2 2 4 
Musher 2007 3 2 5 
Aliberti 2008 2 1 3 
Cabre 2008 1 1 2 
Ramirez 2008 2 2 4 
Griffin 2013 3 2 5 
Dutt  2014 3 2 5 
Tang  2014 2 2 4 
Bello  2015 3 1 4 
Cangemi 2015 3 2 5 
Chen 2015 3 2 5 
Frencken 2017 2 2 4 
Violi 2017 3 2 5 
 
Cohort studies, maximum score= 7 





Selection Comparability Outcome 
Total 
(max=7) 
Mandal 2011 3 2 2 7 
Morlacchi 2011 3 2 1 6 
Perry 2011 2 2 2 6 
Corrales-Medina 2009 3 2 2 7 
Corrales-Medina 2012 3 2 2 7 
Griffin 2013 3 2 2 7 




Cangemi 2014 3 2 2 7 
Corrales-Medina 2014 3 2 2 7 
Aliberti 2015 3 2 2 7 
Shebl 2015 3 0 2 5 
Violi 2015 3 1 2 6 
Zhang 2016 3 2 1 6 
Eurich 2017 3 2 1 6 
Cilli 2018 2 2 2 6 
Cangemi 2019 3 2 2 7 
Pieralli 2019 3 2 2 7 
 
Case-control studies, maximum score= 9 




  Selection Comparability Outcome 
Total 
(max=9) 
Aliberti 2016 4 1 2 7 
 
These scores were based on three broad categories; (1) selection of the study sample, (2) 
comparability of the sample groups (for studies that adjust for confounders, age was a priori 
confounder) for studies investigating the risk factors for developing cardiac complications and (3) 
ascertainment of exposure and outcome. 
 
4.3.3 Incidence of cardiac complications after CAP 
Table 4-3 and Fig 4-2-Fig 4-14 show the incidence of cardiac complications after CAP. 
Three studies which reported data on overall cardiac complications in-hospital were 
included in the meta-analysis, and the pooled proportion was 6.4% (95% CI 1.0-15.4) 
(Table 4-3, Fig 4-2). Two studies that were not included in the meta-analysis reported 
cardiac complications at different time-points; on admission: 14.7%37, ≤7 days: 23.8%37 
and at 30 days: 8.7%.123 Meta-analyses were conducted to summarise the incidence of 
individual cardiac complications after CAP; 27 studies for ACS, 25 studies for heart failure 
and 28 studies for arrhythmia. Across all three cardiac complications, most studies 
reported in-hospital incidence (Table 4-3). The highest pooled proportion was noted for 
in-hospital incidence for ACS (3.1%, 95% CI 2.2-4.0), and arrhythmia (7.9%, 95% CI 5.3-




CI 4.3-18.4). One study (n=502) was not included in the meta-analysis for incidence of 
arrhythmia after CAP as it reported a range of 2-4 patients developed AF in-hospital.114 
 
Table 4-3: Incidence of cardiac complications after CAP 
Cardiac 
complications 




% (95% CI) 
Overall In-hospital 3 6.4% (95% CI 1.0-15.4) 
ACS 
   
 
On admission 4 2.2% (95% CI 0.9-4.2)  
In-hospital 22 3.1% (95% CI 2.2-4.0)  
30 days 5 2.0% (95% CI 1.3-2.8)   
90 days 1 1.1% (95% CI 1.1-1.2)  
Heart failure 
   
 
On admission 3 3% (95% CI 1.4-5.0)  
In-hospital 19 7.7% (95% CI 4.4-11.9)   
30 days 4 10.3% (95% CI 4.3-18.4)   
90 days 2 8.6% (95% CI 8.4-8.9)   
1 year 2 3.3% (95% CI 2.8-3.7)  
Arrhythmia 
   
 
On admission 3 3.8% (95% CI 2.7-5.0)   
In-hospital 23 7.9% (95% CI 5.3-11.0)   
30 days 5 4% (95% CI 1.2-8.2)  
Definition of ‘overall’ cardiac complications: Leroy et al118: ‘acute coronary or ventricular insufficiency’, 
Martinez-Moragon122: ‘cardiac’ complications and Bello et al144: a combination of MI, heart failure and 






Overall cardiac complications 
Fig 4-2: Forest plot of proportions of in-hospital overall cardiac complications after 
community-acquired pneumonia 
 
Definition of ‘overall’ cardiac complications: Leroy et al118: ‘acute coronary or ventricular insufficiency’, 










Fig 4-4: Forest plot of proportions of ACS in-hospital after community-acquired 
pneumonia 
 


















Fig 4-8: Forest plot of proportions of heart failure in-hospital after community-acquired 
pneumonia 
 

















Fig 4-12: Forest plot of proportions of arrhythmia on admission after community-
acquired pneumonia 
 













4.3.4 Risk factors for developing cardiac complications 
Thirteen studies reported risk factors of developing cardiac complications; eight studies 
on overall cardiac complications (Table 4-4), two studies on ACS, one study on heart 
failure and four studies on arrhythmia (Table 4-5). All studies reported the outcome from 
multivariate analysis as odds ratios with their respective confidence intervals, except for 
two studies; Shebl et al147 reported univariate association and Morlacchi et al135 reported 
association from multivariate analysis without the breakdown of figures. The only risk 
factor that could be included in the meta-analysis was age (per year increase); pooled OR 
1.02, 95% CI 1.00-1.04, p=0.017, I2=70.6%, n= 4 studies. Other than age, pre-existing 
cardiac disease was a commonly reported risk factor with strong association for 
development of cardiac complications. In addition, haemodynamic instability 
(tachypnoea, tachycardia and septic shock) was observed to be a strong risk factor 
although counterintuitively, CAP severity (measured by Pneumonia Severity Index score) 
was not. A number of laboratory and radiological findings were found to be associated 
with cardiac complications, with K. pneumonia and hypoalbuminaemia being the 






Table 4-4: Risk factors for developing overall cardiac complications in-hospital, at 30 days 
and at 1 year 
Risk Factors Author Year adjusted OR (95% CI) 
    
Demographics    
Age    
per year  Corrales-Medina* 2012 1.03 (1.02-1.04) 
 Griffin 2013 1.01 (1.00-1.02) 
 Zhang# 2016 1.71 (1.07-3.84) 
 Cilli 2018 1.02 (1.00-1.05) 
>65 Viasus 2013 1.78 (1.28-2.47) 
Gender    
Male Griffin 2013 0.84 (0.66-1.08) 
        
Co-morbidities    
Cardiac    
Heart failure Corrales-Medina* 2012 4.30 (3.00-6.30) 
Cardiac arrhythmia Corrales-Medina* 2012 1.80 (1.20-2.70) 
Coronary heart disease Corrales-Medina* 2012 1.50 (1.04-2.00) 
Hypertension Corrales-Medina* 2012 1.50 (1.10-2.10) 
Chronic heart disease Viasus 2013 3.05 (2.28-4.08) 
Hyperlipidaemia Griffin 2013 2.01 (1.33-3.05) 
Non-cardiac    
CKD Viasus 2013 1.49 (0.96-2.30) 
DM Viasus 2013 1.16 (0.84-1.59) 
CVD Viasus 2013 1.04 (0.68-1.60) 
Anaemia  Viasus 2013 1.22 (0.77-1.96) 
        
History & Examination findings    
RR≥30/ min Corrales-Medina* 2012 1.60 (1.10-2.30) 
Tachycardia  Viasus 2013 1.61 (1.21-2.13) 
Septic shock Viasus 2013 1.70 (1.03-2.56) 
Altered mental status Viasus 2013 0.98 (0.67-1.41) 
Pleural effusion Corrales-Medina* 2012 1.60 (1.10-2.40) 
 Cilli 2018 2.06 (0.96-4.41) 
        
Laboratory and radiological findings   
BUN ≥30mg/dL Corrales-Medina* 2012 1.50 (1.10-2.20) 
Sodium <130 mmol/L Corrales-Medina* 2012 1.80 (1.02-3.10) 
Haematocrit <30% Corrales-Medina* 2012 2.00 (1.30-3.20) 
S. aureus Griffin 2013 1.61 (1.02-2.86) 
K. pneumoniae Griffin 2013 2.95 (1.05-8.68) 
Multilobar pneumonia Viasus 2013 1.36 (1.03-1.81) 
Hypoalbuminaemia  Viasus 2013 2.33 (1.74-3.12) 
Pneumococcal pneumonia Viasus 2013 1.39 (1.05-1.38) 
sCD40L >6.0ng/ml Cangemi 2014 1.23 (1.15-1.33) 




Serum TxB2 >200 ng/ml Cangemi 2014 1.08 (1.01-1.17) 
Mean platelet volume Cangemi 2014 1.03 (1.00-1.05) 
pro-B-type BNP Zhang# 2016 2.38 (1.53-6.79) 
CRP Zhang# 2016 2.43 (0.77-11.4) 
ESR Zhang# 2016 1.01 (0.69-1.31) 
Cardiac troponin I Zhang# 2016 1.83 (0.80-7.29) 
Hypoalbuminaemia Cilli 2018 2.74 (1.12-6.17) 
        
Medications    
Statin therapy Griffin 2013 0.52 (0.33-0.84) 
Empiric macrolide therapy Griffin 2013 0.81 (0.64-1.03) 
Diuretic  Cilli 2018 2.71 (1.42-5.15) 
Haloperidol  Cilli 2018 3.21 (1.64-6.30) 
Vasopressor  Cilli 2018 2.71 (1.43-5.12) 
        
Severity of CAP    
PSI score Griffin 2013 1.02 (1.01-1.02) 
 Cangemi 2014 1.00 (1.00-1.00) 
 Zhang 2016 1.36 (1.02-3.21) 
All studies investigated the risk factors in-hospital except Corrales-Medina* et al.37 at 30 days and Zhang# et 
al.158 at 1 year. 
Letters in grey were not found to be statistically significant. 
BNP: brain natriuretic peptide, CRP: C reactive protein, ESR: erythrocyte sedimentation rate, PSI: pneumonia 
severity index, sCD40L: soluble CD40 ligand, sP-selectin: plasma soluble P-selectin, serum TxB2: serum 
thromboxane B2, DM: diabetes mellitus, CKD: chronic kidney disease, RR: respiratory rate, BUN: blood urea 




Table 4-5: Risk factors of developing individual cardiac complications after CAP  
ACS 
Author Year Country Time Type of ACS Risk factor aOR (95% CI) Confounders adjusted for  
Mandal  2011 Scotland In-hospital NSTEMI/ unstable angina Age≥ 65 4.73 (2.50–8.95)  Age, gender, co-morbidities, smoking 
history, site of care, including admission to 
ICU 
     
Previous MI 1.47 (1.01–2.17)  
    
STEMI Age≥ 65 14.0 (4.39–44.8)       
Previous MI 1.62 (1.26–2.07)       
COPD 2.01 (1.12–3.60)       
Renal failure 1.90 (1.01–3.55)  
Aliberti 2015 Italy, 
Switzerland 
In-hospital Acute MI Female 2.72 (1.02-7.25) Age, CCF, cerebrovascular disease, acute 
respiratory failure on admission, nursing 
home residency, liver disease, CKD 
     
Severe sepsis on 
admission 
4.33 (1.55-12.1) 
     
Liver disease 5.82 (1.83-18.6) 
 
Heart failure 
Author Year Country Time Risk factor aOR (95% CI) Confounders adjusted  
Perry 2011 US 90 days Increasing age 1.03 (1.02-1.03) Gender, marital status, smoking, 
liver disease, peptic ulcer disease, 
unstable angina, CVD 
    
ICU admission 2.08 (1.85-2.34)     
Diabetes (complicated) 1.29 (1.12-1.47)     
Diabetes (uncomplicated) 1.36 (1.25-1.49)     
Renal disease 1.25 (1.11-1.41)     
Malignancy 0.78 (0.71-0.86)     
Metastatic cancer 0.57 (0.44-0.74)     
PVD 1.12 (1.01-1.24)     
Hemi/ paraplegia 0.54 (0.37-0.77)     
Rheumatoid arthritis/ 
collagen vascular disease 
1.30 (1.06-1.60) 
    
MI 1.25 (1.09-1.42)     





Author Year Country Time Type of arrhythmia Risk factor aOR (95% CI) Confounders adjusted 
Mandal  2011 Scotland In-hospital AF Age≥ 65 5.70 (4.21–7.71)  Age, gender, co-morbidities, smoking 
history, site of care, including admission to 
ICU 
     
Previous MI 1.37 (1.01–1.87)       
DM 1.53 (1.28–1.84)  
Perry 2011 US 90 days Symptomatic bradycardia, 
AF, ventricular fibrillation or 
tachycardia, and cardiac 
arrest. 
Increasing age 1.03 (1.02-1.03) Gender, marital status, smoking, liver 
disease, peptic ulcer disease, unstable 
angina, CVD, PVD, renal disease, 
malignancy, rheumatoid arthritis/ collagen 
vascular diseases, MI, unstable angina 
    
ICU admission 3.59 (3.21-4.01)     




    
CCF 1.13 (1.03-1.24) 
Violi 2015 Italy In-hospital AF PSI score 1.02 (1.01-1.04) High-sensitivity cardiac troponin T      
History of PAF 17.27(7.89-37.82) 
     
Soluble Nox2 level 1.04 (1.01-1.07) 
Pieralli  2019 Italy In-hospital AF CURB-65 (each 
point) 
1.41 (1.03-1.92) Age, sex, chronic kidney disease, 
dementia, cancer, chronic liver disease, 
COPD, severity of pneumonia  
     
CHA2DS2VASc> 3 2.30 (1.19-4.44) 
Cangemi 2019 Italy In-hospital AF Enlarged LAAi 5.41 (2.56-11.92) Age, PSI score, hypertension, CHD, 
ejection fraction 
     
Concentric LVH 2.21 (1.06-4.59)      
Paroxysmal AF 11.69 (5.77-23.69) 
PSI: pneumonia severity index, DM: diabetes mellitus, COPD: chronic obstructive pulmonary disease, AF: atrial fibrillation, PAF: paroxysmal AF, PAD: peripheral arterial disease, CKD: chronic kidney 
disease, RR: respiratory rate, BUN: blood urea nitrogen, BP: blood pressure, PVD: peripheral vascular disease, ICU: intensive care unit, CCF: congestive cardiac disease, LAAi: left atrial area index, LVH: 




4.3.5 Mortality associated with cardiac complications 
Meta-analysis of seven studies showed that patients who had cardiac complications after 
admission for CAP were more likely to die than those who did not (Fig 4-15); in-hospital: 
pooled OR 3.45, 95% CI 2.38-4.99, I2=24.5%, n=5 studies and at 30 days: pooled OR 2.65, 
95% CI 1.24-5.68, I2=92%, n=3 studies). Three studies reported results from multivariate 
analysis37,138,155. One study reported adjusted hazards ratio for in-hospital cardiac 
complications, aHR 1.76 (95% CI 1.10-2.82, p=0.019).145  
Fig 4-15: Forest plot of mortality associated with overall cardiac complications after CAP 
 
 
Meta-analysis of two studies showed that patients who developed ACS in-hospital after 
admission for CAP were four times more likely to die than those who did not (pooled OR 




Fig 4-16: Forest plot of mortality associated with ACS after CAP 
 
 
Seven studies reported data on mortality associated with cardiac complications at 
different time points, therefore were not included in the meta-analysis (Table 4-6). 
Table 4-6: Mortality associated with cardiac complications 
Cardiac 
complication 
Author Year Time of 
outcome 




2003 < 48 hours Heart failure or 
cardiac 
arrhythmias 
4/ 1474 0.3 - 
 Zhang 2016 1 year Cardiac  4/372 1.1 - 
ACS 
 Violi 2017 In-hospital - 7/1182 0.6 - 
 Musher 2007 In-hospital - 5/170 2.9 - 
 Mandal 2011 90 days NSTEMI/ unstable 
angina 
- - 1.46 (0.82-2.76) 
 
   
STEMI - - 1.93 (1.6-2.33) 
Heart failure 
 Viasus 2013 ≤ 30 days - - - 3.94 (2.94-5.28) 
 Musher 2007 In-hospital - 4/170 2.4 - 
 Bello  2015 30 days - 1/265 0.4 - 
 
  
181 days- 1 
year 
- 2/265 0.8 - 
 
  
1- 2 years - 3/265 1.1 - 
 
  
2- 3 years - 2/265 0.8 - 
Arrhythmia 
 Viasus 2013 ≤ 30 days - - - 3.36 (2.47-4.57) 






Four studies described various biomarkers as being associated with developing cardiac 
complications. Violi et al. found elevated serum levels of soluble Nox2, a marker of Nox2-
derived oxidative stress activity, was independently associated with increased risk of 
developing in-hospital AF; aOR 1.04 (95% CI 1.01-1.07, p=0.01).149 Zhang et al. found that 
N-Terminal pro-B-type brain natriuretic peptides (NT-pro BNP) was associated with major 
adverse cardiac events, which was a composite outcome of cardiac mortality, heart 
failure and ACS; OR 2.38 (95% CI 1.53-6.79, p=0.009).151 Shebl et al. found three 
biomarkers associated with cardiac complications including procalcitonin (mean level 
(ng/mL) higher in those with cardiac complications than those without; 20 (SD 3.2) vs 5.2 
(SD 1.3), p<0.05), NT-BNP (OR 10.47 (95% CI4.14-26.51), p<0.0001) and troponin I (OR 
6.98 (95% CI 2.74-17.79), p <0.0001).147 Cangemi et al. found platelet activation markers 
were associated with development of myocardial infarction (MI); plasma soluble P-
selectin >26ng/ml (aOR 1.23 (95% CI 1.14-1.33), p<0.001), soluble CD40 ligand> 6ng/ml 
(aOR 1.23 (95% CI 1.15-1.33), p<0.001) and serum thromboxane B2 >200 ng/ml (aOR 1.08 
(95% CI 1.01-1.17), p 0.030). In addition, mean platelet volume was also found to be 





4.4.1 Principal findings 
To our knowledge, this is the first study to quantify the incidence of overall cardiac 
complications, and individual cardiac complications by time of occurrence following 
hospitalisation for CAP. Our study included 134,966 patients from 47 studies. The 
commonest incidence reported was in-hospital incidence; overall cardiac complications: 
6.4%.; ACS: 3.1%, heart failure: 7.7% and arrhythmia: 7.9%. Risk factors for incident 
cardiac complications were explored in the past decade, and the commonly reported risk 
factors include older age, severity of pneumonia and pre-existing cardiac disease. Our 
study is the first to summarise the effect of cardiac complications after hospitalisation for 
CAP on mortality; patients who developed cardiac complications were approximately 
three times more likely to die both in-hospital (OR 3.45) and within 30 days (OR 2.65) of 
admission than those who did not. 
 
4.4.2 Strengths and limitations of the study 
This review comprehensively summarises the current body of knowledge regarding 
cardiac complications after hospitalisation for CAP and was reported in accordance with 
PRISMA checklist. Eligibility criteria were strictly applied to ensure identified studies only 
included patients with radiological confirmation of CAP. Studies with a composite 
outcome for cardiovascular complications were excluded, ensuring studies with only 
cardiac complications were included. Individual cardiac complications including ACS, new 
or worsening heart failure and new or worsening arrhythmia were well-defined in most 
studies, particularly in those conducted over the past decade. Overall, most included 





There are a few limitations that warrant discussion. Firstly, the various was the way in 
which ‘overall cardiac complications’ was defined; studies reported it as ‘cardiac’ 
complications without a breakdown of which specific conditions were included, a 
combination of MI, heart failure and arrhythmia or as ‘acute coronary or ventricular 
insufficiency’. Secondly, where available, we stratified the incidence of cardiac 
complications to ‘on admission’ and ‘in-hospital’ categories. It is possible that some 
studies may have included ‘on admission’ cardiac complications into the ‘in-hospital’ 
category, resulting in bias of classification. Thirdly, there was a significant heterogeneity 
among studies included for the meta-analyses which may be due to differences in CAP 
severity on admission, underlying co-morbidities, healthcare systems and other 
unidentified covariates. Fourthly, we included studies with patients who were 
hospitalised for CAP. Therefore, cardiac complications in patients with low severity CAP 
managed in the community were not assessed in this study. 
 
4.4.3 Comparison with other studies 
Similar to our study, Fine et al. in 1996 reported a pooled incidence rate of 8.6% (95% CI 
6.4-12.3) for heart failure (n=4 studies, 232 patients) following hospitalisation for CAP, 
however the duration of follow-up for the occurrence of heart failure was not 
specified.106 The incidence of overall cardiac complications in our study cannot be 
compared with previous published reviews as they included studies with cardiovascular 
complications. In comparison to our study, the meta-analysis by Corrales-Medina et al. 
reported a notably higher pooled proportion of ACS (5.3%, 95% CI 3.2-8.6) and heart 
failure (14.1%, 95% CI 9.3-20.6) but lower pooled proportion for arrhythmia (4.7%, 95% CI 
2.4-8.9) within 30 days of admission CAP.159 Our pooled proportion of arrhythmia is 
similar to that reported by Tralhao et al. (7.2%, 95% CI 5.6-9.0) but they reported higher 




There are two main differences between our study compared to the study by Tralhao et 
al.; firstly, we used the standard of two independent investigators for study selection in 
systematic reviews compared to a single investigator in Tralhao et al. and secondly, we 
stratified the meta-analyses of the incidence of cardiac complications by the time of 
occurrence of cardiac complications whereas Tralhao et al. did not.160 For example, heart 
failure which occurred in-hospital and 90 days were combined in their analysis without 
making a distinction of the short- and medium/long-term risk of cardiac complications 
after CAP. 
 
The differences observed between our study and the previous reviews may due to the 
way we stratified our study cohorts into ‘on admission’ and ‘in-hospital’ instead of 
combining these and change in the incidence of cardiac complications over time. The 
annual age- and sex-adjusted incidence rate of patients hospitalised for acute MI has 
remarkably reduced from 2000- 2008 by a third, partly due to improvement in the 
primary prevention strategies.161 A study of 4 million patients in the UK revealed that the 
overall age and sex standardized incidence rate of heart failure has declined by 7% over 
12 years, which would be in keeping with the decline in our pooled incidence rate.162 
However, the total number of new cases and the prevalence of heart failure has 
substantially increased, as a result of a rise in the aging population, better medical 
management of heart failure as well as other underlying co-morbidities and longer 
survival after heart failure diagnosis. An increasing trend of age-adjusted incidence and 
prevalence of atrial fibrillation was shown from the analysis of the Framingham cohort 
over 50 years, although this may be partly due to enhanced surveillance.163 
 
In a wider context, a meta-analysis of 16 studies showed that recent influenza infection 




infection) was significantly more likely in AMI cases; pooled OR 2.01 (95% CI 1.47-2.76).164 
Similar to CAP, patients with influenza infection are at higher risk of cardiac complications 
such as new or worsening of heart failure and arrhythmia in the setting of influenza-
associated myocarditis.165 
 
4.4.4 Cardiac complications after CAP: mechanisms 
The potential underlying mechanisms for the association of CAP and cardiac events have 
been extensively reviewed.166–169 Acute coronary syndrome covers a spectrum of 
pathologies including unstable angina, non-ST-elevation MI (NSTEMI) and ST-elevation MI 
(STEMI). With regards to CAP, the two clinically relevant acute MI types are: i) Type 1 MI, 
which occurs secondary to plaque rupture, ulceration or fissuring resulting in thrombus 
formation, reducing myocardial blood flow or distal embolisation and subsequent 
myocardial necrosis, and ii) Type 2 MI, which is an imbalance between oxygen supply and 
demand caused by a condition other than coronary plaque, leading to myocardial 
necrosis.170 Streptococcus pneumonia, the primary causative organism for CAP can drive 
cardiac damage via several mechanisms including causing enlargement of atherosclerotic 
plaques171, directly invading the myocardium, resulting in necroptosis and apoptosis172–
174, and promoting platelet activation, resulting in procoagulant state175. Irrespective of 
the causative pathogen, CAP itself is associated with the activation of systemic 
coagulation, increasing the risk of thrombus formation.176 Lung consolidation in CAP 
impairs gas exchange, resulting in arterial hypoxaemia, which is followed by ventilation-
perfusion mismatch.177 Upregulation of the sympathetic nervous system leads to sinus 
tachycardia, which increases myocardial oxygen demand (Type 2 MI) and results in a drop 





Myocardial dysfunction and increased myocardial oxygen requirements also increase the 
cardiac workload and risk of heart failure.178 Meta-analysis of 31 studies, mostly based on 
polymerase-chain reaction based diagnostic tests showed that viral infection was 
detected in 24.5% of patients with CAP, increasing to 44.2% in studies that obtained 
lower respiratory samples in >50% of the patients.179 Viruses including influenza virus, 
respiratory syncytial virus and adenovirus, and to a lesser extent, bacteria such as S. 
pneumoniae , H. influenzae and M. pneumoniae can result in myocarditis, which could 
cause dilated cardiomyopathy and arrhythmia.180  
 
Atrial fibrillation is the most common cardiac arrhythmia reported after CAP. Acute 
illness, such as CAP is a known risk factor for incident AF.181 Pneumolysin, a pore-forming 
toxin produced by S. pneumoniae can trigger calcium overload which mediates 
mechanical and electrical disturbance to cardiac cells’ function, resulting in arrhythmia.182 
 
4.4.5 Implications for clinicians and policymakers 
Mortality  
In general, several studies have shown a sustained decrease in the mortality for acute MI 
over time due to major improvements in the delivery of care for patients with AMI, 
especially with more frequent use of revascularisation techniques and adjunctive 
evidence-based therapies.183–188 The temporal trends in mortality after incident heart 
failure in the UK showed that although there was a decline in cardiovascular mortality 
due to considerable improvements in heart failure care, there was a significant trend of 
increase in non-cardiovascular deaths, particularly secondary to infections which 
accounted for the largest absolute increase over the 11-year period and chronic 
respiratory conditions.189 Further analysis of causes of death due to infections revealed 




causes of death (2013 vs 2002, RR 1.59, 95% CI 1.26-1.99). In contrast, despite the 
continued high mortality associated with heart failure, there was no difference in 
mortality rate from the Framingham and Cardiovascular Health Study cohorts combined 
from 1990-2009 in US.190 As for mortality in patients with incident AF between 1998-
2010, a mortality reduction was seen in patients aged 55-74 (IRR 0.97, 95% CI 0.95-0.99) 
but no difference in those aged ≥75 years.191 
 
Despite the trend of mortality reduction in some cardiac complications, our study showed 
that cardiac complications following CAP is associated with high risk of mortality; patients 
with cardiac complications were almost three times more likely to die both in-hospital 
and within 30 days of discharge compared to those without. In view of the associated 
high mortality, a high index of suspicion for cardiac complications is needed particularly 
in patients with suboptimal response to standard CAP treatment. These patients should 
be promptly investigated and managed effectively to prevent the progression of the 
cardiac complications.  
 
Risk factors and biomarkers 
Our study showed that the risk factors for developing cardiac complications after CAP 
include older age, pre-existing cardiac disease and haemodynamic instability. There is yet 
a validated prediction tool that clinicians can easily use to identify patients who are at 
high risk of developing cardiac complications when hospitalised for CAP. The role of 
cardiac biomarkers including troponin, BNP, procalcitonin, soluble Nox2 and platelet 






This study substantiates that most cardiac complications occur within 30 days of 
hospitalisation for CAP, however only few studies evaluated the incidence of cardiac 
complications in the medium- (90 days) to long-term (1 year) period after CAP. The 
associated high mortality highlights an urgent need for tailored public health prevention 









Chapter 5 Matched cohort study of 
cardiac complications in adults 





5.1 Introduction  
As discussed in the previous chapter, most studies from the past decade investigated the 
incidence of cardiac complications during hospitalisation, and only few studies 
investigated the incidence at 30 days and 90 days. None of these studies were from the 
UK.  
 
The aims of this study were to determine the incidence of cardiac complications after 
hospitalisation for pneumonia at 30 days, 90 days and 1 year, and the associated risk 
factors, when compared to the general population in a matched cohort study in England. 
 
5.2 Methods 
5.2.1 Data sources  
Hospitalisation data from Hospital Episode Statistics (HES, England), linked to the Clinical 
Practice Research Datalink (CPRD), a UK Government research service that provides 
anonymised electronic health records from general practices, and death registration data 
from Office for National Statistics (ONS), were used for this study.  
 
5.2.2 Study population and follow-up 
Adults aged ≥18 years with the first episode of hospitalisation for pneumonia (index date) 
recorded in HES between 1 July 2002 and 30 June 2017 were included. Pneumonia was 
defined based on J12- J18 ICD-10 codes recorded as the primary code for the first episode 
of hospitalisation. Patients were excluded if they a) had less than a year of time 
registered to the practice before admission, b) hospital-acquired pneumonia (admission 




existing heart failure or arrhythmia for respective analysis. Up to 10 patients without 
pneumonia in CPRD were matched with each patient with pneumonia based on gender, 
age within a year of the index date and general practice. Controls were assigned the 
same index date as their matched cases. Patients for the matched cohort were eligible for 
inclusion if their record was labelled as acceptable by CPRD quality control.58 
Patients were followed up from day one after the date of discharge from hospital to 
either the date of cardiac complications, end of data collection (30 June 2017), date of 
transfer out of practice, date of last data collection for the practice or date of death, 
whichever came first. 
 
5.2.3 Definition of outcome 
Cardiac complications were defined as i) acute coronary syndrome (ACS) including 
unstable angina, non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation 
myocardial infarction (STEMI), ii) new-onset heart failure (HF) or iii) new-onset 
arrhythmia using a combination of ICD-10 codes in HES and medical Read codes in CPRD 
(identified through medical dictionary keyword searches, previously published literature 
and online clinical code repositories) (Appendix 6). 
 
5.2.4 Statistical analysis 
Descriptive statistics for the patient population were calculated. Patient characteristics 
were stratified according to the presence or absence of cardiac complications during 
follow-up. ‘Time to first cardiac complication’ was measured at different time intervals; 
from the ‘start date’ of either day one, day 31 or day 91 after discharge from hospital to 
either the first hospital admission or first presentation to primary care with a cardiac 




different time intervals were determined; 30 days, 31-90 days, and 91 days to 1 year. The 
probability of experiencing cardiac complications during follow-up was plotted using the 
Kaplan-Meier plot and log-rank test was used to examine any difference between the two 
groups of patients. Following review of published literature, directed acyclic graph (DAG) 
was used to identify the minimum sufficient adjustment set of confounders, which 
included age, gender, comorbidities (measured using Charlson Comorbidity Index), and 
smoking status (never smoked, ex-smokers, current smokers, unknown) (Fig 5-1). 
Multivariate competing-risks regression analysis was conducted to determine the risk of 
developing cardiac complications between the patients with and without pneumonia, 
with death as a competing event. Data management and statistical analyses were 





Fig 5-1: Directed Acyclic Graph illustrating the association between admission for 




* Severity of pneumonia, haemodynamic instability, medications and laboratory and radiological 






The overall study cohort comprised 55,808 patients with pneumonia and 438,398 age, 
gender and practice-matched patients without pneumonia (Table 5-1). The median ages 
of patients with and without pneumonia were 73 years (IQR 59-83) and 71 (56-80), 
respectively. Gender distribution was roughly equal in patient with and without 
pneumonia, 49.0% vs 48.6% male. Median follow-up was 1.9 years (IQR 0.5-4.3) in 
patients with pneumonia and 3.4 (1.6-6.3) in patients without pneumonia, with marginal 




Table 5-1: Characteristics of patients with and without pneumonia at 30 days, categorised by cardiac complications (ACS, heart failure and arrhythmia) 




















Age y, median (IQR) 73 (59-83) 71 (56-80) 72 (57-82) 71 (56-80) 71 (56-82) 71 (56-80) 
18-49 8099 15.6 78991 18.0 8037 17.1 78991 18.0 8041 17.9 78991 18.0 
50-64 8716 16.8 83995 19.2 8388 17.9 83995 19.2 8330 18.6 83993 19.2 
65-74 10332 19.9 95619 21.8 9480 20.2 95610 21.8 9196 20.5 95604 21.8 
75-84 14351 27.7 119203 27.2 12396 26.4 119133 27.2 11477 25.6 119074 27.2 
≥85 10357 20.0 60581 13.8 8610 18.4 60310 13.8 7805 17.4 60133 13.7 
Gender                         
Male 25424 49.0 213008 48.6 22840 48.7 212813 48.6 21788 48.6 212683 48.6 
Female 26431 51.0 225381 51.4 24071 51.3 225226 51.4 23061 51.4 225112 51.4 
Smoking status                         
Never 11459 22.1 137513 31.4 10446 22.3 137400 31.4 9942 22.2 137454 31.4 
Ex 8059 15.5 66784 15.2 7050 15.0 66670 15.2 6589 14.7 66731 15.2 
Current 31047 59.9 211348 48.2 28212 60.1 211253 48.2 27126 60.5 211314 48.2 
Unknown 1290 2.5 22744 5.2 1203 2.6 22716 5.2 1192 2.7 22742 5.2 
Charlson Comorbidity 
Index                         
0 13110 25.3 221822 50.6 13110 27.9 221764 50.6 12477 27.8 221713 50.6 
1 11547 22.3 82972 18.9 11142 23.8 82912 18.9 10402 23.2 82864 18.9 
2 9062 17.5 60135 13.7 8239 17.6 60056 13.7 7704 17.2 60009 13.7 
3 6974 13.4 35659 8.1 6064 12.9 35596 8.1 5719 12.8 35555 8.1 
4 4519 8.7 18287 4.2 3595 7.7 18249 4.2 3553 7.9 18225 4.2 




The most common cardiac complication after hospitalisation for pneumonia was new-
onset heart failure, followed by new-onset arrhythmia and ACS. The proportion of cardiac 
complications is listed in Table 5-2. 






30 days 31-90 days 91-365 days 
ACS 282 (0.5) 196 (0.4) 534 (1.0) 1012 (1.8) 
Heart failure 703 (1.3) 553 (1.0) 949 (1.7) 2205 (3.9) 
Arrhythmia 693 (1.2) 353 (0.6) 651 (1.2) 1697 (3.0) 
 
The incidence rates of all cardiac complications were the highest within 30 days of 
discharge following hospitalisation for pneumonia, after which the rate declined (Table 
5-3).  
Table 5-3: Incidence rates (per 1000 person-years) of ACS, HF and arrhythmia after 
hospitalisation for pneumonia. 
Cardiac 
disease 
Incidence rate (/1,000 person-years) 
(95 % CI) 
30 days 31-90 days 91-365 days 
ACS 64.3 (57.2-72.3) 23.2 (20.1-26.6) 15.9 (14.6-17.3) 
Heart failure 161.0 (149.6-173.4) 65.8 (60.5-71.5) 28.6 (26.9-30.5) 
Arrhythmia 158.9 (147.5-171.2) 42.0 (37.9-46.7) 19.6 (18.2-21.2) 
 
In addition to pneumonia, these cardiac complications may contribute to the number of 
years life lost to disease and the number of years lived with disability as a result of the 
disease. The absolute increase in events (per 10,000 patient) was observed to be greater 
in the short-term compared to long-term; 257 events between 1-30 days vs 266 events 




Table 5-4: Absolute increase in events (per 10,000 patients) in patients with pneumonia 
compared to those without pneumonia in the short and long-term. 
 1-30 days 91 days-1 year 
ACS 42 67 
Arrhythmia 115 60 
Heart failure 100 139 
Total 257 266 
 
In view of the declining trend observed with time, the subsequent results focus on 
cardiac complications that occur at 30 days and 90 days. The time to first recorded 
cardiac complication was significantly different between the patients with and without 





Fig 5-2: Kaplan-Meier plots of time to first cardiac complication in patients with and 
without pneumonia. 
 
Incidence rates by year of admission for pneumonia showed an overall decreasing trend 
for ACS, whilst an increasing trend for arrhythmia from 2002-2017 (Fig 5-3). For heart 
failure, there was a significant decrease in incidence rate from 2002-2006, after which 









Table 5-7- Table 5-7 show that patients with pneumonia were significantly at higher risk 
of developing cardiac complications than those without, with greater risk observed within 
30 days compared to 90 days. Age was a strong independent risk factor for developing 
any cardiac complications. Higher Charlson Comorbidity Index score was also identified as 
an independent risk factor across all cardiac complications. 
 
At 30 days, patients with pneumonia were almost six times more likely to develop ACS 
compared to those without pneumonia; sHR 5.82 (95% CI 4.75-7.14) (Table 5-5). The risk 
lowered by more than 50% at 90 days. Males were more likely to develop ACS at 90 days, 
































 30 days 90 days 
 
Crude sHR  
(95% CI) p value 
Adjusted sHR  
(95% CI) p value 
Crude sHR  
(95% CI) p value 
Adjusted sHR  
(95% CI) p value 
Non-pneumonia        1.00 (Reference)         1.00 (Reference)   
Pneumonia       5.82 (4.75-7.14) <0.001       2.45 (2.00-2.98) <0.001 
                          
Age                       
18-49 1.00    1.00     1.00    1.00    
50-64 8.61 (3.42-21.66) <0.001 7.04 (2.79-17.77) <0.001 7.19 (3.44-15.02) <0.001 5.59 (2.66-11.73) <0.001 
65-74 13.09 (5.30-32.28) <0.001 8.94 (3.57-22.36) <0.001 12.89 (6.31-26.34) <0.001 7.97 (3.86-16.47) <0.001 
75-84 21.54 (8.86-52.37) <0.001 13.39 (5.39-33.27) <0.001 14.99 (7.38-30.42) <0.001 8.30 (4.02-17.17) <0.001 
≥85 25.20 (10.31-61.57) <0.001 16.35 (6.54-40.90) <0.001 23.13 (11.36-47.11) <0.001 13.92 (6.66-29.12) <0.001 
Gender                         
Male 1.00          1.00         
Female 0.87 (0.72-1.06) 0.162 0.86 (0.70-1.04) 0.119 0.60 (0.50-0.71) <0.001 0.57 (0.48-0.68) <0.001 
Smoking status                         
Never 1.00          1.00         
Ex 1.57 (1.15-2.14) 0.004 1.16 (0.84-1.59) 0.366 1.73 (1.33-2.26) <0.001 1.16 (0.88-1.51) 0.292 
Current 1.54 (1.20-1.97) 0.001 1.42 (1.10-1.82) 0.006 1.50 (1.21-1.86) <0.001 1.28 (1.03-1.59) 0.028 
Unknown 0.65 (0.31-1.34) 0.242 0.91 (0.44-1.91) 0.81 0.50 (0.26-0.99) 0.047 0.72 (0.37-1.44) 0.357 




0 1.00          1.00         
1 1.83 (1.31-2.57) <0.001 1.37 (0.96-1.94) 0.079 2.57 (1.94-3.42) <0.001 1.98 (1.48-2.65) <0.001 
2 3.21 (2.35-4.39) <0.001 1.97 (1.41-2.76) <0.001 4.12 (3.14-5.42) <0.001 2.64 (1.97-3.53) <0.001 
3 2.93 (2.05-4.19) <0.001 1.66 (1.14-2.42) 0.009 4.41 (3.25-5.97) <0.001 2.62 (1.89-3.63) <0.001 
4 5.59 (3.94-7.93) <0.001 2.98 (2.05-4.35) <0.001 5.31 (3.78-7.46) <0.001 2.96 (2.06-4.25) <0.001 




Patients with pneumonia were approximately nine times more likely to develop heart 
failure at 30 days compared to those without pneumonia; sHR 8.78 (95% CI 7.55-10.22) 
(Table 5-6). Similar to ACS, the risk significantly lowered at 90 days but by just under 50%. 
Unlike ACS, males were more likely to develop heart failure at both 30 days and 90 days. 





Table 5-6: Competing-risks regression for the risk of developing heart failure in patients with and without pneumonia, and the factors associated with the 
risk of developing heart failure. 
 Heart failure 
 30 days 90 days 
 




Adjusted sHR  
(95% CI) p value 
Crude sHR  
(95% CI) p value 
Adjusted sHR  
(95% CI) p value 
Non-pneumonia        1.00 (Reference)         1.00 (Reference)   
Pneumonia       8.78 (7.55-10.22) <0.001       4.85 (4.20-5.60) <0.001 
                          
Age                        
18-49 1.00     1.00     1.00    1.00    
50-64 5.51 (2.82-10.78) <0.001 4.43 (2.25-8.69) <0.001 2.55 (1.41-4.61) 0.002 1.96 (1.08-3.56) 0.027 
65-74 12.93 (6.82-24.51) <0.001 8.50 (4.43-16.28) <0.001 7.09 (4.15-12.11) <0.001 4.26 (2.46-7.36) <0.001 
75-84 20.91 (11.14-39.24) <0.001 12.36 (6.48-23.57) <0.001 17.71 (10.58-29.65) <0.001 9.20 (5.39-15.73) <0.001 
≥85 29.03 (15.42-54.65) <0.001 17.63 (9.22-33.70) <0.001 25.58 (15.22-42.97) <0.001 13.50 (7.85-23.20) <0.001 
Gender                         
Male 1.00           1.00         
Female 0.86 (0.75-0.99) 0.039 0.80 (0.70-0.92) 0.002 0.87 (0.76-0.99) 0.041 0.79 (0.69-0.90) 0.001 
Smoking status                        
Never 1.00           1.00         
Ex 1.45 (1.17-1.80) 0.001 1.02 (0.82-1.27) 0.878 1.63 (1.33-1.99) <0.001 1.10 (0.90-1.35) 0.354 
Current 1.19 (1.00-1.42) 0.046 1.09 (0.92-1.31) 0.317 1.22 (1.04-1.44) 0.018 1.13 (0.95-1.34) 0.158 
Unknown 0.77 (0.48-1.22) 0.265 1.17 (0.73-1.87) 0.514 0.45 (0.26-0.77) 0.004 0.72 (0.42-1.25) 0.242 
Charlson Comorbidity Index                         




1 2.97 (2.31-3.81) <0.001 2.22 (1.71-2.88) <0.001 3.37 (2.63-4.32) <0.001 2.38 (1.84-3.07) <0.001 
2 3.79 (2.94-4.88) <0.001 2.26 (1.73-2.95) <0.001 4.74 (3.70-6.07) <0.001 2.57 (1.98-3.34) <0.001 
3 5.04 (3.86-6.57) <0.001 2.77 (2.09-3.68) <0.001 7.13 (5.55-9.17) <0.001 3.48 (2.66-4.56) <0.001 
4 5.82 (4.33-7.81) <0.001 3.01 (2.20-4.12) <0.001 9.15 (6.96-12.02) <0.001 4.10 (3.05-5.50) <0.001 




Compared to all cardiac complications, the highest risk was for developing arrhythmia at 
30 days; sHR 9.68, 95% CI 8.49-11.04 (Table 5-7). The risk at 90 days was a quarter of that 
observed at 30 days. Similar to ACS, males were more likely to develop arrhythmia at 90 
days, not 30 days. Current smoking was not an independent risk factor for arrhythmia, 










Table 5-7: Competing-risks regression for the risk of developing arrhythmia in patients with and without pneumonia, and the factors associated with the 
risk of developing arrhythmia. 
 Arrythmia 
 30 days 90 days 
 
















Non-pneumonia        1.00 (Reference)         1.00 (Reference)   
Pneumonia       9.68 (8.49-11.04) <0.001       2.62 (2.27-3.02) <0.001 
                          
Age                       
18-49 1.00     1.00     1.00    1.00    
50-64 5.66 (3.28-9.78) <0.001 5.26 (3.04-9.11) <0.001 11.01 (5.08-23.82) <0.001 9.78 (4.51-21.19) <0.001 
65-74 12.85 (7.62-21.67) <0.001 11.42 (6.74-19.35) <0.001 26.88 (12.67-57.03) <0.001 21.67 (10.18-46.15) <0.001 
75-84 19.51 (11.66-32.65) <0.001 17.21 (10.21-29.03) <0.001 53.00 (25.15-111.68) <0.001 41.03 (19.34-87.06) <0.001 
≥85 21.79 (12.96-36.64) <0.001 19.71 (11.62-33.40) <0.001 65.36 (30.92-138.13) <0.001 53.03 (24.90-112.93) <0.001 
Gender                         
Male 1.00           1.00        
Female 1.02 (0.91-1.16) 0.701 0.94 (0.83-1.06) 0.297 0.86 (0.77-0.97) 0.01 0.77 (0.69-0.86) <0.001 
Smoking status                         
Never 1.00           1.00        
Ex 1.28 (1.06-1.54) 0.011 1.01 (0.83-1.22) 0.921 1.60 (1.36-1.88) <0.001 1.17 (0.99-1.38) 0.066 
Current 1.05 (0.91-1.22) 0.521 1.09 (0.93-1.27) 0.275 1.10 (0.96-1.27) 0.156 1.10 (0.96-1.27) 0.168 
Unknown 0.52 (0.33-0.82) 0.005 0.64 (0.40-1.01) 0.053 0.32 (0.19-0.52) <0.001 0.40 (0.24-0.67) <0.001 
Charlson Comorbidity Index                        




1 1.84 (1.53-2.21) <0.001 1.32 (1.09-1.59) 0.004 1.88 (1.58-2.24) <0.001 1.28 (1.07-1.53) 0.006 
2 2.50 (2.08-3.01) <0.001 1.42 (1.17-1.72) <0.001 2.93 (2.48-3.47) <0.001 1.51 (1.27-1.80) <0.001 
3 2.16 (1.73-2.69) <0.001 1.12 (0.89-1.41) 0.326 3.32 (2.76-4.01) <0.001 1.55 (1.27-1.89) <0.001 
4 3.24 (2.57-4.09) <0.001 1.59 (1.24-2.02) <0.001 3.68 (2.95-4.59) <0.001 1.58 (1.25-1.99) <0.001 





5.4.1 Principal findings 
This is the first study in the UK to investigate the incidence of, and risk factors for 
developing cardiac complications after hospitalisation for pneumonia. The most common 
cardiac complication was new-onset heart failure, followed by new-onset arrhythmia and 
ACS. The incidence rates of all cardiac complications were the highest within 30 days of 
discharge. Compared to age, gender and practice-matched patients without pneumonia, 
those with pneumonia were significantly at higher risk of developing all cardiac 
complications, with the highest risk observed for developing arrhythmia at 30 days after 
discharge. The independent risk factors for developing cardiac complications include 
increasing age and higher Charlson Comorbidity Index score. 
 
5.4.2 Strengths and limitations of the study 
A key strength of this study is the large sample size of over 55,000 patients, that is 
representative of the English population with long-term follow-up. The usage of two large 
validated medical record databases, HES-CPRD linkages enabled patients with cardiac 
complications who presented to both primary and secondary care to be accurately 
identified and captured in this study. In addition, compared to previous studies which 
present simple proportions, we have presented the incidence rates of cardiac 
complications which take into account the patients who ‘dropped-out’ of the study, 
therefore reflecting a more accurate occurrence of the cardiac complications during 
follow-up.  
 
However, there are a few limitations that warrant discussion. Firstly, HES data are from 




UK. Secondly, although considerable efforts were taken to ensure data quality, we cannot 
fully exclude the possibility of information bias from miscategorisation of the study 
exposure (pneumonia), confounders (particularly smoking status) and outcomes (ACS, 
heart failure and arrhythmia) in the HES-CPRD dataset. Of those who had ICD-10 code of 
pneumonia within HES, a third of cases did not have evidence of pneumonia on the chest 
radiograph (CXR).30 Equally, CXR was found to have been classified as ‘normal’ when 
chest CT has shown parenchymal infiltrates confirming pneumonia in a third of suspected 
CAP cases.192 This suggests that it is possible for a proportion of cases thought to have 
been miscoded as pneumonia due to normal CXR were not miscoded.  As for the 
diagnosis of cardiac complications in HES-CPRD, high validity was found in both 
datasets.62,193,194 
 
5.4.3 Comparison with other studies 
The proportions of cardiac complications reported in this study were significantly lower 
compared to previous published studies. In the previous chapter, the 30-day incidence 
for ACS, heart failure and arrhythmia were 2.0% (95% CI 1.3-2.8, n=5 studies), 10.3% (95% 
CI 4.3-18.4, n= studies) and 4% (95% CI 1.2-8.2, n=5 studies) respectively.195 A possible 
explanation for the difference seen may be due to marked differences in study 
methodology (administrative data vs predominantly clinical data) and healthcare systems 
(studies included in the meta-analysis were from country with non-universal insurance 
system: US, country with universal private health insurance system: Switzerland, and 
countries with universal government-funded health system similar to the UK: Canada and 
Italy). The latter may impact access to, and utilisation of healthcare services, thus 
impacting the detection and recording of cardiac complications. This emphasizes the 
importance of country-specific data. In the same meta-analysis, the 90-day incidence for 




8.9; n=2 studies) respectively. It is noteworthy that the 90-day incidence was measured 
from date of discharge as opposed to 31-90 days as in this study. In addition, these 
studies used older data (up to 2002 with a maximum study period of six years), compared 
to this study which had latest data up to 2017 with over twice the study period. Over the 
15-year study period, there has been considerable improvement in primary prevention 
strategies resulting in lower incidence of ACS observed, similar to that found by Reynolds 
et al.161 However enhanced surveillance and better management of cardiac disease as 
well as underlying comorbidities in the aging population may have led to a higher 
incidence of heart failure and arrhythmia, in keeping with previous published 
literature.162,163  
 
The strongest risk factor for developing cardiac complications was age. This is in keeping 
with four prior studies of patients with pneumonia, irrespective of follow-up 
duration.136,138,151,155 In contrast to Griffin et al. who found that males were not associated 
with the risk of developing cardiac complications during hospitalisation, we found males 
had a higher risk, particularly at 90 days.137 Other independent risk factors include 
current smoking (for ACS) and higher Charlson Comorbidity Index score which have not 
been previously investigated.  Previous studies have shown underlying cardiac 
comorbidities such as heart failure, arrhythmia, coronary heart disease, hypertension, 
chronic heart disease and hyperlipidaemia were associated with an increased risk whilst 
non-cardiac comorbidities such as diabetes, chronic kidney disease, anaemia and 
cerebrovascular disease were not associated with the development of cardiac 
complications.136–138 
 
In the content of current COVID-19 pandemic, it is noteworthy that studies have reported 




mechanisms include direct cardiotoxicity, ACS secondary to plaque rupture or thrombosis 
(Type I MI) or supply-demand mismatch (Type II MI), myocardial injury due to 
disseminated intravascular complications and non-ischaemic myocardial injury 
(myocarditis, stress-induced cardiomyopathy, or cytokine release syndrome).197 Acute 
myocardial injury, defined by elevated serum levels of troponin T (>99th percentile upper 
reference limit) carries poorer prognosis with greater complications (acute respiratory 
distress syndrome, acute kidney injury, electrolyte disturbance and coagulation 
disorders) and higher mortality.198,199  
 
5.4.4 Implications for clinicians and policymakers 
Most cardiac complications occur within 30 days of hospitalisation for CAP, with declining 
rate at 90 days and subsequently a year after CAP. Concerted efforts should be taken to 
identify patients at risk of developing cardiac complications, especially within 30 days of 
discharge as prevention is the key to reducing the associated burden to patients. Further 
research is warranted to develop and evaluate a risk prediction tool to provide 
individualized risk assessment which could identify those at higher risk of developing 
cardiac complications. Evidence- based risk stratification policy could be used to 
implement strategies, including provision of pneumococcal and influenza vaccination to 
prevent the occurrence of pneumonia and reduce the risk of cardiac complications, 
particularly in the aging population with multiple comorbidities.200–204 The role of 
potential adjunctive therapies such as statins, antiplatelet drugs and angiotensin-
converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), in order to 
prevent the occurrence of cardiac complications is yet to be established.166 
 
An important and modifiable risk factor for ACS in patients hospitalised with pneumonia 




cardiovascular disease as well as pneumonia, with a well-described dose-dependent 
association.205,206 Current tobacco smoking status at index hospitalisation for pneumonia 
has also been shown to be independently associated with a higher risk of recurrent 
pneumonia.207 This highlights the importance of implementing effective smoking 
cessation interventions as a key component of pneumonia management, in accordance 
with the NHS Long Term Plan.93 Patients should be referred to a Stop Smoking Service 




This study corroborates that most cardiac complications occur within 30 days of 
hospitalisation for CAP, and further demonstrates that the rates decline at 90 days and 
subsequently a year after CAP. The focus should be on identifying patients at risk, 
particularly early after hospitalisation for CAP and targeting strategies to prevent cardiac 













Chapter 6 Effect of tobacco smoking on 
the risk of developing community 
acquired pneumonia: A systematic 








6.1 Introduction  
Tobacco smoking is a major cause of morbidity and mortality in high income countries 
and is an important risk factor for CAP.208 Tobacco smoking impairs mucociliary clearance 
by causing an increase in mucous production and number of abnormal cilia alongside 
reduction of ciliary beat frequency.209 Piatti et al. found that tobacco smoking modifies 
buccal epithelial surfaces which causes increased pneumococcal adherence compared to 
never smokers.210 Greater bacterial adherence may lead to greater oropharyngeal 
colonisation and hence a greater risk of developing CAP. Exposure to low levels of 
tobacco smoking or passive smoking has also been shown to be associated with 
modification in the lung cell biology similar to that seen in current smokers.211,212 
 
A recent systematic review of risk factors for CAP in adults published by Almirall et al. 
found that tobacco smoking was a significant risk factor for CAP compared to never 
smokers, however the strength of association was not quantified.26 Passive smoking has 
been shown to increase the risk of lower respiratory tract infections (LRTIs) in children 
whose parents smoke213, yet there has been no systematic review to summarise the risk 
for developing CAP in adults.  
 
The aim of this systematic review and meta-analyses was to summarise the available 
evidence regarding the effect of tobacco smoking and passive smoke exposure on the risk 
of developing CAP in adults, to determine the strength of the association and to examine 
whether there is a ‘dose-response’ association between amount of tobacco smoked and 






This systematic review was conducted using a predefined protocol which was registered 
with PROSPERO database (CRD42018093943, Appendix 7) and reported in accordance 
with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
statement.  
 
6.2.1 Search strategy and study selection 
The search strategy was designed to find published studies. Comprehensive searches of 
the following biomedical electronic databases were conducted: MEDLINE, Embase, 
CINAHL, PsycINFO and Web of Science from the commencement of these databases to 
October 2017. The search strategy included subject headings and keywords related to 
“community acquired pneumonia” and “smoking”. Search keywords were determined 
from the Cochrane review group terms for tobacco.214 Details of the search strategy for 
each database are found in Appendix 8. The reference list of all included studies was 
screened for inclusion.  
 
This review included observational studies; prospective and retrospective cohort studies 
and case-control studies. Cross-sectional studies were excluded. Studies published in all 
languages were considered and no date restrictions were placed on searches. Studies 
comprising adults aged 15 years and above with either a clinical or radiology-confirmed 
diagnosis of CAP were included. Studies comprising patients with hospital acquired 
pneumonia, aspiration pneumonia, active pulmonary TB and post-obstructive pneumonia 





Two authors (VB, AH, RM or TM)  independently screened titles and abstracts using 
Covidence software215 and subsequently reviewed full-texts of retrieved studies for 
eligibility. Disagreement was resolved by discussion and consensus, involving a third 
reviewer (TM or WSL) where necessary. 
 
6.2.2 Data extraction and assessment of methodological quality 
Two authors (VB, RM or TM) independently extracted all data for studies in English whilst 
data from non-English studies were extracted by a single reviewer (TL, LB, MOB or KN) 
who was literate in that particular language using a standardised form (Appendix 9). Any 
disagreements that arose between reviewers were resolved through discussion, or with a 
third reviewer (TM) when required. Information on study population, study design, 
exposure of interest (tobacco smoking) including different exposure categories (e.g. 
never, ever, ex-, current, ‘not current’ and passive smokers), outcome (CAP) and the 
adjusted/ unadjusted effect size (either odds ratios (ORs) or hazard ratios (HRs)) were 
collected. 
 
Methodological quality was assessed using the Newcastle-Ottawa Quality Assessment 
Scale216  for either cohort or case-control studies depending on individual study design. 
This scale is based on three broad categories; (1) selection of the study sample (four 
points), (2) comparability of the sample groups (two points) and (3) ascertainment of 
exposure/ outcome (three points). Thus, studies were scored out of a total of nine points. 
Scores were chosen a priori to indicate different levels of methodological quality (0-3: 





6.2.3 Data synthesis 
We reviewed the extracted results to assess if adequate similarity existed for study 
outcomes to conduct a random-effects meta-analysis using Stata/ SE 15.1 (©StataCorp. 
2017). Meta-analysis was performed using 26 studies comparing current (selecting the 
highest amount of tobacco smoked for current smokers where there was more than one 
category), ever, ex- and passive versus never smokers in addition to comparing current 
versus ‘not current’ smokers. We assessed publication bias visually using a funnel plot for 
the association between current smoking and the risk of CAP given that there were more 
than 10 studies included in this meta-analysis. We summarised studies with pooled ORs 
and HRs separately with 95% confidence intervals. Measures of effect adjusted for 
confounders (age and sex were a priori confounders) were used in preference to crude 
measures of effect. The I2 statistic was used to assist with assessment of heterogeneity 
between studies.  We performed sensitivity analysis excluding studies with only specific 
medical conditions (we use the term ‘selected clinical populations’ in the rest of this 
paper) so that the data would be representative of the general population. In order to 
explore ascertainment bias, we compared the effect size in primary care versus 
secondary care settings. We plotted the log ratio for each category within a study 
(assuming a linear relationship) and estimated the dose-response regression coefficient 
to determine the dose-response association between the dose of current smoking and 







The search strategy initially identified 647 studies, from which 56 full-text articles 
(including five non-English studies; French, Chinese, German and Spanish) were reviewed 
(Fig 6-1). Twenty-five English studies and two non-English studies were included in the 
systematic review (n=460,592 participants). The most common reason for exclusion was 
lack of documented relevant outcome data (n= 17/56). 






6.3.1 Characteristics of included studies 
Of 27 included studies, there were 13 cohort studies and 14 case-control studies. All 
except two studies included both genders; two studies only included men.217,218 Five 
studies had selected clinical populations including patients with human 
immunodeficiency virus (HIV)219, selected HIV-related medical conditions218, minor 
thoracic injury220 and chronic obstructive pulmonary disease (COPD)221,222. One study 
reported an outbreak of Legionnaires’ disease and included participants who visited an 
aquarium.223 Six studies were conducted in primary care, nine in hospitals, four in mixed 
settings, six in community settings and two not specified (Table 6-1). The definition of 
CAP was based on radiological confirmation in 16 studies, diagnostic coding in five studies 
(four studies used ICD-9 codes and one study used Clinical Practice Research Datalink 





Table 6-1: Characteristics of 27 included studies for systematic review; ordered by year, author. 
First 
Author 








Case –control studies 
Almirall 1999 Multicentre 
prospective  
Spain Mixed  Mean age: men 56.1 
(SD 19), women 51.1 
(SD 20.7) 
 
Excluded a secondary 
concurrent disease or 
a noninfectious origin, 











Acute lower respiratory tract 
infections for which antibiotics 
were prescribed, associated or 
not with new focal signs on 
examination of the chest and 
radiographic infiltrate indicative 
of pneumonia. 
Almirall 1999 Multicentre 
retrospective  
Spain Mixed  Mean age: men 56.1 




Excluded HIV, active 
cancer, aspiration, 
active lung TB, nursing 












Acute lower respiratory tract 
infections for which antibiotics 
were prescribed, associated or 
not with new focal signs on 
examination of the chest and 










Mean age: cases 54, 
controls 44 









Acute lower respiratory tract 
infection for which an antibiotic 
was prescribed associated with 
new focal signs on chest 
examination and new  
radiographic pulmonary 
shadowing. 
Farr 2000 Multicentre 
prospective  
England Hospital Age: cases 44.9, 
controls 26.5% ≥60 
Male: cases 60.7%, 
controls 54.3% 
 
Excluded if CAP was 
not the main reason 
for admission, 
expected terminal 
event, distal to a 
bronchial event, 
pulmonary TB, control 











Acute respiratory illness with 
radiological pulmonary 
shadowing which was at least 
segmental or present in more 
than one lobe.Two control 
subjects for each case were 
selected at random from the 
electoral registers for the main 
catchment areas of the hospitals 
where the cases were treated. 
Piednoir 2003 Single centre 
retrospective  












Radiological diagnosis of one or 
more opacities + one of the 
below: 




Excluded if not 
confirmed 
radiologically. 
legionella, cough, wheeze, 
breathing difficulty 
 
§ Greig 2004 Single centre 
retrospective  




who visited an 
aquarium. 
 
Controls excluded if 











Fever, cough, pneumonia in the 
2/52 after a visit to Melbourne 
Aquarium/ close vicinity + 
confirmed by ≥ one test: 
(1) +ve urinary antigen test 
(2) ≥ 4x (to ≥ 128) rise in antibody 
titre against L pneumophila 
between paired acute and 
convalescent phased sera 
(3) Isolation of Legionella spp. 
from resp secretions 
(4) stable high (>512) titre in 
convalescent serum 
Bai 2007 Single centre 
retrospective  

















mean age: 54.6 (SD 
20.7) (women) – 58.6 













Acute lower respiratory tract 
infection for which antibiotics had 
been prescribed, with the 
appearance of previously 
unrecorded focal signs on physical 
examination of the chest and new 





54.6 (SD 20.6) 





active pulmonary TB, 
HAP, nursing homes 
residents. 
 
Jackson 2008 Multicentre 
retrospective  




home/ hospice care 
residents, if they had 
<2 visits to Group 
Health providers in 









ICD-9 codes for CAP; These 
episodes were then validated 
either by review of electronically 
available reports of chest 
radiographs obtained within 30 
days before or after the visit or, 
for events in the hospital, by 
review of the hospital records. 
Tas 2008 Single centre 
retrospective  
Turkey Hospital Mean age: cases 22.18 
(SD 1.22), controls 












Patients with clinical, laboratory 
and radiological findings 





Loeb 2009 Multicentre 
retrospective  
Canada Hospital Mean age: cases 79.1  
(SD 7.6),controls 74.4 
(SD 6.7) 
Male: cases 60.4%, 
controls 31.5% 
 
Excluded nursing home 
residents, infection at 
another site (in 
addition to CAP) at the 
time of enrolment, and 
residence outside the 
study catchment areas. 
Control participants 
were excluded if they 
had been diagnosed 
with CAP in the 
previous 12 months or 










≥ 2 of the following symptoms 
and signs: temperature higher 
than 38.1C, productive cough, 
chest pain, shortness of breath, or 
crackles on auscultation, new 
opacity on a chest radiograph 
interpreted by a radiologist as 
being compatible with 
pneumonia. 
Gau 2010 Single centre 
retrospective  
USA Hospital Mean age: cases 80.3 
(SD 8.5)/, controls 79.8 
(8.1) 














Discharge diagnosis and further 
confirmed by the report of the 
radiographic findings (a new 
infiltrate or consolidation) 




active lung cancer/ 
metastatic disease, 
ventilator-associated/ 




records, patients who 
could not recall 
medication use 
 




Age: cases 34.3, 
controls 32.1 Male: 













International Classification of 
Primary Care (ICPC) code 
R81:Either a confirmation by 
radiography or the presence of ≥ 
3 of the following signs/ 
symptoms:  decreased intensity of 
breath sounds, dullness on chest 
percussion, inspiratory crackles,  
increased vocal resonance, fever,  
local chest pain on deep 
inhalation 
 




Median age: cases 65 
(14-96), controls 63 
(15-100) 












Acute lower respiratory tract 
infection for which antibiotics had 
been prescribed with appearance 







HAP, active lung TB, if 
another non-infectious 
respiratory disease 







focal signs on physical 










Median age: 36-38 
Male: 100% 
 






232 Questionnaire Never 
Current 
 
Illness must be severe enough to 
require a visit to a physician, a 
diagnosis of ‘pneumonia’ by the 
clinician and his prescription of an 
antibiotic. 
Baik  2000 Multicentre 
prospective  
USA Community Age: men 44-79, 
women 27 -44 
 
Excluded HAP,  
diagnosis of 
pneumonia not 
identified by medical 
records or by 
supplemental 
104491 Questionnaire Never 
Ex  
Current 
First documented physician 
diagnosed CAP  
Men: CXR infiltrate documented 






before the beginning 
of the study, those 
who didn’t respond to 
questions on body 
weight and physical 
activity, women with 
probable or possible 
CAP.  
 
Jackson 2004 Multicentre 
prospective  
USA Mixed Age: 53% 65- 74, 38% 













For CAP that required 
hospitalisation: 
Treating physician considered 
CAP as the aetiology 
 
For outpatient CAP: 
ICD 9 codes, chart review 
indicated that pneumonia was the 
most likely diagnosis, CXR within 
14 days of visit, & if the patient 
had not been  hospitalized in the 




O-Meara 2005 Multicentre 
prospective  
USA Community Mean age: 
Hospitalised 75, Not 
hospitalised 72.6 
Male: hospitalised 





ambulatory at home, 
under hospice care, 
receiving radiation or 
chemotherapy for 
cancer, not expected 
to remain in the area 
for ≥ 3 years, unable to 
be interviewed 
 




Pneumonia identified by codes 
assigned to hospital discharge 
diagnoses according to ICD-9 
codes (481, 482, 486) 






Median age: 43 
Male: 72.8% 
 
Included HIV infected 
persons 
5472 Standardised 






(1) ‘‘confirmed’’: compatible 
clinical and radiographic evidence 
with histologic or microbiologic 
support  
(2) ‘‘probable’’: signs and 










USA Community Age ≥ 45 
Male: 44.5% 
214 Questionnaire Never 
Ex 
Current 
Hospitalisations that include 
pneumonia discharge code (ICD-9 
codes 480 - 486) within 36 
months 
§ Chauny 2012 Multicentre 
prospective  
Canada Hospital Mean age: 53 (SD 17) 
Male: 63% 
 
Included patients with 
minor thoracic injury 
 
Excluded spontaneous 






contusion, or any 
other significant 
internal thoracic or 
abdominal injury at 
their initial ED visit, if 








Presence of pneumonia on 
radiologic reports, with 
compatible patient complaints 
and physical examination in the 
first 2 weeks, or the reported 
diagnosis of delayed pneumonia, 




outpatients, or if the 
interval from time of 
injury to ED visit 
exceeded 3 days. 
 
Takahashi 2013 Single centre 
prospective  
Vietnam Hospital Median age: 50 
Male: 52% 
 







Hospitalised with ≥ 2 of the 
following: 
(1) fever and/or cough  
(2) fast and/or difficulty 
of breathing 
(3) any additional severe 
symptoms including respiratory 
rate over 30 per minute, SpO2 
under 90%, systolic blood 
pressure under 90 mmHg, pulse 
rate more than 130/min, white 
blood cell count over 20,000 or 
under 4,000 cells/μL, CRP over 20 
mg/dl, dehydrated, altered 
consciousness and other worse 
general status. 
 
A senior pulmonologist and two 
physicians interpreted all chest X-




was categorised as CAP if ≥ 2 
evaluators agreed on the 
presence of consolidation. 
 
Yende 2013 Multicentre 
prospective  





   CHS: wheelchair 
bound, unable to 
participate in the 
examination at the 
field centre, definitive 
plans to leave the area, 
active cancer. 
   Health ABC: 
recent treatment of 
cancer, severe 
dementia, plans of 
leaving the area within 
3 years. 
 








§ Attia 2015 Multicentre 
prospective 
USA Hospital Median age: 44-50 
Male: 98% 
 










Inpatient ICD-9 code for CAP 






9419 Questionnaire Never 
Ex 
Current 
First episode of pneumonia 
reported either by the 
participants or their physicians 
Jackson 2016 Multicentre 
prospective  
USA Community Age ≥65 
Male: 41% 
3375 Questionnaire 





(ICD-9-CM) codes 480–487.0 or 
507.0 assigned to outpatient and 
inpatient medical encounters.  
• Presumptive pneumonia 
episodes were considered 
validated if manual review of 
chest radiograph reports within 
30 days of first pneumonia 
diagnosis indicated the presence 
of an infiltrate not known to be 
chronic. 
• If no CXR, validated by 
reviewing hospital admission, 









Mean age: 67 
Male: 55.2%  
 





preceding 3 months, 
pulmonary TB and 
unknown smoking 
status.  




diagnosis, identified by read 
codes.  
Abbreviations 
SD: standard deviation, HIV: human immunodeficiency virus, TB: tuberculosis, HAP: hospital acquired pneumonia, ED: emergency department, ICD: International 
Classification of Diseases, COPD: chronic obstructive lung disease, CHS: Cardiovascular Health Study, Health ABC: Health, Aging, and Body Composition 
Legend 
* Smoking categories have been renamed from original studies in this table to match Table 1 for consistency: never and non-smokers in the ‘never’ category; lifetime 
smoking history of > 100 cigarettes, ‘current/ past’ and ‘current/ex-‘ in the ‘ever’ category, ex-, former and past smokers in the ‘ex’ category; and current and active smokers 




‡Studies which had information for ‘never’ smoking category although did not explicitly state the category. 




6.3.2 Risk of bias  
Most of the studies (n=16 studies) included were of moderate quality with a median 
quality score of six (IQR 6-7) (Table 6-2). Using the a priori methodological quality scores, 
we judged ten studies to be of high quality and one study of low quality. Twenty-four 
studies (88.9%) had clear definitions of CAP either using independent blind assessment of 
chest radiographs, medical records or record linkage (e.g. ICD codes) and 23 studies 
(85.2%) adjusted for confounders. Thirteen (92.9%) out of all case-control studies scored 
low as a result of lack of non-response rate reporting and poor smoking status 
ascertainment (obtained information from interview that was not blinded to case/ 
control status or were self-reported). In contrast, over half of the cohort studies (n=8 
studies, 61.5%) scored well for smoking status ascertainment; either from a secure 
medical record or structured interview with the participant. The quality for some of the 
cohort studies dropped due to a combination of lacking a truly representative exposed 
cohort (n=8 studies, 61.5%), not demonstrating that CAP was not present at the start of 
the study (n=8 studies, 61.5%) and not having a statement about loss to follow-up (n=9 
studies, 69.2%). 
 
Table 6-2: Risk of bias for included studies (using Newcastle Ottawa Scale) 
First Author Year Study quality 







Almirall 1999 4 2 1 7 
Almirall 1999 4 2 1 7 
Almirall 2008 4 2 1 7 
Almirall 2014 4 1 1 6 
Attia 2015 2 2 2 6 
Bai 2007 2 2 0 4 
Baik (men) 2000 2 2 3 7 
Baik (women) 2000 2 2 2 6 




Breitling 2016 2 2 2 6 
Chauny 2012 1 0 1 2 
Conley 1996 2 2 2 6 
Farr 2000 4 2 2 8 
Farr 2000 4 2 1 7 
Gau 2010 3 2 2 7 
Gordin 2008 2 2 1 5 
Greig 2004 3 2 1 6 
Jackson 2004 2 2 2 6 
Jackson 2008 3 1 2 6 
Jackson 2016 3 2 2 7 
Loeb 2009 4 2 1 7 
Mannino 2009 1 2 3 6 
O-Meara 2005 2 2 2 6 
Piednoir 2003 2 2 1 5 
Takahashi 2013 1 2 1 4 
Tas 2008 4 1 1 6 
Teepe 2010 3 2 1 6 
Yende 2013 2 2 2 6 
 
6.3.3 Smoking status 
The most commonly used definitions of smoking status are detailed in Table 6-3. Most 
studies state the smoking categories without providing detailed definition for respective 
categories; we have used the definition for each category from the Glossary detailed in 
the Adult Tobacco Use Information by the Centres for Disease Control and Prevention 
(Table 6-3).224  
 
Table 6-3: Smoking categories used in included studies 
Smoking 
categories 




Never Never smoked or lifetime smoking history 
of <100 cigarettes 
Non 27 
Ever Lifetime smoking history of ≥100 
cigarettes 
‘Current/ past’  
‘Current/ ex’ 
4 
Ex Lifetime smoking history of ≥100 
cigarettes and stopped smoking at the 
time of the study 




Current Lifetime smoking history of ≥100 
cigarettes and currently smokes at the 
time of the study 
Active 18 
Passive Never smokers who are exposed to 





Four studies quantified tobacco smoking by documenting pack-years225,226 and reporting 
qualitative descriptions from light through to heavy smoking.218,227 ‘Not current’ smoking 
category which could include never, ever and ex-smokers was used in two studies. The 
proportion of current smokers with CAP was higher in secondary care (31-79%) compared 
to primary care (21-27.3%).  
  
6.3.4 Meta-analyses 
Meta-analysis of 13 studies showed that current smokers were more than twice at risk of 
developing CAP than never smokers (pooled OR 2.17, 95% CI 1.70-2.76, I2=75%) (Fig 6-2). 
Sensitivity analysis excluding studies which were not representative of the general 
population (two studies with selected clinical populations218,220 and one study which 
recruited participants who visited an aquarium223) found a marginally lower effect 
(pooled OR 1.91, 95% CI 1.54–2.38, I2=70.8%, n=10 studies) (Fig 6-2). There was no 
evidence of publication bias identified from the funnel plot for the association between 
current smoking and the risk of CAP (Fig 6-3). Studies that reported hazards ratios found 
that current smokers were 53% more likely to develop CAP than never smokers (pooled 
HR 1.52, 95% CI 1.13-2.04, I2=89.5%, n=7 studies) (Fig 6-4). The risk increased slightly 
when three studies with selected clinical populations were removed (pooled HR 1.72, 
95% CI 1.43-2.07, I2=19.3%) (Fig 6-4). Compared to ‘not current’ smokers, meta-analysis 
of two studies revealed that current smokers were almost three times at risk of 
developing CAP (pooled OR 2.75, 95% CI 1.29-5.88, I2=58.3%, n=2 studies) (Fig 6-5). There 




reported hazards ratio (HR 1.31, 95% CI 1.17-1.46), hence this study was not included in 
the meta-analysis. 228 Meta-analysis of four studies showed that ever smokers were more 
than twice at risk of developing CAP than never smokers (pooled OR 2.31, 95% CI 1.99-
2.69, I2=0%, n=4 studies) (Fig 6-6).  
Fig 6-2: Meta-analysis of risk of community acquired pneumonia in current smokers 
relative to never smokers (Odds Ratio). 
 
Study by Baik et al. had relevant data subdivided by gender, therefore data from this study were 
included as two separate entities (i.e. men and women).  
For Fig 6-2, Fig 6-4 - Fig 6-8: 
Grey box = effect estimates from single studies. Diamond = pooled result with confidence interval. 
Vertical line at ‘1’ on the x-axis is the line of no effect. Weight (in %) = influence an individual study 









Fig 6-4: Meta-analysis of incidence of community acquired pneumonia in current smokers 






Fig 6-5: Meta-analysis of risk of community acquired pneumonia in current smokers 
relative to 'not current' smokers (Odds Ratio) 
 
 
Fig 6-6: Meta-analysis of risk of community acquired pneumonia in current smokers 





Ex-smokers were 49% more likely to develop CAP than never smokers (pooled OR 1.49, 
95% CI 1.26-1.75, I2=13.3%, n=8 studies) (Fig 6-7). Sensitivity analysis excluding two 
studies which were not representative of the general population found a similar result 
(pooled OR 1.51, 95% CI 1.24-1.84, I2=29.9%, n=6 studies). Studies reporting hazard ratios 
had a high level of heterogeneity and did not find a significant effect between ex-smokers 
and the risk of developing CAP (All eligible studies: pooled HR 1.18, 95% CI 0.91-1.52, 
I2=85.4%, n=6 studies and sensitivity analysis: pooled HR 1.25, 95% CI 0.88-1.78, I2=75.3%, 
n=2 studies ) (Fig 6-8).  
Fig 6-7: Meta-analysis of risk of community acquired pneumonia in ex-smokers relative to 





Fig 6-8: Meta-analysis of incidence of community acquired pneumonia in ex-smokers 
relative to never smokers (Hazards Ratio) 
 
 
For studies conducted only within a primary care setting, the effect of current smoking on 
the risk of developing CAP was not statistically significant (pooled OR 1.14, 95% CI 0.72-
1.82, I2=55.1%, n=2 studies and pooled HR 1.21, 95% CI 0.68-2.15, I2=92.8%, n=2 studies) 
whereas for studies conducted in a secondary care setting, current smoking was 
significantly associated with CAP compared to never smokers (pooled OR 1.95, 95% CI 
1.45- 2.62, I2=0.0%, n=4 studies and HR 1.58, 95% CI 1.32-1.89, n=1 study).  
 
Passive smoking was associated with a 13% increased risk of developing CAP compared to 
those who were not exposed to passive smoking, however this result was not statistically 
significant (pooled OR 1.13, 95% CI 0.94-1.36, I2=26.8%, n=5 studies). In a sensitivity 
analysis of those ≥ 65 years old, passive smoking was associated with 64% increased risk 




6.3.5 Dose-response trend: narrative review 
Five studies had information on the dose-response association between amount of 
smoking and the risk of developing CAP. We performed dose-response analyses using the 
data arising from these five studies (Table 6-4) although a meta-analysis was not possible 
due to variations in the method of quantification of smoking exposure across studies. 
Significant dose-response relationships were found in all studies; there were two 
linear225,229 and three non-linear218,227,230 associations with the effect in one study being 
mainly driven by results from the highest two categories (Table 6-4).227  
Table 6-4: Dose-response relationship between amount of smoking and risk of 
developing CAP. Trend (OR)* of 1.xy means xy% increase of risk of CAP per increase in 





















Packs of cigarettes 
smoked daily x 365 




























1.52, 95% CI 1.30- 1.78 <0.001 Non-linear; 
effect mainly 
in the highest 
two categories 











• ≤ half (‘light’) 
• half to <2 
(‘moderate’) 
• >2 (‘heavy’) 
1.51, 95% CI 1.10-2.08 0.011 Non-linear 
$This formula was clarified directly by personal correspondence with study author. 
 
6.4 Discussion  
This study quantified the effect of tobacco smoking on the risk of developing CAP through 
a meta-analysis. Our study revealed robust evidence that current and ex-smokers are 
significantly at higher risk of developing CAP whilst passive tobacco smoke exposure had 
a significant effect only in those aged ≥ 65. The strongest associations were evident in 
studies conducted in secondary care. In addition, a dose-response trend with higher risk 
of CAP amongst current smokers who smoke higher amounts of tobacco was noted.   
 
Current smoking has been associated with a wide spectrum of infectious diseases 
including bacterial pathogens (Streptococcus pneumoniae, Haemophilus influenzae, 
Neisseria meningitidis, Staphylococcus aureus, Legionella pneumophila, Mycobacterium 
tuberculosis) and viral pathogens (influenza, rhinovirus, HIV).231–236 Whether smoking 
increases the risk of infection from different respiratory pathogens by the same degree 
could not been fully examined in this systematic review due to lack of relevant data in the 
included studies. 
 
We quantified the risk of developing CAP in current smokers to be similar to the 
association of smoking with asthma (RR 1.61; 95% CI, 1.07-2.42), idiopathic pulmonary 
fibrosis (OR 1.58; 95% CI 1.27-1.97), obstructive sleep apnoea (RR 1.97; 95% CI 1.02 – 




1.75-2.25) though lower than that of developing lung cancer (HR 13.1; 95% CI 9.90-17.3) 
and COPD (RR 4.01; 95% CI, 3.18-5.05).237–240 
 
Our findings advance the descriptive presentation in two previous systematic reviews 
which reported that smoking is an independent modifiable risk factor for developing CAP 
alongside other lifestyle factors including alcohol abuse, low body mass index, having 
regular contact with children and poor dental hygiene.26,241 Smoking also has an indirect 
effect on the risk of CAP as it is associated with COPD and poor dental health  which are 
themselves independent  risk factors for developing CAP. 226,230,237,242,243 This indirect 
effect has not been quantified.  
 
In a cohort of immunocompetent adults aged 18-64 years old with invasive 
pneumococcal disease (IPD), Nuorti et al. showed that passive smoking was an 
independent risk factor (OR 2.5; 95% CI 1.2-5.1) with increased risk observed with longer 
duration of passive smoke exposure.244 Although passive smoking was not associated 
with increased risk of CAP in adults of all ages, it is noteworthy that meta-analysis of two 
studies showed an increased risk in those ≥65 years; one study recruited patients from 
primary care (exposed to passive smoke at home) and the other following hospitalisation 
for CAP (exposed to any passive smoke). A combination of host factors such as 
comorbidities that accompany advanced age, polypharmacy and immune senescence as 
well as social factors including poor nutrition and crowding or long-term residential care 
may contribute to the increased risk of infection seen in the elderly. 245  
We were able to perform dose-response analyses using data from five studies.  Our 
analyses confirmed that higher levels of smoking exposure are associated with higher 
risks of developing CAP. This is consistent with data from IPD where a linear dose-




the two studies that combined current and ex-smokers in their analyses, the dose-
response relationship between amount of smoking and risk of CAP was linear, whereas in 
the remaining three studies which had current smokers, the relationship was non-linear. 
An individual patient data analysis would be required to determine how the differences 
in the categorisation of smoking status influence the linearity of the dose-response 
relationship.   
 
6.4.1 Tobacco smoking and infection: immune mechanisms 
In addition to structural mechanisms mentioned in the ‘Introduction’ section,209,210,247 
smoking may increase the risk of systemic infections by causing  changes in cellular and 
humoral immune system function.248 Smoking impairs polymorphonuclear leukocyte 
function which plays a significant role in the host defence against bacterial infection 
(depressed neutrophil migration and leukocyte chemotaxis),249,250 decreases CD4+  T cell 
counts which results in reduction of B cells that secrete antibodies (thus lowering serum 
immunoglobulin levels by approximately 10%),251–255  increases CD8+ T cell counts,256 and 
decreases secretion of pro-inflammatory cytokines such as IL-1 and IL-6.257,258 Nicotine 
from tobacco smoking can also suppress natural killer (NK) cell activity; NK cells are 
usually activated as part of the early immune surveillance response against viral 
infections.259 
 
6.4.2 Effect of tobacco smoking cessation 
The only study included in this review that reported time from smoking cessation to 
development of CAP was a population-based case-control study by Almirall et al. which 
reported that the risk of CAP reduced by 50% (OR) after five years of smoking 




smokers reduced by 14% annually and to that of never smokers about 13 years after 
smoking cessation.246 These observations alongside the results from this meta-analysis 
support the notion that ex-smokers have a lower risk of CAP than current smokers and 
that this risk decreases with duration of smoking cessation. 
 
Why ex-smokers remain at risk of CAP is unclear. Bacterial adherence is crucial in the 
pathogenesis of infection. Ex-smokers have been shown to have increased in vitro 
adherence of Streptococcus pneumoniae to buccal epithelial cells for up to three years 
after smoking cessation which may contribute to the increased risk of CAP.247 In terms of 
alterations to immune function, reports have been mixed; one study found a significantly 
lower proportion of NK cells in ex-smokers who had stopped smoking for over 20 years 
compared to never smokers (mean duration since smoking cessation of 10.7 years)260 , 
whereas in another study of 10 ex-smokers where duration since smoking cessation 
ranged from six weeks to 10 years (mean= 4 years),  NK cell activity was comparable to 
that of never smokers.261 In heavy smokers (≥50 pack-years), smoking cessation for six 
weeks has been associated with a return of the CD4/ CD8 ratio to normal.262, Therefore, 
although some of the immune related effects of smoking may be relatively rapidly 
reversed upon stopping smoking, other effects may be more prolonged, or possibly 
irreversible. 
 
6.4.3 Strengths and limitations 
This review comprehensively summarises the current body of knowledge regarding the 
effect of tobacco smoking on the risk of developing CAP and was reported in accordance 
with PRISMA checklist. Eligibility criteria were strictly applied to ensure identified studies 
only included patients with CAP, hence excluding hospital-acquired pneumonia, 




to thoracic malignancy. Overall, included studies were of moderate quality and no 
language restrictions were applied. The statistical heterogeneity for the meta-analysis 
varied across the different analysis, ranging from low (<25%) to high (>75%) level and did 
not change significantly in the sensitivity analysis. 
 
An important limitation was the various ways in which smoking status was defined and 
smoking ‘dose’ quantified. For instance, the lack of distinction of ‘ever’ and ‘not current’ 
smokers from ‘ex-smokers’ precluded seven studies from the meta-analysis involving ex-
smokers. Definitions of CAP also varied, though to a lesser extent. Studies that did not 
adopt the ‘gold standard’ of radiologically confirmed CAP (n=10 studies) may have 
captured some cases of LRTI or acute bronchitis instead. Non-pneumonic respiratory 
tract infections (RTIs) are generally considered to be more likely to be caused by viral 
pathogens instead of bacterial pathogens.263 However, there are no comparative data to 
suggest a differential effect of smoking on the occurrence of viral versus bacterial RTIs. 




This review provides good evidence to support recommendations for smoking cessation 
as well as avoidance of passive exposure to tobacco smoke, particularly in persons at high 
risk of developing pneumonia. Patients who recover from an episode of CAP are 
recognised to be at risk of recurrent CAP57,264,265. Therefore hospitalisation with CAP 






Further research is warranted to establish why and for how long ex-smokers continue to 
be at higher risk of developing CAP following smoking cessation, compared to those who 
have never smoked. For future studies, a more standardised approach to reporting pack-
years of smoking instead of qualitative descriptions with variable definitions would 







Chapter 7 Tobacco smoking is an 
important modifiable risk factor for 







Preventing hospitalisation for pneumonia, especially during winter, is one of the priorities 
for respiratory disease in the NHS Long Term Plan, and for the British Thoracic Society. 
However, there are few studies related to recurrent hospitalisation for pneumonia and 
specifically no studies from the UK. Studies from the past two decades suggest recurrent 
hospitalisation for pneumonia occurs in 9-17.6% of adults during a follow-up of 1-3 years 
following index admission with pneumonia.264,269,270 Non-modifiable factors associated 
with increased risk of recurrent pneumonia include increasing age, impaired functional 
status, comorbidities and medications.271 Unexpectedly, two previous studies found that 
smoking status at index admission was not independently associated with the risk of 
recurrent pneumonia.57,265 This finding contrasts with the well-described dose-dependent 
association of tobacco smoking with the development of pneumonia.205  
 
The aims of this study were to determine the incidence of recurrent hospitalisation with 
pneumonia in England, the association of tobacco smoking as a potentially modifiable risk 
factor, and to describe the proportion of current smokers admitted with pneumonia who 
were offered stop smoking interventions. 
 
7.2 Methods 
7.2.1 Study population and follow-up 
Adults aged ≥18 years with the first episode of hospitalisation for pneumonia (index date) 
recorded in HES between 1 July 2002 and 30 June 2017 were included. The 
‘epidemiological year’ definition of July- June was used as the unit of time in order to 




defined based on J12- J18 ICD-10 codes recorded as the primary code for the first episode 
of hospitalisation. Patients were excluded if they had less than a year of time registered 
to the practice before admission, were admitted for at least a day in the 10 days 
preceding the index admission (identified from HES) or readmitted to hospital within 30 
days of discharge.  
 
Previous studies have defined recurrent pneumonia as a discrete episode of pneumonia 
separated by a variable interval of 30-90 days after the index pneumonia, a radiographic 
clearing of the acute infiltrate or both.57,265,270,272–274 Patients are believed to have 
achieved ‘clinical cure’ or recovered from pneumonia when there is resolution of signs 
and symptoms related to pneumonia without recurrence.50 Radiographic clearance of 
CAP varies between 50.6% at 2 weeks to 66.7% at 4 weeks, with slower clearance in older 
patients.51,52 Bruns et al. reported physician-based clinical cure in 88.9% at 28 days after 
hospitalisation for mild to moderate CAP, though radiological resolution was seen in 
68.4% and symptoms were completely resolved in only 41.7%, highlighting the 
discordance between physician rated clinical cure, radiographic resolution and patient 
reported symptoms.53 In this study, readmission within 30 days of discharge was 
considered to be readmission for the index episode, accepting the limitation that some 
patients may have been readmitted for the index pneumonia. 
 
Patients were followed up from day one after the date of discharge from hospital to 
either the date of admission for recurrent pneumonia, end of data collection (30 June 
2017), date of transfer out of practice, date of last data collection for the practice or date 






Read code lists for smoking status and stop smoking interventions were developed using 
a combination of validated medical Read codes and product Read codes under British 
National Formulary (BNF) listing of "Drugs used in substance dependence: Nicotine 
dependence" (Appendix 10).70,76 The most recent documented smoking status (current, 
ex and never smokers) in CPRD before the index admission was used.   
 
7.2.3 Statistical analysis 
Descriptive statistics for the patient population were calculated. ‘Time to first recurrence’ 
was measured from day one after discharge from hospital to admission with recurrent 
pneumonia. Incidence rates (per 100 person-years) for recurrent pneumonia at different 
time intervals were determined; 90 days, 1 year and 5 years. The proportion of patients 
who developed recurrent pneumonia at 90 days and 1 year were determined. Cumulative 
incidence rates for recurrent pneumonia were plotted using the Nelson-Aalen plot. 
Proportion of current smokers who received stop smoking interventions a year before 
index pneumonia admission and at 90 days, 6 months and 12 months after discharge 
were determined. 
 
Directed acyclic graph (DAG) was used to identify the minimum set of confounders to 
close the back-door paths, which included age, gender, deprivation, alcohol consumption 
and comorbidities ( 
Fig 7-1). Multiple imputation using chained equations was performed with 10 imputed 
datasets for smoking status (2.9% missing data) and alcohol consumption (15.1% missing 
data). Competing-risks regression analyses were conducted to determine the effect of 




event. The proportion of patients who quit smoking after hospitalisation for index 
pneumonia was determined. Statistical analyses were performed using StataMP/ 15.1. 
 
Fig 7-1: Directed Acyclic Graph illustrating the association between smoking status 
(exposure) and developing recurrence of pneumonia (outcome). 
 
*Functional status, severity of pneumonia, cardiac complications after index pneumonia and 






The study cohort comprised 56,396 patients (Fig 7-2).  
Fig 7-2: Flowchart of study population 
 
The median time to recurrence was 1.3 years (IQR 0.5-2.6 years). The incidence rates (per 
100 person-years) for recurrent pneumonia at 90 days, 1 year and 5 years were 13.6 (95% 
CI 13.0-14.2), 11.1 (95% CI 10.8-11.4) and 7.10 (95% CI 6.97-7.23) correspondingly. The 






Fig 7-3: Nelson-Aalen plot of cumulative incidence of pneumonia recurrence in the first 5 
years after index pneumonia 
 
 
Within 90 days and 1 year of follow-up, 1,733 (3.1%) and 5,064 (9.0%) developed 
recurrent pneumonia respectively, with 1,866 (36.9%) patients hospitalised for more 
than one recurrence during the 1-year follow-up period. The 30-day mortality for a 
recurrent pneumonia hospitalisation was 23.7% (n=3,011).  Over the period 2002 to 
2017, the proportion of recurrent pneumonia within one year of index admission 





Fig 7-4: Trend of recurrence of pneumonia within 30-90 days and 1 year of index 
pneumonia admission 
Note: 1-year recurrence refers to recurrence between 30-365 days after discharge for 
index pneumonia. Patients readmitted to hospital within 30 days of discharge were 
considered to be readmissions for the index episode, hence excluded. 
 
Current smoking at index admission was independently associated with a 42% increased 
risk of recurrent pneumonia compared to having never smoked at any point in time 
(Table 7-1). This risk was halved in ex-smokers. Of note, ex-smokers had quit smoking for 
a median of 25.5 years (IQR 15.2-36.9) prior to index CAP; data were available in 69.5% 
ex-smokers (n=9,814). Other factors independently associated with an increased risk of 
recurrent pneumonia were increasing age, male gender, residence in the most deprived 






Table 7-1: Factors independently associated with recurrent pneumonia within a year of 
discharge: Competing-risks regression (CRR) analysis with death as competing event 
 Without recurrence With recurrence Multivariate CRR p value 
 n (%) n (%) sHR (95% CI) 
Number of patients 51332 5064     
Smoking status               
Never 16932 (93.0) 1274 (7.0) 1.00 Reference   
Ex 12995 (89.5) 1517 (10.5) 1.24 (1.15-1.34) <0.001 
Current 21405 (90.4) 2273 (9.6) 1.42 (1.32-1.53) <0.001 
Age               
18-49 7961 (97.0) 247 (3.0) 1.00 Reference   
50-64 8274 (93.7) 556 (6.3) 1.76 (1.51-2.05) <0.001 
65-74 9513 (90.6) 986 (9.4) 2.37 (2.05-2.75) <0.001 
75-84 13625 (89.0) 1692 (11.0) 2.78 (2.41-3.22) <0.001 
≥85 11959 (88.3) 1583 (11.7) 3.17 (2.73-3.67) <0.001 
Gender               
Male 25283 (90.3) 2719 (9.7) 1.00 Reference   
Female 26049 (91.7) 2345 (8.3) 0.85 (0.80-0.90) <0.001 
Alcohol status               
Non-drinker 13329 (90.2) 1451 (9.8) 1.00 Reference   
Former drinker 2938 (88.5) 381 (11.5) 1.08 (0.96-1.22) 0.176 
Occasional drinker 8193 (90.6) 854 (9.4) 0.95 (0.87-1.04) 0.237 
Moderate drinker 19696 (91.7) 1772 (8.3) 0.88 (0.82-0.95) 0.001 
Heavy drinker 7176 (92.2) 606 (7.8) 0.90 (0.81-1.01) 0.063 
IMD (patient-level)               
1 (least deprived) 9721 (91.7) 875 (8.3) 1.00 Reference   
2 10384 (91.0) 1023 (9.0) 1.06 (0.97-1.16) 0.195 
3 10841 (91.0) 1068 (9.0) 1.06 (0.97-1.16) 0.228 
4 10286 (91.3) 977 (8.7) 1.02 (0.93-1.12) 0.689 
5 (most deprived) 10054 (90.0) 1117 (10.0) 1.21 (1.10-1.32) <0.001 
Unknown 46 (92.0) 4 (8.0) 1.14 (0.45-2.89) 0.776 
Charlson Index              
0 13028 (95.5) 608 (4.5) 1.00 Reference   
1 11335 (92.2) 955 (7.8) 1.43 (1.29-1.59) <0.001 
2 8926 (90.1) 986 (9.9) 1.65 (1.48-1.84) <0.001 
3 6910 (88.9) 867 (11.1) 1.76 (1.58-1.97) <0.001 
4 4462 (87.6) 634 (12.4) 1.90 (1.69-2.14) <0.001 
≥5 6671 (86.8) 1014 (13.2) 2.00 (1.79-2.23) <0.001 
                
Co-morbidities               
COPD 9988 (84.7) 1810 (15.3) 1.77 (1.65-1.89) <0.001 
Asthma 11876 (89.0) 1471 (11.0) 1.11 (1.03-1.18) 0.004 
*Chronic lung disease 790 (88.2) 106 (11.8) 1.56 (1.29-1.90) <0.001 
Congestive cardiac failure 4943 (87.5) 705 (12.5) 1.12 (1.02-1.23) 0.016 




*Other cardiac diseases 20982 (90.0) 2344 (10.1) 1.05 (0.98-1.12) 0.149 
Malignancy 10995 (88.7) 1402 (11.3) 1.17 (1.10-1.25) <0.001 
Chronic renal disease 9631 (87.8) 1343 (12.2) 1.16 (1.09-1.24) <0.001 
Cerebrovascular disease 5609 (88.0) 768 (12.0) 1.05 (0.97-1.12) 0.228 
Diabetes mellitus 8394 (89.4) 996 (10.6) 1.14 (1.05-1.23) 0.001 
Cognitive impairment 5174 (88.7) 660 (11.3) 1.11 (1.02-1.21) 0.017 
Liver disease 478 (90.0) 53 (10.0) 1.24 (0.94-1.62) 0.128 
*Chronic lung disease excluding COPD and asthma 
# Other cardiac diseases excluding CCF and MI (e.g. hypertension, arrhythmias, valvular heart 
disease, conduction disorder of the heart, pericarditis, myocarditis) 
 
Two multivariate models were conducted: Model 1: all variables + Charlson Comorbidity Index 
(without individual comorbidities) and Model 2: all variables + individual comorbidities (without 
Charlson Comorbidity Index). Results are presented from Model 1, except for individual 
comorbidities from Model 2 as estimates for other variables in both models were similar 
 
 
Approximately 40% of current smokers received stop smoking interventions a year before 
admission for index pneumonia (Table 7-2). Of these, 2.6% (n=253) received stop 
smoking interventions on the day of admission to hospital and a further 11.7% (n=1,126) 
received advice two weeks prior to admission. After discharge, 30% of current smokers 
received stop smoking interventions within a year.  
Table 7-2: Current smokers who were given stop smoking interventions before admission 
for index pneumonia or after discharge 
Stop smoking 
interventions  
Before admission After discharge* 
1 year 90 days 6 months 1 year 
n (%) n (%) n (%) n (%) 
Given 9599 (41.6) 3353 (14.5) 4831 (21.0) 6805 (29.5) 
*From date of discharge to 90 days, 6 months and 1 year respectively 
 
A change of smoking status from current smoker to ex-smoker was documented in 
primary care in 31.7% (n=7,312) within 12 months of discharge. This dropped to 21% 






7.4.1 Principal findings 
This study investigated the incidence of, and risk factors for recurrent hospitalisation for 
pneumonia. Within 90 days and 1 year of follow-up, 1,733 (3.1%) and 5,064 (9.0%) 
developed recurrent pneumonia respectively. Current tobacco smoking status at index 
hospitalisation for pneumonia was independently associated with a higher risk of 
recurrent pneumonia. Approximately 40% of patients hospitalised with pneumonia 
received stop smoking interventions in the year before and 30% in the year after 
admission for index pneumonia.  
 
7.4.2 Comparison with other studies 
Recurrent pneumonia 
Studies from other countries having reported a range of incidences of recurrent 
pneumonia over different time-periods; 16.3% during a median follow-up of 475 days in 
Japan to 3.5% over an 11-year period in Sweden.264,273 Marked differences in study 
methodology and healthcare system are likely to account for the variation, emphasising 
the importance of country-specific data. Our results are similar to data from Canada and 
Sweden; 2% recurrent pneumonia at 30 to 90 days from index admission, and 17.6% 
recurrent pneumonia during a mean follow-up of under 3 years.57,270 Of note, we 
observed a 23.7% 30-day mortality for recurrent pneumonia, twice as high as 30-day 
inpatient mortality for index pneumonia based on BTS National Audit data.30 Similarly, 
Ishifuji et al. found that patients with recurrent pneumonia were almost three times 
more likely to have fatal outcomes during over a year’s follow-up compared to those 
without (HR 2.81, p<0.001).264 Our study also revealed a significant trend of increasing 




Pneumonia Audit observed a decrease in mortality from index pneumonia over a ten-
year period (2009 to 2019).30 Whether these trends in survival are related to the trends in 
pneumonia recurrence requires further investigation. 
 
Tobacco smoking is associated with an increased risk of developing CAP.205 We extend 
this observation to an association between tobacco smoking status at the time of index 
hospitalisation and recurrent pneumonia. In a case-control study, El Sohl et al. reported 
that current smokers were twice more likely to be admitted with recurrent pneumonia 
compared to never smokers (HR=2.04, 95% CI 1.48-2.82).274 Conversely, two prospective 
cohort studies (Canada, n=2709 and Spain, n=1556) did not find any association between 
smoking and recurrent pneumonia.57,265 These studies included younger patients (mean 
cohort ages 63 and 67 years).  
 
Smoking cessation 
Previous published literature have demonstrated that smoking cessation reduces the risk 
of developing CAP, with those having quit ≥10 years having similar risk to never 
smokers.225,275,276 Yet, we found only 30% received stop smoking interventions within a 
year of discharge after hospitalisation for pneumonia. This is similar to the stop smoking 
interventions given to patients after hospitalisation for acute coronary syndrome (ACS) 
using a similar study design; 23% within 3 months.277 Findings from the Smoking Toolkit 
Study, using monthly household surveys in England show that 7.6% quit smoking in the 
past 12 months, an improvement noted in June 2020 after a declining trend 2 years prior 
to that.  
 
Current smokers who quit smoking after hospitalisation for any reason may relapse 




abstinence in 21% (4 weeks) to 14% (3 months) in the intervention group vs 19% to 14% 
in the usual care group whilst Murray et al. reported a drop from 38% (4 weeks) to 19% 
(6 months) in the intervention group vs 17% to 9% in the usual care group.278,279 Rigotti et 
al. reported tobacco abstinence in 15% (usual care group)- 26% (intervention group) at 6 
months.280 Our study showed that 31.7% of current smokers quit smoking within 12 
months after being hospitalised for pneumonia, and this declined to 21% in the 
subsequent year. Taking into account that smoking status in the trials were self-reported 
and validated by measuring exhaled carbon monoxide compared to coded data in our 
study, the higher proportion observed in our study may be due a higher level of 
motivation in patients hospitalised with a specific smoking-related illness (pneumonia) as 
opposed to patients hospitalised for any reason.281 Smoking cessation were reported to 
be up to 30% in patients hospitalised with COPD and as high as 57% within a year in 
patients hospitalised for ACS, other smoking-related illnesses.282–285 Studies have shown 
that patients admitted with a smoking-related disease during admission, alongside high 
confidence in quitting and having a plan to quit were more likely to be successful at 
quitting at 6-12 months of follow-up.286–288 
 
7.4.3 Strengths and weaknesses of the study  
A key strength of this study is the large sample size of over 56,000 patients which is 
representative of the English population, long-term follow-up and good data quality. The 
usage of two large validated medical record databases, HES-CPRD linkage enabled 
patients hospitalised with pneumonia to be accurately identified and allowed confident 
exclusion of patients with hospital- acquired pneumonia. We applied robust statistical 
methods including causal models using directed acyclic graphs (DAG) to identify potential 
confounders and multiple imputation to handle missing data which increase the 




However, there are a few limitations that warrant discussion. Firstly, although CPRD 
contains data from all of the UK, these data are predominantly from England and linked 
datasets including HES are available only from English practices. Therefore, the results 
from this study may not be generalisable to the rest of the UK. Secondly, in spite of the 
considerable efforts taken to ensure data quality, we cannot fully exclude the possibility 
of information bias from miscategorisation of the study exposure, confounders and 
outcomes. Thirdly, data regarding the type of tobacco smoked were only available in 
about half of the patients, with most consuming cigarettes and few consuming cigars 
(<5%). Fourthly, both CPRD clinical and prescription data only indicate whether smoking 
cessation advice was given and smoking cessation drugs were prescribed, not whether 
the advice directly resulted in a current smoker quitting or medications taken as 
recommended. Some of the 31.7% of patients who quit smoking within a year of 
hospitalisation for pneumonia may have done so by willpower alone and may not have 
received any smoking cessation advice or therapy.  
 
7.4.4 Implications  
Smoking is ranked as the commonest risk factor contributing to years of life lost in 
England.289 In 2019, the proportion of current smokers in England was 13.9%, accounting 
for 5.7 million people.290 The prevalence of smoking in our cohort was 40.9%. Despite the 
significant reduction in the prevalence of smoking in the past decade, there were more 
than 500,000 hospital admissions attributable to smoking in 2018-2019.290,291 Though 
only 30% received stop smoking interventions within a year of discharge in our cohort, 
these were delivered in primary care and whilst many may have received these 
interventions during hospitalisation, these data were not available. Evidence-based stop 
smoking interventions include behavioural support, pharmacotherapy (bupropion, 




review which included 50 trials reported that high intensity behavioural interventions 
initiated during hospitalisation and continue for at least a month after discharge promote 
smoking cessation irrespective of admitting diagnosis.293 This highlights the importance of 
referring patients to a Stop Smoking Service during hospitalisation for pneumonia and the 
subsequent continuous support that patients need upon discharge. All healthcare 
professionals, both in primary and secondary care should routinely provide brief advice 
to all current smokers.294 If patients are not ready to quit in hospital, close 
communications with primary care physicians are paramount so that they could 
opportunistically intervene against smoking at a future routine consultation in the 
community.295 
 
Smoking is estimated to cost the economy in excess of £11 billion annually.296 Of these, 
£2.5 billion fell to the NHS with primary care consultations and smoking-related hospital 
admissions, including pneumonia. Stop smoking interventions are highly cost-effective.292 
The British Thoracic Society smoking cessation audit in 2019 revealed that only 1 in 8 
patients admitted to acute hospitals were referred to smoking cessation service.297 The 
UK and devolved governments recognise that reducing the prevalence of smoking and 
harm caused by tobacco use are important public health issues, thus have developed a 
number of strategies for wider tobacco control.296,298–300 
 
7.4.5 Conclusion 
In conclusion, our findings confirm a high and rising incidence of recurrent hospitalisation 
for pneumonia in England, and that current smoking status at index admission is 
associated with an increased risk of recurrent pneumonia. Our study also provides an 
insight into stop smoking interventions given to patients in primary care before and after 




as a key component of pneumonia management, in accordance with the NHS Long Term 








Chapter 8 Co-infection in COVID-19: A 
retrospective multicentre study in 
patients admitted to the Intensive Care 





During previous viral pandemics, reported co-infection rates and implicated pathogens 
have varied. In the 1918 influenza pandemic, an estimated 95% of severe illness and 
death was complicated by bacterial co-infection, predominantly Streptococcus 
pneumoniae and Staphylococcus aureus.301 
 
As of 3 September 2020, over 25 million cases and 850 000 deaths due to COVID-19 
infection have been reported world-wide.302 The symptoms associated with COVID-19 
infection are relatively non-specific. Fever and lower respiratory tract symptoms, such as 
a cough or breathlessness, are common in patients who require hospital care and 
radiological changes consistent with pneumonia are evident in up to 97% of these 
patients.303 Confirmation of acute COVID-19 infection is reliant on a positive SARS-CoV-2 
polymerase chain reaction (PCR) test result. The immune response to SARS-CoV2 
infection includes a rise in IL-6 and C-reactive protein (CRP), with higher levels associated 
with more severe disease.198,304 
 
The contribution of secondary or co-pathogens to COVID-19 infection is not well 
understood. The lack of an effective anti-viral agent against SARS-CoV2 combined with 
challenges in differentiating secondary bacterial co-infection from severe COVID-19 
infection alone, has fostered the widespread use of empirical antibiotics in the 
immediate management of patients hospitalised with COVID-19 infection. Over the 






The utility of specific biomarkers such as procalcitonin to guide antibiotic therapy in 
severe respiratory tract infection, and specifically COVID-19 infection, is as yet 
uncertain.306,307 In the meantime, a better understanding of the incidence of co-infection 
in patients with COVID-19 infection and the pathogens involved is necessary for effective 
antimicrobial stewardship. The primary objective of this study was to determine the rate 
of laboratory-proven co-infection in critically ill adults with COVID-19 infection in 
England. Secondary aims were to describe the organisms, the characteristics of patients 
with co-infection and the antibiotic susceptibilities of identified bacteria.  
 
8.2 Methods 
8.2.1 Data source 
A retrospective observational multicentre study of co-infection in adults with confirmed 
COVID-19 requiring intensive care unit (ICU) admission was performed. Seven acute 
hospitals from across England participated in the study including large (>1000 beds) 
tertiary hospitals and medium (500- 1000 beds) district hospitals: Nottingham University 
Hospitals NHS Trust, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Brighton and 
Sussex University Hospitals NHS Trust, Guy’s and St Thomas’ NHS Foundation Trust, 
Salford Royal NHS Foundation Trust, University Hospitals of Derby and Burton NHS 
Foundation Trust and University College London Hospitals NHS Foundation Trust.  
 
8.2.2 Study population 
Case inclusion criteria were adults aged >16 years with completed ICU admissions 
(discharged from or died whilst in ICU) for COVID-19 pneumonia (i.e. requiring Level 2 or 
Level 3 care according to the classification by the Intensive Care Society, UK) from disease 




polymerase chain reaction (RT-PCR) from a respiratory specimen. Participating sites were 
asked to enter data for either: 1) all identified patients, or 2) a random selection of at 
least ten patients from across their eligible cohort. Where more than one critical care 
area existed at a participating site, a random selection from across areas was requested 
to avoid selection bias. Exclusion criteria were defined as: COVID-19 infection diagnosed 
>48 hours after hospital admission or a hospital admission in the last 14 days (hospital-
acquired COVID-19) and patients transferred into ICU from a different hospital.  
 
8.2.3 Data collection 
Personal information was removed at the point of participating site data entry onto a 
secure online database platform (REDCap Cloud). Data were gathered from electronic 
medical records. Fields collected were: demographics (age, gender, ethnicity, presence or 
absence of co-morbidity as defined in the Intensive Care National Audit & Research 
Centre (ICNARC) report on COVID-19 in critical care and type 2 diabetes mellitus); 
hospital admission details (date, days of symptom onset prior to admission and radiology 
findings); ICU details (date of admission, mechanical ventilation during the first 24 hours, 
advanced respiratory support (Table 8-1), acute physiology and chronic health evaluation 
(APACHE II) score and outcomes); antibiotics received and all microbiology test results to 
the end of the ICU admission (including any identified antimicrobial resistance).  
Table 8-1: Definition (based on ICNARC report on COVID-19 in critical care)308 
Comorbidities must have been evident within the six months prior to critical care and 
documented at or prior to critical care: 
• Cardiovascular: symptoms at rest 
• Respiratory: shortness of breath with light activity or home ventilation 
• Renal: renal replacement therapy for end-stage renal disease 
• Liver: biopsy-proven cirrhosis, portal hypertension or hepatic encephalopathy 
• Metastatic disease: distant metastases 





• Immunocompromise: chemotherapy, radiotherapy or daily high dose steroid 
treatment in previous six months, HIV/AIDS or congenital immune deficiency 
• Type II diabetes mellitus 
Mechanical ventilation during the first 24 hours was identified by the recording of a ventilated 
respiratory rate, indicating that all or some of the breaths or a portion of the breaths (pressure 
support) were delivered by a mechanical device. This usually indicates invasive ventilation; 
BPAP (bi-level positive airway pressure) would meet this definition but CPAP (continuous 
positive airway pressure) does not. 
Advanced respiratory support was defined as invasive ventilation, BPAP via trans-laryngeal 
tube or tracheostomy, CPAP via trans-laryngeal tube, extracorporeal respiratory support.  
 
8.2.4 Definitions 
Diagnostic microbiology tests were performed as per standard testing protocols within 
NHS laboratories at individual participating sites. Microbiology results included in the 
analysis were: standard culture (blood, sputum, tracheal-aspirate, bronchoalveolar lavage 
(BAL), urine) and validated culture-independent tests such as respiratory viral PCR (Table 
8-2) and urinary antigens. Co-infection was defined as present if a likely pathogen was 
identified in a clinical sample taken for diagnostic purposes. Culture results were 
considered to represent contamination in the following situations: blood cultures yielding 
common skin contaminants in a single sample (Coagulase-negative Staphylococci, 
Micrococcus spp., viridans group streptococci, Propionibacterium spp., Corynebacterium 
spp., Bacillus spp.) without a concurrent positive culture from an indwelling line tip309–311, 
Candida spp. cultured from respiratory and urinary catheter samples312,313, respiratory 
samples yielding Gram-positive organisms typically present in the oropharyngeal flora314, 
growth of Enterococcus spp. in a single catheter urinary specimen.315 Despite this effort, 
culture results from some non-sterile respiratory samples may represent colonisation, 
hence the term co-infection/ co-colonisation is used for respiratory samples. Radiology 




reporting template.316 Where both chest CT and CXR findings were available, chest CT 
findings were prioritised. 
Table 8-2: Viral testing panel by study site 
Study site  Viral testing panel 
Nottingham University Hospitals Influenza A & B, RSV, Rhinovirus, Enterovirus, 
Adenovirus, Parechovirus, Parainfluenza pool 
(types 1-4), Human metapneumovirus, 
Bocavirus 
Newcastle Upon Tyne Hospitals Influenza A & B, Respiratory syncytial virus 
(RSV), Rhinovirus, Human metapneumovirus, 
Adenovirus, Parainfluenza pool (types 1-4) 
Brighton and Sussex University Hospitals Influenza A & B, RSV 
Guy’s & St Thomas’ Influenza A & B, RSV, Enterovirus, Rhinovirus, 
Parainfluenza, Adenovirus, Human 
metapneumovirus  
Salford Royal Influenza A & B, RSV 
University Hospitals of Derby & Burton Influenza A & B, RSV, Parainfluenza, Rhinovirus, 
Human metapneumovirus, Adenovirus 
University College London Influenza A & B, RSV, Parainfluenza pool (types 
1-4), Human metapneumovirus, Adenovirus, 
Rhinovirus 
 
8.2.5 Statistical analysis 
Demographics, clinical and disease characteristics were described using appropriate 
descriptive statistics for: i) those with co-infection, and ii) those without co-infection. 
Characteristics of patients in the study were also compared with the patients in the 
Intensive Care National Audit & Research Centre (ICNARC) report on COVID-19 in critical 
care, 22 May 2020. The proportion of co-infection (%) was determined at three time 
points: on admission, within 48 hours, and during ICU admission (from day of ICU 
admission to ICU discharge or death in ICU). The co-infection rate was calculated per 
1000 person-days based on the first co-infection detected in hospital per patient (person-
time was determined from date of hospital admission to date of first co-infection, date of 




Univariate logistic regression analyses were conducted to determine the association 
between selected variables (age, gender, study site, ethnicity and co-morbidities) and the 
odds of a) developing co-infection during admission, and b) co-infection and mortality in 
ICU. Competing-risks regression analysis was conducted to assess if patients with co-
infection had a longer length of hospital stay (from hospital admission to the end of ICU 
admission) than those without co-infection, with death as a competing-event. Co-
pathogens were described separately for bacterial, viral and fungal infections. The 
proportion of bacterial co-pathogens with antimicrobial resistance was recorded.  
 
An analysis of type of pathogens identified at different time points from admission was 
performed (≤48 hours and >48 hours following admission) to identify those with 
community vs hospital-acquired co-infection. Pathogens identified within 48 hours of 
hospital admission were listed by type of test performed. A sub-analysis of the hospital-
acquired co-infection was performed to identify the type of pathogens detected early (3-
7 days into hospital admission) and late (>7 days into hospital admission). Statistical 






Of 579 eligible patients during the study period, 254 patients with completed ICU 
episodes were studied (Fig 8-1, Table 8-3).   
 
Fig 8-1: Flowchart of study population 
 




















(% of those 
eligible) 
Nottingham University Hospitals 97 11 1 85 79 (92.9) 
Newcastle Upon Tyne Hospitals 100 4 20 76 48 (63.2) 
Brighton and Sussex University 
Hospitals 
58 8 4 46 45 (64.3) 
Guy’s & St Thomas’ NHS 
Foundation Trust 
316 0 103 213 34 (16.0) 
Salford Royal 46 3 11 32 22 (68.8) 
University Hospitals of Derby & 
Burton 
54 1 0 53 16 (30.2) 
University College Hospitals 
London 
138 32 32 74 10 (13.5) 
Total 809 59 171 579 254 (43.9) 
d= a- (b+c) 
 
The median age of the study cohort was 59 years (IQR 49-69, range 19-84) and 164 
(64.6%) patients were male; similar to corresponding data from the ICNARC cohort (Table 
8-4).308 Patients were admitted to hospital between 21 Feb 2020 and 1 May 2020. The 
median time from onset of symptoms to admission was seven days (IQR 5-10). The 
median time from hospital admission to ICU admission was one day (IQR 0-2). Antibiotics 
were prescribed to 35 (13.8%) patients before hospital admission and to 228 (89.8%) 
patients within 48 hours of admission. Throughout the course of admission, 241 (94.9%) 






Table 8-4: Characteristics of study population in comparison with ICNARC data 








n (%)   
Number of patients 171 (67.3) 83 (32.7) 9026 
Age     * 
    18-49 47 (27.5) 17 (20.5)  
    50-64 51 (29.8) 42 (50.6)  
    65-74 47 (27.5) 19 (22.9)  
    75-84 26 (15.2) 5 (6.0)  
Gender     [N=9022] 
    Male  106 (62.0) 58 (69.9) 6403 (71.0) 
    Female 65 (38.0) 25 (30.1) 2619 (29.0) 
Ethnicity     [N=8185] 
White 108 (63.2) 44 (53.0) 5468 (66.8) 
Black 13 (7.6) 10 (12.1) 1245 (15.2) 
Asian 16 (9.4) 5 (6.0) 797 (9.7) 
Mixed 3 (1.8) 2 (2.4) 138 (1.7) 
Other 4 (2.3) 3 (3.6) 537 (6.6) 
§BAME 36 (21.1) 20 (24.1) - 
Unknown 27 (15.8) 19 (22.9) - 
Co-morbidities     [N=8777] 
    Cardiovascular 3 (1.8) 0 (0.0) 42 (0.5) 
    Respiratory 0 (0.0) 2 (2.4) 74 (0.8) 
    Renal 3 (1.8) 2 (2.4) 144 (1.6) 
    Liver 0 (0.0) 0 (0.0) 33 (0.4) 
    Metastatic disease 0 (0.0) 0 (0.0) 38 (0.4) 
    Haematological malignancy 6 (3.5) 1 (1.2) 144 (1.6) 
    Immunocompromised 11 (6.5) 2 (2.4) 295 (3.4) 
    Type 2 diabetes mellitus 47 (27.5) 19 (22.9) N/A 
Indicator of acute severity    
    Mechanically ventilated 
    within first 24h 
  
5298 (62.8)b 
    APACHE II Score, mean (SD) 13.3 (5.6) 14.2 (5.5) 14.7 (5.3)c 
    PaO2/FiO2 ratio (kPa), 






        ≤ 13.3 kPa (< 100 mmHg) 
        > 13.3 and ≤ 26.7kPa  
(100 - 200 mmHg) 













LOS from hospital admission to 
the end of ICU admission (days), 
median (IQR) 
    
 
Survivors 9 (4-14) 22 (17-27) N/A 






a Intensive Care National Audit & Research Centre (ICNARC) report from 22 May 2020308 
* Median age= 60 (51-68) 
§ BAME is the total of Black, Asian, Mixed and Other ethnicities 
Denominators:  b N=8433, c N=8648 and d N=8104 
 
The overall median length of stay (LOS) in ICU was nine days (IQR 4-17); 10 days (IQR 4-
18) for survivors and nine days (IQR 5-15) for non-survivors. One hundred and fifty-one 
patients (59.5%) were mechanically ventilated within 24 hours of admission, and 158 
patients (62.2%) received advanced respiratory support (invasive ventilation, CPAP via 
trans-laryngeal tube, extracorporeal respiratory support) during admission. Of those who 
were discharged from ICU (n=172 patients), two patients (1.2%) died in hospital, 147 
patients (85.5%) were discharged from hospital and 23 patients (13.4%) remained in 
hospital at the end of the study. 
 
All patients had either a CXR (n=246 patients) and/or a chest CT scan (n= 74 patients). 
Classic/ probable COVID-19 radiographic changes were recorded in 209 patients (82.3%), 
five (2%) had normal imaging, 27 (10.6%) had indeterminate changes and 13 (5.1%) had 
non-COVID19 findings. 
 
In total, co-infection/ co-colonisation was identified in 83 (32.7%) patients from hospital 
admission to the end of ICU stay; median time to co-infection/ co-colonisation was 9 days 
(IQR 6-14). The list of identified potential pathogens and contaminants from standard 
cultures (blood, BAL, sputum and tracheal aspirate) is available in Appendix 11. On the 
day of admission, potential co-pathogens were identified in four patients (1.6%), rising to 
14 (5.5%) patients within the first 48 hours of hospital admission. Fifteen potential 
pathogens were identified from 14 patients within 48 hours; 14 bacterial and one viral 






Table 8-5: Organisms identified within 48 hours of hospital admission 
Type of test Potential Pathogens 
No of 
pathogens 
Tracheal aspirate or 
sputum culture    
  Escherichia coli 1 
  aPseudomonas sp 1 
 Pseudomonas aeruginosa 1 
 Enterobacter cloacae complex (AmpC) 1 
  aStaphylococcus aureus (MSSA) 2 
BAL PCR/ culture    
  bStaphylococcus aureus (MSSA & MRSA) 2 
  Klebsiella pneumoniae 1 
Other tests    
Pneumococcal urinary 
antigen test 
aStreptococcus pneumoniae 2 
MSU Escherichia coli 2 




a Pathogens identified on the day of admission (Pseudomonas sp, one out of two MSSA and one 
out of two S.pneumoniae identified, and Metapneumovirus), total= 4  
b One out of two organisms was Methicillin-resistant Staphylococcus aureus (MRSA). The same 
patient also had MRSA in pleural fluid culture after 48 hours into hospital admission. 
 
 
In a sensitivity analysis excluding the hospital which contributed a third of cases, the 48-
hour co-infection/ co-colonisation rate remained similar (Table 8-6).  
Table 8-6: Co-infection rate within 48 hours (1000 person-days) for the overall study 
population and excluding the hospital which contributed a third of cases. 
 Co-infection rate within 48 hours 
(1000 person-days) (95% CI) 
Overall 28.2 (16.7-47.7) 
Excluding Nottingham University Hospitals 32.0 (17.7-57.8) 
 
The commonest potential co-pathogen within 48 hours of hospital admission was 
S.aureus, three methicillin-susceptible (MSSA) and one methicillin-resistant S.aureus 




deemed false positives and excluded from the analysis. The number of tests performed 
within 48 hours of hospital admission are listed in Table 8-7, by type of tests. For 
bacterial co-pathogens, the antimicrobial susceptibilities are described in Table 8-8. 
Table 8-7: Number of tests performed within 48 hours of hospital admission, by type of 
tests 
Type of tests 
On admission 
After admission  
(within 48 hours) 
Overall 
n N n N n N 
Blood culture 223 174 89 46 312 220 
BAL PCR/ culture, sputum culture, 
tracheal culture 
18 15 34 31 52 46 
Urinary pneumococcal antigen 25 25 55 51 80 76 
Urinary legionella antigen 36 34 55 54 91 88 
Respiratory viral PCR 119 106 32 22 151 128 
Legend: 
n= Number of tests done 




Table 8-8: Antimicrobial susceptibilities for identified bacterial pathogens 
  AMR  No AMR Unknown Total Resistance n (%) 
Klebsiella spp. 10 4 2 16 Co-amoxiclav, 2 (20); Cefuroxime, 7 (70); Piperacillin/Taz, 5 (50); Meropenem, 1 (10); Co-trimoxazole, 1 (10); 
Trimethoprim, 1 (10); Chloramphenicol, 1 (10) 
Escherichia coli 11 9 0 20 Amoxicillin, 8 (72.7); Co-amoxiclav, 5 (45.5); Meropenem, 1 (9.1); Ertapenem, 1 (9.1) 
Enterobacter aerogenes 3  2 0 5 Cefuroxime, 2 (40); Cefadroxil, 1 (20); Ceftazidime, 1 (20); Meropenem, 1 (20); Gentamicin, 1 (20) 
Pseudomonas spp. 7 4 2 13 Ciprofloxacin, 2 (28.6); Ceftazidime, 2 (28.6); Piperacillin/Taz, 5 (71.4); Meropenem, 3 (42.9); Gentamicin, 1 
(14.3); Amikacin, 1(14.3); Ticarcillin/ clavulanate, 1 (14.3) 
Serratia marcescens 1 0 0 1 Piperacillin/Taz, 1 (100) 
Citrobacter koseri 1 3 1 5 Piperacillin/Taz, 1(100); Meropenem, 1 (100) 
Staphylococcus aureus  4 7 0 11 Flucloxacillin, 1 (25); Doxycycline, 2 (50); Clarithromycin, 3 (75); Clindamycin, 1(25) 
Haemophilus influenzae 3 0 1 4 Amoxicillin, 3 (100); Co-amoxiclav, 3 (100); Cefuroxime, 2 (66.7); Doxycycline, 1 (33.3) 
Acinetobacter baumanii 1 1 0 2 Ceftazidime, 1 (100) 
Burkholderia multivorans 1 0 0 1 Meropenem, 1 (100); Ceftolozane/Tazobactam, 1 (100) 
Enterococcus spp. 1 3 4 8 Amoxicillin, 1 (100); Gentamicin, 1 (100) 
Morganella morganii 1 0 0 1 Cefuroxime, 1 (100); Piperacillin/Taz, 1 (100)       
Raoultella sp. 1 0 0 1 Piperacillin/Taz, 1 (100) 
Total 45 33 10 88 
 
Legend 
• AMR is defined as resistance reported to one or more antimicrobial agents tested (excluding intrinsic resistances).317 Information in this table is based on the 
antimicrobial patterns released by individual sites for clinicians, other resistance may have been present but not reported 
• Piperacillin/Taz= Piperacillin/Tazobactam 
• Co-pathogens (with AMR) breakdown by species 
o Klebsiella spp.: Klebsiella pneumoniae (2), Klebsiella aerogenes (7), Klebsiella voriicola (1) 
o Pseudomonas spp.: Pseudomonas sp (1), Pseudomonas aeruginosa (6) 




Beyond 48 hours of hospital admission to the end of ICU stay, 124 potential co-pathogens 
were identified in 77 (30.3%) patients; 29 potential pathogens from Days 3 – 7 and 95 
potential pathogens from Day 8 onwards (Fig 8-2). The co-infection/ co-colonisation rate 
>48 hours after admission was 27.0 per 1000 person-days (95% CI 21.3-34.1). All were 
bacterial pathogens (n=122) except for two fungal organisms. The commonest potential 
co-pathogens identified were Gram-negative bacteria, including Klebsiella spp. (23 
patients) and Escherichia coli (20 patients). No viral co-pathogens were detected. Of the 
two fungal co-pathogens, one was Aspergillus fumigatus from a tracheal aspirate culture 
obtained on Day 5 in a 54-year old male. The other was Candida parapsilosis from a blood 
culture taken at Day 7 in a 55-year old lady. Neither patient had any pre-existing co-
morbidities.  
Fig 8-2: Bacterial pathogens detected after 48 hours of hospital admission; 124 potential 
pathogens detected 
  
Reported as proportion (%) of the total number of bacterial pathogens detected within ‘3-7 days’ 
and ‘>7 days’ from hospital admission. 





























On univariate analyses, patients aged 50-64 years were more likely to have a co-
infection/ co-colonisation than those aged 18-49 years. No other significant association 
was found (Table 8-9). Patients with co-infections/ co-colonisation were more likely to 
die in ICU (with coinfections/ co-colonisation, n=34 vs without coinfections/ co-
colonisation, n=48, crude OR 1.78, 95% CI 1.03-3.08, p=0.04) and had a longer hospital 
LOS (measured from admission to hospital to the end of ICU admission, subhazard ratio 
(likelihood of discharge from ICU) = 0.53, 95% CI 0.39-0.71, p< 0.001). 
Table 8-9: Univariate logistic regression analyses investigating the association between 






Number of patients   
Age       
    18-49 1 (Reference)   
    50-64 2.28 (1.14-4.53) 0.019* 
    65-74 1.12 (0.52-2.41) 0.777 
    75-84 0.53 (0.18-1.61) 0.263 
Gender       
    Male  1 (Reference)   
    Female 0.70 (0.40-1.23) 0.218 
Ethnicity       
White 1 (Reference)   
Black 1.89 (0.77-4.62) 0.164 
Asian 0.77 (0.26-2.22) 0.625 
Mixed 1.64 (0.26-10.13) 0.597 
Other 1.84 (0.40-8.57) 0.437 
aBAME 1.36 (0.71-2.61) 0.349 
Unknown 1.73 (0.87-3.42) 0.117 
Co-morbidities       
    Cardiovascular -   
    Respiratory -   
    Renal 1.38 (0.23-8.43) 0.725 
    Liver -   
    Metastatic disease -   
    Haematological malignancy 0.34 (0.04-2.83) 0.316 
    Immunocompromise 0.36 (0.08-1.65) 0.187 




*p value of <0.05 denotes a significant difference  
 # median and IQR 
aBAME is the total of Black, Asian, Mixed and Other ethnicities 
 
8.4 Discussion 
8.4.1 Principal findings 
Bacterial co-infection/ co-colonisation within 48 hours of hospital admission for COVID-
19 infection in adults was uncommon; 1.6% on admission and 5.5% within 48 hours. The 
commonest pathogens identified within the first 48 hours of hospital admission were 
Staphylococcus aureus and Streptococcus pneumoniae. The proportion of co-pathogens 
detected increased with duration of ICU stay and consisted largely of Gram-negative 
bacteria, particularly Klebsiella pneumoniae and Escherichia coli. The co-infection/ co-
colonisation rate >48 hours after admission was 27.0 per 1000 person-days (95% CI 21.3-
34.1). 
 
8.4.2 Comparison with literature: 
Concern regarding co-infection during viral pandemics, specifically respiratory co-
infection with a bacterial pathogen, is borne from previous experience in influenza. 
During the 2009 H1N1 influenza A pandemic, early co-infection rates were high; 22.5% 
within 72 hours of admission in adults requiring critical care.318 In contrast, limited 
evidence from studies of Severe Acute Respiratory Syndrome and Middle East 
Respiratory Syndrome suggest lower co-infection rates (10.3 to 18.5%).319,320 In COVID-19, 
systematic reviews based on studies predominantly from China reported low estimates 
(<7%) of bacterial co-infection.321–323 In the UK, a retrospective cohort study detected 
early bacterial infection (0-5 days from admission) in 3.2% of all hospitalised patients 




Youngs et al. reported bacterial co-infection within 48 hours of admission to ICU in 8% of 
patients with COVID-19 compared to 58% of patients with influenza, with no difference in 
the incidence of late infection between the two groups.325 In the US, higher early 
bacterial co-infection rates (16.6%) were identified by Crotty et al.; respiratory cultures 
positive for oral bacteria flora constituted 15/25 of these cases.326 In contrast to studies 
that relied on predominantly culture-based techniques, Kreitmann et al. identified early 
bacterial co-infection in 27.7% (13/47) of their prospective cohort of ventilated patients 
using a multiplex PCR assay with only one case identified by conventional culture.327 
Variations in case definitions, diagnostic testing and geography may partly account for 
the differences observed between studies although overall, there is a suggestion that 
increased severity of disease, particularly when ICU care is required, is associated with 
increased rates of co-infection.  
 
The prevalence of nosocomial infection is 20.6% and increases with duration of ICU 
stay.328,329 Our observed co-infection/ co-colonisation rate is relatively high, consistent 
with a patient cohort with long ICU stays (median 10 days) and requiring high levels of 
respiratory support.  
 
Consistent with reports from other studies, the commonest potential co-infecting 
bacteria identified within 48 hours of admission was S. aureus.324,327,330 In patients in 
whom early co-infection is suspected clinically, due consideration of S. aureus is 
warranted. However, the rate of S. aureus co-infection is markedly lower than that 
observed in pandemic influenza, suggesting it is a less significant issue with COVID-19 
infection.318 The predominant late pathogens observed were Gram-negative bacteria, 
particularly K. pneumoniae. These pathogens are commonly associated with hospital and 




COVID-19 infections, particularly ICU cohorts.321,322,331–333 The predominance of Gram-
negative bacteria in these studies likely reflects nosocomial infection following prolonged 
ICU stay and empirical antibiotic use.  
 
Viral co-pathogen was identified in one patient in our cohort; lower than the 3% (95% CI 
1-6%) viral co-infection rate reported in systematic reviews and in contrast to the 20.7% 
viral co-detection rate reported by Kim et al. in Northern California.321,334 The 2019/20 
influenza season in the UK ended in late March.335 Other UK cohorts recruited during the 
spring wave of COVID-19 (March - May 2020) similarly reported very little or no viral co-
infection.324,333 
 
8.4.3 Strengths and limitations 
This pragmatic multicentre study provides novel data on both community-acquired and 
nosocomial co-infection/ co-colonisation in patients with COVID-19 requiring ICU care in 
England. The ICU cohort represents those with severe disease who were subject to more 
rigorous microbiology sampling.  
 
A key limitation of the study is its retrospective observational design subject specifically 
to case selection, ascertainment and sampling biases. Inclusion of consecutive eligible 
patients was not feasible due to pandemic workload constraints. To minimise case 
selection bias, participating sites submitted a random sample of their eligible cohort, 
although random sampling methods were not standardised. The impact of ascertainment 
bias due to differences in the proportion of eligible cases submitted by each institution 
was reduced through the participation of multiple centres. The study cohort was 
comparable to the ICNARC cohort except for an under-representation of patients of 




with larger BAME populations. Restriction of our cohort to those with completed ICU 
admissions excluded: i) frailer patients in whom ICU care was deemed not appropriate, 
and ii) patients with very long ICU stays. Co-infection, particularly nosocomial infection, 
may be higher in these patients. A second key limitation is that although results likely to 
represent contamination were excluded, some pathogens found in respiratory tract 
samples may represent colonisation rather than active co-infection. However, as sputum 
samples sent from ICU should reflect clinical concern of lower respiratory tract infection 
(especially during the pandemic timeframe) and positive culture represents predominant 
presence of a pathogen rather than as part of mixed flora, we have taken these results to 
represent infection. If colonising pathogens were wrongly attributed as causing infection, 
the direction of bias would be towards falsely higher co-infection rates observed in our 
study. Thirdly, reliance on culture dependent techniques may have falsely decreased co-
infection rates. Antibiotic use prior to admission was low (13.8%), increasing the 
reliability of culture-based methods on admission. However, detection of pathogens later 
into admission would have been influenced by sampling bias and the use of empirical 
antibiotics. Fourthly, although seven hospitals participated in this study, one study site 
contributed a third of cases; observed 48-hour co-infection/ co-colonisation rate 
excluding this site was, however, similar to overall results.  
 
8.4.4 Implications for future work 
Notwithstanding these limitations, our data indicate that early in hospitalisation, 
bacterial co-infection in COVID-19 is very uncommon and support the recommendations 
that empirical antibiotics should not be started routinely in primary care or at the point 
of hospital admission without clinical suspicion of bacterial infection.307 The high rate of 
co-infection found late in illness among patients requiring ICU and involving nosocomial 




exposure in patients with COVID-19 could reduce their risk of late, Gram negative, 
potentially antibiotic resistant infections.336,337  
 
Since study completion, dexamethasone has been shown to decrease mortality in 
patients hospitalised with COVID-19 who require oxygen support or invasive mechanical 
ventilation.338 Consequently, dexamethasone has become established as standard of care 
for these patients in many countries. This may increase the already high rate of bacterial 
co-infection we observed in ICU-treated patients. A high level of microbiological vigilance 
is recommended as part of the management of these patients. In the setting of seasonal 
changes in respiratory pathogens, ongoing surveillance for co-infections in patients 
hospitalised with COVID-19, ideally through prospective studies with standardised 



















9.1 Key findings  
This thesis has investigated different aspects of morbidity after CAP and these are the key 
findings: 
1. Chapter 3: A previously unrecognised large burden of morbidity during recovery 
from pneumonia was found, with almost 56% of patients consulting primary care 
within 30 days of hospital discharge. The highest rate of consultation occurred 
early, i.e. within 7 days. Nearly 40% of consultations were for a respiratory 
disorder and 30% of patients consulting received further antibiotics.  
2. Chapter 4: The systematic review of 47 studies found in-hospital incidence of 
cardiac complications of 3.1% for ACS, 7.7% for heart failure and 7.9% for 
arrhythmia. The commonly reported risk factors include older age, severity of 
pneumonia and pre-existing cardiac disease. Patients who developed cardiac 
complications were approximately three times more likely to die both in-hospital 
and within 30 days of admission than those who did not.  
3. Chapter 5: Compared to age, gender and practice-matched patients without 
pneumonia in the population-based study, those with pneumonia were 
significantly at higher risk of developing all cardiac complications, with the 
highest risk observed for developing arrhythmia at 30 days after discharge, and 
declining incidence at 90 days and 1 year.  
4. Chapter 6: The systematic review of 27 studies found that current and ex-
smokers were both significantly at higher risk of developing CAP whilst passive 
tobacco smoke exposure had a significant effect only in those aged ≥ 65. With 
current smokers, a dose-response trend with higher risk of CAP in those where 




5. Chapter 7: From the population-based study, 3.1% and 9.0% developed recurrent 
pneumonia within 90 days and 1 year of follow-up respectively. Current tobacco 
smoking status at index hospitalisation for pneumonia was independently 
associated with a higher risk of recurrent pneumonia. Only 40% of patients who 
smoke that were hospitalised with pneumonia received stop smoking 
interventions in the year before and even less with 30% in the year after 
admission for index pneumonia.  
6. Chapter 8: Bacterial co-infection within 48 hours of hospital admission for COVID-
19 infection in adults was uncommon; 1.6% on admission and 5.5% within 48 
hours. The commonest pathogens identified within the first 48 hours of hospital 
admission were S. aureus and S. pneumoniae. The proportion of co-pathogens 
detected increased with duration of ICU stay and consisted largely of Gram-
negative bacteria, particularly Klebsiella pneumoniae and Escherichia coli. 
Patients with co-infections were more likely to die in ICU (crude OR 1.78,95% CI 
1.03-3.08, p=0.04) compared to those without co-infections.  
 
9.2 Implications 
Taken together, this thesis highlights that patients experience a significant morbidity 
during recovery from pneumonia. After discharge from hospital, patients often continue 
to report persistence of symptoms, including fatigue, cough and dyspnoea, associated 
with functional impairment for several weeks.54 Previous studies have demonstrated that 
patients often lack a clear understanding about the short and long-term consequences of 
CAP, or the natural course of their symptoms.95,96 Ongoing unaddressed patient needs 
may contribute towards the high level of primary care consultation observed as patients 




context of current COVID-19 pandemic, ‘long covid’ is a term that is widely used to 
describe signs and symptoms which develop during or after a COVID-19 infection which 
persists for more than 12 weeks, without an alternative diagnosis.339 Symptoms described 
are similar to that seen in CAP generally, irrespective of the causative pathogen including 
fatigue, cough and breathlessness.101 Education of patients, the public, clinicians and 
policy makers regarding the sometimes prolonged morbidity associated with 
hospitalisation with pneumonia is necessary to support patient recovery. 
 
This thesis has also provided a deeper insight into the importance of preventing or 
reducing considerable burden of morbidity that patients experience after pneumonia, 
with specific focus to cardiac complications after pneumonia and addressing tobacco 
smoking. Most cardiac complications occur within 30 days of hospitalisation for CAP, with 
declining rate at 90 days and subsequently a year after CAP. An individualized risk 
assessment would be useful to identify patients at risk in order to target measures for 
preventing the occurrence of cardiac complications. These may include provision of 
pneumococcal and influenza vaccination alongside potential adjunctive therapies as 
discussed in Chapter 5.  A major concern noted in this thesis was that cardiac 
complications following CAP is associated with high risk of mortality. In view of this, a 
high index of suspicion for cardiac complications is needed; these patients should be 
promptly investigated and managed effectively to prevent the progression of the cardiac 
complications. 
 
Tobacco smoking is associated with an increased risk of developing cardiovascular 
disease as well as pneumonia, with a well-described dose-dependent association.205,206 
This observation is further extended to an association between tobacco smoking, a 




implementing effective smoking cessation interventions, which include behavioural 
support, pharmacotherapy (bupropion, nicotine replacement therapy and varenicline) 
and very brief advice as a key component of pneumonia management, in accordance 
with the NHS Long Term Plan.93,292  
 
Chapter 8 in this thesis raises a crucial issue on the management of critically ill patients 
with COVID-19 infection. A better understanding of the incidence of co-infection in these 
patients and the pathogens involved is necessary for effective antimicrobial stewardship. 
Only limited evidence for community-acquired bacterial co-infection was found, but 
there was a high rate of Gram-negative infection acquired during ICU stay. This study 
supports the recommendation that empirical antibiotics should not be started routinely 
in primary care or at the point of hospital admission without clinical suspicion of bacterial 
infection.307 The high rate of co-infection found late in illness among patients requiring 
ICU and involving nosocomial pathogens is concerning. It is plausible that reducing 
unnecessary early antibiotic exposure in patients with COVID-19 could reduce their risk of 
late, Gram negative, potentially antibiotic resistant infections.336,337 
 
9.3 Future research recommendations 
Research in this thesis have identified that a lack of recognition of the burden of 
morbidity during recovery from pneumonia has thus far meant that evidence-based 
interventions to meet patients’ needs have not been adequately developed. Future 
research should focus on developing targeted interventions to improve patients’ 
knowledge of their condition and recovery, therefore empowering them to become more 
aware of when to seek medical attention, and in turn reducing avoidable healthcare 




standardised patient information resource (for instance, in the form of written 
information leaflet, dedicated website, video, mobile app on its own or in combination), 
and patient support using telephone helpline by a dedicated pneumonia specialist nurse 
compared to ‘usual care’ would provide valuable information on the appropriate cost-
effective measures that should be implemented to improve patient experience when 
diagnosed with pneumonia (Table 9-1). As part of this initiative, I have worked closely 
with the Graphic Design and Video Production team locally to design and complete the 
recording of a patient information video about pneumonia which has been uploaded to 
The Pneumonia Trust website (http://www.pneumoniatrust.co.uk). This video would be a 
useful resource for patients, families and healthcare professionals who want to obtain 
more information about what is pneumonia, the causes, prevention, diagnosis, treatment 






Patients - Adults (≥18) hospitalised with community-acquired pneumonia (CAP) 
Intervention – Randomised-controlled trial of enhanced nurse-led support, delivered 
by dedicated pneumonia specialist nurse versus usual care 
• providing standardised patient information resource (for instance, in the 
form of written information leaflet, dedicated website, video, and mobile 
application) prior to discharge from hospital 
• stop smoking interventions 
• physiotherapy review 
• active telephone contact at 7 days (unless otherwise stated by patient) 
• passive helpline for patients to contact after discharge (up to 6 weeks) 
• offer of face-to-face clinic visit if deemed necessary from telephone 
conversation. 
Control - usual care which consist of verbal information 
 
 






















Deciding whether a consultation is warranted, or not, is a clinical decision that includes 
consideration of a range of factors including social, medical and behavioural factors. The 
current study in Chapter 3 provides the platform to design and conduct further studies 
that will address the many remaining unanswered questions in this field, including the 
proportion of post-discharge consultations that are warranted, how many and which 
consultations may be avoided and whether there are barriers to consultation (for those 
who should consult but do not). To accurately measure and assess the value of a 
consultation would ideally require a prospective study design that captures the opinion of 
the attending healthcare professional as well as collection of data relating to the full 
range of actions arising from a consultation, such as referral for an x-ray, secondary care 
consultation, other investigations, and input from other healthcare professionals.  
Outcome - 
• Primary outcome measured at 6 weeks: healthcare utilisation rate 
(including primary care, urgent care, emergency department visits and 
hospital readmissions)  
• Secondary outcomes measured at 6 weeks, 90 days and 1 year: 
o functional impairment: return to work, loss of independence, job loss 
o patient experience: change in patient reported outcome measure 
(CAP-symptom questionnaire), change in Hospital Anxiety and 
Depression Scale (HADS) score  
o smoking status 
o incidence of cardiac complications 
 
The main difference in the suggested care pathway compared to current care is the 
provision of additional package of information and enhanced nurse-led support.  The 
health economic cost would take into account the cost of employing a dedicated 
pneumonia specialist nurse, cost of telephone support, cost of running a drop-in 
clinic.  There is a potential cost saving from reduction in healthcare resource 
utilisation (e.g., reduction in length of hospital stay, readmission and primary care, 






Antibiotic use is associated with the development of antimicrobial resistance (AMR) 
which is acknowledged globally as a major threat to public and individual health. This is 
evidenced by the World Health Organisation (WHO)’s commitment to tackling AMR, the 
selection of AMR by the UK public as the challenge for the current “Longitude Prize”, and 
the Department of Health’s strategic paper on AMR.340–342 With regards to antibiotic 
prescribing at post-discharge consultation, further studies are required to determine the 
reasons for antibiotic prescription at these consultations especially at the interface 
between primary and secondary care, and their appropriateness. 
 
Most cardiac complications occur within 30 days of hospitalisation for CAP, with 
associated high mortality. There is yet a validated prediction tool that clinicians can easily 
use to identify patients who are at high risk of developing cardiac complications when 
hospitalised for CAP. This tool could include identified risk factors from this thesis such as 
age, gender, smoking status, pre-existing heart disease and potentially including cardiac 
biomarkers if more evidence becomes available. A change of approach in managing 
patients with pneumonia is warranted; although the identified risk factors are also 
intuitively the common risk factors for developing heart disease, unless a high index of 
suspicion for cardiac complications after pneumonia is present amongst treating 
physicians, these patients will not receive the optimum medical management. In 
addition, randomised controlled trials would be required to assess the role of 
vaccinations (pneumococcal and influenza) and potential adjunctive therapies such as 
statins, antiplatelet drugs and angiotensin-converting enzyme inhibitors (ACEI) or 






As previously discussed, tobacco smoking is an important modifiable risk factor for 
developing index pneumonia, recurrent pneumonia and cardiac complications. 
Reassuringly, the risk is lower in ex-smokers. However, further research is warranted to 
establish why and for how long ex-smokers continue to be at higher risk following 
smoking cessation, compared to those who have never smoked. An extension to the 
study in Chapter 7 could potentially be to assess the risk of recurrent pneumonia in ex-
smokers. In order to investigate this, a prospective study design is needed, documenting 
the conversion of current smokers on admission for index hospitalisation for pneumonia 
to ex-smokers on or after discharge. Data on change in smoking status can be collected 
using self-reported smoking status and validated by measuring exhaled carbon monoxide. 
The risk of recurrent CAP can be subsequently measured at 6-month or 12-month follow-
up.343  
 
Chalmers et al. concluded that pneumonia is an ‘underestimated, neglected and 
underfunded’ condition in the UK.344 The COVID-19 pandemic has in many ways paved 
pathways to improve our understanding on morbidity after CAP. There is a surge in 
research worldwide assessing the long-term effects of COVID-19 or ‘long covid’.102 The 
Post-hospitalisation COVID-19 Study (PHOSP-COVID) in the UK aims to recruit 10, 000 
patients, who will be followed-up for a year.345 Similar studies assessing the long-term 




In conclusion, this thesis highlights that patients experience a significant morbidity during 




has thus far meant that evidence-based interventions to meet patients’ needs have not 
been adequately developed. The COVID-19 pandemic has in many ways paved pathways 
to improve our understanding on the morbidity after CAP. The recognition of ‘long covid’ 
and the surge in current global research into assessing the long-term effects of COVID-19 
may inform relevant interventions that could be applied to effectively reduce the 
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Appendix 1: ISAC Protocol 
ISAC APPLICATION FORM 
PROTOCOLS FOR RESEARCH USING THE CLINICAL PRACTICE 
RESEARCH DATALINK (CPRD) 
       













Please refer to the guidance for ‘Completing the ISAC application 
form’ found on the CPRD website (www.cprd.com/isac). If you have 




SECTION A: GENERAL INFORMATION ABOUT THE PROPOSED RESEARCH STUDY 
 
1. Study Title§ (Please state the study title below) 
Study of recovery in patients hospitalised with community acquired pneumonia using 
Clinical Practice Research Datalink (CPRD), linked to Hospital Episode Statistics. 
 
§Please note: This information will be published on the CPRD’s website as part of its transparency policy.  
2. Has any part of this research proposal or a related proposal been previously submitted to 
ISAC?  
Yes *   No  √ 
 
*If yes, please provide the previous protocol number/s below. Please also state in your current submission how 
this/these are related or relevant to this study. 
       
 
3. Has this protocol been peer reviewed by another Committee? (e.g. grant award or ethics 
committee) 
Yes*    No  √ 
 
*If Yes, please state the name of the reviewing Committee(s)  below and provide an outline of the review process 
and outcome as an Appendix to this protocol :       
 
4. Type of Study (please tick all the relevant boxes which apply) 
 
Adverse Drug Reaction/Drug Safety     Drug Effectiveness                               
Drug Utilisation                √ Pharmacoeconomics       
Disease Epidemiology      √ Post-authorisation Safety                         
Health care resource utilisation     √ Methodological  Research                                     
Health/Public Health Services Research               Other*                                                                                   
  
*If Other, please specify the type of study here and in the lay summary below: 
 
5. Health Outcomes to be Measured§ 
§Please note: This information will be published on CPRD’s website as part of its transparency policy. 
 
Please summarise below the primary/secondary health outcomes to be measured in this research 
protocol: 
Primary outcomes 
• Reconsultation rate following hospitalisation for CAP, stratified by time: within the first 7 days, 
8- 14 days, 15- 30 days, 31- 60 days 





• Antibiotic prescription rate at reconsultation 
 
Secondary outcomes 
• Types of antibiotics prescribed at reconsultation 
• Association of antibiotic prescription at reconsultation with further reconsultation episodes 
within 30 days 
• Assocation of reconsultation with underlying comorbid illnesses  
• Incidence of incipient cognitive decline and cardiac disease following CAP at 30 days, 90 
days and 1 year.  
• To determine whether current smokers admitted with index pneumonia were given smoking 
cessation advice both before and after developing pneumonia  
• To determine the rate of recurrent pneumonia by smoking status 
• To determine the effect of tobacco smoking on hospitalisation for recurrence of pneumonia 
   
 
6. Publication: This study is intended for (please tick all the relevant boxes which apply): 
 
Publication in peer-reviewed journals  √ Presentation at scientific conference √ 
Presentation at company/institutional meetings √ Regulatory purposes    
Other*       
 
*If Other, please provide further information:       
SECTION B: INFORMATION ON INVESTIGATORS AND COLLABORATORS 
 
7. Chief Investigator§  
Please state the full name, job title, organisation name & e-mail address for correspondence - see guidance 
notes for eligibility. Please note that there can only be one Chief Investigator per protocol.  
 
Tricia McKeever 
Division of Epidemiology and Public Health 
Clinical Sciences Building 
Nottingham City Hospital 
Tricia.McKeever@nottingham.ac.uk 
 
§Please note: The name and  organisation of the Chief Investigator and  will be published on CPRD’s website as part of its 
transparency policy 
 
CV has been previously submitted to ISAC  √   CV number:  655_16 
A new CV is being submitted with this protocol              
An updated CV is being submitted with this protocol        
 
 
8. Affiliation of Chief Investigator (full address) 
 
Tricia McKeever 
Division of Epidemiology and Public Health 
Clinical Sciences Building 




9. Corresponding Applicant§ 
Please state the full name, affiliation(s) and e-mail address below: 
 
Dr Vadsala Baskaran 
Nottingham University Hospitals NHS Trust 






Nottingham NG5 1PB 
vadsala.baskaran@nhs.net 
 
§Please note: The name and  organisation of the corresponding applicant and their organisation  name will be published on 
CPRD’s website as part of its transparency policy 
 
Same as chief investigator       
CV has been previously submitted to ISAC    CV number:        
A new CV is being submitted with this protocol             √  
An updated CV is being submitted with this protocol        
 
10. List of all investigators/collaborators§  
Please list the full name, affiliation(s) and e-mail address* of all collaborators, other than the Chief Investigator 
below: 
 
§Please note: The name of all investigators and their organisations/institutions will be published on CPRD’s website as part of 
its transparency policy 
 
Other investigator:  
 
Professor Wei Shen Lim 
Nottingham University Hospitals NHS Trust 
City Hospital Campus 
Hucknall Road 
Nottingham NG5 1PB 
 
CV has been previously submitted to ISAC    CV number:        
A new CV is being submitted with this protocol             √  
An updated CV is being submitted with this protocol        
 
Other investigator:       
CV has been previously submitted to ISAC    CV number:        
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
Other investigator:       
CV has been previously submitted to ISAC    CV number:        
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
Other investigator:       
CV has been previously submitted to ISAC    CV number:        
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
[Please add more investigators as necessary] 
 
*Please note that your ISAC application form and protocol must be copied to all e-mail addresses listed above at the time of 
submission of your application to the ISAC mailbox. Failure to do so will result in delays in the processing of your application. 
 
11. Conflict of interest statement*  
Please provide a draft of the conflict (or competing) of interest (COI) statement that you intend to include in any 
publication which might result from this work 
 
Each publication will acknowledge National Institute of Health Research (NIHR) Nottingham 
BRC as the study funder.  
VB- received salary derived from NIHR Nottingham BRC 







*Please refer to the International Committee of Medical Journal Editors (ICMJE) for guidance on what constitutes a COI. 
 
12. Experience/expertise available  
Please complete the following questions to indicate the experience/ expertise available within the team of 
investigators/collaborators actively involved in the proposed research, including the analysis of data and 
interpretation of results. 
 
 Previous GPRD/CPRD Studies Publications using GPRD/CPRD data 
None                        
1-3                         
> 3  √                      √  
 
Experience/Expertise available  Yes No 
Is statistical expertise available within the research team? 
If yes, please indicate the name(s) of the relevant investigator(s)   
 Tricia McKeever  
√  
Is experience of handling large data sets (>1 million records) 
available within the research team? 
If yes, please indicate the name(s) of the relevant investigator(s) 
 Tricia McKeever 
√  
Is experience of practising in UK primary care available to or within 
the research team? 
If yes, please indicate the name(s) of the relevant investigator(s)  
 Tricia McKeever 
√  
13. References relating to your study 
Please list up to 3 references (most relevant) relating to your proposed study:  
 
Daniel P, Bewick T, McKeever TM, Roberts M, Ashton D, Smith D, et al. Healthcare reconsultation in 
working-age adults following hospitalisation for community-acquired pneumonia. Clin Med J R Coll 
Physicians London. 2018;18(1):41–6.  
 
Millett ERC, Quint JK, Smeeth L, Daniel RM, Thomas SL. Incidence of community-acquired lower 
respiratory tract infections and pneumonia among older adults in the United Kingdom: A population-
based study. PLoS One. 2013;8(9).  
 
Lim WS, Baudouin S V, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the 
management of community acquired pneumonia in adults: update 2009. Thorax [Internet]. 







SECTION C: ACCESS TO THE DATA  
 
14. Financial Sponsor of study§ 
§Please note: The name of the source of funding will be published on CPRD’s website as part of its transparency policy 
 
Pharmaceutical Industry             Please specify name and country       
Academia   √              Please specify name and country: NIHR Nottingham BRC 
Government / NHS             Please specify name and country:      
Charity              Please specify name and country:      
Other              Please specify name and country:      
None    
 
15. Type of Institution conducting the research 
 
Pharmaceutical Industry             Please specify name and country:      
Academia   √           Please specify name and country: University of Nottingham 
Government Department             Please specify name and country:      
Research Service Provider             Please specify name and country:      
NHS                 Please specify name and country:  
Other               Please specify name and country:      
16. Data access arrangements 
 
The financial sponsor/ collaborator* has a licence for CPRD GOLD and will extract  the data               
                
The institution carrying out the analysis has a licence for CPRD GOLD and will extract the data**        
√ 
A data set will be provided by the CPRD¥€            
 
CPRD has been commissioned to extract the data and perform the analyses€                                       
  
Other:          
 
If Other, please specify:       
 
*Collaborators supplying data for this study must be named on the protocol as co-applicants. 
**If data sources other than CPRD GOLD are required, these will be supplied by CPRD 
¥Please note that datasets provided by CPRD are limited in size; applicants should contact CPRD (enquiries@cprd.com) if a 
dataset of >300,000 patients is required. 
€Investigators must discuss their request with a member of the CPRD Research team before submitting an ISAC application. 
Please contact the CPRD Research Team on +44 (20) 3080 6383 or email (enquiries@cprd.com) to discuss your 
requirements. Please  also state the name of CPRD Research team with whom you have discussed this request (provide the 
date of discussion and any relevant reference information):   
 
 Name of CPRD Researcher   Tarita Murray-Thomas       Reference number (where available) -                      
Date of contact 8/2/18    
17. Primary care data  
Please specify which primary care data set(s) are required) 
Vision only (Default for CPRD studies               √       Both Vision and EMIS®*            
EMIS® only*          
       
Note: Vision and EMIS are different practice management systems. CPRD has traditionally collected data from Vision practice. 
Data collected from EMIS is currently under evaluation prior to wider release.  
*Investigators requiring the use of EMIS data must discuss the study with a member of the CPRD Research team before 
submitting an ISAC application 
 
Please state the name of the CPRD Researcher with whom you have discussed your request for 
EMIS data: 
Name of CPRD Researcher           Reference number (where available)          Date of contact 






18. Site Location of Data 
a) Processing location(s): 
 
Location area - UK / EEA / Worldwide: UK 
 




Note: Please enter the location details of where the data for this study will be used (processed). 
b) Storage Location(s) 
 
Location area - UK / EEA / Worldwide: UK 
 








Note: Please enter the location details of where the data for this study will be stored. 






Note: Please enter the details of where the data for this study will be analysed. 
SECTION D: INFORMATION ON DATA LINKAGES 
 
19. Does this protocol seek access to linked data 
 
Yes* √  No          If No, please move to section E. 
 
*Research groups which have not previously accessed CPRD linked data resources must discuss access to these resources 
with a member of the CPRD Research team, before submitting an ISAC application. Investigators requiring access to HES 
Accident and Emergency data, HES Diagnostic Imaging Dataset, PROMS data, the Pregnancy Register, Cancer Registration, 
SACT and CPES data and the Mental Health Services Data Set must also discuss this with a member of the CPRD Research 
team before submitting an ISAC application. Please contact the CPRD Research Team on +44 (20) 3080 6383 or email 
enquiries@cprd.comto discuss your requirements before submitting your application. 
 
Please state the name of the CPRD Researcher with whom you have discussed your linkage request.  
 
Name of CPRD Researcher Elizabeth Crellin       Reference number (where available)            Date 
of contact 10.07.2018    
 
Please note that as part of the ISAC review of linkages, your protocol may be shared - in confidence - with a representative of 
the requested linked data set(s) and summary details may be shared - in confidence - with the Confidentiality Advisory Group 
of the Health Research Authority.  
 
20. Please select the source(s) of linked data being requested§ 
§Please note: This information will be published on the CPRD’s website as part of its transparency policy.  
 
 ONS Death Registration Data                             
√   HES Admitted Patient Care                   NCRAS (National Cancer Registration and Analysis Service) 
Cancer Registration Data * 
  HES Outpatient                                      NCRAS Cancer Patient Experience Survey (CPES) data* 
   HES Accident and Emergency               NCRAS Systemic Anti-Cancer Treatment (SACT) data* 
 HES Diagnostic Imaging Dataset   
 HES PROMS (Patient Reported 






 CPRD Mother Baby Link  
 Pregnancy Register  
  
 Practice Level Index of Multiple Deprivation (Standard) 
 Practice Level Index of Multiple Deprivation (Bespoke) 
 Patient Level  Index of Multiple Deprivation*** 
 Patient Level Townsend Score *** 
 
*Applicants seeking access to NCRAS data must complete a Cancer Dataset Agreement form (available from CPRD). This 
should be submitted to the ISAC as an appendix to your protocol. Please also note that applicants seeking access to cancer 
registry data must provide consent for publication of their study title and study institution on the UK Cancer Registry website.  
**Assessment of the quality of care delivered to NHS patients in England undergoing four procedures: hip replacement, knee 
replacement, groin hernia and varicose veins. Please note that patient level PROMS data are only available for non-
commercial purposes, such as academic research, or in connection with delivering services to the NHS. 
*** ‘Patient level IMD and Townsend scores will not be supplied for the same study 
****If “Other” is specified, please provide the name of the individual in the CPRD Research team with whom this linkage has 
been discussed.  
 
Name of CPRD Researcher Elizabeth Crellin    Reference number (where available)                                
Date of contact 10.07.2018  
 
21. Total number of linked datasets requested including CPRD GOLD  
 
Number of linked datasets requested (practice/ ’patient’ level Index of Multiple Deprivation, Townsend Score, the 
CPRD Mother Baby Link and the Pregnancy Register should not be included in this count)  2 
 
Please note:  Where ≥5  linked datasets are requested, approval may be required from the Confidentiality Advisory Group 
(CAG) to access these data 
 
22. Is linkage to a local¥ dataset with <1 million patients being requested?  
 
 
Yes *   No  √ 
 
 *If yes, please provide further details:       
¥ Data from defined geographical areas i.e. non-national datasets. 
 
23. If you have requested one or more linked data sets, please indicate whether the Chief 
Investigator or any of the collaborators listed in question 5 above, have access to these 
data in a patient identifiable form (e.g. full date of birth, NHS number, patient post code), or 
associated with an identifiable patient index. 
Yes*             No  √ 
 
* If yes, please provide further details:       
 
24. Does this study involve linking to patient identifiable data (e.g. hold date of birth, NHS 
number, patient post code) from other sources? 
Yes   No  √ 
 
SECTION E: VALIDATION/VERIFICATION 
 
25. Does this protocol describe a purely observational study using CPRD data? 
 
Yes*  √  No**   
 
 * Yes: If you will be using data obtained from the CPRD Group, this study does not require separate ethics approval from an 
NHS Research Ethics Committee. 
** No: You may need to seek separate ethics approval from an NHS Research Ethics Committee for this study. The ISAC will 
provide advice on whether this may be needed. 
 






Yes*    No  √ 
 
 * If yes, please indicate what will be required:  
 
  Completion of questionnaires by the GP        Yes         No  
     Is the questionnaire a validated instrument?                                              Yes         No  
     If yes, has permission been obtained to use the instrument?                     Yes        No   
     Please provide further information:       
 
  Other (please describe)       
 
 Any questionnaire for completion by GPs or other health care professional must be approved by ISAC before circulation for 
completion.  
  
27. Does this study require contact with patients in order for them to complete a 
questionnaire? 
 
Yes*    No  √ 
 
*Please note that any questionnaire for completion by patients must be approved by ISAC before circulation for completion.  
 
28. Does this study require contact with patients in order to collect a sample? 
 
Yes*    No  √ 
 
* Please state what will be collected:         
 
SECTION F: DECLARATION 
 
29. Signature from the Chief Investigator 
 
▪ I have read the guidance on ‘Completion of the ISAC application form’ and ‘Contents of CPRD ISAC 
Research Protocols’ and have understood these; 
▪ I have read the submitted version of this research protocol, including all supporting documents, and confirm 
that these are accurate.  
▪ I am suitably qualified and experienced to perform and/or supervise the research study proposed. 
▪ I agree to conduct or supervise the study described in accordance with the relevant, current protocol  
▪ I agree to abide by all ethical, legal and scientific guidelines that relate to access and use of CPRD data for 
research  
▪ I understand that the details provided in sections marked with (§) in the application form and protocol will be 
published on the CPRD website in line with CPRD’s transparency policy. 
▪ I agree to inform the CPRD of the final outcome of the research study: publication, prolonged delay, 
completion or termination of the study. 
 







PROTOCOL INFORMATION REQUIRED 
 
The following sections below must be included in the CPRD ISAC research protocol. Please 
refer to the guidance on ‘Contents of CPRD ISAC Research Protocols’ (www.cprd.com/isac) 
for more information on how to complete the sections below.  Pages should be numbered. All 
abbreviations must be defined on first use. 
 
Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
 
A. Study Title§ 
§Please note: This information will be published on CPRD’s website as part of its transparency policy 
 
Study of recovery in patients hospitalised with community acquired pneumonia using 
Clinical Practice Research Datalink (CPRD), linked to Hospital Episode Statistics. 
 
B. Lay Summary (Max. 200 words)§ 
§Please note: This information will be published on CPRD’s website as part of its transparency policy 
 
Community acquired pneumonia (CAP) is a common condition. Each year in the UK, over 
100,000 adults are hospitalised because of CAP. Most (85 % - 90%) survive and are 
discharged after an average hospital stay of 7 days. Following discharge, patients report 
slow recovery lasting many weeks (~50% still have symptoms at 4 weeks). Some develop 
new heart problems. Many (>60%) reconsult their GPs after discharge, and a third 
receive more antibiotics. 
 
The frequency at which post-discharge complications and reconsultation occurs are 
poorly described. Who suffers most and why are not understood. We propose using data 
from the Clinical Practice Research Datalink linked to Hospital Episode Statistics to 
determine the: 
• frequency of reconsultation following a hospitalisation with CAP and the reasons thereof  
• frequency and type of antibiotic prescription at reconsultation 
• frequency of new heart and memory problems in the months following hospitalisation. 
 
We will investigate who is more likely to develop problems during recovery from CAP, 
what those problems are and why these problems develop. We will also explore the 
value of additional antibiotic use after hospital treatment. These findings will aid 
identification of strategies to improve the care of patients recovering from CAP. 
 
C. Technical Summary (Max. 200 words)§ 
§Please note: This information will be published on CPRD’s website as part of its transparency policy 
 
Objectives 
To determine the incidence and reasons for reconsultation following hospitalisation with CAP, 
including antibiotic usage at reconsultation. 
 
Methods 
Adults with a first episode of hospitalised CAP between July 2002- June 2017 as recorded 
in CPRD linked to HES based on ICD-10 codes (J12- J18) will be included.  
 
Data analysis 
Statistical analyses will be performed using Stata 15. Incidence of CAP and other diseases 
(cognitive decline and cardiac complications) following CAP will be estimated using the 
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adjusted incidence rate ratios and 95% confidence intervals will be described. 
 
The independent association between patient characteristics and rate of reconsultation 
(overall/ patients without co-morbidities /patients with underlying respiratory disease) 
will be calculated using a multivariate logistic regression model; adjusted for age, gender, 
smoking, social deprivation, co-morbidities, vaccine status, length of hospital stay and 
intensive care unit admission. Causes of reconsultation will be divided into either 
respiratory or non-respiratory (cardiac symptoms and cognitive decline) symptoms. 
 
We will measure the number of antibiotic prescriptions at reconsultation and where 
possible, the type of antibiotics prescribed. Association of antibiotic prescription at 
reconsultation with further reconsultation episodes will also be analysed. 
 
D. Objectives, Specific Aims and Rationale 
Objectives 




• To determine the rate of reconsultation following hospitalisation for CAP 
• To determine the cause(s) of reconsultation  
• To determine the number and type of antibiotic prescriptions at reconsultation 
• To explore whether antibiotic prescription at reconsultation is associated with further 
reconsultation episodes. 
• To investigate the association between reconsultation rate and underlying co-morbid 
diseases.  
• To investigate  the medium and longer-term extra-pulmonary impacts of CAP by 
determining the incidence of incipient cognitive decline and cardiac disease at 30 days, 
90 days and 1 year after hospitalisation for CAP. 
. 
Rationale 
Patients report a high level of morbidity in the weeks following hospital treatment for 
CAP. However, there is almost no evidence-base to guide the management of patients 
post-discharge. Reconsultation and additional antibiotic use is common though their 
appropriateness is unknown. The CPRD-HES dataset provides a valuable means to close 
this evidence gap. The findings from this study will provide the grounding needed for the 
identification and development of interventions with the ultimate aim of reducing 
patient morbidity and healthcare resource utilisation. 
 
E. Study Background 
Lower respiratory tract infections (LRTIs) were reported as the ‘most deadly 
communicable disease’ worldwide in 2015, causing 3.2 million deaths.27 It is the second 
commonest cause of death globally after ischaemic heart disease.346 LRTI is a common 
diagnosis seen by primary care general practitioners, covering a spectrum of disease 
ranging from acute bronchitis to severe community acquired pneumonia (CAP). 
Community acquired pneumonia accounts for 5- 12% of LRTIs presenting to general 
practitioners.23 Of these, 22- 42% are referred to hospital for further management.3 
Every year, over 100 000 patients with CAP are admitted to hospital in the UK.97,347 
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shown that between 35-86.5% of patients report at least one-CAP related symptom 30 
days following radiographic evidence of pneumonia. 29,348 In a study of pneumococcal 
pneumonia, the symptoms that persisted were cough, dyspnoea, sputum production, 
pleuritic chest pain and fatigue349. The effect of prolonged symptom persistence during 
recovery on healthcare utilisation is not fully explored. In a study by Daniel et al, 65.7% 
of working age adults (18-65) reconsulted healthcare services within 28 days of discharge 
from hospital; 90.1% of these patients consulted their GP within 2 weeks of hospital 
discharge and 37% received further antibiotics.47  
 
Patients with CAP have been shown to develop new-onset cognitive impairment in both 
young and old adult patients.350 Significant cardiac complications occur in patients within 
30 days of CAP diagnosis.159  
 
F. Study Type 
This study is primarily descriptive and hypothesis generating. We will explore the 
epidemiology of hospitalised CAP, healthcare resource utilisation/ reconsultations at 
both primary and secondary care and usage of further antibiotics at reconsultations. The 
association between reconsultation and potential explanatory factors (patient 
characteristics, comorbid diseases) will be investigated. We will also explore the value of 
antibiotics prescribed at reconsultation.  
 
G. Study Design 
Cohort study 
H. Feasibility counts 
 
A similar study conducted by Millett et al had a population size of 1,534,443 with 916,128 HES-






I. Sample size considerations 
There is no formal power calculation for this study as we will use the entire population that meet 
the eligibility criteria listed in section K for our study. As mentioned in the previous section, a 
similar study conducted by Millett et al had a population size of 1,534,443 with 916,128 HES-




J. Data Linkage Required (if applicable):§ 
§Please note that the data linkage/s requested in research protocols will be published by the CPRD as part of its 
transparency policy 
CPRD data linked to HES Admitted Patient Care and HES Accident and Emergency will be 
used to determine the proportion of patients who are hospitalised for CAP. We will also 
be able to identify the proportion of patients who reconsult healthcare professionals (i.e. 
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K. Study population 
Only permanently registered acceptable patients and ‘up-to-standard’ follow-up will be 
included for the study. All patients with first episode of hospitalised CAP recorded in 
CPRD linked to HES Admitted Patient Care between 1st of July 2002 to 30th of June 2017 
will be included. Information on the rate and cause for reconsultation as well as further 
antibiotic prescription at different time frames (i.e. within the first 7 days, 8- 14 days, 15- 
30 days, 31- 60 days) will be examined.  
 
Inclusion criteria: 




• Hospital admission in the preceding 10 days; identified either by CPRD hospital code or 
HES-linked data (ICD 10 code: Y95) which shows admission for any illness. 
• Active tuberculosis 
 
 
Index date is defined as the day of CAP diagnosed in hospital. All patients will be 
followed up from the index date to the end of data collection (1 year), date of transfer 
out of the practice or patient’s death, whichever came first. 
 
 





M. Exposures, Health Outcomes§ and Covariates  
§Please note: Summary information on health outcomes (as included on the ISAC application form  above )will be 
published on CPRD’s website as part of its transparency policy 
 
Exposures/ Outcomes: 
Record of a ICD-10 code (J12- J18) for community acquired pneumonia as listed in 
Appendix A, and documented in the patient clinical or referral record will be used. 
 
Data Sources: 
Data sources for this study will include primary care clinical records, prescription drug 
files and HES linked data to hospital admissions and emergency department attendances. 
 
Covariates: 
Covariates that will be considered in this study include age, gender, smoking, social 




N. Data/ Statistical Analysis 
Statistical analyses will be performed using Stata 15. Incidence of CAP and other diseases 
(cardiac complications and cognitive decline) will be estimated using the whole CPRD as 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
incidence rate ratios (IRR) and 95% confidence intervals (CIs) will be described.  
 
Baseline demographics and co-morbid diseases of adults who reconsulted will be 
compared to those who did not reconsult. The independent association between patient 
characteristics and rate of reconsultation (overall/ patients without co-morbidities 
/patients with underlying respiratory disease) will be calculated using a multivariable 
logistic regression model; adjusted for age, gender, smoking, social deprivation, the 
presence of co-morbidities (Charlson co-morbidity index), vaccine status, length of 
hospital stay and intensive care unit admission. The included variables in the final model 
will be those associated with healthcare reconsultation during univariate analysis. Cause 
of reconsultation will be divided into either ‘CAP-related’ (respiratory symptoms) or ‘not 
CAP-related’ (cardiac symptoms and cognitive decline). 
 
We will measure the number of antibiotic prescriptions at reconsultation and where 
possible, the type of antibiotics prescribed.  
 
O. Plan for addressing confounding 
Study will be adjusted for confounding factors such as age, gender, smoking, social 
deprivation, co-morbidities, vaccine status, length of hospital stay and intensive care unit 
admission using multivariable logistic regression model. 
 
P. Plans for addressing missing data  
The potential for missing data, particularly on covariates such as smoking and vaccine 
status may not be documented. This will be reported and recognised as a potential 
limitation.   
 
Q. Patient or user group involvement (if applicable) 
Not applicable 
 
R. Plans for disseminating and communicating study results, including the presence or 
absence of any restrictions on the extent and timing of publication  
S.  
All data arising from this study will be owned by University of Nottingham. On 
completion of the study, the data will be analysed, tabulated and a Final Study Report 
will be prepared which will be accessible via the Chief Investigator.  
 
The study protocol, full study report, anonymised participant level dataset, and statistical 
code for generating the results will be made publicly available.  
 
Manuscripts resulting from the research will be conceived, written, and published at the 
discretion of the Chief Investigator, and other members of the research team as 
appropriate. This activity will be independent from the Research Funder, who will not 
have any control over the content or results of any publications. It is anticipated that the 
research will lead to publications in subject-specific international peer-reviewed journals 
and presentations at international conferences. 
 
T. Limitations of the study design, data sources, and analytic methods  
This large, population based study will be generalisable given that it will include 
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admission and attendances to the emergency department. The cohort of patients in this 
study will be representative of the UK population with reference to age, gender and 
ethnicity. 351 
 
Information gathered in this study is deduced from the code sets used in CPRD, HES 
Admitted Patient Care and HES Accident and Emergency. Therefore it is recognised that 
the study assumes that the healthcare professionals have used the most accurate code 
set at each patient visit, accepting that there may be variations in coding of the disease 
between healthcare professionals. 
 
U. References 
1.  Chapman S, Robinson G, Stradling J, West S. Respiratory infection: bacterial. In: Oxford 
Handbook of Respiratory Medicine. ; 2012:420-429. 
2.  Lim WS, Baudouin S V, George RC, et al. BTS guidelines for the management of 
community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1-iii55. 
doi:10.1136/thx.2009.121434 
3.  National Institue for Health and Care Excellence. Pneumonia in adults : diagnosis and 
management. NICE Guidel. 2014;(December):1-26. 
4.  Diehr P, Wood RW, Bushyhead J, Krueger L, Wolcott B, Tompkins RK. Prediction of 
pneumonia in outpatients with acute cough-A statistical approach. J Chronic Dis. Published 
online 1984. doi:10.1016/0021-9681(84)90149-8 
5.  O’Brien WTS, Rohweder DA, Lattin GEJ, et al. Clinical indicators of radiographic findings in 
patients with suspected community-acquired pneumonia: who needs a chest x-ray?. J Am 
Coll Radiol. 2006;3(9):703-706. 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=174
12152 
6.  Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired 
pneumonia in adults in Europe: A literature review. Thorax. Published online 2013. 
doi:10.1136/thoraxjnl-2013-204282 
7.  NHS Digital. Hospital Admitted Patient Care Activity, 2019-20: Diagnosis. 
https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-
care-activity/2019-20 
8.  Rodrigo C, Bewick T, Sheppard C, et al. Impact of infant 13-valent pneumococcal 
conjugate vaccine on serotypes in adult pneumonia. Eur Respir J. 2015;45(6):1632-1641. 
doi:10.1183/09031936.00183614 
9.  Gutiérrez F, Masiá M, Mirete C, et al. The influence of age and gender on the population-
based incidence of community-acquired pneumonia caused by different microbial 
pathogens. J Infect. Published online 2006. doi:10.1016/j.jinf.2005.11.006 
10.  Quan TP, Fawcett NJ, Wrightson JM, et al. Increasing burden of community-acquired 






Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
11.  Millett ERC, L DSB, Quint JK, Smeeth L, Thomas SL. Risk factors for hospital admission in 
the 28 days following a community-acquired pneumonia diagnosis in older adults, and their 
contribution to increasing hospitalisation rates over time: A cohort study. BMJ Open. 
2015;5(12):e008737. doi:http://dx.doi.org/10.1136/bmjopen-2015-008737 
12.  Guest JF, Morris  a. Community-acquired pneumonia: the annual cost to the National 
Health Service in the UK. Eur Respir J. 1997;10:1530-1534. 
doi:10.1183/09031936.97.10071530 
13.  Niederman MS, McCombs JS, Unger  a N, Kumar  a, Popovian R. The cost of treating 
community-acquired pneumonia. Clin Ther. 1998;20(4):820-837. 
http://www.ncbi.nlm.nih.gov/pubmed/9737840 
14.  Campling J, Jones D, Chalmers J, et al. Clinical and financial burden of hospitalised 
community-acquired pneumonia in patients with selected underlying comorbidities in 
England. BMJ Open Respir Res. 2020;7(1):e000703. doi:10.1136/bmjresp-2020-000703 
15.  Black, C. D., & Frost D. Health at Work-an Independent Review of Sickness Absence . Vol 
8205. The Stationery Office; 2011. 
16.  Bonafede MM, Suaya JA, Wilson KL, Mannino DM, Polsky D. Incidence and cost of CAP in 
a large working-age population. Am J Manag Care. 2012;18(7):380-387. 
17.  Broulette J, Yu H, Pyenson B, Iwasaki K, Sato R. The incidence rate and economic burden 
of community-acquired pneumonia in a working-age population. Am Heal drug benefits. 
2013;6(8):494-503. https://pubmed.ncbi.nlm.nih.gov/24991378 
18.  Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired 
pneumonia among adults in Europe. Thorax. 2012;67(1):71-79. 
doi:10.1136/thx.2009.129502 
19.  Burk M, El-Kersh K, Saad M, Wiemken T, Ramirez J, Cavallazzi R. Viral infection in 
community-acquired pneumonia: A systematic review and meta-analysis. Eur Respir Rev. 
Published online 2016. doi:10.1183/16000617.0076-2015 
20.  Hendley JO, Sande MA, Stewart PM, Gwaltney JMJ. Spread of Streptococcus pneumoniae 
in families. I. Carriage rates and distribution  of types. J Infect Dis. 1975;132(1):55-61. 
doi:10.1093/infdis/132.1.55 
21.  Daniel P, Rodrigo C, Bewick T, et al. Increased incidence of adult pneumococcal 
pneumonia during school holiday periods. ERJ open Res. 2017;3(1):100-2016. 
doi:10.1183/23120541.00100-2016 
22.  Musher DM. How Contagious Are Common Respiratory Tract Infections? N Engl J Med. 
2003;348(13):1256-1266. doi:10.1056/NEJMra021771 
23.  Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization 
and invasion. Nat Rev Microbiol. 2018;16(6):355-367. doi:10.1038/s41579-018-0001-8 
24.  Morimura A, Hamaguchi S, Akeda Y, Tomono K. Mechanisms Underlying Pneumococcal 
Transmission and Factors Influencing Host-Pneumococcus Interaction: A Review. Front 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
25.  Rodrigo C, Bewick T, Sheppard C, et al. Pneumococcal serotypes in adult non-invasive 
and invasive pneumonia in relation to child contact and child vaccination status. Thorax. 
2014;69(2):168 LP - 173. doi:10.1136/thoraxjnl-2013-203987 
26.  Almirall J, Serra-Prat M, Bolíbar I, Balasso V. Risk Factors for Community-Acquired 
Pneumonia in Adults: A Systematic Review of Observational Studies. Respiration. 
2017;94(3):299-311. doi:10.1159/000479089 
27.  World Health Organisation (WHO). The top 10 causes of death. Published 2018. 
http://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death 
28.  Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 
(GBD 2019) Disease and Injury Burden 1990-2019. Seattle, United States of America: 
Institute for Health Metrics and Evaluation (IHME). Published 2020. Accessed November 
18, 2020. http://www.healthdata.org/results/gbd_summaries/2019 
29.  Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-
acquired pneumonia. A meta-analysis. JAMA. 1996;275(2):134-141. 
doi:10.1001/jama.1996.03530260048030 
30.  Lim WS, Lawrence H. National Audit Report: Adult Community Acquired Pneumonia Audit 
2018-2019. Br Thorac Soc Reports. 10(4). https://www.brit-thoracic.org.uk/quality-
improvement/clinical-audit/national-adult-community-acquired-pneumonia-audit-201819/ 
31.  Ewig S, Birkner N, Strauss R, et al. New perspectives on community-acquired pneumonia 
in 388 406 patients. Results from a nationwide mandatory performance measurement 
programme in healthcare quality. Thorax. 2009;64(12):1062-1069. 
doi:10.1136/thx.2008.109785 
32.  Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with 
community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research 
Team (PORT) cohort study. Arch Intern Med. 1999;159(9):970-980. doi:10326939 
33.  Bordon JM, Fernandez-Botran R, Wiemken TL, et al. Bacteremic pneumococcal 
pneumonia: clinical outcomes and preliminary results of inflammatory response. Infection. 
2015;43(6):729-738. doi:https://dx.doi.org/10.1007/s15010-015-0837-z 
34.  Kornum JB, Thomsen RW, Riis A, Lervang HH, Schønheyder HC, Sørensen HT. Type 2 
diabetes and pneumonia outcomes: A population-based cohort study. Diabetes Care. 
2007;43(6):729-738. doi:10.2337/dc06-2417 
35.  Mannu GS, Loke YK, Curtain JP, Pelpola KN, Myint PK. Prognosis of multi-lobar 
pneumonia in community-acquired pneumonia: a systematic review and meta-analysis. Eur 
J Intern Med. 2013;24(8):857-863. doi:https://dx.doi.org/10.1016/j.ejim.2013.05.001 
36.  Naucler P, Darenberg J, Morfeldt E, Ortqvist A, Henriques Normark B. Contribution of host, 
bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic 
pneumococcal pneumonia. Thorax. 2013;68(6):571-579. 
doi:https://dx.doi.org/10.1136/thoraxjnl-2012-203106 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
complications in patients with community-acquired pneumonia incidence, timing, risk 
factors, and association with short-term mortality. Circulation. 2012;125(6):773-781. 
doi:10.1161/CIRCULATIONAHA.111.040766 
38.  Garcia-Vidal C, Fernandez-Sabe N, Carratala J, et al. Early mortality in patients with 
community-acquired pneumonia: causes and risk factors. Eur Respir J. 2008;32(3):733-
739. doi:https://dx.doi.org/10.1183/09031936.00128107 
39.  Kolditz M, Bauer TT, Konig T, Rohde G, Ewig S. 3-day mortality in hospitalised community-
acquired pneumonia: frequency and risk factors. Eur Respir J. 2016;47(5):1572-1574. 
doi:https://dx.doi.org/10.1183/13993003.00113-2016 
40.  Bruns AHW, Oosterheert JJ, Cucciolillo MC, et al. Cause-specific long-term mortality rates 
in patients recovered from community-acquired pneumonia as compared with the general 
Dutch population. Clin Microbiol Infect. 2011;17(5):763-768. 
doi:http://dx.doi.org/10.1111/j.1469-0691.2010.03296.x 
41.  Bordon J, Wiemken T, Peyrani P, et al. Decrease in long-term survival for hospitalized 
patients with community-acquired pneumonia. Chest. 2010;138(2):279-283. 
doi:https://dx.doi.org/10.1378/chest.09-2702 
42.  Yende S, Angus DC, Ali IS, et al. Influence of comorbid conditions on long-term mortality 
after pneumonia in older people. J Am Geriatr Soc. 2007;55(4):518-525. 
doi:http://dx.doi.org/10.1111/j.1532-5415.2007.01100.x 
43.  Holter JC, Ueland T, Jenum PA, et al. Risk factors for long-term mortality after 
hospitalization for community-acquired pneumonia: a 5-year prospective follow-up study. 
PLoS One. Published online 2016. doi:10.1371/journal.pone.0148741 
44.  Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-
acquired pneumonia: Results from the pneumonia patient outcomes research team cohort 
study. Arch Intern Med. 2002;162(9):1059-1064. 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed8&NEWS=N&AN=34
492537 
45.  Bruns AHW, Oosterheert JJ, Cucciolillo MC, et al. Cause-specific long-term mortality rates 
in patients recovered from community-acquired pneumonia as compared with the general 
Dutch population. Clin Microbiol Infect. Published online 2011. doi:10.1111/j.1469-
0691.2010.03296.x 
46.  Klukowska A, Lim WS, Mckeever TM, Pick H, Ashton D. RF14 A systematic review of 30-
day readmissions in adults hospitalised with community-acquired pneumonia. J Epidemiol 
Community Heal. 2018;72(1). 
47.  Daniel P, Bewick T, McKeever TM, et al. Healthcare reconsultation in working-age adults 
following hospitalisation for community-acquired pneumonia. Clin Med J R Coll Physicians 
London. 2018;18(1):41-46. doi:10.7861/clinmedicine.18-1-41 
48.  Moore M, Little P, Rumsby K, et al. Effect of antibiotic prescribing strategies and an 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
Br J Gen Pract. 2009;59(567):728-734. doi:10.3399/bjgp09X472601 
49.  Holmes WF, Macfarlane JT, Macfarlane RM, Lewis S. The influence of antibiotics and 
other factors on reconsultation for acute lower respiratory tract illness in primary care. Br J 
Gen Pract. 1997;47(425):815-818. 
50.  Chow AW, Hall CB, Klein JO, Kammer RB, Meyer RD, Remington JS. General guidelines 
for the evaluation of new anti-infective drugs for the treatment of respiratory tract infections: 
Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Clin 
Infect Dis. Published online 1992. doi:10.1093/clind/15.Supplement_1.S62 
51.  Mittl RL, Schwab RJ, Duchin JS, Goin JE, Albeida SM, Miller WT. Radiographic resolution 
of community-acquired pneumonia. Am J Respir Crit Care Med. Published online 1994. 
doi:10.1164/ajrccm.149.3.8118630 
52.  El Solh AA, Aquilina AT, Gunen H, Ramadan F. Radiographic Resolution of Community-
Acquired Bacterial Pneumonia in the Elderly. J Am Geriatr Soc. Published online 2004. 
doi:10.1111/j.1532-5415.2004.52059.x 
53.  Bruns AHW, Oosterheert JJ, El Moussaoui R, Opmeer BC, Hoepelman AIM, Prins JM. 
Pneumonia recovery; Discrepancies in perspectives of the radiologist, physician and 
patient. J Gen Intern Med. Published online 2010. doi:10.1007/s11606-009-1182-7 
54.  Pick HJ, Bolton CE, Lim WS, McKeever TM. Patient-reported outcome measures in the 
recovery of adults hospitalised with community-acquired pneumonia: A systematic review. 
Eur Respir J. 2019;53(3):1802165. doi:10.1183/13993003.02165-2018 
55.  Gladman JRF, Barer D, Venkatesan P, Berman P, Macfarlane JT. The outcome of 
pneumonia in the elderly: A hospital survey. Clin Rehabil. Published online 1991. 
doi:10.1177/026921559100500305 
56.  Waterer G. Recovery from community acquired pneumonia: the view from the top of the 
iceberg. Eur Respir J. Published online 2017. doi:10.1183/13993003.00571-2017 
57.  Dang TT, Eurich DT, Weir DL, Marrie TJ, Majumdar SR. Rates and risk factors for 
recurrent pneumonia in patients hospitalized with community-acquired pneumonia: 
Population-based prospective cohort study with 5 years of follow-up. Clin Infect Dis. 
Published online 2014. doi:10.1093/cid/ciu247 
58.  Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice 
Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827-836. doi:10.1093/ije/dyv098 
59.  Boyd A, Cornish R, Johnson L, et al. CLOSER Resource Report: Understanding Hospital 
Episode Statistics (HES).; 2018. 
60.  CPRD. Small Area Level Data Based on Practice Postcode: Documentation and Data 
Dictionary. 
61.  Office for National Statistics. 2011 Census: Population and Household Estimates for Small 







Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
ndwales/2012-11-23 
62.  Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of 
diagnoses in the General Practice Research Database: A systematic review. Br J Clin 
Pharmacol. Published online 2010. doi:10.1111/j.1365-2125.2009.03537.x 
63.  Department of Health. About the Quality and Outcomes Framework (QOF). Accessed 
September 8, 2020. https://www.health-ni.gov.uk/articles/about-quality-and-outcomes-
framework-qof 
64.  Lewis JD, Brensinger C. Agreement between GPRD smoking data: A survey of general 
practitioners and a population-based survey. Pharmacoepidemiol Drug Saf. Published 
online 2004. doi:10.1002/pds.902 
65.  Booth HP, Prevost AT, Gulliford MC. Validity of smoking prevalence estimates from 
primary care electronic health records compared with national population survey data for 
England, 2007 to 2011. Pharmacoepidemiol Drug Saf. Published online 2013. 
doi:10.1002/pds.3537 
66.  Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data Resource Profile: 
Hospital Episode Statistics Admitted Patient Care (HES APC). Int J Epidemiol. 
2017;46(4):1093-1093i. doi:10.1093/ije/dyx015 
67.  Burns EM, Rigby E, Mamidanna R, et al. Systematic review of discharge coding accuracy. 
J Public Health (Bangkok). 2012;34(1):138-148. doi:10.1093/pubmed/fdr054 
68.  Audit Commission for Local Authorities and the National Health Service in England. 
Improving Data Quality in the NHS: Annual Report on the PbR Assurance Programme.; 
2010. https://www.bl.uk/collection-items/improving-data-quality-in-the-nhs-annual-report-
on-the-pbr-assurance-programme# 
69.  Julie G, Shah A. Smoking Status (primary care). Health Data Research UK. Published 
2013. Accessed March 20, 2019. 
https://www.caliberresearch.org/portal/show/smoking_status_gprd 
70.  University of Manchester Institute of Population Health. ClinicalCodes. Accessed July 23, 
2020. https://clinicalcodes.rss.mhs.man.ac.uk/ 
71.  George J, Udumyan R, Hemingway H. Drinking status. Health Data Research UK. 
Published 2011. Accessed March 20, 2019. 
https://www.caliberresearch.org/portal/show/alcohol_drinker_gprd 
72.  Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic 
comorbidity in longitudinal studies: Development and validation. J Chronic Dis. Published 
online 1987. doi:10.1016/0021-9681(87)90171-8 
73.  Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index 
for Read/OXMIS coded databases. BMC Fam Pract. Published online 2010. 
doi:10.1186/1471-2296-11-1 
74.  Hobbs FDR, Bankhead C, Mukhtar T, et al. Clinical workload in UK primary care: a 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
2016;387(10035):2323-2330. doi:10.1016/S0140-6736(16)00620-6 
75.  Kontopantelis E, Olier I, Planner C, et al. Primary care consultation rates among people 
with and without severe mental illness: A UK cohort study using the Clinical Practice 
Research Datalink. BMJ Open. 2015;5(12). doi:10.1136/bmjopen-2015-008650 
76.  Health Data Research UK. CALIBERcodelists. Accessed July 23, 2020. 
http://caliberresearch.org/ 
77.  Millett ERC, Quint JK, Smeeth L, Daniel RM, Thomas SL. Incidence of community-acquired 
lower respiratory tract infections and pneumonia among older adults in the United 
Kingdom: A population-based study. PLoS One. 2013;8(9):e75131. 
doi:10.1371/journal.pone.0075131 
78.  Department for Communities and Local Government. The English Indices of Deprivation 
2015.; 2015. 
79.  Sterne JAC, White IR, Carlin JB, et al. Multiple imputation for missing data in 
epidemiological and clinical research: Potential and pitfalls. BMJ. Published online 2009. 
doi:10.1136/bmj.b2393 
80.  Chalitsios C V., McKeever TM, Shaw DE. Incidence of osteoporosis and fragility fractures 
in asthma: a UK population-based matched cohort study. Eur Respir J. Published online 
2020. doi:10.1183/13993003.01251-2020 
81.  Hong JL, Jonsson Funk M, Locasale R, et al. Generalizing Randomized Clinical Trial 
Results: Implementation and Challenges Related to Missing Data in the Target Population. 
In: American Journal of Epidemiology. ; 2018. doi:10.1093/aje/kwx287 
82.  Chalitsios C V., Shaw DE, Mckeever TM. Risk of osteoporosis and fragility fractures in 
asthma due to oral and inhaled corticosteroids: Two population-based nested case-control 
studies. Thorax. Published online 2021. doi:10.1136/thoraxjnl-2020-215664 
83.  Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and 
risk of breast cancer: Nested case-control studies using the QResearch and CPRD 
databases. BMJ. Published online 2020. doi:10.1136/bmj.m3873 
84.  Office for National Statistics. Population Estimates for UK, England and Wales, Scotland 
and Northern Ireland.; 2019. 
85.  Snijders B, van der Hoek W, Stirbu I, van der Sande MAB, van Gageldonk-Lafeber AB. 
General practitioners’ contribution to the management of community-acquired pneumonia 
in the Netherlands: a retrospective analysis of primary care, hospital, and national mortality 
databases with individual data linkage. Prim Care Respir J. 2013;22(4):400-405. 
doi:https://dx.doi.org/10.4104/pcrj.2013.00085 
86.  Adamuz J, Viasus D, Simonetti A, et al. Impact of an educational program to reduce 
healthcare resources in community-acquired pneumonia: The EDUCAP randomized 
controlled trial. PLoS One. 2015;10(10):e0140202. doi:10.1371/journal.pone.0140202 
87.  Adamuz J, Viasus D, CampreciOs-RodrIguez P, et al. A prospective cohort study of 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
pneumonia. Respirology. 2011;16(7):1119-1126. doi:http://dx.doi.org/10.1111/j.1440-
1843.2011.02017.x 
88.  Macfarlane J, Prewett J, Rose D, et al. Prospective case-control study of role of infection in 
patients who reconsult after initial antibiotic treatment for lower respiratory tract infection in 
primary care. Br Med J. 1997;315(7117):1206-1210. doi:10.1136/bmj.315.7117.1206 
89.  Cals JWL, Hood K, Aaftink N, et al. Predictors of patient-initiated reconsultation for lower 
respiratory tract infections in general practice. Br J Gen Pract. 2009;59(567):761-764. 
doi:10.3399/bjgp09X472656 
90.  Little P, Stuart B, Smith S, et al. Antibiotic prescription strategies and adverse outcome for 
uncomplicated lower respiratory tract infections: Prospective cough complication cohort 
(3C) study. BMJ. 2017;357:j2148. doi:10.1136/bmj.j2148 
91.  Macfarlane JT, Holmes WF, Macfarlane RM. Reducing reconsultations for acute lower 
respiratory tract illness with an information leaflet: A randomized controlled study of 
patients in primary care. Br J Gen Pract. 1997;47(424):719-722. 
92.  Little P, Rumsby K, Kelly J, et al. Information leaflet and antibiotic prescribing strategies for 
acute lower respiratory tract infection: A randomized controlled trial. J Am Med Assoc. 
2005;293(24):3029-3035. doi:10.1001/jama.293.24.3029 
93.  NHS England. The NHS Long Term Plan.; 2019. https://www.england.nhs.uk/long-term-
plan/ 
94.  Baxter S, Johnson M, Chambers D, Sutton A, Goyder E, Booth A. The effects of integrated 
care: A systematic review of UK and international evidence. BMC Health Serv Res. 
2018;18(1):1-3. doi:10.1186/s12913-018-3161-3 
95.  Baldie DJ, Entwistle VA, Davey PG. The information and support needs of patients 
discharged after a short hospital stay for treatment of low-risk Community Acquired 
Pneumonia: implications for treatment without admission. BMC Pulm Med. 2008;8(1):11. 
doi:https://dx.doi.org/10.1186/1471-2466-8-11 
96.  Ashton D, Pick H, Bains M, Lim WS. P24 Patient experience of recovering from pneumonia 
– a qualitative longitudinal interview study. Thorax. 2018;73(4). 
97.  Trotter CL, Stuart JM, George R, Miller E. Increasing Hospital Admissions for Pneumonia, 
England. Emerg Infect Dis. 2008;14(5):727-733. doi:10.3201/eid1405.071011 
98.  Curtis LA, Burns A. Unit Costs of Health and Social Care 2019.; 2019. 
doi:https://doi.org/10.22024/UniKent%2F01.02.79286 
99.  National Institute for Health and Care Excellence (NICE). Costing Statement: Pneumonia – 
Diagnosis and Management of Community- and Hospital-Acquired Pneumonia in Adults.; 
2014. 
100.  National Institute for Health and Care Excellence. Antimicrobial stewardship: prescribing 
antibiotics | Guidance and guidelines | NICE. NICE Guidel. Published online 2019. 
doi:10.1038/nmicrobiol.2017.72 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
25, 2020. https://www.bmj.com/content/bmj/370/bmj.m3489.full.pdf 
102.  Mahase E. Covid-19: What do we know about “long covid”? BMJ. Accessed September 25, 
2020. https://www.bmj.com/content/bmj/370/bmj.m2815.full.pdf 
103.  Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia 
aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. 
Thorax. 2001;56(4):296-301. doi:10.1136/thorax.56.4.296 
104.  World Health Organisation (WHO). About cardiovascular diseases. Accessed September 
30, 2020. https://www.who.int/cardiovascular_diseases/about_cvd/en/ 
105.  NHS England. Cardiovascular disease (CVD). Accessed October 7, 2020. 
https://www.england.nhs.uk/ourwork/clinical-policy/cvd/ 
106.  Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-
acquired pneumonia: A meta-analysis. J Am Med Assoc. 1996;275(2):134-141. 
doi:http://dx.doi.org/10.1001/jama.275.2.134 
107.  Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with 
community-acquired pneumonia: A systematic review and meta-analysis of observational 
studies. PLoS Med. 2011;8(6):e1001048. 
doi:http://dx.doi.org/10.1371/journal.pmed.1001048 
108.  Tralhão A, Póvoa P. Cardiovascular Events after Community-Acquired Pneumonia: A 
Global Perspective with Systematic Review and Meta-Analysis of Observational Studies. J 
Clin Med. Published online 2020. doi:10.3390/jcm9020414 
109.  Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for 
systematic reviews. Syst Rev. Published online 2016. doi:10.1186/s13643-016-0384-4 
110.  Nyaga VN, Arbyn M, Aerts M. Metaprop: A Stata command to perform meta-analysis of 
binomial data. Arch Public Heal. Published online 2014. doi:10.1186/2049-3258-72-39 
111.  Perry TW, Pugh MJ V., Waterer GW, et al. Incidence of cardiovascular events after 
hospital admission for pneumonia. Am J Med. Published online 2011. 
doi:10.1016/j.amjmed.2010.11.014 
112.  Hunter JP, Saratzis A, Sutton AJ, Boucher RH, Sayers RD, Bown MJ. In meta-analyses of 
proportion studies, funnel plots were found to be an inaccurate method of assessing 
publication bias. J Clin Epidemiol. Published online 2014. 
doi:10.1016/j.jclinepi.2014.03.003 
113.  Esposito AL. Community-Acquired Bacteremic Pneumococcal Pneumonia. Arch Intern 
Med. Published online 1984. doi:10.1001/archinte.1984.00350170081016 
114.  SC. A. Lobar pneumonia in Northern Zambia: clinical study of 502 adult patients. Thorax. 
Published online 1984. 
115.  Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-
year prospective study. Rev Infect Dis. Published online 1989. doi:10.1093/clinids/11.4.586 
116.  Fine MJ, Smith DN, Singer DE. Hospitalization decision in patients with community-





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
doi:10.1016/0002-9343(90)90211-U 
117.  Venkatesan P, Gladman J, Macfarlane JT, et al. A hospital study of community acquired 
pneumonia in the elderly. Thorax. Published online 1990. doi:10.1136/thx.45.4.254 
118.  Leroy O, Santré C, Beuscart C, et al. A five-year study of severe community-acquired 
pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. 
Intensive Care Med. Published online 1995. doi:10.1007/BF02425150 
119.  The British Thoracic Society Research Committee, The Public Health Laboratory Service. 
The aetiology, management and outcome of severe community-acquired pneumonia on 
the intensive care unit. Respir Med. Published online 1992. doi:10.1016/S0954-
6111(06)80141-1 
120.  Musher DM, Alexandraki I, Graviss EA, et al. Bacteremic and nonbacteremic 
pneumococcal pneumonia: A prospective study. Medicine (Baltimore). Published online 
2000. doi:10.1097/00005792-200007000-00002 
121.  Fernandez-Sabe N, Carratala J, Roson B, et al. Community-acquired pneumonia in very 
elderly patients: Causative organisms, clinical characteristics, and outcomes. Medicine 
(Baltimore). 2003;82(3):159-169. doi:http://dx.doi.org/10.1097/00005792-200305000-
00002 
122.  Martinez-Moragon E, L GF, B SS, E FF, A GB, R JP. Community-acquired pneumonia 
among the elderly: Differences between patients living at home and in nursing homes. Arch 
Bronconeumol. 2004;40(12):547-552. doi:http://dx.doi.org/10.1157/13068796 
123.  Menendez R, Torres A, Zalacain R, et al. Risk factors of treatment failure in community 
acquired pneumonia: implications for disease outcome. Thorax. 2004;59(11):960-965. 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=155
16472 
124.  Querol-Ribelles JM, Tenias JM, Querol-Borras JM, et al. Levofloxacin versus ceftriaxone 
plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring 
hospitalization. Int J Antimicrob Agents. 2005;25(1):75-83. 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=156
20830 
125.  Diaz A, Alvarez M, Callejas C, Rosso R, Schnettler K, Saldias F. Clinical picture and 
prognostic factors for severe community-acquired pneumonia in adults admitted to the 
intensive care unit. Arch Bronconeumol. 2005;41(1):20-26. 
doi:http://dx.doi.org/10.1157/13070280 
126.  Marrie TJ, Huang JQ. Low-risk patients admitted with community-acquired pneumonia. Am 
J Med. 2005;118(12):1357-1363. doi:http://dx.doi.org/10.1016/j.amjmed.2005.06.035 
127.  O’Meara ES, White M, Siscovick DS, Lyles MF, Kuller LH. Hospitalization for pneumonia in 
the Cardiovascular Health Study: Incidence, mortality, and influence on longer-term 






Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
128.  Becker T, Moldoveanu A, Cukierman T, Gerstein HC. Clinical outcomes associated with 
the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in 
hospitalized patients with pneumonia. Diabetes Res Clin Pract. Published online 2007. 
doi:10.1016/j.diabres.2007.05.003 
129.  Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal 
pneumonia and acute cardiac events. Clin Infect Dis. 2007;45(2):158-165. 
doi:http://dx.doi.org/10.1086/518849 
130.  Aliberti S, Amir A, Peyrani P, et al. Incidence, etiology, timing, and risk factors for clinical 
failure in hospitalized patients with community-acquired pneumonia. Chest. 
2008;134(5):955-962. doi:http://dx.doi.org/10.1378/chest.08-0334 
131.  Cabré M, Serra-Prat M, Force L, Palomera E, Pallarés R. Functional status as a risk factor 
for mortality in very elderly patients with pneumonia. Med Clin (Barc). Published online 
2008. doi:10.1157/13124262 
132.  Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients 
with community-acquired pneumonia. Clin Infect Dis. 2008;47(2):182-187. 
doi:http://dx.doi.org/10.1086/589246 
133.  Corrales-Medina VF, Serpa J, Rueda AM, et al. Acute bacterial pneumonia is associated 
with the occurrence of acute coronary syndromes. Medicine (Baltimore). 2009;88(3):154-
159. doi:10.1097/MD.0b013e3181a692f0 
134.  Mandal P, Chalmers JD, Choudhury G, Akram AR, Hill AT. Vascular complications are 
associated with poor outcome in community-acquired pneumonia. QJM. 2011;104(6):489-
495. doi:http://dx.doi.org/10.1093/qjmed/hcq247 
135.  Morlacchi L, Aliberti S, Gramegna A, et al. The impact of cardiovascular events in 
hospitalized patients with community-acquired pneumonia (CAP): Preliminary results from 
the FAILCAP study. Eur Respir J. 2011;38(SUPPL. 55). 
http://erj.ersjournals.com/content/38/Suppl_55/4708 
136.  Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ. Cardiac 
complications in patients with community acquired pneumonia: Incidence, timing, risk 
factors, and association with short-term mortality. Circulation. Published online 2012. 
doi:http://dx.doi.org/10.1161/CIRCULATIONAHA.111.040766 
137.  Griffin AT, Wiemken TL, Arnold FW. Risk factors for cardiovascular events in hospitalized 
patients with community-acquired pneumonia. Int J Infect Dis. 2013;17(12):e1125-e1129. 
doi:http://dx.doi.org/10.1016/j.ijid.2013.07.005 
138.  Viasus D, Garcia-Vidal C, Manresa F, Dorca J, Gudiol F, Carratala J. Risk stratification and 
prognosis of acute cardiac events in hospitalized adults with community-acquired 
pneumonia. J Infect. 2013;66(1):27-33. doi:http://dx.doi.org/10.1016/j.jinf.2012.09.003 
139.  Cangemi R, Casciaro M, Rossi E, et al. Platelet activation is associated with myocardial 
infarction in patients with pneumonia. Albanese F  Carnevale R, Catasca E, Celestini A, 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
Proietti M, Capparuccia Marco R, Russo A, Russo R, Sarallo V, Salvatori G, Scarpellini 
MG, Ullo I BE, ed. J Am Coll Cardiol. 2014;64(18):1917-1925. 
doi:https://dx.doi.org/10.1016/j.jacc.2014.07.985 
140.  Corrales-Medina VF, Taljaard M, Fine MJ, et al. Risk stratification for cardiac complications 
in patients hospitalized for community-acquired pneumonia. Mayo Clin Proc. 
2014;89(1):60-68. doi:http://dx.doi.org/10.1016/j.mayocp.2013.09.015 
141.  Dutt TS, Tousheed SZ, Mohan B V. Community acquired pneumonia and cardiac 
diseases: a fatal association. Indian J Chest Dis Allied Sci. 2014;56(3):153-156. 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed16&NEWS=N&AN=6
03987698 
142.  Tang VL, Halm EA, Fine MJ, Johnson CS, Anzueto A, Mortensen EM. Predictors of 
rehospitalization after admission for pneumonia in the veterans affairs healthcare system. J 
Hosp Med. 2014;9(6):379-383. doi:http://dx.doi.org/10.1002/jhm.2184 
143.  Aliberti S, Ramirez J, Cosentini R, et al. Acute myocardial infarction versus other 
cardiovascular events in communityacquired pneumonia. ERJ Open Res. Published online 
2015. doi:10.1183/23120541.00020-2015 
144.  Bello S, Fandos S, Lasierra AB, et al. Red blood cell distribution width [RDW] and long-
term mortality after community-acquired pneumonia. A comparison with 
proadrenomedullin. Respir Med. 2015;109(9):1193-1206. 
doi:http://dx.doi.org/10.1016/j.rmed.2015.07.003 
145.  Cangemi R, Calvieri C, Falcone M, et al. Relation of cardiac complications in the early 
phase of community-acquired pneumonia to long-term mortality and cardiovascular events. 
Am J Cardiol. 2015;116(4):647-651. doi:http://dx.doi.org/10.1016/j.amjcard.2015.05.028 
146.  Chen PC, Liao WI, Wang YC, et al. An Elevated Glycemic Gap is Associated with Adverse 
Outcomes in Diabetic Patients with Community-Acquired Pneumonia. Med (United States). 
Published online 2015. doi:10.1097/MD.0000000000001456 
147.  R ES, Hamouda MS. Outcome of community-acquired pneumonia with cardiac 
complications. Egypt J Chest Dis Tuberc. 2015;64(3):633-638. 
doi:http://dx.doi.org/10.1016/j.ejcdt.2015.03.009 
148.  Vannucchi V, Fissi E, Farnetani I, et al. Role of CURB-65 to predict cardiovascular 
complications in elderly patients with community acquired pneumonia. Ital J Med. 
2015;9(SUPPL. 2):114. doi:http://dx.doi.org/10.4081/itjm.2015.s2 
149.  Violi F, Carnevale R, Calvieri C, et al. Nox2 up-regulation is associated with an enhanced 
risk of atrial fibrillation in patients with pneumonia. Thorax. 2015;70(10):961-966. 
doi:http://dx.doi.org/10.1136/thoraxjnl-2015-207178 
150.  Aliberti S, Tobaldini E, Giuliani F, et al. Cardiovascular autonomic alterations in 
hospitalized patients with community-acquired pneumonia. Respir Res. 2016;17(1):98. 
doi:http://dx.doi.org/10.1186/s12931-016-0414-8 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
cardiac events in community-acquired pneumonia: A retrospective study. Int J Clin Exp 
Med. 2016;9(7):14411-14417. http://www.ijcem.com/files/ijcem0027749.pdf 
152.  Eurich DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SR. Risk of heart failure after 
community acquired pneumonia: Prospective controlled study with 10 years of follow-up. 
BMJ. 2017;356:j413. doi:http://dx.doi.org/10.1136/bmj.j413 
153.  Violi F, Cangemi R, Falcone M, et al. Cardiovascular complications and short-term 
mortality risk in community-acquired pneumonia. Clin Infect Dis. 2017;64(11):1486-1493. 
doi:http://dx.doi.org/10.1093/cid/cix164 
154.  Frencken JF, van Baal L, Kappen TH, et al. Myocardial injury in critically Ill patients with 
community-acquired pneumonia a cohort study. Ann Am Thorac Soc. Published online 
2019. doi:10.1513/AnnalsATS.201804-286OC 
155.  Cilli A, Cakin O, Aksoy E, et al. Acute cardiac events in severe community-acquired 
pneumonia: A multicenter study. Clin Respir J. Published online 2018. 
doi:10.1111/crj.12791 
156.  Cangemi R, Calvieri C, Taliani G, et al. Left Atrium Dilatation and Left Ventricular 
Hypertrophy Predispose to Atrial Fibrillation in Patients With Community-Acquired 
Pneumonia. Am J Cardiol. Published online 2019. doi:10.1016/j.amjcard.2019.05.051 
157.  Pieralli F, Biondo B, Vannucchi V, et al. Performance of the CHA 2 DS 2 -VASc score in 
predicting new onset atrial fibrillation during hospitalization for community-acquired 
pneumonia. Eur J Intern Med. Published online 2019. doi:10.1016/j.ejim.2019.01.012 
158.  Zhang J, Huang X, Chen Y, Zeng M. N-terminal pro-b-type natriuretic peptide as a 
predictor of 28-day mortality in elderly patients with severe pneumonia. Chest. 2016;149(4 
SUPPL. 1):A90. doi:http://dx.doi.org/10.1016/j.chest.2016.02.095 
159.  Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with 
community-acquired pneumonia: A systematic review and meta-analysis of observational 
studies. PLoS Med. 2011;8(6). doi:10.1371/journal.pmed.1001048 
160.  Higgins J, Thomas J, Chandler J, et al. Chapter 1: Starting a review. Cochrane Handbook 
for Systematic Reviews of Interventions (version 6.1). Accessed October 2, 2020. 
https://training.cochrane.org/handbook/current/chapter-01 
161.  Reynolds K, Go AS, Leong TK, et al. Trends in Incidence of Hospitalized Acute Myocardial 
Infarction in the Cardiovascular Research Network (CVRN). Am J Med. Published online 
2017. doi:10.1016/j.amjmed.2016.09.014 
162.  Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: a 
population-based study of 4 million individuals. Lancet. Published online 2018. 
doi:10.1016/S0140-6736(17)32520-5 
163.  Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, 
incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study. 
Lancet. Published online 2015. doi:10.1016/S0140-6736(14)61774-8 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
myocardial infarction and influenza: A meta-analysis of case-control studies. Heart. 
Published online 2015. doi:10.1136/heartjnl-2015-307691 
165.  Sellers SA, Hagan RS, Hayden FG, Fischer WA. The hidden burden of influenza: A review 
of the extra-pulmonary complications of influenza infection. Influenza Other Respi Viruses. 
2017;11(5):372-393. doi:10.1111/irv.12470 
166.  Restrepo MI, Reyes LF. Pneumonia as a cardiovascular disease. Respirology. 
2018;23(3):250-259. doi:http://dx.doi.org/10.1111/resp.13233 
167.  Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the 
cardiovascular system. Lancet (London, England). 2013;381(9865):496-505. 
doi:https://dx.doi.org/10.1016/S0140-6736(12)61266-5 
168.  Singanayagam  a, Elder DHJ, Chalmers JD. Is community-acquired pneumonia an 
independent risk factor for cardiovascular disease? Eur Respir J. Published online 2012. 
doi:10.1183/09031936.00049111 
169.  Rae N, Finch S, Chalmers JD. Cardiovascular disease as a complication of community-
acquired pneumonia. Curr Opin Pulm Med. 2016;22(3):212-218. 
doi:http://dx.doi.org/10.1097/MCP.0000000000000261 
170.  Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute 
coronary syndromes in patients presenting without persistent st-segment elevation: Task 
force for the management of acute coronary syndromes in patients presenting without 
persistent ST-segment elevation of . Eur Heart J. Published online 2016. 
doi:10.1093/eurheartj/ehv320 
171.  Bazaz R, Francis S, Dockrell D. 215 Increased Atherosclerotic Plaque Macrophage 
Content following Streptococcus Pneumoniae Pneumonia. Heart. Published online 2015. 
doi:10.1136/heartjnl-2015-308066.215 
172.  Brown AO, Mann B, Gao G, et al. Streptococcus pneumoniae Translocates into the 
Myocardium and Forms Unique Microlesions That Disrupt Cardiac Function. PLoS Pathog. 
Published online 2014. doi:10.1371/journal.ppat.1004383 
173.  Gilley RP, González-Juarbe N, Shenoy AT, et al. Infiltrated macrophages die of 
pneumolysin-mediated necroptosis following pneumococcal myocardial invasion. Infect 
Immun. Published online 2016. doi:10.1128/IAI.00007-16 
174.  Reyes LF, Restrepo MI, Hinojosa CA, et al. Severe pneumococcal pneumonia causes 
acute cardiac toxicity and subsequent cardiac remodeling. Am J Respir Crit Care Med. 
Published online 2017. doi:10.1164/rccm.201701-0104OC 
175.  Nel JG, Durandt C, Mitchell TJ, Feldman C, Anderson R, Tintinger GR. Pneumolysin 
Mediates Platelet Activation In Vitro. Lung. Published online 2016. doi:10.1007/s00408-
016-9900-5 
176.  Milbrandt EB, Reade MC, Lee M, et al. Prevalence and significance of coagulation 






Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
177.  Light RB. Pulmonary pathophysiology of pneumococcal pneumonia. Semin Respir Infect. 
1999;14(3):218-226. 
178.  Walley KR. Sepsis-induced myocardial dysfunction. Curr Opin Crit Care. 2018;24(4):292-
299. doi:10.1097/MCC.0000000000000507 
179.  Burk M, El-Kersh K, Saad M, Wiemken T, Ramirez J, Cavallazzi R. Viral infection in 
community-acquired pneumonia: a systematic review and meta-analysis. Eur Respir Rev. 
2016;25(140):178-188. doi:https://dx.doi.org/10.1183/16000617.0076-2015 
180.  Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, 
diagnosis, management, and therapy of myocarditis: A position statement of the European 
Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 
2013;34:2636-2648. doi:10.1093/eurheartj/eht210 
181.  Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and 
management of atrial fibrillation developed in collaboration with the European Association 
of Cardio-Thoracic Surgery (EACTS). Eur Heart J. Published online 2020:ehaa612. 
doi:10.1093/eurheartj/ehaa612 
182.  Alhamdi Y, Neill DR, Abrams ST, et al. Circulating Pneumolysin Is a Potent Inducer of 
Cardiac Injury during Pneumococcal Infection. PLoS Pathog. Published online 2015. 
doi:10.1371/journal.ppat.1004836 
183.  Ortolani P, Marino M, Melandri G, et al. Recent temporal trends for first-time hospitalization 
for acute myocardial infarction. Treatment patterns and clinical outcome in a large cohort 
study. Am Heart J. Published online 2013. doi:10.1016/j.ahj.2013.08.026 
184.  Schmidt M, Jacobsen JB, Lash TL, Bøtker HE, Sørensen HT. 25 Year trends in first time 
hospitalisation for acute myocardial infarction, subsequent short and long term mortality, 
and the prognostic impact of sex and comorbidity: A Danish nationwide cohort study. BMJ. 
2012;344:e356. doi:10.1136/bmj.e356 
185.  Smolina K, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality 
from acute myocardial infarction in England between 2002 and 2010: Linked national 
database study. BMJ. 2012;344:d8059. doi:10.1136/bmj.d8059 
186.  Yeh RW, Sidney S, Chandra M, Sorel M, Selby J V., Go AS. Population trends in the 
incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362(23):2155-
2165. doi:10.1056/NEJMoa0908610 
187.  Krumholz HM, Wang Y, Chen J, et al. Reduction in acute myocardial infarction mortality in 
the United States: Risk-standardized mortality rates from 1995-2006. JAMA - J Am Med 
Assoc. 2009;302(7):767-773. doi:10.1001/jama.2009.1178 
188.  Fox KAA, Steg PG, Eagle KA, et al. Decline in rates of death and heart failure in acute 
coronary syndromes, 1999-2006. J Am Med Assoc. 2007;297(17):1892-1900. 
doi:10.1001/jama.297.17.1892 
189.  Conrad N, Judge A, Canoy D, et al. Temporal Trends and Patterns in Mortality after 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
Published online 2019. doi:10.1001/jamacardio.2019.3593 
190.  Tsao CW, Lyass A, Enserro D, et al. Temporal Trends in the Incidence of and Mortality 
Associated With Heart Failure With Preserved and Reduced Ejection Fraction. JACC Hear 
Fail. Published online 2018. doi:10.1016/j.jchf.2018.03.006 
191.  Lane DA, Skjøth F, Lip GYH, Larsen TB, Kotecha D. Temporal trends in incidence, 
prevalence, and mortality of atrial fibrillation in primary care. J Am Heart Assoc. Published 
online 2017. doi:10.1161/JAHA.116.005155 
192.  Claessens YE, Debray MP, Tubach F, et al. Early chest computed tomography scan to 
assist diagnosis and guide treatment decision for suspected community-acquired 
pneumonia. Am J Respir Crit Care Med. Published online 2015. doi:10.1164/rccm.201501-
0017OC 
193.  N. S-M, C. R, C. B, et al. A validation exercise: Identifying hospitalizations for heart failure 
among patients with COPD in the CPRD. Pharmacoepidemiol Drug Saf. Published online 
2019. 
194.  Herrett E, Shah AD, Boggon R, et al. Completeness and diagnostic validity of recording 
acute myocardial infarction events in primary care, hospital care, disease registry, and 
national mortality records: Cohort study. BMJ. Published online 2013. 
doi:10.1136/bmj.f2350 
195.  Baskaran V, Lim WS, Mckeever TM. Cardiac Complications Following Community-
Acquired Pneumonia: A Systematic Review and Meta-analysis. (Unpublished). Published 
online 2020. 
196.  Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am 
J Emerg Med. Published online 2020. doi:10.1016/j.ajem.2020.04.048 
197.  Kang Y, Chen T, Mui D, et al. Cardiovascular manifestations and treatment considerations 
in COVID-19. Heart. Published online 2020. doi:10.1136/heartjnl-2020-317056 
198.  Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients 
with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. Published online 
2020. doi:10.1016/S0140-6736(20)30566-3 
199.  Shi S, Qin M, Shen B, et al. Association of Cardiac Injury with Mortality in Hospitalized 
Patients with COVID-19 in Wuhan, China. JAMA Cardiol. Published online 2020. 
doi:10.1001/jamacardio.2020.0950 
200.  Vlachopoulos C V, Terentes-Printzios DG, Aznaouridis KA, Pietri PG, Stefanadis CI. 
Association between pneumococcal vaccination and cardiovascular outcomes: A 
systematic review and meta-analysis of cohort studies. Eur J Prev Cardiol. 
2015;22(9):1185-1199. doi:http://dx.doi.org/10.1177/2047487314549512 
201.  Ren S, Newby D, Li SC, et al. Effect of the adult pneumococcal polysaccharide vaccine on 
cardiovascular disease: a systematic review and meta-analysis. Open Hear. 
2015;2:e000247. doi:10.1136/openhrt-2015-000247 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
pneumococcal vaccination on cardiovascular disease in adults: A systematic review and 
meta-analysis. Int J Infect Dis. Published online 2020. doi:10.1016/j.ijid.2020.07.038 
203.  Grijalva CG, Zhu Y, Williams DJ, et al. Association between hospitalization with 
community-acquired laboratory-confirmed influenza pneumonia and prior receipt of 
influenza vaccination. JAMA - J Am Med Assoc. 2015;314(14):1488-1497. 
doi:10.1001/jama.2015.12160 
204.  Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and 
cardiovascular outcomes in high-risk patients: A meta-analysis. JAMA - J Am Med Assoc. 
2013;310(16):1711-1720. doi:10.1001/jama.2013.279206 
205.  Baskaran V, Murray RL, Hunter A, Lim WS, McKeever TM. Effect of tobacco smoking on 
the risk of developing community acquired pneumonia: A systematic review and meta-
analysis. PLoS One. Published online 2019. doi:10.1371/journal.pone.0220204 
206.  Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular 
disease prevention in clinical practice. The Sixth Joint Task Force of the European Society 
of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical 
Practice (constituted by representati. G Ital Cardiol (Rome). 2016;37(29):2315-2381. 
doi:10.1714/2729.27821 
207.  Baskaran V, Lim WS, Mckeever TM. Current tobacco smoking status at index 
hospitalisation for pneumonia was independently associated with a higher risk of recurrent 
pneumonia. (Unpublished). Published online 2020. 
208.  Wald NJ, Hackshaw AK. Cigarette smoking: an epidemiological overview. Br Med Bull. 
1996;52(1):3-11. doi:10.1093/oxfordjournals.bmb.a011530 
209.  Verra F, Escudier E, Lebargy F, Bernaudin JF, De Cremoux H, Bignon J. Ciliary 
abnormalities in bronchial epithelium of smokers, ex-smokers, and nonsmokers. Am J 
Respir Crit Care Med. 1995;151(3 I):630-634. doi:10.1164/ajrccm/151.3_Pt_1.630 
210.  Piatti G, Gazzola T, Allegra L. Bacterial adherence in smokers and non-smokers. 
Pharmacol Res. 1997;36(6):481-484. doi:10.1006/phrs.1997.0255 
211.  Strulovici-Barel Y, Omberg L, O’Mahony M, et al. Threshold of biologic responses of the 
small airway epithelium to low levels of tobacco smoke. Am J Respir Crit Care Med. 
Published online 2010. doi:10.1164/rccm.201002-0294OC 
212.  Dye J, Adler K. Effects of cigarette smoke on epithelial cells of the respiratory tract. Thorax. 
1994;49:825-834. 
213.  Jones LL, Hashim A, McKeever T, Cook DG, Britton J, Leonardi-Bee J. Parental and 
household smoking and the increased risk of bronchitis, bronchiolitis and other lower 
respiratory infections in infancy: Systematic review and meta-analysis. Respir Res. 
Published online 2011. doi:10.1186/1465-9921-12-5 
214.  Lancaster T, Stead LF, Cahill K, Lindson-Hawley N, Hartmann-Boyce J, West R, Aveyard 






Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
wiley.com/o/cochrane/clabout/articles/TOBACCO/sect0-meta.html 
215.  Veritas Health Innovation, Melbourne A. Covidence systematic review sofware. Covidence. 
Published 2016. www.covidence.org 
216.  Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing 
the quality of nonrandomized studies in meta-analyses. Ottawa Hosp Res Inst. 2013;(3):1-
4. doi:10.2307/632432 
217.  Tas D, Sevketbeyoglu H, Aydin AF, Celik K, Karaca MA. The relationship between nicotine 
dependence level and community-acquired pneumonia in young soldiers: a case control 
study. Intern Med. 2008;47(24):2117-2120. doi:10.2169/internalmedicine.47.1219 
218.  Conley LJ, Bush TJ, Buchbinder SP, Penley KA, Judson FN, Holmberg SD. The 
association between cigarette smoking and selected HIV-related medical conditions. AIDS. 
1996;10(10):1121-1126. http://www.ncbi.nlm.nih.gov/pubmed/8874629 
219.  Gordin FM, Roediger MP, Girard PM, et al. Pneumonia in HIV-infected persons: Increased 
risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med. 
2008;178(6):630-636. doi:10.1164/rccm.200804-617OC 
220.  Chauny JM, Émond M, Plourde M, et al. Patients with Rib fractures do not develop delayed 
pneumonia: A prospective, multicenter cohort study of minor thoracic injury. Ann Emerg 
Med. 2012;60(6):726-731. doi:10.1016/j.annemergmed.2012.03.020 
221.  Attia EF, McGinnis KA, Feemster LC, et al. Association of COPD with risk for pulmonary 
infections requiring hospitalization in HIV-infected veterans. J Acquir Immune Defic Syndr. 
2015;70(3):280-288. doi:10.1097/QAI.0000000000000751 
222.  Braeken DC, Rohde GG, Franssen FM, et al. Risk of community-acquired pneumonia in 
chronic obstructive pulmonary disease stratified by smoking status: a population-based 
cohort study in the United Kingdom. Int J Chron Obstruct Pulmon Dis. 2017;Volume 
12:2425-2432. doi:10.2147/COPD.S138435 
223.  Greig JE, Carnie JA, Tallis GF, et al. An outbreak of Legionnaires’ disease at the 
Melbourne Aquarium, April 2000: Investigation and case-control studies. Med J Aust. 
2004;180(11):566-572. 
224.  CDC/ National Center for Health Statistics. Adult Tobacco Use Information. Published 
2017. Accessed January 15, 2019. 
https://www.cdc.gov/nchs/nhis/tobacco/tobacco_glossary.htm 
225.  Almirall J, González CA, Balanzó X, Bolíbar I. Proportion of community-acquired 
pneumonia cases attributable to tobacco smoking. Chest. 1999;116(2):375-379. 
doi:10.1378/chest.116.2.375 
226.  Almirall J, Bolibar I, Serra-Prat M, et al. New evidence of risk factors for community-
acquired pneumonia: A population-based study. Eur Respir J. 2008;31(6):1274-1284. 
doi:10.1183/09031936.00095807 
227.  Farr BM, Bartlett CL, Wadsworth J, Miller DL. Risk factors for community-acquired 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
Group. Respir Med. 2000;94(10):954-963. doi:10.1053/rmed.2000.0865 
228.  Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired 
pneumonia in seniors: Results of a population-based study. Clin Infect Dis. 
2004;39(11):1642-1650. doi:http://dx.doi.org/10.1086/425615 
229.  Almirall J, Bolíbar I, Serra-Prat M, et al. New evidence of risk factors for community-
acquired pneumonia: a population-based study. Eur Respir J. 2008;31(6):1274-1284. 
doi:10.1183/09031936.00095807 
230.  Almirall J, Bolibar I, Balanzo X, Gonzalez CA. Risk factors for community-acquired 
pneumonia in adults: a population-based case-control study. Eur Respir J. 1999;13(2):349-
355. 
231.  Feldman C, Anderson R. Cigarette smoking and mechanisms of susceptibility to infections 
of the respiratory tract and other organ systems. J Infect. Published online 2013. 
doi:10.1016/j.jinf.2013.05.004 
232.  Slama K, Chiang C-Y, Enarson D a, et al. Tobacco and tuberculosis: a qualitative 
systematic review and meta-analysis. Int J Tuberc Lung Dis. Published online 2007. 
233.  Lin H-H, Ezzati M, Murray M. Tobacco Smoke, Indoor Air Pollution and Tuberculosis: A 
Systematic Review and Meta-Analysis. PLoS Med. Published online 2007. 
doi:10.1371/journal.pmed.0040020 
234.  Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from 
exposure to tobacco smoke: A systematic review and meta-analysis. Arch Intern Med. 
Published online 2007. doi:10.1001/archinte.167.4.335 
235.  Royal College of Physicians. Hiding in Plain Sight: Treating Tobacco Dependency in the 
NHS.; 2018. 
236.  Furber AS, Maheswaran R, Newell JN, Carroll C. Is smoking tobacco an independent risk 
factor for HIV infection and progression to AIDS? A systemic review. Sex Transm Infect. 
Published online 2007. doi:10.1136/sti.2005.019505 
237.  Jayes L, Haslam PL, Gratziou CG, et al. SmokeHaz: Systematic Reviews and Meta-
analyses of the Effects of Smoking on Respiratory Health. In: Chest. ; 2016. 
doi:10.1016/j.chest.2016.03.060 
238.  Taskar VS. Is Idiopathic Pulmonary Fibrosis an Environmental Disease? Proc Am Thorac 
Soc. Published online 2006. doi:10.1513/pats.200512-131TK 
239.  Mons U, M?ezzinler A, Gellert C, et al. Impact of smoking and smoking cessation on 
cardiovascular events and mortality among older adults: Meta-analysis of Individual 
participant data from prospective cohort studies of the CHANCES consortium. BMJ. 
Published online 2015. doi:10.1136/bmj.h1551 
240.  Ordóñez-Mena JM, Schöttker B, Mons U, et al. Quantification of the smoking-associated 
cancer risk with rate advancement periods: Meta-analysis of individual participant data 






Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
241.  Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired 
pneumonia in adults in Europe: A literature review. Thorax. 2013;68(11):1057-1065. 
doi:http://dx.doi.org/10.1136/thoraxjnl-2013-204282 
242.  Arbes SJ, Agústsdóttir H, Slade GD, Slade GD. Environmental tobacco smoke and 
periodontal disease in the United States. Am J Public Health. Published online 2001. 
243.  Tomar SL, Asma S. Smoking-Attributable Periodontitis in the United States: Findings From 
NHANES III. J Periodontol. Published online 2000. doi:10.1902/jop.2000.71.5.743 
244.  Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal 
disease. Active Bacterial Core Surveillance Team. N Engl J Med. Published online 2000. 
doi:10.1056/NEJM200003093421002 
245.  High KP. Infection in the Elderly. In: Jeffrey B. Halter, Joseph G. Ouslander, Mary E. 
Tinetti, Stephanie Studenski, Kevin P. High SA, ed. Hazzard’s Geriatric Medicine and 
Gerontology. 6th ed. The McGraw-Hill Companies; 2009:1507-1509. 
246.  Nuorti JP, Butler JC, Farley MM, et al. Cigarette Smoking and Invasive Pneumococcal 
Disease. N Engl J Med. 2000;342(10):681-689. doi:10.1056/NEJM200003093421002 
247.  Raman AS, Swinburne AJ, Fedullo AJ. Pneumococcal adherence to the buccal epithelial 
cells of cigarette smokers. Chest. 1983;83(1):23-27. doi:10.1378/chest.83.1.23 
248.  Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med. Published online 
2004. doi:10.1001/archinte.164.20.2206 
249.  Corberand J, Nguyen F, Do AH, et al. Effect of tobacco smoking on the functions of 
polymorphonuclear leukocytes. Infect Immun. Published online 1979. 
250.  Noble RC, Penny BB. Comparison of leukocyte count and function in smoking and 
nonsmoking young men. Infect Immun. Published online 1975. 
251.  Mili F, Flanders WD, Boring JR, Annest JL, Destefano F. The associations of race, 
cigarette smoking, and smoking cessation to measures of the immune system in middle-
aged men. Clin Immunol Immunopathol. Published online 1991. doi:10.1016/0090-
1229(91)90017-5 
252.  McMillan SA, Douglas JP, Archbold GP, McCrum EE, Evans AE. Effect of low to moderate 
levels of smoking and alcohol consumption on serum immunoglobulin concentrations. J 
Clin Pathol. Published online 1997. doi:10.1136/jcp.50.10.819 
253.  Andersen P, Pedersen OF, Bach B, Bonde GJ. Serum antibodies and immunoglobulins in 
smokers and nonsmokers. Clin Exp Immunol. Published online 1982. 
254.  Ferson M, Edwards A, Lind A, Milton GW, Hersey P. Low natural killer‐cell activity and 
immunoglobulin levels associated with smoking in human subjects. Int J Cancer. Published 
online 1979. doi:10.1002/ijc.2910230504 
255.  Jedrychowski WA , Maugeri U AB. Effect of smoking on serum immunoglobulins and 
cellular blood constituents in healthy individuals. G Ital Med Lav. 1986;8(2):53-56. 
256.  Costabel U, Bross KJ, Reuter C, Rühle KH, Matthys H. Alterations in immunoregulatory T-





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
lymphocytes. Chest. Published online 1986. doi:10.1378/chest.90.1.39 
257.  Twigg HL, Soliman DM, Spain BA. Impaired alveolar macrophage accessory cell function 
and reduced incidence of lymphocytic alveolitis in HIV-infected patients who smoke. AIDS. 
Published online 1994. doi:10.1097/00002030-199405000-00006 
258.  McCrea KA, Ensor JE, Nall K, Bleecker ER, Hasday JD. Altered cytokine regulation in the 
lungs of cigarette smokers. Am J Respir Crit Care Med. Published online 1994. 
doi:10.1164/ajrccm.150.3.8087340 
259.  Brandstadter JD, Yang Y. Natural killer cell responses to viral infection. J Innate Immun. 
Published online 2011. doi:10.1159/000324176 
260.  Tollerud DJ, Clark JW, Brown LM, et al. Association of cigarette smoking with decreased 
numbers of circulating natural killer cells. Am Rev Respir Dis. Published online 1989. 
doi:10.1164/ajrccm/139.1.194 
261.  Hughes DA, Haslam PL, Townsend PJ, Turner-Warwick M. Numerical and functional 
alterations in circulatory lymphocytes in cigarette smokers. Clin exp Immunol. Published 
online 1985. 
262.  Miller LG, Goldstein G, Murphy M, Ginns LC. Reversible alterations in immunoregulatory T 
cells in smoking. Analysis by monoclonal antibodies and flow cytometry. Chest. Published 
online 1982. doi:10.1378/chest.82.5.526 
263.  Creer DD, Dilworth JP, Gillespie SH, et al. Aetiological role of viral and bacterial infections 
in acute adult lower respiratory tract infection (LRTI) in primary care. Thorax. Published 
online 2006. doi:10.1136/thx.2004.027441 
264.  Ishifuji T, Sando E, Kaneko N, et al. Recurrent pneumonia among Japanese adults: 
Disease burden and risk factors. BMC Pulm Med. Published online 2017. 
doi:10.1186/s12890-016-0359-1 
265.  Garcia-Vidal C, Carratalà J, Fernández-Sabé N, et al. Aetiology of, and risk factors for, 
recurrent community-acquired pneumonia. Clin Microbiol Infect. Published online 2009. 
doi:10.1111/j.1469-0691.2009.02918.x 
266.  Lawson PJ, Flocke SA. Teachable moments for health behavior change: A concept 
analysis. Patient Educ Couns. Published online 2009. doi:10.1016/j.pec.2008.11.002 
267.  McBride CM, Emmons KM, Lipkus IM. Understanding the potential of teachable moments: 
The case of smoking cessation. Health Educ Res. Published online 2003. 
doi:10.1093/her/18.2.156 
268.  Tofler GH, May R, Bartrop R, Kirkness A, Glinatsis H, de Burgh S. Acute Coronary 
Syndrome as a Teachable Moment for Smoking Cessation. J Smok Cessat. 2015;10(01):5-
11. doi:10.1017/jsc.2013.35 
269.  Garcia-Vidal C, Viasus D, Roset A, et al. Low incidence of multidrug-resistant organisms in 
patients with healthcare-associated pneumonia requiring hospitalization. Clin Microbiol 
Infect. 2011;17(11):1659-1665. doi:http://dx.doi.org/10.1111/j.1469-0691.2011.03484.x 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
adults after hospital-treated pneumonia: Aetiology and predisposing conditions. Scand J 
Infect Dis. 1997;29(4):387-392. 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed7&NEWS=N&AN=27
464249 
271.  Dang TT, Majumdar SR, Marrie TJ, Eurich DT. Recurrent Pneumonia: A Review with 
Focus on Clinical Epidemiology and Modifiable Risk Factors in Elderly Patients. Drugs and 
Aging. 2014;32(1):13-19. doi:http://dx.doi.org/10.1007/s40266-014-0229-6 
272.  Winterbauer RH, Bedon GA, Ball WC. Recurrent pneumonia. Predisposing illness and 
clinical patterns in 158 patients. Ann Intern Med. Published online 1969. doi:10.7326/0003-
4819-70-4-689 
273.  Ekdahl K, Braconier JH, Rollof J. Recurrent pneumonia: A review of 90 adult patients. 
Scand J Infect Dis. Published online 1992. doi:10.3109/00365549209048403 
274.  El Sohl, Ali A.; Brewer, Thomas; Okada, Mifue; Bashir, Omar; Gough M. Indicators of 
Recurrent Hospitalization for Pneumonia in the Elderly. J Am Geriatr Soc. 52(12):2010-
2015. 
275.  Baik I, Curhan GC, Rimm EB, Bendich  a, Willett WC, Fawzi WW. A prospective study of 
age and lifestyle factors in relation to community-acquired pneumonia in US men and 
women. Arch Intern Med. 2000;160:3082-3088. doi:10.1001/archinte.160.20.3082 
276.  Cecere LM, Williams EC, Sun H, et al. Smoking cessation and the risk of hospitalization for 
pneumonia. Respir Med. 2012;106(7):1055-1062. doi:10.1016/j.rmed.2012.03.018 
277.  Boggon R, Timmis A, Hemingway H, Raju S, Malvestiti FM, Van Staa TP. Smoking 
cessation interventions following acute coronary syndrome: A missed opportunity? Eur J 
Prev Cardiol. Published online 2014. doi:10.1177/2047487312460517 
278.  Thorley R, Britton J, Nyakutsikwa B, Opazo Breton M, Lewis SA, Murray RL. Enhanced 
smoking cessation support for newly abstinent smokers discharged from hospital (the 
Hospital to Home trial): a randomized controlled trial. Addiction. Published online 2019. 
doi:10.1111/add.14720 
279.  Murray RL, Leonardi-Bee J, Marsh J, et al. Systematic identification and treatment of 
smokers by hospital based cessation practitioners in a secondary care setting: Cluster 
randomised controlled trial. BMJ. Published online 2013. doi:10.1136/bmj.f4004 
280.  Rigotti NA, Regan S, Levy DE, et al. Sustained care intervention and postdischarge 
smoking cessation among hospitalized adults a randomized clinical trial. JAMA - J Am Med 
Assoc. Published online 2014. doi:10.1001/jama.2014.9237 
281.  United States Department of Health and Human Services. The Health Consequences of 
Smoking—50 Years of Progress A Report of the Surgeon General. A Rep Surg Gen. 
Published online 2014. 
282.  Warnier MJ, Van Riet EES, Rutten FH, De Bruin ML, Sachs APE. Smoking cessation 






Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
283.  Snaterse M, Scholte op Reimer WJM, Dobber J, et al. Smoking cessation after an acute 
coronary syndrome: Immediate quitters are successful quitters. Netherlands Hear J. 
Published online 2015. doi:10.1007/s12471-015-0755-9 
284.  Yudi MB, Farouque O, Andrianopoulos N, et al. The prognostic significance of smoking 
cessation after acute coronary syndromes: An observational, multicentre study from the 
Melbourne interventional group registry. BMJ Open. Published online 2017. 
doi:10.1136/bmjopen-2017-016874 
285.  van den Berg MJ, van der Graaf Y, Deckers JW, et al. Smoking cessation and risk of 
recurrent cardiovascular events and mortality after a first manifestation of arterial disease. 
Am Heart J. Published online 2019. doi:10.1016/j.ahj.2019.03.019 
286.  Streck JM, Chang Y, Tindle HA, et al. Smoking cessation after hospital discharge: Factors 
associated with abstinence. J Hosp Med. Published online 2018. doi:10.12788/jhm.2997 
287.  Harrington K, Young-il K, Meifang C, et al. Web-Based Intervention for Transitioning 
Smokers From Inpatient to Outpatient Care: An RCT. Am J Prev Med. Published online 
2016. doi:10.1016/j.amepre.2016.04.008 
288.  Lando H, Hennrikus D, McCarty M, Vessey J. Predictors of quitting in hospitalized 
smokers. Nicotine Tob Res. Published online 2003. doi:10.1080/0955300031000083436 
289.  N. S, J.A. F, J.N. N, et al. Changes in health in the countries of the UK and 150 English 
Local Authority areas 1990–2016: a systematic analysis for the Global Burden of Disease 
















292.  National Institute for Health and Care Excellence (NICE). Stop Smoking Interventions and 
Services: NICE Guideline [NG92]. 
https://www.nice.org.uk/guidance/ng92/chapter/recommendations#very-brief-advice 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
hospitalised patients. Cochrane database Syst Rev. Published online 2012. 
doi:10.1002/14651858.CD001837.pub3 
294.  Coleman T. ABC of smoking cessation: Use of simple advice and behavioural support. Br 
Med J. Published online 2004. 
295.  Coleman T. Cessation interventions in routine health care. BMJ. Published online 2004. 
doi:10.1136/bmj.328.7440.631 
296.  Department of Health and Social Care. Towards a Smokefree Generation: A Tobacco 




297.  Mangera, Zaheer; Devani N. National Smoking Cessation Audit Report 2019. Br Thorac 
Soc Reports. 11(2). 
298.  The Welsh Government. Tobacco Control Delivery Plan for Wales 2017-2020.; 2017. 
299.  The Scottish Government. Creating a Tobacco-Free Generation: A Tobacco Control 
Strategy for Scotland.; 2013. 
300.  Department of Health Social Services and Public Safety. Ten-Year Tobacco Control 
Strategy for Northern Ireland. 
301.  McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev 
Microbiol. 2014;12(4):252-262. doi:10.1038/nrmicro3231 
302.  World Health Organisation (WHO). WHO COVID-19 Dashboard. Published 2020. 
Accessed June 2, 2020. 
https://covid19.who.int/?gclid=CjwKCAjw8df2BRA3EiwAvfZWaJWnmCWZBUjJdJZGVdH4
hGENu8orjqQTHDsIst5u_gYXoQcl8sS_ZxoCIxEQAvD_BwE 
303.  Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N 
Engl J Med. Published online 2020. doi:10.1056/NEJMoa2002032 
304.  Herold T, Jurinovic V, Arnreich C, et al. Elevated levels of IL-6 and CRP predict the need 
for mechanical ventilation in COVID-19. J Allergy Clin Immunol. Published online 2020. 
doi:10.1016/j.jaci.2020.05.008 
305.  International Severe Acute Respiratory and emerging Infection Consortium (ISARIC). 
COVID-19 Clinical Data Report: 03 September 2020.; 2020. https://isaric.tghn.org/covid-
19-clinical-research-resources/ 
306.  Tan C, Huang Y, Shi F, et al. C-reactive protein correlates with CT findings and predicts 
severe COVID-19 early. J Med Virol. n/a(n/a). doi:10.1002/jmv.25871 
307.  NICE. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital (NICE 
Guideline 173). National Institute for Health and Care Excellence. 
308.  Intensive Care National Audit & Research Centre. ICNARC Report on COVID-19 in Critical 
Care 22 May 2020.; 2020. 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
A College of American Pathologists Q-Tracks study of 356 institutions. Arch Pathol Lab 
Med. Published online 2005. doi:10.1043/1543-2165(2005)129[1222:TIBCCA]2.0.CO;2 
310.  Hall KK, Lyman JA. Updated review of blood culture contamination. Clin Microbiol Rev. 
Published online 2006. doi:10.1128/CMR.00062-05 
311.  Freeman JT, Chen LF, Sexton DJ, Anderson DJ. Blood culture contamination with 
Enterococci and skin organisms: Implications for surveillance definitions of primary 
bloodstream infections. Am J Infect Control. Published online 2011. 
doi:10.1016/j.ajic.2010.07.014 
312.  Gajdács M, Dóczi I, Ábrók M, Lázár A, Burián K. Epidemiology of candiduria and Candida 
urinary tract infections in inpatients and outpatients: Results from a 10-year retrospective 
survey. Cent Eur J Urol. Published online 2019. doi:10.5173/ceju.2019.1909 
313.  Pendleton KM, Huffnagle GB, Dickson RP. The significance of Candida in the human 
respiratory tract: Our evolving understanding. Pathog Dis. Published online 2017. 
doi:10.1093/femspd/ftx029 
314.  Public Health England (PHE). SMI B 57: Investigation of Bronchoalveolar Lavage, Sputum 
and Associated Specimens.; 2019. https://www.gov.uk/government/publications/smi-b-57-
investigation-of-bronchoalveolar-lavage-sputum-and-associated-specimens 
315.  Lin E, Bhusal Y, Horwitz D, Shelburne SA, Trautner BW. Overtreatment of enterococcal 
bacteriuria. Arch Intern Med. Published online 2012. doi:10.1001/archinternmed.2011.565 
316.  British Society of Thoracic Imaging (BSTI). COVID-19 BSTI reporting templates and codes. 
Published 2020. https://www.bsti.org.uk/covid-19-resources/covid-19-bsti-reporting-
templates/ 
317.  The European committee and Antimicrobial susceptibility testing. Intrinsic Resistance and 
Unusual Phenotypes version 3.2 February 2020. 
Https://EucastOrg/Expert_Rules_and_Intrinsic_Resistance/. Published online 2020. 
318.  Rice TW, Rubinson L, Uyeki TM, et al. Critical illness from 2009 pandemic influenza A virus 
and bacterial coinfection in the United States. Crit Care Med. 2012;40(5):1487-1498. 
doi:10.1097/CCM.0b013e3182416f23 
319.  Arabi YM, Al-Omari A, Mandourah Y, et al. Critically Ill Patients With the Middle East 
Respiratory Syndrome: A Multicenter Retrospective Cohort Study. Crit Care Med. 
2017;45(10):1683-1695. doi:10.1097/ccm.0000000000002621 
320.  Jang TN, Yeh DY, Shen SH, Huang CH, Jiang JS, Kao SJ. Severe acute respiratory 
syndrome in Taiwan: analysis of epidemiological characteristics in 29 cases. J Infect. 
2004;48(1):23-31. doi:10.1016/j.jinf.2003.09.004 
321.  Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a 
systematic review and meta-analysis. J Infect. doi:10.1016/j.jinf.2020.05.046 
322.  Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in 
patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
323.  Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with 
coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 
Published online 2020. doi:10.1093/cid/ciaa530 
324.  Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection 
among hospitalized patients with COVID-19: a retrospective cohort study in a UK 
secondary-care setting. Clin Microbiol Infect. Published online 2020. 
doi:https://doi.org/10.1016/j.cmi.2020.06.025 
325.  Youngs J, Wyncoll D, Hopkins P, Arnold A, Ball J, Bicanic T. Improving antibiotic 
stewardship in COVID-19: Bacterial co-infection is less common than with influenza. J 
Infect. Published online 2020. doi:https://doi.org/10.1016/j.jinf.2020.06.056 
326.  Crotty MP, Akins RL, Nguyen AT, et al. Investigation of subsequent and co-infections 
associated with SARS-CoV-2 (COVID-19) in hospitalized patients. medRxiv. Published 
online 2020:2020.05.29.20117176. doi:10.1101/2020.05.29.20117176 
327.  Kreitmann L, Monard C, Dauwalder O, Simon M, Argaud L. Early bacterial co-infection in 
ARDS related to COVID-19. Intensive Care Med. Published online 2020. 
doi:10.1007/s00134-020-06165-5 
328.  Vincent J-L. Nosocomial infections in adult intensive-care units. Lancet. 
2003;361(9374):2068-2077. doi:https://doi.org/10.1016/S0140-6736(03)13644-6 
329.  Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of 
infection in intensive care units. Jama. 2009;302(21):2323-2329. 
doi:10.1001/jama.2009.1754 
330.  Nori P, Cowman K, Chen V, et al. Bacterial and Fungal Co-Infections in COVID-19 Patients 
Hospitalized During the New York City Pandemic Surge. Infect Control Hosp Epidemiol. 
Published online 2020:1-13. doi:10.1017/ice.2020.368 
331.  Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-
associated bacterial pneumonia. Clin Infect Dis. 2010;51 Suppl 1:S81-7. 
doi:10.1086/653053 
332.  Garcia-Vidal C, Sanjuan G, Moreno-García E, et al. Incidence of co-infections and 
superinfections in hospitalised patients with COVID-19: a retrospective cohort study. Clin 
Microbiol Infect. Published online 2020. doi:10.1016/j.cmi.2020.07.041 
333.  Dhesi Z, Enne VI, Brealey D, et al. Organisms causing secondary pneumonias in COVID-
19 patients at 5 UK ICUs as detected with the FilmArray test. medRxiv. Published online 
2020:2020.06.22.20131573. doi:10.1101/2020.06.22.20131573 
334.  Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection Between SARS-CoV-2 
and Other Respiratory Pathogens. Jama. Published online 2020. 
doi:10.1001/jama.2020.6266 







Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
336.  Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 Days of Antibiotic Therapy for 
Ventilator-Associated Pneumonia in Adults: A Randomized Trial. J Am Med Assoc. 
Published online 2003. doi:10.1001/jama.290.19.2588 
337.  Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic 
therapy for patients with pulmonary infiltrates in the intensive care unit: A proposed solution 
for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. Published online 
2000. doi:10.1164/ajrccm.162.2.9909095 
338.  Dexamethasone in Hospitalized Patients with COVID-19 — Preliminary Report. N Engl J 
Med. Published online 2020. doi:10.1056/nejmoa2021436 
339.  NICE, SIGN and RCGP set out further details about the UK guideline on management of 
the long-term effects of COVID-19. Accessed November 24, 2020. 
https://www.nice.org.uk/news/article/nice-sign-and-rcgp-set-out-further-details-about-the-
uk-guideline-on-management-of-the-long-term-effects-of-covid-19 
340.  World Health Organisation (WHO). Global Action Plan on Antimicrobial Resistance.; 2015. 
341.  The Longitude Prize. Accessed November 24, 2020. https://longitudeprize.org/ 
342.  Department of Health and Social Care. Tackling Antimicrobial Resistance 2019–2024: The 
UK’s Five-Year National Action Plan. Accessed November 24, 2020. 
https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-
resistance-2019-to-2024 
343.  West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: 
Proposal for a common standard. Addiction. Published online 2005. doi:10.1111/j.1360-
0443.2004.00995.x 
344.  Chalmers J, Campling J, Ellsbury G, Hawkey PM, Madhava H, Slack M. Community-
acquired pneumonia in the United Kingdom: a call to action. Pneumonia. Published online 
2017. doi:10.1186/s41479-017-0039-9 
345.  The Post-hospitalisation COVID-19 Study (PHOSP-COVID). Accessed November 24, 
2020. https://www.phosp.org/ 
346.  GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national 
age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-
2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, 
England). 2015;385(9963):117-171. doi:10.1016/S0140-6736(14)61682-2 
347.  Strehlow MC, Emond SD, Shapiro NI, Pelletier AJ, Camargo CA. National Study of 
Emergency Department Visits for Sepsis, 1992 to 2001. Ann Emerg Med. 2006;48(3). 
doi:10.1016/j.annemergmed.2006.05.003 
348.  Metlay JP, Atlas SJ, Borowsky LH, Singer DE. Time course of symptom resolution in 
patients with community-acquired pneumonia. Respir Med. 1998;92(9):1137-1142. 
doi:10.1016/S0954-6111(98)90408-5 
349.  Brandenburg JA, Marrie TJ, Coley CM, et al. Clinical presentation, processes and 





Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
2000;15(9):638-646. doi:10.1046/j.1525-1497.2000.04429.x 
350.  Girard TD, Self WH, Edwards KM, et al. Long-Term Cognitive Impairment after 
Hospitalization for Community-Acquired Pneumonia: a Prospective Cohort Study. Journal 
of General Internal Medicine. 2018:1-7. 
351.  Clinical Practice Research Datalink (CPRD). https://www.cprd.com/researcher/ 
 
 










Changes in Part 2: 
  
Section C: Technical Summary (Max. 200 words)§ 
Original statement: 
Data analysis (paragraph 2) 
The independent association between patient characteristics and rate of reconsultation 
(overall/ patients without co-morbidities /patients with underlying respiratory disease) 
will be calculated using a multivariate logistic regression model; adjusted for age, gender, 
smoking, social deprivation, co-morbidities, vaccine status, length of hospital stay and 
intensive care unit admission. Causes of reconsultation will be divided into either 
respiratory or non-respiratory (cardiac symptoms and cognitive decline) symptoms. 
We will measure the number of antibiotic prescriptions at reconsultation and where 
possible, the type of antibiotics prescribed. Association of antibiotic prescription at 
reconsultation with further reconsultation episodes will also be analysed. 
Amended statement: 
The independent association between patient characteristics and rate of reconsultation 
(overall/ patients without co-morbidities /patients with underlying respiratory disease) 
will be calculated using a competing-risks regression with death and readmission as 
competing events; adjusted for age, gender, smoking, alcohol consumption, practice 
region, primary care consultation in the previous year, social deprivation, co-morbidities, 
vaccine status, length of hospital stay, and admission year. Causes of reconsultation will 
be divided into either respiratory or non-respiratory (cardiac symptoms and cognitive 
decline) symptoms. We will measure the number of antibiotic prescriptions at 
reconsultation and where possible, the type of antibiotics prescribed. Association of 
antibiotic prescription at reconsultation with further reconsultation episodes will also be 
analysed.  
Proportion of patients who received smoking cessation advice before and after the index 
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person-years) will be determined by smoking status. Effect of smoking on hospitalization 
for recurrence of pneumonia will be determined using competing-risks regression (death 
as a competing event), adjusted for variables determined using directed acyclic graph 
(DAG). 
 




Amended statement: (Addendum to Specific Aims subheading) 
• To determine whether current smokers admitted with pneumonia were given smoking 
cessation advice both before and after developing pneumonia  
• To determine the rate of pneumonia recurrence by smoking status 
• To determine the effect of tobacco smoking on hospitalisation for recurrence of 
pneumonia 
 
Section M: Exposures, Health Outcomes§ and Covariates  
Addendum to Exposures/ Outcomes: 
 
Primary care reconsultation was considered to have occurred if medical Read codes were 
recorded after the date of discharge from hospital; administration-related codes were 
excluded to capture face-to-face consultations.74,75 If there were multiple Read codes 
recorded in a day per patient, this was counted as a single episode of consultation.  
 
Smoking cessation advice/stop smoking interventions will be assessed using Read codes 
within CPRD. These Read code list will be developed using a combination of validated 
medical Read codes and product Read codes under British National Formulary (BNF) 
listing of "Drugs used in substance dependence: Nicotine dependence".70,76 
 
‘Recurrent pneumonia’ was defined as hospitalisation with pneumonia 30 days after the 




Covariates that will be considered in this study include age, gender, smoking, social 
deprivation, co-morbidities, vaccine status, length of hospital stay and intensive care unit 
admission. 
Amended statement: 
Covariates that will be considered in this study include age, gender, smoking, alcohol 
consumption, practice region, primary care consultation in the previous year, social 
deprivation, co-morbidities, vaccine status, length of hospital stay, and admission year. 
Validated codelists were used for pneumonia, smoking status, alcohol consumption, 
Charlson Comorbidity Index and specific co-morbidities of interest.70,76,77 
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Statistical analyses will be performed using Stata 15. Incidence of CAP and other diseases 
(cardiac complications and cognitive decline) will be estimated using the whole CPRD as 
the denominator population. Incidence rates (IR) per 100,000 person-years, adjusted 
incidence rate ratios (IRR) and 95% confidence intervals (CIs) will be described.  
 
Baseline demographics and co-morbid diseases of adults who reconsulted will be 
compared to those who did not reconsult. The independent association between patient 
characteristics and rate of reconsultation (overall/ patients without co-morbidities 
/patients with underlying respiratory disease) will be calculated using a multivariable 
logistic regression model; adjusted for age, gender, smoking, social deprivation, the 
presence of co-morbidities (Charlson co-morbidity index), vaccine status, length of 
hospital stay and intensive care unit admission. The included variables in the final model 
will be those associated with healthcare reconsultation during univariate analysis. Cause 
of reconsultation will be divided into either ‘CAP-related’ (respiratory symptoms) or ‘not 
CAP-related’ (cardiac symptoms and cognitive decline). 
 
We will measure the number of antibiotic prescriptions at reconsultation and where 
possible, the type of antibiotics prescribed.  
 
Amended statement: 
Statistical analyses will be performed using Stata 15. Incidence of CAP and other diseases 
(cardiac disease and cognitive decline) will be estimated using the whole CPRD as the 
denominator population. Incidence rates (IR) per 100,000 person-years, adjusted 
incidence rate ratios (IRR) and 95% confidence intervals (CIs) will be described. For the 
estimation of cardiac disease, we will also calculate the incidence in age, sex and GP 
practice matched population to that of CAP to compare the incidence the rate of cardiac 
disease after CAP vs the general population. 
 
The independent association between patient characteristics and rate of reconsultation 
(overall/ patients without co-morbidities /patients with underlying respiratory disease) 
will be calculated using a competing-risks regression with death and readmission as 
competing events; adjusted for age, gender, smoking, alcohol consumption, practice 
region, primary care consultation in the previous year, social deprivation, co-morbidities, 
vaccine status, length of hospital stay, and admission year. Causes of reconsultation will 
be divided into either respiratory or non-respiratory (cardiac symptoms and cognitive 
decline) symptoms. We will measure the number of antibiotic prescriptions at 
reconsultation and where possible, the type of antibiotics prescribed. Association of 
antibiotic prescription at reconsultation with further reconsultation episodes will also be 
analysed.  
Proportion of patients who received smoking cessation advice before and after the index 
pneumonia episode will be calculated. The rate of pneumonia recurrence (per 100 
person-years) will be determined by smoking status. Effect of smoking on hospitalization 
for recurrence of pneumonia will be determined using competing-risks regression (death 
as a competing event), adjusted for variables determined using directed acyclic graph 
(DAG). 
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takes into account any reconsultation before death or readmission in the former analysis 
whilst the latter does not. This given a more accurate results of the outcome of interest, 
for both reconsultation in primary care and recurrent pneumonia hospitalisation. 
 
 
Section O : Plan for addressing confounding 
Original statement: 
Study will be adjusted for confounding factors such as age, gender, smoking, social 
deprivation, co-morbidities, vaccine status, length of hospital stay and intensive care unit 
admission using multivariable logistic regression model. 
Amended statement: 
Study will be adjusted for confounding factors such as age, gender, smoking, alcohol 
consumption, practice region, primary care consultation in the previous year, social 
deprivation, co-morbidities, vaccine status, length of hospital stay, and admission year 
using competing-risks regression 
Directed acyclic graph (DAG) will used to identify the minimum set of confounders to 
close the back-door paths to address the objective of determining the effect of smoking 
on the risk of recurrent pneumonia. 
 
Section P:  Plans for addressing missing data  
Original statement: 
The potential for missing data, particularly on covariates such as smoking and vaccine 




There may be missing data, particularly on covariates such as smoking status and alcohol 
consumption. If there were >3% missing data, we will use multiple imputation with 








Appendix 2: Read codes  
Comorbidities 
Chronic pulmonary disease 
Medcode Description 
105420 Asthma self-management plan review 
38146 Asthma disturbs sleep weekly 
233 Severe asthma attack 
102209 Mini asthma quality of life questionnaire 
100509 Under care of asthma specialist nurse 
78 Asthma 
103998 Asthma limits activities most days 
73522 Work aggravated asthma 
103612 Asthma never causes night symptoms 
21232 Allergic asthma nec 
102713 Asthma limits activities 1 to 2 times per month 
13065 Moderate asthma 
4606 Exercise induced asthma 
26503 Asthma causes daytime symptoms most days 
10043 Asthma annual review 
9552 Change in asthma management plan 
3366 Severe asthma 
105674 Asthma self-management plan agreed 
102400 Asthma causes night time symptoms 1 to 2 times per week 
19519 Asthma treatment compliance unsatisfactory 
107167 Number days absent from school due to asthma in past 6 month 
5267 Intrinsic asthma 
93353 Sequoiosis (red-cedar asthma) 
13176 Asthma follow-up 
106805 Chronic asthma with fixed airflow obstruction 
16070 Asthma nos 
45782 Extrinsic asthma nos 
98185 Asthma control test 
9663 Step up change in asthma management plan 
100397 Asthma control questionnaire 
24479 Emergency asthma admission since last appointment 
102952 Asthma trigger - warm air 
102341 Asthma trigger - pollen 
18224 Asthma control step 3 
3458 Occasional asthma 
185 Acute exacerbation of asthma 
103813 Asthma trigger - cold air 
40823 Brittle asthma 
2290 Allergic asthma 
26501 Asthma never causes daytime symptoms 
39570 Asthma causes night symptoms 1 to 2 times per month 
102449 Asthma trigger - respiratory infection 
58196 Intrinsic asthma with status asthmaticus 
102888 Asthma limits activities 1 to 2 times per week 
26861 Asthma sometimes restricts exercise 





8335 Asthma attack nos 
9018 Number of asthma exacerbations in past year 
7731 Pollen asthma 
93736 Royal college of physicians asthma assessment 
25791 Asthma clinical management plan 
16785 Asthma control step 1 
5627 Hay fever with asthma 
13064 Asthma severity 
7058 Emergency admission, asthma 
38144 Asthma limits walking up hills or stairs 
103955 Asthma trigger - tobacco smoke 
6707 Extrinsic asthma with asthma attack 
4892 Status asthmaticus nos 
10487 Asthma - currently active 
39478 Wood asthma 
31167 Asthma night-time symptoms 
38145 Asthma limits walking on the flat 
3665 Late onset asthma 
12987 Late-onset asthma 
5867 Exercise induced asthma 
103945 Asthma trigger - damp 
103318 Health education - structured patient focused asthma discuss 
103952 Asthma trigger - emotion 
1555 Bronchial asthma 
19520 Asthma treatment compliance satisfactory 
7146 Extrinsic (atopic) asthma 
10274 Asthma medication review 
8355 Asthma monitored 
15248 Hay fever with asthma 
26504 Asthma never restricts exercise 
7378 Asthma management plan given 
24884 Asthma causes daytime symptoms 1 to 2 times per week 
20886 Asthma control step 4 
102170 Asthma review using roy colleg of physicians three questions 
100740 Health education - structured asthma discussion 
3018 Mild asthma 
47337 Asthma accident and emergency attendance since last visit 
16667 Asthma control step 2 
232 Asthma attack 
102395 Asthma causes symptoms most nights 
46529 Attends asthma monitoring 
30458 Asthma monitoring by doctor 
81 Asthma monitoring 
29325 Intrinsic asthma without status asthmaticus 
103631 Royal college physician asthma assessment 3 question score 
100107 Health education - asthma self management 
41017 Aspirin induced asthma 
4442 Asthma unspecified 
7416 Asthma disturbing sleep 
31225 Asthma causes daytime symptoms 1 to 2 times per month 
38143 Asthma never disturbs sleep 
18323 Intrinsic asthma with asthma attack 
26506 Asthma severely restricts exercise 
102871 Asthma trigger - exercise 
25181 Asthma restricts exercise 





42824 Asthma daytime symptoms 
102301 Asthma trigger - seasonal 
47684 Detergent asthma 
103321 Asthma trigger - animals 
19167 Asthma monitoring by nurse 
41020 Absent from work or school due to asthma 
30815 Asthma causing night waking 
13175 Asthma disturbs sleep frequently 
103944 Asthma trigger - airborne dust 
14777 Extrinsic asthma without status asthmaticus 
22752 Occupational asthma 
24506 Further asthma - drug prevent. 
27926 Extrinsic asthma with status asthmaticus 
99793 Patient has a written asthma personal action plan 
7191 Asthma limiting activities 
11370 Asthma confirmed 
20860 Asthma control step 5 
45771 Chronic obstructive pulmonary disease does not disturb sleep 
15626 Chronic catarrhal bronchitis 
18476 Copd follow-up 
3243 Chronic bronchitis 
40788 Other emphysema 
64721 Chronic emphysema due to chemical fumes 
11150 Mucopurulent chronic bronchitis 
38074 Chronic obstructive pulmonary disease monitor phone invite 
104608 End stage chronic obstructive airways disease 
67040 Other specified chronic obstructive pulmonary disease 
106945 Chronic obstructive pulmonary disease rescue pack declined 
66043 Other chronic bronchitis 
34202 Chronic obstructive pulmonary disease monitoring 2nd letter 
65733 [x]other specified chronic obstructive pulmonary disease 
9520 Chronic obstructive pulmonary disease monitoring 
794 Emphysema 
45089 Chronic tracheobronchitis 
37959 Fetid chronic bronchitis 
34215 Chronic obstructive pulmonary disease monitoring 3rd letter 
37371 Chronic obstructive pulmonary disease monitoring due 
42313 Health education - chronic obstructive pulmonary disease 
70787 Atrophic (senile) emphysema 
66058 [x]other emphysema 
56860 Segmental bullous emphysema 
5909 Chronic wheezy bronchitis 
99536 Bullous emphysema with collapse 
26018 Chronic obstructive pulmonary disease monitoring by nurse 
16410 Other emphysema nos 
7884 Chronic obstructive pulmonary disease with acute exacerbation, unspecified 
42258 Chronic obstructive pulmonary disease monitoring verb invite 
33450 Emphysema nos 
44525 Obstructive chronic bronchitis nos 
5710 Chronic obstructive airways disease nos 
10802 Moderate chronic obstructive pulmonary disease 
10980 Centrilobular emphysema 
104985 On chronic obstructive pulmonary disease supprtv cre pathway 
998 Chronic obstructive airways disease 
1001 Chronic obstructive pulmonary disease 





68662 Zonal bullous emphysema 
61513 Mucopurulent chronic bronchitis nos 
5798 Chronic asthmatic bronchitis 
11287 Chronic obstructive pulmonary disease annual review 
9876 Severe chronic obstructive pulmonary disease 
68066 Other chronic bronchitis nos 
103494 History of chronic obstructive pulmonary disease 
102685 Chronic obstructive pulmonary disease 3 monthly review 
18621 Chronic obstructive pulmonary disease follow-up 
104481 Has chronic obstructive pulmonary disease care plan 
61118 Simple chronic bronchitis nos 
93568 Very severe chronic obstructive pulmonary disease 
46578 Panlobular emphysema 
25603 Simple chronic bronchitis 
10863 Mild chronic obstructive pulmonary disease 
45770 Chronic obstructive pulmonary disease disturbs sleep 
7092 Recurrent wheezy bronchitis 
109774 Telehealth chronic obstructive pulmonary disease monitoring 
23492 Chronic bullous emphysema nos 
15157 Chronic bronchitis nos 
18792 Chronic obstructive pulmonary disease monitoring admin 
105457 Chronic obstructive pulmonary disease care pathway 
45998 Chronic obstructive pulmonary disease monitoring by doctor 
45777 Chronic obstructive pulmonary disease clini management plan 
60188 Giant bullous emphysema 
24248 Mixed simple and mucopurulent chronic bronchitis 
14798 Emphysematous bronchitis 
12166 Other specified chronic obstructive airways disease 
28755 Chronic obstructive pulmonary disease monitoring 1st letter 
1446 Acute exacerbation of chronic obstructive airways disease 
106637 Seen in chronic obstructive pulmonary disease clinic 
37247 Chronic obstructive pulmonary disease nos 
40159 Purulent chronic bronchitis 
21061 Chronic obstructive pulmonary disease with acute lower respiratory infection 
103007 Chronic obstructive pulmonary disease 6 monthly review 
27819 Obstructive chronic bronchitis 
101042 Issue of chronic obstructive pulmonary disease rescue pack 
41491 Post-infective bronchiectasis 
2195 Bronchiectasis 
109816 H/o: bronchiectasis 
15693 Tuberculous bronchiectasis 
20364 Recurrent bronchiectasis 
56427 Congenital bronchiectasis 
32679 Bronchiectasis nos 
62442 Allergic extrinsic alveolitis nos 
63174 Hamman - rich syndrome 
51410 Asbestosis nos 
31423 Pneumoconiosis nos 
46460 Silica and silicate pneumoconiosis 
65376 Pneumoconiosis due to other inorganic dust 
47718 Myositis in sarcoidosis 
4084 Airways obstructn irreversible 
103559 Usual interstitial pneumonitis 
7791 Postinflammatory pulmonary fibrosis 
8303 Asbestosis 





51858 Other allergic alveolitis 
8317 Interstitial lung disease nec 
34437 Sarcoid myocarditis 
23461 Pneumoconiosis due to inorganic dust nos 
52519 Myopathy due to sarcoidosis 
55552 Other allergic alveolitis nos 
28853 Fibrosing alveolitis associated with rheumatoid arthritis 
6051 Diffuse pulmonary fibrosis 
65060 [x]other interstitial pulmonary diseases with fibrosis 
47037 Sarcoid heart disease 
91912 [x]other specified interstitial pulmonary diseases 
53095 Allergic alveolitis and pneumonitis nos 
55612 Multiple cranial nerve palsies in sarcoidosis 
49454 Meningitis due to sarcoidosis 
49075 Sarcoidosis of lymph nodes 
28229 Idiopathic fibrosing alveolitis nos 
40613 Sarcoid arthropathy 
103753 Idiopathic pulmonary fibrosis 
5519 Cryptogenic fibrosing alveolitis 
105939 [x]pneumoconiosis due to other dust containing silica 
6837 Idiopathic fibrosing alveolitis 
46977 Allergic alveolitis and pneumonitis nos 
25013 Pneumoconioses 
26405 Hepatic granulomas in sarcoidosis 
3865 Sarcoidosis 
11312 Extrinsic allergic alveolitis 
103472 Pulmonary fibrosis 
23446 Silica pneumoconiosis nos 
3859 Pulmonary sarcoidosis 
60805 Talc pneumoconiosis 
27769 Sarcoidosis of skin 
58841 Sarcoidosis of lung with sarcoidosis of lymph nodes 
72595 Sarcoidosis of inferior turbinates 
33980 Sarcoidosis of lung 
19492 Coal workers' pneumoconiosis 









96838 [x]acute transmural myocardial infarction of unspecif site 
109035 [x]subsequent myocardial infarction of other sites 
99991 [x]subsequent myocardial infarction of unspecified site 
40429 Acute anteroapical infarction 
12139 Acute anterolateral infarction 
17872 Acute anteroseptal infarction 
28736 Acute atrial infarction 
9276 Acute coronary insufficiency 
11983 Acute coronary syndrome 
8935 Acute inferolateral infarction 
29643 Acute inferoposterior infarction 
241 Acute myocardial infarction 
14658 Acute myocardial infarction nos 
9507 Acute non-q wave infarction 
10562 Acute non-st segment elevation myocardial infarction 
62626 Acute papillary muscle infarction 
32854 Acute posterolateral myocardial infarction 
30330 Acute q-wave infarct 
41221 Acute septal infarction 
12229 Acute st segment elevation myocardial infarction 
3704 Acute subendocardial infarction 
29758 Acute transmural myocardial infarction of unspecif site 
14897 Anterior myocardial infarction nos 
23708 Atrial septal defect/curr comp folow acut myocardal infarct 
13566 Attack - heart 
30421 Cardiac rupture following myocardial infarction (mi) 
36423 Certain current complication follow acute myocardial infarct 
2491 Coronary thrombosis 
26975 Ecg: antero-septal infarct. 
52705 Ecg: lateral infarction 
59032 Ecg: myocardial infarct nos 
7783 Ecg: myocardial infarction 
55401 Ecg: subendocardial infarct 
26972 Ecg:posterior/inferior infarct 
50372 H/o: myocardial infarction in last year 
24126 Haemopericardium/current comp folow acut myocard infarct 
16408 Healed myocardial infarction 
1204 Heart attack 
1678 Inferior myocardial infarction nos 
14898 Lateral myocardial infarction nos 
1677 Mi - acute myocardial infarction 
68357 Microinfarction of heart 
4017 Old myocardial infarction 
34803 Other acute myocardial infarction 
46017 Other acute myocardial infarction nos 
5387 Other specified anterior myocardial infarction 
17464 Personal history of myocardial infarction 
9555 Post infarct angina 
23892 Posterior myocardial infarction nos 
23579 Postmyocardial infarction syndrome 
59189 Ruptur cardiac wall w'out haemopericard/cur comp fol ac mi 
59940 Ruptur chordae tendinae/curr comp fol acute myocard infarct 





69474 Rupture papillary muscle/curr comp fol acute myocard infarct 
17689 Silent myocardial infarction 
18842 Subsequent myocardial infarction 
45809 Subsequent myocardial infarction of anterior wall 
38609 Subsequent myocardial infarction of inferior wall 
72562 Subsequent myocardial infarction of other sites 
46166 Subsequent myocardial infarction of unspecified site 
13571 Thrombosis - coronary 
29553 Thrombosis atrium,auric append&vent/curr comp foll acute mi 
63467 True posterior myocardial infarction 
37657 Ventric septal defect/curr comp fol acut myocardal infarctn 
46276 Postoperative transmural myocardial infarction inferior wall 
46112 Postoperative transmural myocardial infarction anterior wall 
32272 Postoperative myocardial infarction 
35119 Post infarction pericarditis 
68748 Postoperative myocardial infarction, unspecified 
41835 Postoperative subendocardial myocardial infarction 
106812 Postoperative transmural myocardial infarction unspec site 
39904 Ecg: old myocardial infarction 
35674 H/o: myocardial infarct <60 
40399 H/o: myocardial infarct >60 
 
Congestive cardiac failure 
Medcode Description 
21235 Suspected heart failure 
9913 Heart failure confirmed 
5155 O/e - pulmonary oedema 
46672 New york heart assoc classification heart failure symptoms 
18853 New york heart association classification - class i 
13189 New york heart association classification - class ii 
19066 New york heart association classification - class iii 
51214 New york heart association classification - class iv 
8464 Acute cor pulmonale 
5141 Congestive cardiomyopathy 
2062 Heart failure 
1223 Cardiac failure 
398 Congestive heart failure 
2906 Congestive cardiac failure 
10079 Right heart failure 
10154 Right ventricular failure 
9524 Biventricular failure 
23707 Acute congestive heart failure 
32671 Chronic congestive heart failure 
27884 Decompensated cardiac failure 
11424 Compensated cardiac failure 
884 Left ventricular failure 
43618 Pulmonary oedema - acute 
5942 Impaired left ventricular function 
5255 Acute left ventricular failure 
27964 Acute heart failure 
4024 Heart failure nos 
17278 Cardiac failure nos 
7321 Pulmonary oedema nos 





48466 Acute oedema of lung, unspecified 
5293 Acute pulmonary oedema nos 
66306 Heart failure as a complication of care 
26242 New york heart assoc classification heart failure symptoms 
57987 Hyperten heart&renal dis+both(congestv)heart and renal fail 
22262 Rheumatic left ventricular failure 
20822 Congenital cardiac failure 
72668 Malignant hypertensive heart disease with ccf 
62718 Hypertensive heart disease nos with ccf 
21837 Hypertensive heart&renal dis wth (congestive) heart failure 
 
Other cardiac diseases 
Medcode Description 
204 Hypertensive disease 
351 High blood pressure 
426 Sinus arrhythmia 
561 Mitral regurgitation 
562 Left ventricular hypertrophy 
799 Essential hypertension 
939 Endocarditis, valve unspecified, nos 
999 Aortic stenosis, non-rheumatic 
1005 Aortic regurgitation alone, cause unspecified 
1007 Aortic incompetence alone, cause unspecified 
1267 Mitral valve diseases 
1268 Paroxysmal atrial fibrillation 
1294 Mitral valve prolapse 
1297 Paroxysmal atrial tachycardia 
1344 Coronary artery disease 
1381 Paroxysmal tachycardia nos 
1414 Angina on effort 
1430 Angina pectoris 
1431 Unstable angina 
1490 Heart disease nos 
1535 Cardiac dysrhythmia nos 
1536 Supraventricular tachycardia nos 
1655 Triple vessel disease of the heart 
1664 Atrial fibrillation 
1757 Atrial flutter 
1779 Tricuspid incompetence, non-rheumatic 
1811 Other heart disease nos 
1885 Mitral stenosis 
1894 Benign essential hypertension 
2155 Ventricular cardiac aneurysm 
2212 Atrial fibrillation and flutter 
2249 Ectopic beats unspecified 
2343 Aortic stenosis alone, cause unspecified 






2669 Pulmonary stenosis, cause unspecified 
2724 Ventricular hypertrophy 
2817 Tricuspid valve disorders, non-rheumatic 
2977 Mitral valve incompetence 
3032 Bundle branch block unspecified 
3204 Cardiomyopathy 
3399 Acute pericarditis 
3418 Paroxysmal ventricular tachycardia 
3499 Hypertrophic non-obstructive cardiomyopathy 
3603 Partial atrioventricular block 
3704 Acute subendocardial infarction 
3712 Hypertension nos 
3729 Ventricular dilatation 
3757 Ecg: atrial fibrillation 
3769 Stokes-adams syndrome 
3810 Complete atrioventricular block 
3849 Persistent sinus bradycardia 
3909 Premature beats 
3999 Single coronary vessel disease 
4044 Cardiac dysrhythmias 
4372 Systolic hypertension 
4374 Ventricular fibrillation and flutter 
4421 Heart beats irregular 
4548 Aortic valve disorders 
4549 Heart block 
4656 Crescendo angina 
4668 Hypertensive renal disease 
4772 Skipped beat 
4802 Ventricular ectopic beats 
4827 Ventricular fibrillation 
4915 Alcoholic cardiomyopathy 
4939 Bacterial endocarditis 
4940 Paroxysmal supraventricular tachycardia 
5058 Mitral incompetence, non-rheumatic 
5141 Congestive cardiomyopathy 
5254 Double coronary vessel disease 
5413 Coronary atherosclerosis 
5449 Subacute bacterial endocarditis - sbe 
5484 Ventricular flutter 
5576 Sick sinus syndrome 
5714 Atrioventricular dissociation 
5743 Valvular heart disease 
6077 Pulmonary regurgitation, cause unspecified 
6331 Aneurysm of heart 
6503 Cardiac arrhythmias 





7057 Hypertensive disease nos 
7320 Ischaemic cardiomyopathy 
7329 Secondary hypertension 
7347 Unstable angina 
7410 Sinoatrial node dysfunction nos 
7457 Ectopic beats 
7482 Left bundle branch hemiblock 
7535 Primary dilated cardiomyopathy 
7696 Syncope anginosa 
7794 Ventricular tachycardia 
7827 Other cardiac dysrhythmias 
7839 Right ventricular thrombosis 
7963 Aortic regurgitation - rheumatic 
8010 Hypertrophic obstructive cardiomyopathy 
8230 Wolff-parkinson-white syndrome 
8274 Mitral and aortic stenosis 
8411 Viral pericarditis nos 
8568 Cardiac syndrome x 
8651 Nodal rhythm disorder 
8732 Bp - hypertensive disease 
9023 Atrial premature depolarization 
9276 Acute coronary insufficiency 
9286 Tricuspid regurgitation, cause unspecified 
9312 Chronic rheumatic heart disease 
9391 Rheumatic aortic stenosis 
9402 Secondary dilated cardiomyopathy 
9413 Other acute and subacute ischaemic heart disease 
9450 Mitral valve regurgitation 
9479 Implant intravenous pacemaker for atrial fibrillation 
9507 Acute non-q wave infarction 
9515 Bigeminal pulse 
9555 Post infarct angina 
9563 Pulse missed beats 
9591 Aortic stenosis 
9906 Right bundle branch block 
10078 Diseases of mitral and aortic valves 
10109 Heart diseases 
10111 Stenosis of unspecified heart valve 
10187 Aortic regurgitation, non-rheumatic 
10415 Myocarditis nos 
10712 Trifascicular block 
10818 Essential hypertension nos 
10922 Mobitz type ii atrioventricular block 
10964 Aortic valve stenosis with insufficiency 
11048 Variant angina pectoris 
11878 Mitral and aortic regurgitation 





12312 Pulmonary valve disorders 
12775 Acute and subacute endocarditis 
12804 Stable angina 
12986 Prinzmetal's angina 
13250 Cardiac diseases 
13854 Ecg: heart block 
14646 Other and unspecified acute pericarditis 
14723 Pulmonary stenosis, non-rheumatic 
14998 Aortic incompetence, non-rheumatic 
15089 Acute pericarditis in diseases ec nos 
15106 Hypertensive renal disease nos 
15132 Rheumatic endocarditis nos 
15377 Malignant essential hypertension 
15496 Pulmonary regurgitation, non-rheumatic 
15534 Haemopericardium 
15640 Pulmonary insufficiency, non-rheumatic 
15643 Other specified chronic rheumatic heart disease 
15661 Dressler's syndrome 
15754 Other chronic ischaemic heart disease nos 
15782 Chronic pulmonary heart disease nos 
15792 Cardiac tamponade 
15889 Atrial dilatation 
15990 Endomyocardial fibrosis 
16059 Secondary hypertension nos 
16173 Hypertensive heart disease nos 
16240 Postcardiotomy syndrome 
16292 Hypertensive heart disease 
16373 Tricuspid valve disease nec 
16545 Rheumatic mitral valve disease 
16996 Tb - acute pericarditis 
17133 Mural thrombosis 
17146 Other diseases of endocardium 
17206 Bifascicular block 
17307 Angina at rest 
17434 Nephrosclerosis 
17596 Mitral stenosis and aortic regurgitation 
17597 Ecg: supraventricular arrhythmia 
17840 Left bundle branch block 
18100 Rheumatic aortic valve disease 
18117 Other bundle branch block 
18118 Worsening angina 
18125 Nocturnal angina 
18268 Severe sinus bradycardia 
18293 Pericardial effusion - noninflammatory 
18437 Sinoatrial block 
18475 Combined disorders of mitral, aortic and tricuspid valves 





18877 Chronic pericarditis 
18889 Asymptomatic coronary heart disease 
19019 Aortic valve disorders nos 
19191 Conduction disorders of heart 
19337 Long q-t syndrome 
19655 Angina at rest 
19699 Disorders of both mitral and tricuspid valves 
19707 Ecg: ventricular arrhythmia 
19957 Pulmonary valve disorders nos 
19979 Supraventricular ectopic beats 
20001 Chronic rheumatic heart disease nos 
20011 Hyperkinetic heart disease 
20035 Thyrotoxic heart disease 
20095 Angina decubitus 
20157 Constrictive pericarditis 
20416 Atherosclerotic heart disease 
21807 Mitral incompetence - rheumatic 
21837 Hypertensive heart&renal dis wth (congestive) heart failure 
21844 Transient myocardial ischaemia 
21852 Familial cardiomyopathy 
21854 Left ventricular thrombosis 
21980 Tricuspid regurgitation - rheumatic 
22003 Regurgitation of unspecified heart valve 
22262 Rheumatic left ventricular failure 
22383 Other specified ischaemic heart disease 
22412 Heart disease - pulmonary 
22639 Acute myocarditis 
22691 Romano - ward syndrome 
22837 Mitral regurgitation - rheumatic 
22993 Cardiomyopathy nos 
23078 Chronic myocardial ischaemia 
23437 Atrial fibrillation and flutter nos 
23481 Asthma - cardiac 
23494 Wandering atrial pacemaker 
23608 Pulmonary incompetence, non-rheumatic 
23619 Acute rheumatic pancarditis 
23647 Paroxysmal atrioventricular tachycardia 
23708 Atrial septal defect/curr comp folow acut myocardal infarct 
24126 Haemopericardium/current comp folow acut myocard infarct 
24377 Third degree atrioventricular block 
24540 Chronic coronary insufficiency 
24557 Mitral valve disorders nos 
24636 Acute rheumatic pericarditis 
24683 Myocardial degeneration 
24783 Arteriosclerotic heart disease 
25147 Anomalous atrioventricular excitation 





25371 Secondary benign renovascular hypertension 
25617 Acute and subacute bacterial endocarditis 
25842 Angina pectoris nos 
26318 Left main stem bundle branch block 
26863 New onset angina 
26973 Ecg:shows myocardial ischaemia 
26975 Ecg: antero-septal infarct. 
27375 Atrioventricular block nos 
27413 Ectopic beats nos 
27463 Pulsus alternans 
27484 Cardiac aneurysm 
27606 Acute pericarditis - unspecified 
27683 Cardiomyopathy in myotonic dystrophy 
27843 Infective endocarditis in diseases ec, nos 
27874 Other conduction disorders 
27928 Mobitz type i (wenckebach) atrioventricular block 
27951 Other acute and subacute ischaemic heart disease 
27977 Other acute and subacute ischaemic heart disease nos 
28138 Other chronic ischaemic heart disease 
28554 Angina pectoris nos 
28662 Nonrheumatic mitral valve stenosis 
28684 Hypertensive heart and renal disease with renal failure 
28850 Heart valve disorders - non rheumatic 
29158 Mitral and aortic valve disease nos 
29180 Cardiac septal defect, acquired 
29310 Renal hypertension 
29371 Ecg: ventricular arrhythmia nos 
29421 Silent myocardial ischaemia 
29491 Paroxysmal nodal tachycardia 
29551 Acute pericarditis in diseases ec 
29654 Junctional premature depolarization 
29902 Angina decubitus nos 
30171 Other forms of heart disease 
30443 Mitral valve disease nos 
30454 Atrial thrombosis 
30610 Aortic valve sclerosis 
30667 Amyloid heart disease 
31133 Other cardiac dysrhythmia nos 
31286 Ecg: ventricular fibrillation 
31308 Acute bacterial endocarditis 
31341 Hypertension secondary to drug 
31387 Secondary renovascular hypertension nos 
31464 Hypertensive heart disease nos 
31505 Rheumatic tricuspid stenosis 
31690 Re-entry ventricular arrhythmia 
31727 Mitral and aortic incompetence 





31759 Mitral incompetence and aortic stenosis 
31784 Rupture of chordae tendinae 
31809 Ventricular premature depolarization 
31839 Mitral valve prolapse 
31979 Endocarditis, valve unspecified 
32059 Ventricular pre-excitation 
32211 Rheumatic aortic insufficiency 
32423 Hypertensive renal disease with renal failure 
32435 Rheumatic mitral stenosis 
32450 Ischaemic chest pain 
33262 Mitral insufficiency and aortic stenosis 
33348 Atrial hypertrophy 
33370 Other pericardial disease nos 
33673 Conduction disorders 
33899 Cardiac arrest with successful resuscitation 
33907 Mitral regurgitation and aortic stenosis 
34065 Secondary pulmonary hypertension 
34240 Mitral incompetence, cause unspecified 
34290 Acute endocarditis nos 
34326 Lown-ganong-levine syndrome 
34328 Refractory angina 
34437 Sarcoid myocarditis 
34633 Other specified chronic ischaemic heart disease 
34744 Hypertension secondary to endocrine disorders 
34869 Tricuspid incompetence, cause unspecified 
34932 Pulmonary valve stenosis with insufficiency 
35119 Post infarction pericarditis 
35124 Paroxysmal supraventricular tachycardia nos 
35127 Non-rheumatic atrial fibrillation 
35372 Tricuspid regurgitation, non-rheumatic 
35713 Other specified chronic ischaemic heart disease nos 
35724 Tricuspid stenosis, non-rheumatic 
35947 Right fascicular block 
36193 Other specified heart disease 
36227 Conduction disorders nos 
36423 Certain current complication follow acute myocardial infarct 
36496 Acute pericarditis - pneumococcal 
36609 Atherosclerotic cardiovascular disease 
36629 Second degree atrioventricular block 
36755 Acute pericarditis nos 
36768 Rheumatic pulmonary valve disease nos 
36854 Coronary artery spasm 
36886 Acute rheumatic endocarditis 
37628 Calcification of pericardium 
37657 Ventric septal defect/curr comp fol acut myocardal infarctn 
38299 Pulmonary insufficiency, cause unspecified 





38876 Acute and subacute endocarditis unspecified 
39003 Other bundle branch block nos 
39423 Diphtheritic myocarditis 
39449 Coronary thrombosis not resulting in myocardial infarction 
39546 [x]other forms of angina pectoris 
39649 Malignant hypertensive renal disease 
39671 Incompetence of unspecified heart valve 
39693 Subendocardial ischaemia 
39843 Other heart block 
39916 Mitral valve leaf prolapse 
39956 Jervell and lange-nielsen syndrome 
40239 Multiple valve diseases 
40427 Other diseases of pericardium 
40569 Chronic bacterial endocarditis 
40582 Disorders of both aortic and tricuspid valves 
40793 Papillary muscle degeneration 
40834 Other primary cardiomyopathy nos 
40949 Mitral valve insufficiency 
40956 Acute pericarditis - uraemic 
40957 Adherent rheumatic pericardium 
41163 Pericardial 'milk spots' 
41179 Other ill-defined heart disease nos 
41221 Acute septal infarction 
41488 Constrictive cardiomyopathy 
41527 Acute myocarditis nos 
41677 Aneurysm of heart nos 
41916 Ventricular fibrillation and flutter nos 
42014 Cardiac dilatation nos 
42024 Other specified pericardial disease nos 
42043 Secondary cardiomyopathy nos 
42128 Tricuspid insufficiency, cause unspecified 
42229 Secondary hypertension nos 
42239 Tricuspid incompetence - rheumatic 
42803 Anomalous atrioventricular excitation nos 
42901 Kyphoscoliotic heart disease 
43347 Aortic incompetence - rheumatic 
43816 Rheumatoid carditis 
43855 Tricuspid valve disorders nos 
43935 Benign hypertensive renal disease 
43937 Papillary muscle atrophy 
44096 Conduction disorders unspecified 
44167 Rheumatic pulmonary valve disease 
44328 Mitral stenosis with regurgitation 
44376 Chronic rheumatic pericarditis 
44488 Mitral stenosis with insufficiency 
44756 Rheumatic fever with heart involvement 





45311 Pericardial effusion - acute 
46178 Other heart block nos 
46237 Endocarditis in disease ec 
46294 Chronic pulmonary heart disease 
46736 Pulmonary incompetence, cause unspecified 
46992 Prolonged p-r interval 
47037 Sarcoid heart disease 
47637 [x]other forms of chronic ischaemic heart disease 
47887 Aortic insufficiency, non-rheumatic 
48024 Subacute endocarditis nos 
48099 Acute rheumatic myocarditis 
48340 Acute and subacute infective endocarditis in diseases ec 
49185 Aortic valve calcification 
49272 [x]other aortic valve disorders 
49355 Mitral stenosis and aortic insufficiency 
49551 Tricuspid stenosis and regurgitation, cause unspecified 
49735 Rupture of papillary muscle 
49787 Rheumatoid myocarditis 
49844 Beriberi heart disease 
50157 Malignant hypertensive heart disease 
50720 Adhesive pericarditis 
50788 Accelerated atrioventricular conduction 
50809 Rheumatic aortic valve disease nos 
50983 Mitral stenosis with incompetence 
51140 Electromechanical dissociation with successful resuscitation 
51472 Endocarditis, valve unspecified, os 
51635 Secondary benign hypertension nos 
51845 Paroxysmal junctional tachycardia 
51879 Rheumatic mitral insufficiency 
52127 Benign hypertensive heart disease with ccf 
52271 Nonrheumatic tricuspid valve stenosis with insufficiency 
52427 Benign hypertensive heart disease 
52517 [x]ischaemic heart diseases 
53518 Acute myocarditis - coxsackie 
53756 [x]other mitral valve diseases 
53826 Left bundle branch hemiblock nos 
53878 Rheumatic heart disease unspecified 
53893 [x]other specified cardiac arrhythmias 
53959 [x]other pulmonary valve disorders 
54088 Rheumatic pulmonary insufficiency 
54113 Other chronic pulmonary heart disease 
54478 Endocardial fibroelastosis 
54535 Stenocardia 
54554 Interventricular block nos 
55416 Toxic myocarditis 
55646 Acute myocarditis - influenzal 





56029 Tricuspid stenosis, cause unspecified 
56180 Concato's disease 
56621 Cardiovascular arteriosclerosis unspecified 
57069 Right bbb with left anterior fascicular block 
57126 Acute pericarditis - tuberculous 
57288 Secondary benign hypertension 
57306 Other primary cardiomyopathies 
57334 Gouty tophi of heart 
57338 Multiple valve disease, unspecified 
57633 Ruptured mitral valve cusp 
57916 Other diseases of pericardium os 
57980 Other and unspecified rheumatic heart disease 
57987 Hyperten heart&renal dis+both(congestv)heart and renal fail 
58032 Atrioventricular block unspecified 
58769 Acute pericarditis - coxsackie 
58810 Aortic insufficiency alone, cause unspecified 
58938 Cardiomyopathy due to drugs and other external agents 
59102 Acute idiopathic pericarditis 
59140 Pick's disease of heart 
59189 Ruptur cardiac wall w'out haemopericard/cur comp fol ac mi 
59193 Aneurysm of coronary vessels 
59213 Fatty infiltration heart 
59275 Rheumatic valvulitis, chronic nos 
59383 Secondary malignant renovascular hypertension 
59677 Acute pericarditis - streptococcal 
59687 Other ill-defined heart disease 
59854 Other rheumatic heart disease nos 
60047 Essential paroxysmal tachycardia 
60266 Rheumatic tricuspid insufficiency 
60411 Pyopericardium 
61072 Myocardial infarction aborted 
61124 Cardiac hypertrophy nos 
61166 Hypertensive heart disease nos without ccf 
61250 Mitral stenosis and aortic incompetence 
61379 Acute pericarditis - meningococcal 
61492 Acute myocarditis, unspecified 
61660 Benign hypertensive heart disease without ccf 
61774 Papillary muscle scarring 
61878 Pulmonary stenosis, cause unspecified 
61929 Fistula of pericardium 
62186 Rheumatic tricuspid stenosis and incompetence 
62207 Rheumatic pulmonary stenosis 
62349 Left anterior fascicular block 
62404 Rheumatic myocarditis 
62494 Endocarditis - typhoid 
62626 Acute papillary muscle infarction 





62736 Acute myocarditis in diseases ec, nos 
63000 Benign hypertensive heart and renal disease 
63078 Other acute myocarditis nos 
63217 Acute pulmonary heart disease 
63466 Hypertensive heart and renal disease 
63675 Fibrosis of pericardium 
63960 Rheumatic aortic stenosis with insufficiency 
64481 Acute purulent pericarditis unspecified 
64673 Nutritional and metabolic cardiomyopathy nos 
64837 Dystrophic cardiomyopathy 
65073 Other conduction disorders nos 
65533 Acute pulmonary heart disease nos 
65653 Right fascicular block 
65807 Constrictive pericarditis nos 
66121 Acute and subacute endocarditis unspecified, nos 
66388 Status anginosus 
67087 Other cardiac wall aneurysm 
67232 Malignant hypertensive heart and renal disease 
67291 Acute myocarditis - toxoplasmosis 
67528 Papillary muscle disease 
67780 Endocarditis - q fever 
68126 Other chronic rheumatic endocardial disease 
68401 [x]other forms of acute ischaemic heart disease 
68411 Acute myocarditis - meningococcal 
68659 Hypertensive heart and renal disease nos 
68685 Obscure african cardiomyopathy 
68766 Congestive obstructive cardiomyopathy 
68849 Acute rheumatic heart disease nos 
68979 [x]other forms of heart disease 
69216 Accessory atrioventricular conduction 
69474 Rupture papillary muscle/curr comp fol acute myocard infarct 
69593 Endocarditis - coxsackie 
69753 [x]hypertensive diseases 
69809 Left posterior fascicular block 
69995 Rheumatic chorea with heart involvement 
70366 Bouveret-hoffmann syndrome 
70648 [x]other hypertrophic cardiomyopathy 
70698 Multiple mitral and aortic valve involvement 
70855 Cardiomyopathy in friedreich's ataxia 
71004 [x]aortic valve disorders in diseases classified elsewhere 
71046 Other chronic pulmonary heart disease nos 
71848 Septic myocarditis nos 
72110 Other acute myocarditis 
72306 Tricuspid stenosis and insufficiency, cause unspecified 
72409 Idiopathic myocarditis nos 
72562 Subsequent myocardial infarction of other sites 





72628 Chronic rheumatic myopericarditis 
72653 Other bilateral bundle branch block 
72888 Pre-excitation atrioventricular conduction 
73153 [x]myocarditis in viral diseases classified elsewhere 
73283 Becker's disease 
73293 Secondary malignant hypertension nos 
73540 Other acute rheumatic heart disease 
83473 Diastolic hypertension 
89579 Insufficiency of unspecified heart valve 
91774 Acquired atrioventricular fistula of heart 
91847 Acute myocarditis - tuberculous 
92266 [x]other restrictive cardiomyopathy 
92267 Papillary muscle dysfunction 
93113 Rheumatic tricuspid stenosis and regurgitation 
93114 Rheumatic tricuspid stenosis and insufficiency 
94521 [x]other rheumatic aortic valve diseases 
94870 Congestive heart failure due to valvular disease 
94872 Mitral and aortic insufficiency 
95334 Malignant hypertensive heart disease without ccf 
95488 [x]pulmon heart disease & diseases of pulmonary circulation 
95919 Brugada syndrome 
96076 Persistent atrial fibrillation 
96101 Adhesive pericarditis nos 
96277 Permanent atrial fibrillation 
96799 Post cardiac operation heart failure nos 
96838 [x]acute transmural myocardial infarction of unspecif site 
97160 [x]other specified conduction disorders 
97533 [x]hypertension secondary to other renal disorders 
97617 [x]other cardiomyopathies 
97738 Tricuspid insufficiency, non-rheumatic 
97780 Arrhythmogenic right ventricular cardiomyopathy 
97821 [x]other and unspecified right bundle-branch block 
98020 Cardiomyopathy in diseases ec, nos 
98167 Giant cell myocarditis 
98538 Nonrheumatic tricuspid valve disorder, unspecified 
98560 [x]other nonrheumatic mitral valve disorders 
98634 [x]cardiomyopathy in metabolic diseases ce 
98638 [x]other acute myocarditis 
98675 Right bbb with left posterior fascicular block 
98751 Right ventricular dilatation 
99051 [x]cardiovascular disease, unspecified 
99077 [x]other tricuspid valve diseases 
99338 External ventricular defibrillation 
99959 Post cardiac operation functional disturbance 
100051 [x]other acute rheumatic heart disease 
100572 Endocarditis - gonococcal 





100910 [x]multiple valve disorders/diseases ce 
100924 Acute myoendocarditis nos 
100966 Nutritional and metabolic cardiomyopathies 
101015 Takotsubo cardiomyopathy 
101485 Pacemaker twiddler's syndrome 
101712 [x]other specified heart block 
101922 [x]other and unspecified fascicular block 
102458 [x]other secondary hypertension 
102955 Tachycardiomyopathy 
103046 Malignant hypertensive heart disease nos 
103752 Mobitz type 1 second degree atrioventricular block 
103850 Acute pericarditis - gonococcal 
104081 Acute pericarditis - staphylococcal 
104373 Septic myocarditis - pneumococcal 
104529 Tachycardia-induced cardiomyopathy 
104658 Stress cardiomyopathy 
104697 Acute aseptic myocarditis of the newborn 
104876 Right ventricular diastolic dysfunction 
105192 Pericardial effusion 
105226 Suspected arrhythmia 
105250 Mural cardiac aneurysm 
105274 Stage 2 hypertension (nice - nat ins for hth clin excl 2011) 
105316 Stage 1 hypertension 
105371 Stage 1 hypertension (nice - nat ins for hth clin excl 2011) 
105479 Coronary microvascular disease 
105480 Hypertension resistant to drug therapy 
105487 Severe hypertension 
105615 Other acute rheumatic heart disease nos 
105626 Rheumatic pulmonary stenosis and insufficiency 
105651 Amyloid cardiomyopathy 
105798 Cardiac amyloidosis 
105938 Benign hypertensive heart disease nos 
105989 Severe hypertension (nat inst for health clinical ex 2011) 
106049 [x]other and unspecified atrioventricular block 
106928 [x]other diseases of pulmonary vessels 
107257 Septic myocarditis - staphylococcal 
107462 Rheumatic heart disease 
107472 Paroxysmal atrial flutter 
107591 Carditis due to rheumatic fever 
107662 Chronic pericardial effusion 
107704 Primary hypertension 
107770 Papillary muscle disorder nos 
108136 Stage 1 hyperten (nice 2011) without evidnce end organ damge 
108180 Right ventricular systolic dysfunction 
108258 [x]pericarditis in other diseases classified elsewhere 
109797 Stage 1 hyperten (nice 2011) with evidnce end organ damge 





110488 [x]tricuspid valve disorders/diseases ce 
110531 [x]endocarditis,valve unspecified,in diseases ce 
110634 [x]other specified pulmonary heart diseases 
110717 [x]acute myocarditis, unspecified 
111837 Acute myocarditis in diseases ec 
112041 Acute pericarditis - syphilitic 
112042 Acute myocarditis - syphilitic 





73901 [x]cerebrovascular diseases 
96630 [x]intracerebral haemorrhage in hemisphere; unspecified 
92036 [x]occlusion and stenosis of other cerebral arteries 
90572 [x]occlusion and stenosis of other precerebral arteries 
53810 [x]other intracerebral haemorrhage 
19280 Anterior cerebral artery syndrome 
8443 Brain stem stroke syndrome 
13564 Cerebellar haemorrhage 
17322 Cerebellar stroke syndrome 
54744 Cerebral degeneration due to cerebrovascular disease 
27975 Cerebral infarction due to embolism of cerebral arteries 
1298 Cva unspecified 
7017 Evacuation of intracerebral haematoma nec 
34135 H/o: cva/stroke 
5871 H/o: stroke 
5051 Intracerebral haemorrhage 
31060 Intracerebral haemorrhage in hemisphere; unspecified 
3535 Intracerebral haemorrhage nos 
30202 Intracerebral haemorrhage; intraventricular 
57315 Intracerebral haemorrhage; multiple localized 
20284 Intracranial haemorrhage nos 
7780 Left sided cva 
28314 Left sided intracerebral haemorrhage; unspecified 
18689 Middle cerebral artery syndrome 
98642 Multiple and bilateral precerebral arterial occlusion 
71274 Occlusion??? Of multiple and bilat cerebral arteries 
51326 Other precerebral artery occlusion 
19354 Other transient cerebral ischaemia 
19260 Posterior cerebral artery syndrome 
45781 Precerebral arterial occlusion 
71585 Precerebral artery occlusion nos 
33499 Pure motor lacunar syndrome 
51767 Pure sensory lacunar syndrome 
12833 Right sided cva 
19201 Right sided intracerebral haemorrhage; unspecified 
29939 Ruptured berry aneurysm 
48149 Sequelae of intracerebral haemorrhage 
63830 Stenosis of precerebral arteries 
6155 Stroke due to cerebral arterial occlusion 





6253 Stroke unspecified 
18912 Subdural haemorrhage nos 
504 Transient cerebral ischaemia 
15788 Transient cerebral ischaemia nos 
1895 Transient cerebral ischaemia nos 
8181 Traumatic subdural haemorrhage 
111096 [x]other specified cerebrovascular diseases 
65745 [x]other subarachnoid haemorrhage 
108668 [x]subarachnoid haemorrhage from other intracranial arteries 
2418 Cerebrovascular disease 
10062 Cerebrovascular disease nos 
38304 Closed traumatic subarachnoid haemorrhage 
6960 Cva - cerebrovascular accid due to intracerebral haemorrhage 
6116 Cva - cerebrovascular accident unspecified 
40053 Generalised ischaemic cerebrovascular disease nos 
12555 Generalised ischaemic cerebrovascular disease nos 
23361 Late effects of cerebrovascular disease 
96717 Open traumatic subarachnoid haemorrhage 
13577 Other cerebrovascular disease 
37493 Other cerebrovascular disease nos 
34117 Other cerebrovascular disease os 
51311 Other specified cerebrovascular disease 
44740 Sequelae of subarachnoid haemorrhage 
51138 Sequelae/other unspecified cerebrovascular diseases 
1469 Stroke and cerebrovascular accident unspecified 
17326 Subarachnoid haemorrh from intracranial artery; unspecif 
1786 Subarachnoid haemorrhage 
28807 Subarachnoid haemorrhage following injury 
42331 Subarachnoid haemorrhage from anterior communicating artery 
41910 Subarachnoid haemorrhage from basilar artery 
56007 Subarachnoid haemorrhage from carotid siphon and bifurcation 
19412 Subarachnoid haemorrhage from middle cerebral artery 
9696 Subarachnoid haemorrhage from posterior communicating artery 
60692 Subarachnoid haemorrhage from vertebral artery 
23580 Subarachnoid haemorrhage nos 
58545 Traumatic subarachnoid haemorrhage 
99367 [x]other cerebrovascular disorders in diseases ce 
108630 [x]subarachnoid haemorrh from intracranial artery, unspecif 
70536 Acute cerebrovascular insufficiency nos 
569 Infarction - cerebral 
63360 Subarachnoid haemorrhage due to birth injury 
106511 Subarachnoid h'ge inj + open intracran wnd+concussion unspec 
102130 Subarachnoid h'ge inj no open intracran wnd+no loss consc 
10792 Stroke monitoring 
16956 Cerebral palsy; not congenital or infantile; acute 
45002 Perinatal subarachnoid haemorrhage 
 
Diabetes without complications  
Medcode Description 
52212 [X]Diabetes mellitus 
41686 [X]Other specified diabetes mellitus 
112365 [X]Pre-existing diabetes mellitus, unspecified 





711 Diabetes mellitus 
43453 Diabetes mellitus autosomal dominant 
36695 Diabetes mellitus autosomal dominant type 2 
61122 Diabetes mellitus induced by non-steroid drugs 
11551 Diabetes mellitus induced by steroids 
72345 Diabetes mellitus NOS with hyperosmolar coma 
42505 Diabetes mellitus NOS with ketoacidosis 
65062 Diabetes mellitus NOS with ketoacidotic coma 
50972 Diabetes mellitus NOS with no mention of complication 
70821 Diabetes mellitus NOS with other specified manifestation 
65025 Diabetes mellitus NOS with peripheral circulatory disorder 
21482 Diabetes mellitus with hyperosmolar coma 
1682 Diabetes mellitus with ketoacidosis 
15690 Diabetes mellitus with ketoacidotic coma 
38986 Diabetes mellitus with no mention of complication 
33343 Diabetes mellitus with other specified manifestation 
110997 Diabetes mellitus, juvenile, + other specified manifestation 
14803 Diabetes mellitus; adult onset; no mention of complication 
43139 Diabetes mellitus; adult onset; with hyperosmolar coma 
54856 Diabetes mellitus; adult onset; with ketoacidosis 
63371 Diabetes mellitus; adult; other specified manifestation 
24490 Diabetes mellitus; juvenile type; no mention of complication 
40023 Diabetes mellitus; juvenile type; with hyperosmolar coma 
53200 Diabetes mellitus; juvenile type; with ketoacidosis 
42567 Diabetes mellitus; juvenile type; with ketoacidotic coma 
12675 Diabetes: shared care programme 
43951 Diabetic - cooperative patient 
13071 Diabetic - good control 
2378 Diabetic - poor control 
22023 Diabetic - poor control NOS 
6125 Diabetic annual review 
8842 Diabetic on insulin 
28769 Diabetic on insulin and oral treatment 
1684 Diabetic on oral treatment 
34152 Diabetic peripheral angiopathy 
24363 Diabetic stabilisation 
36633 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
18505 IDDM-Insulin dependent diabetes mellitus 
31310 Insulin dependent diabetes maturity onset 
97849 Insulin dependent diabetes maturity onset 
1038 Insulin dependent diabetes mellitus 
1647 Insulin dependent diabetes mellitus 
51261 Insulin dependent diabetes mellitus 
6791 Insulin dependent diabetes mellitus - poor control 
72702 Insulin dependent diabetes mellitus - poor control 
44440 Insulin dependent diabetes mellitus with hypoglycaemic coma 
37648 Insulin treated non-insulin dependent diabetes mellitus 
1407 Insulin treated Type 2 diabetes mellitus 
18278 Insulin treated Type 2 diabetes mellitus 
18264 Insulin treated Type II diabetes mellitus 
64668 Insulin treated Type II diabetes mellitus 
56448 Insulin-dependent diabetes without complication 
99719 Insulin-dependent diabetes without complication 
43857 Lipoatrophic diabetes mellitus 
52236 Malnutrition-related diabetes mellitus 





33969 Malnutrition-related diabetes mellitus with ketoacidosis 
14889 Maturity onset diabetes 
46624 Maturity onset diabetes in youth 
98392 Maturity onset diabetes in youth type 1 
59991 Maturity onset diabetes in youth type 2 
5884 NIDDM - Non-insulin dependent diabetes mellitus 
8403 Non-insulin dependant diabetes mellitus - poor control 
506 Non-insulin dependent diabetes mellitus 
43785 Non-insulin dependent diabetes mellitus with hypoglyca coma 
4513 Non-insulin-dependent diabetes mellitus 
29979 Non-insulin-dependent diabetes mellitus without complication 
59288 Other specified diabetes mellitus with coma 
38617 Other specified diabetes mellitus with ketoacidosis 
12213 Patient on maximal tolerated therapy for diabetes 
50960 Pre-existing diabetes mellitus; insulin-dependent 
50609 Pre-existing diabetes mellitus; non-insulin-dependent 
55431 Pre-existing diabetes mellitus; unspecified 
109133 Pre-existing malnutrition-related diabetes mellitus 
22487 Secondary diabetes mellitus 
94383 Secondary diabetes mellitus without complication 
51697 Secondary pancreatic diabetes mellitus 
96506 Secondary pancreatic diabetes mellitus without complication 
32193 Steroid induced diabetes 
26108 Steroid induced diabetes mellitus without complication 
1549 Type 1 diabetes mellitus 
17858 Type 1 diabetes mellitus 
35288 Type 1 diabetes mellitus - poor control 
45914 Type 1 diabetes mellitus - poor control 
40682 Type 1 diabetes mellitus maturity onset 
97446 Type 1 diabetes mellitus maturity onset 
39070 Type 1 diabetes mellitus with hypoglycaemic coma 
70766 Type 1 diabetes mellitus with hypoglycaemic coma 
10692 Type 1 diabetes mellitus with ketoacidosis 
40837 Type 1 diabetes mellitus with ketoacidotic coma 
69676 Type 1 diabetes mellitus without complication 
111106 Type 1 diabetes mellitus without complication 
758 Type 2 diabetes mellitus 
17859 Type 2 diabetes mellitus 
25627 Type 2 diabetes mellitus - poor control 
45913 Type 2 diabetes mellitus - poor control 
46917 Type 2 diabetes mellitus with hypoglycaemic coma 
61071 Type 2 diabetes mellitus with hypoglycaemic coma 
32627 Type 2 diabetes mellitus with ketoacidosis 
51756 Type 2 diabetes mellitus with ketoacidotic coma 
47954 Type 2 diabetes mellitus without complication 
105784 Type 2 diabetes mellitus without complication 
12455 Type I diabetes mellitus 
24423 Type I diabetes mellitus 
46850 Type I diabetes mellitus - poor control 
105337 Type I diabetes mellitus - poor control 
63017 Type I diabetes mellitus maturity onset 
96235 Type I diabetes mellitus maturity onset 
42729 Type I diabetes mellitus with hypoglycaemic coma 
62209 Type I diabetes mellitus with ketoacidosis 
66145 Type I diabetes mellitus with ketoacidotic coma 





95992 Type I diabetes mellitus without complication 
18219 Type II diabetes mellitus 
22884 Type II diabetes mellitus 
24458 Type II diabetes mellitus - poor control 
47315 Type II diabetes mellitus - poor control 
56268 Type II diabetes mellitus with hypoglycaemic coma 
53392 Type II diabetes mellitus without complication 
109103 Type II diabetes mellitus without complication 
9013 Unstable diabetes 
26855 Unstable insulin dependent diabetes mellitus 
54600 Unstable insulin dependent diabetes mellitus 
43921 Unstable type 1 diabetes mellitus 
97474 Unstable type 1 diabetes mellitus 
49949 Unstable type I diabetes mellitus 
60107 Unstable type I diabetes mellitus 
 
Diabetes with complications 
Medcode Description 
99628 [X]Glomerular disorders in diabetes mellitus 
100292 [X]Unspecified diabetes mellitus with renal complications 
10099 Advanced diabetic maculopathy 
35107 Diabetes mellitis with nephropathy NOS 
22573 Diabetes mellitus NOS with neurological manifestation 
34283 Diabetes mellitus NOS with ophthalmic manifestation 
16230 Diabetes mellitus with neurological manifestation 
7795 Diabetes mellitus with neuropathy 
33254 Diabetes mellitus with ophthalmic manifestation 
16491 Diabetes mellitus with polyneuropathy 
68843 Diabetes mellitus, adult onset, with ketoacidotic coma 
35105 Diabetes mellitus, adult onset, with renal manifestation 
68792 Diabetes mellitus, juvenile type, + unspecified complication 
67853 Diabetes mellitus, juvenile, + neurological manifestation 
39317 Diabetes mellitus; adult onset;  neurological manifestation 
41389 Diabetes mellitus; adult onset;  ophthalmic manifestation 
69748 Diabetes mellitus; juvenile type;  ophthalmic manifestation 
93922 Diabetes mellitus; juvenile type; with renal manifestation 
32556 Diabetes with gangrene 
2340 Diabetic amyotrophy 
59903 Diabetic amyotrophy 
10659 Diabetic cataract 
3837 Diabetic maculopathy 
37315 Diabetic mononeuropathy 
2475 Diabetic nephropathy 
2342 Diabetic neuropathy 
5002 Diabetic polyneuropathy 
1323 Diabetic retinopathy 
11626 Diabetic retinopathy NOS 
18056 Foot abnormality - diabetes related 
65463 High risk non proliferative diabetic retinopathy 
30477 High risk proliferative diabetic retinopathy 
34450 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
39809 Insulin dependent diab mell with neuropathic arthropathy 





100770 Insulin dependent diabetes mellitus with diabetic cataract 
109051 Insulin dependent diabetes mellitus with gangrene 
99716 Insulin dependent diabetes mellitus with hypoglycaemic coma 
24694 Insulin dependent diabetes mellitus with mononeuropathy 
45276 Insulin dependent diabetes mellitus with multiple complicat 
52104 Insulin dependent diabetes mellitus with multiple complicatn 
57621 Insulin dependent diabetes mellitus with nephropathy 
102163 Insulin dependent diabetes mellitus with nephropathy 
41716 Insulin dependent diabetes mellitus with polyneuropathy 
101311 Insulin dependent diabetes mellitus with polyneuropathy 
6509 Insulin dependent diabetes mellitus with retinopathy 
93875 Insulin dependent diabetes mellitus with retinopathy 
98704 Insulin dependent diabetes mellitus with ulcer 
52283 Insulin-dependent diabetes mellitus with neurological comps 
101735 Insulin-dependent diabetes mellitus with neurological comps 
49276 Insulin-dependent diabetes mellitus with ophthalmic comps 
98071 Insulin-dependent diabetes mellitus with ophthalmic comps 
46963 Insulin-dependent diabetes mellitus with renal complications 
102946 Insulin-dependent diabetes mellitus with renal complications 
45499 Kimmelstiel - Wilson disease 
100347 Malnutritn-relat diabetes melitus wth periph circul complctn 
39420 Myasthenic syndrome due to diabetic amyotrophy 
10755 Non proliferative diabetic retinopathy 
69278 Non-insulin depend diabetes mellitus with diabetic cataract 
40962 Non-insulin dependent d m with neuropathic arthropathy 
72320 Non-insulin dependent diabetes mellitus with mononeuropathy 
59365 Non-insulin dependent diabetes mellitus with nephropathy 
45467 Non-insulin dependent diabetes mellitus with polyneuropathy 
54212 Non-insulin-dependent d m with peripheral angiopath 
55842 Non-insulin-dependent diabetes mellitus with neuro comps 
50429 Non-insulin-dependent diabetes mellitus with ophthalm comps 
52303 Non-insulin-dependent diabetes mellitus with renal comps 
17262 Non-insulin-dependent diabetes mellitus with retinopathy 
47144 O/E - diabetic maculopathy absent both eyes 
9835 O/E - diabetic maculopathy present both eyes 
49640 O/E - left chronic diabetic foot ulcer 
35116 O/E - Left diabetic foot - ulcerated 
11129 O/E - left eye background diabetic retinopathy 
13108 O/E - left eye diabetic maculopathy 
13103 O/E - left eye preproliferative diabetic retinopathy 
13101 O/E - left eye proliferative diabetic retinopathy 
52041 O/E - left eye stable treated prolif diabetic retinopathy 
62384 O/E - right chronic diabetic foot ulcer 
35316 O/E - Right diabetic foot - ulcerated 
17095 O/E - Right diabetic foot at risk 
11433 O/E - right eye background diabetic retinopathy 
13102 O/E - right eye diabetic maculopathy 
13099 O/E - right eye preproliferative diabetic retinopathy 
13097 O/E - right eye proliferative diabetic retinopathy 
47328 O/E - right eye stable treated prolif diabetic retinopathy 
52630 O/E - sight threatening diabetic retinopathy 
46290 Other specified diabetes mellitus with multiple comps 
61523 Other specified diabetes mellitus with neurological comps 
47377 Other specified diabetes mellitus with ophthalmic complicatn 
112402 Other specified diabetes mellitus with periph circ comps 





11599 Pan retinal photocoagulation for diabetes 
63555 Polyneuropathy in disease NOS 
2986 Preproliferative diabetic retinopathy 
3286 Proliferative diabetic retinopathy 
22967 Retinal abnormality - diabetes related 
49554 Type 1 diabetes mellitus with diabetic cataract 
110400 Type 1 diabetes mellitus with diabetic cataract 
22871 Type 1 diabetes mellitus with exudative maculopathy 
55239 Type 1 diabetes mellitus with gastroparesis 
68105 Type 1 diabetes mellitus with mononeuropathy 
47650 Type 1 diabetes mellitus with multiple complications 
10418 Type 1 diabetes mellitus with nephropathy 
42831 Type 1 diabetes mellitus with neurological complications 
61829 Type 1 diabetes mellitus with neurological complications 
18230 Type 1 diabetes mellitus with neuropathic arthropathy 
54008 Type 1 diabetes mellitus with neuropathic arthropathy 
47649 Type 1 diabetes mellitus with ophthalmic complications 
102740 Type 1 diabetes mellitus with ophthalmic complications 
30294 Type 1 diabetes mellitus with persistent microalbuminuria 
46301 Type 1 diabetes mellitus with polyneuropathy 
21983 Type 1 diabetes mellitus with renal complications 
47582 Type 1 diabetes mellitus with renal complications 
18387 Type 1 diabetes mellitus with retinopathy 
41049 Type 1 diabetes mellitus with retinopathy 
68390 Type 1 diabetes mellitus with ulcer 
44779 Type 2 diabetes mellitus with diabetic cataract 
44982 Type 2 diabetes mellitus with diabetic cataract 
25591 Type 2 diabetes mellitus with exudative maculopathy 
46150 Type 2 diabetes mellitus with gangrene 
63690 Type 2 diabetes mellitus with gastroparesis 
62674 Type 2 diabetes mellitus with mononeuropathy 
65267 Type 2 diabetes mellitus with multiple complications 
108005 Type 2 diabetes mellitus with multiple complications 
12640 Type 2 diabetes mellitus with nephropathy 
24836 Type 2 diabetes mellitus with nephropathy 
34268 Type 2 diabetes mellitus with neurological complications 
45919 Type 2 diabetes mellitus with neurological complications 
35385 Type 2 diabetes mellitus with neuropathic arthropathy 
66965 Type 2 diabetes mellitus with neuropathic arthropathy 
47321 Type 2 diabetes mellitus with ophthalmic complications 
70316 Type 2 diabetes mellitus with ophthalmic complications 
18425 Type 2 diabetes mellitus with polyneuropathy 
109865 Type 2 diabetes mellitus with polyneuropathy 
18209 Type 2 diabetes mellitus with renal complications 
18777 Type 2 diabetes mellitus with renal complications 
18496 Type 2 diabetes mellitus with retinopathy 
42762 Type 2 diabetes mellitus with retinopathy 
17545 Type I diabetes mellitus with diabetic cataract 
97894 Type I diabetes mellitus with exudative maculopathy 
102112 Type I diabetes mellitus with gangrene 
99231 Type I diabetes mellitus with mononeuropathy 
91942 Type I diabetes mellitus with multiple complications 
108007 Type I diabetes mellitus with multiple complications 
66872 Type I diabetes mellitus with nephropathy 
49146 Type I diabetes mellitus with neurological complications 





99311 Type I diabetes mellitus with ophthalmic complications 
102620 Type I diabetes mellitus with persistent microalbuminuria 
91943 Type I diabetes mellitus with polyneuropathy 
61344 Type I diabetes mellitus with renal complications 
109837 Type I diabetes mellitus with renal complications 
38161 Type I diabetes mellitus with retinopathy 
95343 Type I diabetes mellitus with retinopathy 
93878 Type I diabetes mellitus with ulcer 
48192 Type II diabetes mellitus with diabetic cataract 
93727 Type II diabetes mellitus with diabetic cataract 
111798 Type II diabetes mellitus with exudative maculopathy 
104323 Type II diabetes mellitus with gangrene 
98723 Type II diabetes mellitus with hypoglycaemic coma 
106528 Type II diabetes mellitus with ketoacidosis 
106061 Type II diabetes mellitus with ketoacidotic coma 
50813 Type II diabetes mellitus with mononeuropathy 
95351 Type II diabetes mellitus with mononeuropathy 
43227 Type II diabetes mellitus with multiple complications 
64571 Type II diabetes mellitus with nephropathy 
102201 Type II diabetes mellitus with nephropathy 
67905 Type II diabetes mellitus with neurological complications 
98616 Type II diabetes mellitus with neurological complications 
47816 Type II diabetes mellitus with neuropathic arthropathy 
109197 Type II diabetes mellitus with neuropathic arthropathy 
59725 Type II diabetes mellitus with ophthalmic complications 
100964 Type II diabetes mellitus with ophthalmic complications 
104639 Type II diabetes mellitus with peripheral angiopathy 
85991 Type II diabetes mellitus with persistent microalbuminuria 
60796 Type II diabetes mellitus with persistent proteinuria 
47409 Type II diabetes mellitus with polyneuropathy 
50527 Type II diabetes mellitus with polyneuropathy 
50225 Type II diabetes mellitus with renal complications 
57278 Type II diabetes mellitus with renal complications 
49655 Type II diabetes mellitus with retinopathy 
58604 Type II diabetes mellitus with retinopathy 
91646 Type II diabetes mellitus with ulcer 
64449 Unspecified diabetes mellitus with multiple complications 
18642 Type 1 diabetes mellitus with arthropathy 
62352 Type I diabetes mellitus with arthropathy 
65616 Insulin dependent diabetes mellitus with arthropathy 
103902 Type II diabetes mellitus with arthropathy 
49869 Type 2 diabetes mellitus with arthropathy 
59253 Type 2 diabetes mellitus with arthropathy 
24693 Non-insulin dependent diabetes mellitus with arthropathy 
18143 Type II diabetes mellitus with arthropathy 
 
Peptic ulcer disease 
Medcode Description 
68661 Acute peptic ulcer without mention of complication 
32856 Acute peptic ulcer 
15175 Duodenal ulcer nos 
64710 Resection of gastric ulcer by cautery 





23688 Operations on gastric ulcer 
23087 Perforated chronic duodenal ulcer 
18625 Bleeding chronic duodenal ulcer 
55933 Operation on duodenal ulcer nos 
24021 Peptic ulcer of oesophagus 
44335 Acute duodenal ulcer without mention of complication 
18027 Acute duodenal ulcer 
24040 Acute gastric ulcer 
57958 Unspecified gastric ulcer with haemorrhage 
14671 Acute gastric ulcer with perforation 
63001 Anti-platelet induced gastric ulcer 
67356 Chronic gastric ulcer with obstruction 
53336 Chronic gastric ulcer with perforation 
50497 Unspecified peptic ulcer 
67082 Unspecified peptic ulcer without mention of complication 
64111 Unspecified peptic ulcer with perforation 
45184 Acute gastrojejunal ulcer 
102177 Acute gastrojejunal ulcer with perforation 
110244 Chronic gastrojejunal ulcer with haemorrhage and perforation 
63482 Unspecified gastrojejunal ulcer 
40489 [v]personal history of duodenal ulcer 
6321 H/o: duodenal ulcer 
51406 Chronic duodenal ulcer nos 
4741 Closure of perforated duodenal ulcer 
6865 Stomach ulcer operations 
94104 Other specified operation on gastric ulcer 
29317 Recurrent duodenal ulcer 
44324 Acute gastric ulcer nos 
4643 Peptic ulcer symptoms 
52138 Chronic duodenal ulcer unspecified 
33438 Chronic duodenal ulcer without mention of complication 
71881 Chronic duodenal ulcer with haemorrhage and perforation 
18654 Chronic gastric ulcer 
36461 Unspecified gastric ulcer with perforation 
48946 Chronic gastric ulcer without mention of complication 
44309 Chronic gastric ulcer nos 
66092 Unspecified gastrojejunal ulcer nos 
53669 Unspecified duodenal ulcer 
67711 Acute peptic ulcer unspecified 
41271 [v] personal history of gastric ulcer 
60346 Unspecified gastrojejunal ulcer with haemorrhage 
73338 Unspecified gastric ulcer without mention of complication 
352 Duodenal ulcer - (du) 
71403 Acute gastric ulcer with haemorrhage and perforation 
22918 Duodenal ulcer disease 
44284 Unspecified gastric ulcer nos 
64556 Chronic gastric ulcer unspecified 
70390 Chronic peptic ulcer unspecified 
109546 Acute gastric ulcer with obstruction 
94397 Unspec gastric ulcer; unspec haemorrhage and/or perforation 
99430 Chronic peptic ulcer without mention of complication 
9981 Jejunal ulcer 
96090 Chronic gastrojejunal ulcer 
44073 Chronic duodenal ulcer with obstruction 
3462 Duodenal erosion 





37643 Chronic duodenal ulcer with perforation 
96628 Acute gastrojejunal ulcer with haemorrhage 
69663 Chronic peptic ulcer nos 
11104 Perforated chronic gastric ulcer 
9853 Chronic duodenal ulcer 
73697 Unspecified gastric ulcer with obstruction 
2812 H/o: peptic ulcer 
45278 Primary ulcer of intestine 
5928 Operations on duodenal ulcer 
657 Unspecified duodenal ulcer with perforation 
3101 Pyloric ulcer 
64014 Closure of gastric ulcer nec 
53747 Ulceration of intestine nos 
53797 Acute duodenal ulcer nos 
30054 Acute gastric ulcer with haemorrhage 
33914 Operation on gastric ulcer nos 
2814 Unspecified duodenal ulcer with haemorrhage 
50048 Acute peptic ulcer nos 
20677 Closure of perforated gastric ulcer 
56005 Other specified operation on duodenal ulcer 
18319 Healed gastric ulcer leaving a scar 
26261 [v]personal history of peptic ulcer 
71904 Unspecified duodenal ulcer with obstruction 
60249 Unspecified peptic ulcer nos 
18324 Acute duodenal ulcer with perforation 
24342 Acute gastric ulcer unspecified 
11124 Bleeding acute gastric ulcer 
99670 Unspecified peptic ulcer with obstruction 
89227 Anti-platelet induced gastric ulcer nos 
37620 Chronic peptic ulcer with perforation 
85989 Non steroidal anti inflammatory drug induced duodenal ulcer 
19928 Peptic ulcer nos 
52323 Multiple gastric ulcers 
7108 H/o: gastric ulcer 
71897 Chronic gastric ulcer with haemorrhage and perforation 
36583 Bleeding chronic gastric ulcer 
70456 Unspecified peptic ulcer with haemorrhage 
92695 Balfour excision of gastric ulcer 
53081 Unspecified gastric ulcer 
84227 Repair perforated gastric ulcer 
48730 Acute duodenal ulcer with haemorrhage and perforation 
64913 Gastrocolic ulcer 
70005 Suture of ulcer of stomach nec 
40997 Chronic peptic ulcer 
73417 Acute duodenal ulcer with obstruction 
89234 Anti-platelet induced duodenal ulcer 
55350 Oversew of blood vessel of duodenal ulcer 
23082 Gastrojejunal ulcer (gju) 
96622 Unspecified peptic ulcer with haemorrhage and perforation 
71150 Unspecified duodenal ulcer without mention of complication 
15821 Stress ulcer nos 
5521 Acute peptic ulcer with perforation 
52313 Chronic peptic ulcer with obstruction 
63582 Chronic gastric ulcer with haemorrhage 
53822 Acute duodenal ulcer unspecified 





65737 Unspecified duodenal ulcer nos 
670 Peptic ulcer - (pu) site unspecified 
15979 Unspecified gastrojejunal ulcer with perforation 
37268 Suture of duodenal ulcer not elsewhere classified 
1262 Gastric ulcer - (gu) 
45981 Endoscopic injection haemostasis of duodenal ulcer 
28366 Unspec duodenal ulcer; unspec haemorrhage and/or perforation 
18001 Acute duodenal ulcer with haemorrhage 
89023 Non steroidal anti inflammatory drug induced gastric ulcer 
90899 Repair perforated peptic ulcer 
106330 Acute gastrojejunal ulcer with haemorrhage and perforation 
48951 Chronic duodenal ulcer with haemorrhage 
93436 Unspecified duodenal ulcer with haemorrhage and perforation 
45304 Acute peptic ulcer with haemorrhage and perforation 
64165 Acute gastric ulcer without mention of complication 
53126 Chronic peptic ulcer with haemorrhage 
29771 Gastric ulcer nos 
44637 Acute peptic ulcer with haemorrhage 
6333 Prepyloric ulcer 
 
Connective tissue disease 
Medcode Description 
45284 Systemic lupus erythematosus with renal 
57313 Polyneuropathy in collagen vascular disease 
47465 Polyneuropathy in polyarteritis nodosa 
71258 Polyneuropathy in collagen vascular disease NOS 
6599 Muscular dystrophies and other myopathies 
63541 Symptomatic inflammatory myopathy in disease EC 
57888 Myopathy due to polyarteritis nodosa 
43816 Rheumatoid carditis 
62323 Polyarteritis nodosa and allied conditions 
1471 Polyarteritis nodosa 
68136 Polyarteritis nodosa and allied conditions NOS 
58750 Nephrotic syndrome in polyarteritis nodosa 
79981 Sero negative rheumatoid arthritis 
77143 Sero positive rheumatoid arthritis 
10953 Arthropathies and related disorders 
31438 Diffuse diseases of connective tissue 
57675 Libman-Sacks disease 
36942 Drug-induced systemic lupus erythematosus 
68277 Acrosclerosis 
110174 Systemic sclerosis induced by drugs and chemicals 
23552 Felty's syndrome 
56838 Caplan's syndrome 
10919 Sero negative polyarthritis 
96456 Endemic polyarthritis 
1408 Polymyalgia rheumatica 
29472 Giant cell arteritis with polymyalgia rheumatica 
93927 Polymyositis ossificans 
43192 Scoliosis in connective tissue anomalies 
16640 Musculoskeletal or connective tissue diseases OS 
43085 [X]Addtnl musculskeletal+connectv tissue dis classfctn terms 





68965 [X]Other systemic diseases of connective tissue 
92421 [X]Systemic disorders/connective tissue in other diseases CE 
25642 [X]Other disord musculoskeletal system and connective tissue 
28247 Unspecified anomaly of connective tissue 
44095 Polyneuropathy in disseminated lupus erythematosus 
62401 Polyneuropathy in rheumatoid arthritis 
108072 Myopathy due to disseminated lupus erythematosus 
31209 Myopathy due to rheumatoid arthritis 
55601 Myopathy due to scleroderma 
94751 Eyelid discoid lupus erythematosus 
9954 Rheumatoid lung 
94996 Lung disease with systemic sclerosis 
42940 Lung disease with polymyositis 
31564 Lung disease with systemic lupus erythematosus 
47672 Nephrotic syndrome in systemic lupus erythematosus 
22205 Lupus nephritis 
4125 Lupus erythematosus 
33449 Lupus erythematosus chronicus 
2667 Discoid lupus erythematosus 
40797 Lupus erythematosus migrans 
65391 Lupus erythematosus nodularis 
46148 Lupus erythematosus profundus 
44984 Lupus erythematosus tumidus 
63955 Lupus erythematosus unguium mutilans 
25390 Subacute cutaneous lupus erythematosus 
7522 Lupus erythematosus NOS 
100692 [X]Other local lupus erythematosus 
10885 Musculoskeletal and connective tissue diseases 
22509 Collagen diseases 
7871 Systemic lupus erythematosus 
20007 Disseminated lupus erythematosus 
29519 Systemic lupus erythematosus with organ or sys involv 
11920 Systemic lupus erythematosus with pericarditis 
42719 Systemic lupus erythematosus NOS 
3670 Scleroderma 
28417 Systemic sclerosis 
44141 Progressive systemic sclerosis 
15511 Polymyositis 
20271 Other specified diffuse collagen diseases 
21151 Collagen disease NOS 
27603 Rheumatoid arthritis and other inflammatory polyarthropathy 
844 Rheumatoid arthritis 
21358 Rheumatoid arthritis of shoulder 
107963 Rheumatoid arthritis of sternoclavicular joint 
100914 Rheumatoid arthritis of acromioclavicular joint 
59738 Rheumatoid arthritis of elbow 
63365 Rheumatoid arthritis of distal radio-ulnar joint 
48832 Rheumatoid arthritis of wrist 
42299 Rheumatoid arthritis of MCP joint 
41941 Rheumatoid arthritis of PIP joint of finger 
63198 Rheumatoid arthritis of DIP joint of finger 
49067 Rheumatoid arthritis of hip 
100776 Rheumatoid arthritis of sacro-iliac joint 
50863 Rheumatoid arthritis of knee 
107791 Rheumatoid arthritis of tibio-fibular joint 





73619 Rheumatoid arthritis of subtalar joint 
70658 Rheumatoid arthritis of talonavicular joint 
71784 Rheumatoid arthritis of other tarsal joint 
51238 Rheumatoid arthritis of 1st MTP joint 
99414 Rheumatoid arthritis of lesser MTP joint 
107112 Rheumatoid arthritis of IP joint of toe 
6916 Seronegative rheumatoid arthritis 
8350 Flare of rheumatoid arthritis 
46436 Rheumatoid lung disease 
9707 Seropositive errosive rheumatoid arthritis 
12019 Seropositive rheumatoid arthritis; unspecified 
31724 Rheumatoid lung 
28853 Fibrosing alveolitis associated with rheumatoid arthritis 
106440 [X]Rheumatoid arthritis 
93715 [X]Other seropositive rheumatoid arthritis 
70221 [X]Other specified rheumatoid arthritis 
56202 [X]Seropositive rheumatoid arthritis; unspecified 
58706 [X]Other forms of systemic lupus erythematosus 
71763 [X]Other forms of systemic sclerosis 
2175 Musculoskeletal and connective tissue diseases NOS 
6639 H/O: rheumatoid arthritis 
33264 O/E-hands-rheumatoid spindling 
24641 Circumscribed scleroderma 
73485 Unspecified circumscribed scleroderma 
25463 Linear scleroderma 
72288 Circumscribed scleroderma NOS 
4909 Connective tissue diseases 
99435 Neonatal lupus erythematosus 
17675 CREST syndrome 
4908 Dermatomyositis 
40387 Poikilodermatomyositis 
32649 Juvenile dermatomyositis 
91559 Dermatopolymyositis in neoplastic disease 
28316 Dermatopolymyositis, unspecified 
44743 Rheumatoid arthritis of cervical spine 
44203 Other rheumatoid arthritis of spine 
30548 Rheumatoid vasculitis 
18155 Rheumatoid bursitis 
53621 Rheumatoid nodule 
31054 Rheumatoid arthritis - multiple joint 
49227 Other rheumatoid arthropathy + visceral/systemic involvement 
8583 Rheumatic carditis 
5723 Rheumatoid nodule 
37431 Rheumatoid arthropathy + visceral/systemic involvement NOS 
4186 Juvenile rheumatoid arthritis - Still's disease 
50644 Juvenile rheumatoid arthropathy unspecified 
47831 Acute polyarticular juvenile rheumatoid arthritis 
21533 Pauciarticular juvenile rheumatoid arthritis 
36276 Monarticular juvenile rheumatoid arthritis 
27557 Juvenile rheumatoid arthritis NOS 
3944 Chronic post-rheumatic arthropathy 
58543 Nodular fibrositis of chronic rheumatic disease 
31360 Juvenile rheumatoid arthritis 
53862 [X]Other dermatomyositis 
95437 [X]Dermatopolymyositis, unspecified 





9614 Rheumatism, excluding the back 
33474 Rheumatism and fibrositis unspecified 
1029 Rheumatism unspecified 
17085 Muscular rheumatism 
35937 Rheumatism or fibrositis NOS 
35759 Other specified nonarticular rheumatism 
15205 Nonarticular rheumatism NOS 
 
Peripheral vascular disease 
Medcode Description 
14796 [D]Failure of peripheral circulation 
4970 [D]Gangrene 
37750 [D]Gangrene NOS 
53634 [D]Gangrene of toe in diabetic 
51634 [D]Gangrene; spreading cutaneous 
30484 [D]Peripheral circulatory failure 
31053 [D]Widespread diabetic foot gangrene 
18423 Arterial insufficiency 
23497 Buerger's disease 
6853 Claudication 
108675 Congenital anomaly of peripheral vascular system OS 
61062 Congenital peripheral aneurysm 
65025 Diabetes mellitus NOS with peripheral circulatory disorder 
35399 Diabetes mellitus with peripheral circulatory disorder 
63357 Diabetes mellitus, adult, + peripheral circulatory disorder 
70448 Diabetes mellitus, juvenile +peripheral circulatory disorder 
32556 Diabetes with gangrene 
12735 Gangrene of foot 
5414 Gangrene of toe 
69124 IDDM with peripheral circulatory disorder 
1826 Ischaemia of legs 
56803 NIDDM with peripheral circulatory disorder 
54212 Non-insulin-dependent d m with peripheral angiopath 
11680 O/E - gangrene 
9454 Other aneurysm 
73738 Other congenital anomaly of peripheral vascular system NOS 
45384 Other peripheral vascular system anomalies 
41728 Other specified pulmonary circulation disease NOS 
18269 Peripheral arterio-venous aneurysm 
9204 Peripheral gangrene 
6827 Peripheral ischaemia 
5702 Peripheral ischaemic vascular disease 
16148 Peripheral vascular complications of care 
44528 Peripheral vascular complications of care NOS 
56429 Peripheral vascular system anomaly NOS 
40068 Presenile gangrene 
102719 [X]Aortic aneurysm of unspecified site; nonruptured 
102725 [X]Aortic aneurysm of unspecified site; ruptured 
73961 [X]Other specified peripheral vascular diseases 
17345 AAA - Abdominal aortic aneurysm without mention of rupture 
17767 Abdominal aortic aneurysm which has ruptured 
1867 Abdominal aortic aneurysm without mention of rupture 





6872 Aortic aneurysm NOS 
1736 Aortic aneurysm repair 
16034 Aortic aneurysm without mention of rupture NOS 
34152 Diabetic peripheral angiopathy 
16521 Dissecting aortic aneurysm 
17220 Emergency repair of aortic aneurysm 
16993 H/O: aortic aneurysm 
59534 H/O: Peripheral vascular disease procedure 
28109 Inflammatory abdominal aortic aneurysm 
64446 Insulin dependent diab mell with peripheral angiopathy 
1517 Intermittent claudication 
45521 Juxtarenal aortic aneurysm 
9759 Leaking abdominal aortic aneurysm 
5943 Other peripheral vascular disease 
38907 Other specified peripheral vascular disease 
4325 Other specified peripheral vascular disease NOS 
2760 Peripheral vascular disease NOS 
3530 Peripheral vascular disease NOS 
13572 Ruptured abdominal aortic aneurysm 
15304 Ruptured aortic aneurysm NOS 
63920 Ruptured suprarenal aortic aneurysm 
16800 Ruptured thoracic aortic aneurysm 
27563 Thoracic aortic aneurysm which has ruptured 
23532 Thoracic aortic aneurysm without mention of rupture 
11430 Thoracoabdominal aortic aneurysm; ruptured 
40787 Thoracoabdominal aortic aneurysm; without mention of rupture 
63408 Tube graft abdominal Aortic aneurysm (emergency) 
26232 Tube graft of Abdominal aortic aneurysm 
93468 Type 1 diabetes mellitus with peripheral angiopathy 
60699 Type 2 diabetes mellitus with peripheral angiopathy 
37806 Type 2 diabetes mellitus with peripheral angiopathy 
54899 Type II diabetes mellitus with peripheral angiopathy 
104639 Type II diabetes mellitus with peripheral angiopathy 
51166 Y graft abdominal Aortic aneurysm 
92925 Y graft of abdominal Aortic aneurysm (emergency) 
70260 Aortic aneurysm - syphilitic 
103613 Aortic aneurysm monitoring 
91462 Endov insertion of stent graft for thoracic aortic aneurysm 
83577 Endovas ins stent graft for infrarenal abdom aortic aneurysm 
94682 Endovas insert of stent graft for suprarenal aortic aneurysm 
99859 Endovas insert stent for aortic aneurysm of bifurcation nec 
97217 Endovascul insert stent infrarenal abdominal aortic aneurysm 
98542 Endovascular insertion of stent for thoracic aortic aneurysm 
106780 Endovascular insertion stent for suprarenal aortic aneurysm 
100195 Endovascular stenting for aortic aneurysm of bifurcation nec 
70446 Endovascular stenting infrarenal abdominal aortic aneurysm 
97030 Endovascular stenting of suprarenal aortic aneurysm 
51061 Endovascular stenting of thoracic aortic aneurysm 
101379 Infrarenal abdominal aortic aneurysm 
18499 Peripheral vascular disease monitoring 
106260 Peripheral vascular disease monitoring first letter 
106224 Peripheral vascular disease monitoring invitation 
106660 Peripheral vascular disease monitoring second letter 
106855 Peripheral vascular disease monitoring third letter 





Cognitive impairment, including dementia 
Medcode Description 
1993 Memory loss - amnesia 
3639 Amnesia symptom 
5777 Memory loss symptom 
2908 Memory disturbance 
27788 Temporary loss of memory 
103453 Short-term memory loss 
39507 Poor visual sequential memory 
40821 Poor auditory sequential memory 
67163 Disturbance of memory for order of events 
110307 Memory impairment 
7674 Cognitive decline 
107282 Mild cognitive impairment 
107482 Moderate cognitive impairment 
107402 Severe cognitive impairment 
108266 Cognitive impairment 
52947 Memory: own age not known 
53146 Memory: present time not known 
53014 Memory: present place not known 
52948 Memory: present year not known 
53125 Memory: own dob not known 
52825 Memory: present month not known 
52800 Memory: important event not known 
52801 Memory: important person not known 
52805 Memory: count down unsuccessful 
53016 Memory: address recall unsuccessful 
65856 Gds level 2 - very mild cognitive decline 
60263 Gds level 3 - mild cognitive decline 
60726 Gds level 4 - moderate cognitive decline 
70057 Gds level 5 - moderately severe cognitive decline 
94717 Gds level 6 - severe cognitive decline 
72520 Gds level 7 - very severe cognitive decline 
6387 Mild memory disturbance 
6061 Organic memory impairment 
11936 [x]mild cognitive disorder 
110729 [x]cognitive communication disorder 
31572 Visual disorientation syndrome 
7711 [d]memory deficit 
20683 [d]disorientation, unspecified 
112378 [x]symptoms/signs involving cognition, percept, emotion state & behaviour 
52939 [x]other & unspecified symptom/signs involving cognitive function/awareness 
52811 [x]disorientation, unspecified 
10822 Impaired cognition 
61639 Unable to recognise surroundings 
47279 Mistakes people's identity 
67565 Does not recognise self 
61869 Does not recognise photographs of self 
92635 Unable to recognise parts of own body 
101458 Unable to recognise objects 
100788 Unable to recognise faces 
91516 Unable to recognise familiar people 
59539 Unable to reason 
52550 Difficulty reasoning 





46320 Difficulty using verbal reasoning 
99474 Difficulty using visuospatial reasoning 
48506 Unable to process information 
50446 Difficulty processing information 
61308 Unable to process information accurately 
57609 Difficulty processing information accurately 
109311 Unable to process information at normal speed 
99588 Difficulty processing information at normal speed 
56044 Unable to analyse information 
57608 Difficulty analysing information 
50843 Difficulty performing logical sequencing 
66172 Isolated memory skills 
19719 Orientation confused 
64219 Orientation poor 
66012 Disorientation for person 
55460 Spatial disorientation 
51379 Memory disturbance (& amnesia (& symptom)) 
67838 Memory loss symptom 
103375 Memory loss - amnesia 
105538 Memory disturbance 
102880 Loss of memory 
10123 Memory loss 
68230 Memory gone 
12805 Memory loss - amnesia 
19297 Loss of memory 
12277 Lom - loss of memory 
32367 Impairment of working memory 
65696 Impairment of primary memory 
37191 Poor memory for remote events 
9786 Loss of memory for recent events 
67802 No memory for recent events 
67998 Temporary loss of memory 
47882 Transient memory loss 
10514 Memory impairment 
39915 Memory dysfunction 
50418 Memory deficit 
26434 Bad memory 
12057 Memory problem 
12583 Poor memory 
19073 Memory lapses 
51739 Distortion of memory 
64892 Invents experiences to compensate for loss of memory 
11410 Poor short-term memory 
10571 Short-term memory loss 
53978 Poor long-term memory 
47581 Long-term memory loss 
98798 Delayed verbal memory 
46860 Difficulty making plans 
46564 Difficulty making decisions 
53388 Unable to use decision-making strategies 
107021 Difficulty using decision-making strategies 
65319 Unable to make considered choices 
43204 Difficulty making considered choices 
59242 Difficulty solving problems 
40002 Language-related cognitive disorder 





1350 Senile/presenile dementia 
7323 Uncomplicated senile dementia 
15165 Presenile dementia 
42602 Uncomplicated presenile dementia 
30032 Presenile dementia with paranoia 
27677 Presenile dementia with depression 
38438 Presenile dementia nos 
44674 Senile dementia with depressive or paranoid features 
18386 Senile dementia with paranoia 
21887 Senile dementia with depression 
41089 Senile dementia with depressive or paranoid features nos 
37015 Senile dementia with delirium 
19477 Arteriosclerotic dementia 
43089 Uncomplicated arteriosclerotic dementia 
55467 Arteriosclerotic dementia with paranoia 
43292 Arteriosclerotic dementia with depression 
42279 Arteriosclerotic dementia nos 
25386 Dementia in conditions ec 
4951 Chronic confusional state 
7664 [x]dementia in alzheimer's disease 
49263 [x]dementia in alzheimer's disease with early onset 
25704 [x]presenile dementia,alzheimer's type 
60059 [x]primary degen dementia, alzheimer's type, presenile onset 
61528 [x]alzheimer's disease type 2 
38678 [x]dementia in alzheimer's disease with late onset 
46762 [x]alzheimer's disease type 1 
11379 [x]senile dementia,alzheimer's type 
43346 [x]primary degen dementia of alzheimer's type, senile onset 
30706 [x]dementia in alzheimer's dis, atypical or mixed type 
29386 [x]dementia in alzheimer's disease, unspecified 
8195 [x]alzheimer's dementia unspec 
6578 [x]vascular dementia 
9565 [x]arteriosclerotic dementia 
46488 [x]vascular dementia of acute onset 
55838 [x]predominantly cortical dementia 
8934 [x]subcortical vascular dementia 
31016 [x]mixed cortical and subcortical vascular dementia 
55313 [x]other vascular dementia 
19393 [x]vascular dementia, unspecified 
12621 [x]dementia in other diseases classified elsewhere 
28402 [x]dementia in pick's disease 
26270 [x]lewy body dementia 
64267 [x]dementia in other specified diseases classif elsewhere 
4693 [x] unspecified dementia 
48501 [x] presenile dementia nos 
34944 [x] primary degenerative dementia nos 
4357 [x] senile dementia nos 
27759 [x] senile dementia, depressed or paranoid type 
1917 Alzheimer's disease 
16797 Alzheimer's disease with early onset 
32057 Alzheimer's disease with late onset 
11136 Pick's disease 
29512 Senile degeneration of brain 
7572 Lewy body disease 
59122 [x]other alzheimer's disease 





11175 [x]multi-infarct dementia 
9509 [x]dementia in parkinson's disease 
49513 Presenile dementia with delirium 
53446 [x]delirium superimposed on dementia 
56912 Arteriosclerotic dementia with delirium 
 
Mild liver disease 
Medcode Description 
107896 [x]chronic viral hepatitis, unspecified 
108343 [x]other chronic viral hepatitis 
21713 Alcoholic fibrosis and sclerosis of liver 
7957 Autoimmune chronic active hepatitis 
9029 Chronic active hepatitis 
1755 Chronic aggressive hepatitis 
7602 Chronic alcoholic hepatitis 
66534 Chronic lobular hepatitis 
23578 Chronic persistent hepatitis 
26367 Chronic viral hepatitis 
24813 Chronic viral hepatitis b with delta-agent 
41096 Chronic viral hepatitis b without delta-agent 
30586 Chronic viral hepatitis c 
32277 Chronic viral hepatitis, unspecified 
42843 Other non-alcoholic chronic liver disease 
39351 Toxic liver disease with chronic active hepatitis 
64750 Toxic liver disease with chronic lobular hepatitis 
17219 Toxic liver disease with chronic persistent hepatitis 
6015 [x]other and unspecified cirrhosis of liver 
4743 Alcoholic cirrhosis of liver 
73482 Bacterial portal cirrhosis 
9494 Biliary cirrhosis 
58630 Biliary cirrhosis nos 
91591 Biliary cirrhosis of children 
40567 Capsular portal cirrhosis 
1754 Chronic hepatitis 
15489 Chronic hepatitis nos 
53877 Chronic hepatitis unspecified 
16725 Cirrhosis - non alcoholic 
6863 Cirrhosis and chronic liver disease 
1638 Cirrhosis of liver nos 
18739 Cryptogenic cirrhosis of liver 
3450 Diffuse nodular cirrhosis 
44676 Fatty portal cirrhosis 
68376 Florid cirrhosis 
19512 Glycogenosis with hepatic cirrhosis 
92909 Hypertrophic portal cirrhosis 
48928 Infectious cirrhosis nos 
96664 Juvenile portal cirrhosis 
100474 Laennec's cirrhosis 
22841 Macronodular cirrhosis of liver 
69204 Multilobular portal cirrhosis 
16455 Non-alcoholic cirrhosis nos 
8206 Pigmentary cirrhosis of liver 





55454 Portal cirrhosis unspecified 
5638 Primary biliary cirrhosis 
15424 Secondary biliary cirrhosis 
112044 Syphilitic portal cirrhosis 
44120 Toxic liver disease with fibrosis and cirrhosis of liver 
100253 Xanthomatous portal cirrhosis 
109540 Zooparasitic portal cirrhosis 
111969 Chronic hepatitis annual review 
99898 Chronic hepatitis annual review - enhanced services admin 
102922 Cystic fibrosis related cirrhosis 
10539 Chronic liver disease nos 
33597 Other non-alcoholic chronic liver disease nos 
 
Severe liver disease 
Medcode Description 
105611 [X]Oesophageal varices in diseases classified elsewhere 
48102 Other sequelae of chronic liver disease 
73139 Oesophageal varices without bleeding in diseases EC 
5129 Portal hypertension 
24989 Oesophageal varices with bleeding 
30655 Oesophageal varices without bleeding 
47214 Rigid oesophagoscopic injection sclerotherapy oesoph varices 
1641 Oesophageal varices 
62582 Oesophageal varices in diseases EC NOS 
10636 Hepatorenal syndrome 
10797 Oesophageal varices NOS 
108800 Liver abscess and chronic liver disease causing sequelae NOS 
23511 Hepatic coma 
96756 Oesophageal varices with bleeding in diseases EC 
26319 Oesophageal varices in cirrhosis of the liver 
44424 Oesophageal varices in diseases EC 
89587 Other specified viral hepatitis with hepatic coma NOS 
8363 Oesophageal varices in alcoholic cirrhosis of the liver 
89445 Auxillary liver transplant 
65050 Viral hepatitis C with coma 
69053 Viral hepatitis B with coma 
99745 O/E - breath musty - hepatic 
47861 Exploration of liver transplant 
99250 Other specified transplantation of liver 
55962 Viral hepatitis A with coma 
71422 Heterotopic transplantation of liver 
112028 [X]Unspecified viral hepatitis with coma 
64451 Central haemorrhagic necrosis of liver 
100073 Piggy back liver transplant 
69552 Other specified viral hepatitis with coma 
32025 Orthotopic transplantation of liver 
69194 Replacement of previous liver transplant 
4405 Transplantation of liver 
111975 Unspecified viral hepatitis with coma 
22411 Encephalopathy - hepatic 
89717 fibreopt endoscop rubber band ligation of upper git varices 
16759 fibreoptic endoscopic banding of oesophageal varices 





43404 local ligation of oesophageal varices 
20912 open injection sclerotherapy to oesophageal varices 
20233 open operation on oesophageal varices nos 
24220 open operations on oesophageal varices 
107975 other specified open operation on oesophageal varices 
46647 rigid oesophagoscopic banding of oesophageal varices 
62038 tanner devascularisation for bleeding varices 
11972 varices - other 
111976 viral hepatitis with hepatic coma 




20122 Spastic hemiplegia 
1749 Hemiplegia 
3063 Paraplegia 
8492 Hemiplegia nos 
8933 Left hemiplegia 
3293 Right hemiplegia 
22135 O/e - hemiplegia 
46175 Flaccid paraplegia 
39085 Flaccid hemiplegia 
9375 Spastic paraplegia 
3514 Hereditary spastic paraplegia 
36133 O/e - paraplegia 
58576 Tropical spastic paraplegia 
59494 Massive muscular calcification associated with paraplegia 
37160 Congenital paraplegia 
27966 Congenital hemiplegia 
2019 Infantile hemiplegia nos 




17177 H/o: * leukaemia 
19692 Suspected leukaemia 
2755 Cancers 
111289 Malignant neoplasm of upper lip; buccal aspect 
112660 Malignant neoplasm of lip unspecified; frenulum 
112528 Malignant neoplasm of vestibule of mouth nos 
110775 Malignant neoplasm of interlobular biliary canals 
108667 Angiosarcoma of spleen 
110993 Malignant neoplasm of first metacarpal bone 
108638 Malignant neoplasm of third metacarpal bone 
111779 Malignant neoplasm of patella 
111426 Malignant neoplasm of second metatarsal bone 
110192 Malig neopl of connective and soft tissue - sacrum or coccyx 
111311 Malignant neoplasm; overlap lesion connective & soft tissue 
109002 Malignant melanoma of perianal skin 
112379 Malignant neoplasm of extraocular muscle of orbit 





109473 Malignant neoplasm of cerebral pia mater 
108886 Hodgkin's mixed cellularity of lymph nodes inguinal and leg 
111942 Hodgkin's lymphocytic depletion of head; face and neck 
110563 Hodgkin's lymphocytic depletion lymph nodes inguinal and leg 
111766 Nodular lymphoma of lymph nodes of axilla and upper limb 
112570 Malignant histiocytosis of lymph nodes of axilla and arm 
110903 Malignant histiocytosis of lymph nodes of multiple sites 
109342 Unspec malig neop lymphoid/histiocytic of intrapelvic nodes 
37182 Multiple myeloma and immunoproliferative neoplasms 
112440 Other myeloid leukaemia 
108715 Histiocytic leukaemia 
63653 Heilmeyer - schoner disease 
20564 [m]carcinoma in situ nos 
21914 [m]intraepithelial carcinoma nos 
1950 [m]transitional cell papillomas and carcinomas 
27827 [m]adenocarcinoma in situ 
111172 [m]carcinoid tumour, argentaffin, malignant 
42273 [m]papillary adenomas and adenocarcinomas 
40632 [m]mucinous adenoma and adenocarcinoma 
112307 [m]interstitial cell tumour, malignant 
17366 [m]soft tissue tumours and sarcomas nos 
100371 Epithelial nephroblastoma 
112383 Pancreatoblastoma 
104147 [m]infantile embryonal carcinoma 
22712 [m]epithelioid haemangioendothelioma nos 
108682 [m]germinoblastic sarcoma nos 
43459 Plasma cell tumours 
64068 Plasma cell tumour nos 
110349 [m]plasma cell leukaemia nos 
111904 [x]malignant neoplasm/upper resp tract; part unspecified 
109714 [x]oth and unspecif peripheral & cutaneous t-cell lymphomas 
51718 Histiocytosis x , chronic 
36736 Histiocytosis x , unspecified 
37126 Histiocytosis, unspecified 
40000 Langerhans' cell histiocytosis 
111040 Langerhans' cell histiocytosis 
36020 [x]other histiocytosis syndromes 
12106 [v]personal history of malignant neoplasm 
62814 [v]personal history of malig neop of gastrointestinal tract 
68018 [v]personal history of malignant neoplasm of anus 
64568 [v]personal history of malig neop of gastrointestinal tract 
57727 [v]personal history of malignant neoplasm of large intestine 
58177 [v]personal history of malignant neoplasm of liver 
51001 [v]personal history of malignant neoplasm of oesophagus 
62785 [v]personal history of malignant neoplasm of rectum 
49447 [v]personal history of malignant neoplasm of stomach 
99931 [v]personal history of malignant neoplasm of tongue 
49289 [v]personal history of malig neop of trachea/bronchus/lung 
32246 [v]personal history of malignant neoplasm of bronchus 
29284 [v]personal history of malignant neoplasm of lung 
72262 [v]personal history of malig neop other intrathoracic organ 
61655 [v]personal history of malignant neoplasm - accessory sinus 
43311 [v]personal history of malignant neoplasm of larynx 
39863 [v]personal history of malignant neoplasm of nose 
16639 [v]personal history of malignant neoplasm of breast 





23936 [v]personal history of malignant neoplasm of cervix uteri 
109429 [v]personal history of malignant neoplasm of genital organ 
52141 [v]personal history of malignant neoplasm of ovary 
37306 [v]personal history of malignant neoplasm of prostate 
48808 [v]personal history of malignant neoplasm of testis 
46779 [v]personal history of malignant neoplasm of uterine body 
30322 [v]personal history of malignant neoplasm of urinary organ 
35816 [v]personal history of malignant neoplasm of bladder 
47683 [v]personal history of malignant neoplasm of kidney 
28881 [v]personal history of malignant neoplasm of kidney 
36693 [v]personal history of leukaemia 
94597 [v]personal history of lymphoid leukaemia 
110058 [v]personal history of myeloid leukaemia 
72204 [v]personal history other lymphatic/haematopoietic neoplasm 
40561 [v]personal history of hodgkin's disease 
66457 [v]personal history of other specified malignant neoplasm 
46282 [v]personal history of malignant neoplasm of bone 
48085 [v]personal history of malignant neoplasm of brain 
103100 [v]personal history of malignant neoplasm of eye 
47669 [v]personal history of malignant neoplasm of skin 
35771 [v]personal history of malignant neoplasm of thyroid 
45803 [v]personal history of malignant neoplasm of tongue 
68612 [v]personal history of unspecified malignant neoplasm 
60918 Lymphoma stage i 
94935 Lymphoma stage ii 
32240 Lymphoma stage iii 
71672 Lymphoma stage iv 
44617 Hiv disease resulting in burkitt's lymphoma 
66367 Hiv dis resulting oth types of non-hodgkin's lymphoma 
69767 [x]hiv disease resulting in other non-hodgkin's lymphoma 
19415 Malignant neoplasm of lip; oral cavity and pharynx 
24374 Carcinoma of lip; oral cavity and pharynx 
14712 Malignant neoplasm of lip 
9984 Carcinoma of lip 
73962 Malignant neoplasm of upper lip; vermilion border 
66270 Malignant neoplasm of upper lip; external 
50296 Malignant neoplasm of upper lip; lipstick area 
98740 Malignant neoplasm of upper lip; vermilion border nos 
67446 Malignant neoplasm of lower lip; vermilion border 
66384 Malignant neoplasm of lower lip; external 
95480 Malignant neoplasm of lower lip; lipstick area 
101707 Malignant neoplasm of lower lip; vermilion border nos 
99493 Malignant neoplasm of upper lip; inner aspect 
99001 Malignant neoplasm of upper lip; frenulum 
98500 Malignant neoplasm of upper lip; mucosa 
90610 Malignant neoplasm of upper lip; oral aspect 
100721 Malignant neoplasm of upper lip; inner aspect nos 
71147 Malignant neoplasm of lower lip; inner aspect 
67504 Malignant neoplasm of lower lip; buccal aspect 
91843 Malignant neoplasm of lower lip; frenulum 
89909 Malignant neoplasm of lower lip; mucosa 
94441 Malignant neoplasm of lower lip; oral aspect 
96782 Malignant neoplasm of lower lip; inner aspect nos 
61692 Malignant neoplasm of lip unspecified; inner aspect 
73614 Malignant neoplasm of lip unspecified; buccal aspect 





100144 Malignant neoplasm of lip; oral aspect 
96783 Malignant neoplasm of commissure of lip 
18882 Malignant neoplasm of overlapping lesion of lip 
37553 Malignant neoplasm of lip; unspecified 
100906 Malignant neoplasm of lip; unspecified; external 
94251 Malignant neoplasm of lip; unspecified; lipstick area 
69761 Malignant neoplasm of lip; vermilion border nos 
10283 Malignant neoplasm of tongue 
43431 Malignant neoplasm of base of tongue 
69671 Malignant neoplasm of posterior third of tongue 
34409 Malignant neoplasm of base of tongue dorsal surface 
91035 Malignant neoplasm of fixed part of tongue nos 
43642 Malignant neoplasm of dorsal surface of tongue 
107258 Malignant neoplasm of midline of tongue 
43781 Malignant neoplasm of dorsum of tongue nos 
36161 Malignant neoplasm of tongue; tip and lateral border 
62840 Malignant neoplasm of ventral surface of tongue 
102142 Malignant neoplasm of anterior 2/3 of tongue ventral surface 
63979 Malignant neoplasm of frenulum linguae 
38488 Malignant neoplasm of ventral tongue surface nos 
58121 Malignant neoplasm of anterior 2/3 of tongue unspecified 
37096 Malignant neoplasm of tongue; junctional zone 
24852 Malignant neoplasm of lingual tonsil 
47205 Malignant overlapping lesion of tongue 
41530 Malignant neoplasm of other sites of tongue 
40557 Malignant neoplasm of tongue nos 
20292 Malignant neoplasm of major salivary glands 
4388 Malignant neoplasm of parotid gland 
51786 Malignant neoplasm of submandibular gland 
70928 Malignant neoplasm of sublingual gland 
70696 Malignant neoplasm of other major salivary glands 
50475 Malignant neoplasm of major salivary gland nos 
43400 Malignant neoplasm of gum 
32024 Malignant neoplasm of upper gum 
49360 Malignant neoplasm of lower gum 
101753 Malignant neoplasm of other sites of gum 
93218 Malignant neoplasm of gum nos 
20092 Malignant neoplasm of floor of mouth 
45408 Malignant neoplasm of anterior portion of floor of mouth 
45986 Malignant neoplasm of lateral portion of floor of mouth 
17912 Malignant neoplasm; overlapping lesion of floor of mouth 
56709 Malignant neoplasm of other sites of floor of mouth 
36716 Malignant neoplasm of floor of mouth nos 
14792 Malignant neoplasm of other and unspecified parts of mouth 
31364 Malignant neoplasm of cheek mucosa 
30402 Malignant neoplasm of buccal mucosa 
103796 Malignant neoplasm of vestibule of mouth 
95772 Malignant neoplasm of upper buccal sulcus 
97530 Malignant neoplasm of lower buccal sulcus 
37590 Malignant neoplasm of hard palate 
40292 Malignant neoplasm of soft palate 
37516 Malignant neoplasm of uvula 
70819 Malignant neoplasm of palate unspecified 
96003 Malignant neoplasm of junction of hard and soft palate 
69951 Malignant neoplasm of roof of mouth 





37724 Malignant neoplasm of retromolar area 
37916 Malignant neoplasm of other specified mouth parts 
55015 Malignant neoplasm of mouth nos 
37549 Kaposi's sarcoma of palate 
22893 Malignant neoplasm of oropharynx 
16241 Malignant neoplasm of tonsil 
26448 Malignant neoplasm of faucial tonsil 
101988 Malignant neoplasm of palatine tonsil 
102151 Malignant neoplasm of overlapping lesion of tonsil 
53884 Malignant neoplasm tonsil nos 
24397 Malignant neoplasm of tonsillar fossa 
55066 Malignant neoplasm of tonsillar pillar 
51926 Malignant neoplasm of faucial pillar 
99185 Malignant neoplasm of glossopalatine fold 
61510 Malignant neoplasm of palatoglossal arch 
93842 Malignant neoplasm of palatopharyngeal arch 
100002 Malignant neoplasm of tonsillar fossa nos 
39554 Malignant neoplasm of vallecula 
46728 Malignant neoplasm of anterior epiglottis 
26134 Malignant neoplasm of epiglottis; free border 
91895 Malignant neoplasm of glossoepiglottic fold 
73439 Malignant neoplasm of anterior epiglottis nos 
48519 Malignant neoplasm of junctional region of epiglottis 
56355 Malignant neoplasm of lateral wall of oropharynx 
90124 Malignant neoplasm of posterior wall of oropharynx 
67323 Malignant neoplasm of oropharynx; other specified sites 
91037 Malignant neoplasm of other specified site of oropharynx nos 
43200 Malignant neoplasm of oropharynx nos 
24675 Malignant neoplasm of nasopharynx 
94390 Malignant neoplasm of roof of nasopharynx 
95429 Malignant neoplasm of posterior wall of nasopharynx 
33388 Malignant neoplasm of adenoid 
46548 Malignant neoplasm of pharyngeal tonsil 
96869 Malignant neoplasm of posterior wall of nasopharynx nos 
59004 Malignant neoplasm of lateral wall of nasopharynx 
37940 Malignant neoplasm of pharyngeal recess 
102205 Malignant neoplasm of lateral wall of nasopharynx nos 
44139 Malignant neoplasm of anterior wall of nasopharynx 
106915 Malignant neoplasm of nasopharyngeal soft palate surface 
99386 Malignant neoplasm posterior margin nasal septum and choanae 
100918 Malignant neoplasm of anterior wall of nasopharynx nos 
66422 Malignant neoplasm; overlapping lesion of nasopharynx 
55630 Malignant neoplasm of other specified site of nasopharynx 
28665 Malignant neoplasm of nasopharynx nos 
34012 Malignant neoplasm of hypopharynx 
43548 Malignant neoplasm of postcricoid region 
39897 Malignant neoplasm of pyriform sinus 
57248 Malignant neoplasm aryepiglottic fold; hypopharyngeal aspect 
64462 Malignant neoplasm of posterior pharynx 
88362 Malignant neoplasm of other specified hypopharyngeal site 
28451 Malignant neoplasm of hypopharynx nos 
46114 Malig neop other/ill-defined sites lip; oral cavity; pharynx 
16297 Malignant neoplasm of pharynx unspecified 
95016 Malignant neoplasm of waldeyer's ring 
39084 Malignant neoplasm of laryngopharynx 





39430 Malignant neoplasm of lip; oral cavity and pharynx nos 
15709 Malignant neoplasm of digestive organs and peritoneum 
3357 Carcinoma of digestive organs and peritoneum 
1062 Malignant neoplasm of oesophagus 
61695 Malignant neoplasm of cervical oesophagus 
41362 Malignant neoplasm of thoracic oesophagus 
63470 Malignant neoplasm of abdominal oesophagus 
50789 Malignant neoplasm of upper third of oesophagus 
54171 Malignant neoplasm of middle third of oesophagus 
42416 Malignant neoplasm of lower third of oesophagus 
67497 Malignant neoplasm; overlapping lesion of oesophagus 
53591 Malignant neoplasm of other specified part of oesophagus 
30700 Malignant neoplasm of oesophagus nos 
4865 Oesophageal cancer 
8386 Malignant neoplasm of stomach 
32022 Malignant neoplasm of cardia of stomach 
100584 Malignant neoplasm of cardiac orifice of stomach 
22894 Malignant neoplasm of cardio-oesophageal junction of stomach 
94278 Malignant neoplasm of gastro-oesophageal junction 
37859 Malignant neoplasm of cardia of stomach nos 
21620 Malignant neoplasm of pylorus of stomach 
48237 Malignant neoplasm of prepylorus of stomach 
41215 Malignant neoplasm of pyloric canal of stomach 
59092 Malignant neoplasm of pylorus of stomach nos 
19318 Malignant neoplasm of pyloric antrum of stomach 
32362 Malignant neoplasm of fundus of stomach 
43572 Malignant neoplasm of body of stomach 
42193 Malignant neoplasm of lesser curve of stomach unspecified 
55434 Malignant neoplasm of greater curve of stomach unspecified 
51690 Malignant neoplasm; overlapping lesion of stomach 
55019 Malignant neoplasm of other specified site of stomach 
65312 Malignant neoplasm of anterior wall of stomach nec 
96802 Malignant neoplasm of posterior wall of stomach nec 
65372 Malignant neoplasm of other specified site of stomach nos 
14800 Malignant neoplasm of stomach nos 
6806 Malignant neoplasm of small intestine and duodenum 
18613 Malignant neoplasm of duodenum 
43479 Malignant neoplasm of jejunum 
33871 Malignant neoplasm of ileum 
63995 Malignant neoplasm of meckel's diverticulum 
66166 Malignant neoplasm; overlapping lesion of small intestine 
99896 Malignant neoplasm of other specified site small intestine 
43390 Malignant neoplasm of small intestine nos 
1220 Malignant neoplasm of colon 
9088 Malignant neoplasm of hepatic flexure of colon 
6935 Malignant neoplasm of transverse colon 
10864 Malignant neoplasm of descending colon 
2815 Malignant neoplasm of sigmoid colon 
3811 Malignant neoplasm of caecum 
22163 Carcinoma of caecum 
18632 Malignant neoplasm of appendix 
10946 Malignant neoplasm of ascending colon 
18619 Malignant neoplasm of splenic flexure of colon 
93478 Malignant neoplasm; overlapping lesion of colon 
48231 Malignant neoplasm of other specified sites of colon 





9118 Colonic cancer 
35357 Malignant neoplasm of rectum; rectosigmoid junction and anus 
27855 Malignant neoplasm of rectosigmoid junction 
1800 Malignant neoplasm of rectum 
7219 Carcinoma of rectum 
5901 Rectal carcinoma 
24370 Malignant neoplasm of anal canal 
9491 Anal carcinoma 
46159 Malignant neoplasm of cloacogenic zone 
27897 Malignant neoplasm of anus unspecified 
55659 Malig neop other site rectum; rectosigmoid junction and anus 
50974 Malignant neoplasm rectum;rectosigmoid junction and anus nos 
8918 Malignant neoplasm of liver and intrahepatic bile ducts 
25535 Primary malignant neoplasm of liver 
16126 Primary carcinoma of liver 
31210 Hepatoblastoma of liver 
68410 Primary angiosarcoma of liver 
22187 Hepatocellular carcinoma 
44399 Primary malignant neoplasm of liver nos 
16915 Malignant neoplasm of intrahepatic bile ducts 
65124 Malignant neoplasm of interlobular bile ducts 
89593 Malignant neoplasm of intrahepatic biliary passages 
58088 Malignant neoplasm of intrahepatic gall duct 
61643 Malignant neoplasm of intrahepatic bile ducts nos 
26393 Malignant neoplasm of liver unspecified 
38978 Malignant neoplasm of liver and intrahepatic bile ducts nos 
54103 Malignant neoplasm gallbladder and extrahepatic bile ducts 
16105 Malignant neoplasm of gallbladder 
31393 Carcinoma gallbladder 
23433 Malignant neoplasm of extrahepatic bile ducts 
72445 Malignant neoplasm of cystic duct 
52537 Malignant neoplasm of hepatic duct 
7982 Malignant neoplasm of common bile duct 
36495 Carcinoma common bile duct 
105613 Malignant neoplasm of sphincter of oddi 
74896 Malignant neoplasm of extrahepatic bile ducts nos 
10949 Malignant neoplasm of ampulla of vater 
35039 Malignant neoplasm; overlapping lesion of biliary tract 
60312 Malignant neoplasm other gallbladder/extrahepatic bile duct 
15907 Malignant neoplasm gallbladder/extrahepatic bile ducts nos 
8166 Malignant neoplasm of pancreas 
8771 Malignant neoplasm of head of pancreas 
40810 Malignant neoplasm of body of pancreas 
39870 Malignant neoplasm of tail of pancreas 
35535 Malignant neoplasm of pancreatic duct 
35795 Malignant neoplasm of islets of langerhans 
97875 Malignant neoplasm; overlapping lesion of pancreas 
48537 Malignant neoplasm of other specified sites of pancreas 
96635 Malignant neoplasm of ectopic pancreatic tissue 
95783 Malignant neoplasm of specified site of pancreas nos 
34388 Malignant neoplasm of pancreas nos 
44108 Malignant neoplasm of retroperitoneum and peritoneum 
21330 Malignant neoplasm of retroperitoneum 
65159 Malignant neoplasm of perinephric tissue 
24048 Malignant neoplasm of retrocaecal tissue 





17874 Mesothelioma of peritoneum 
101907 Overlapping malign lesion of retroperitoneum and peritoneum 
46613 Malignant neoplasm of specified parts of peritoneum 
59388 Malignant neoplasm of mesocaecum 
30165 Malignant neoplasm of mesorectum 
50898 Malignant neoplasm of omentum 
64516 Malignant neoplasm of parietal peritoneum 
39413 Malignant neoplasm of pelvic peritoneum 
69821 Malignant neoplasm of the pouch of douglas 
90290 Malignant neoplasm of mesentery 
64106 Malignant neoplasm of specified parts of peritoneum nos 
16298 Malignant neoplasm of retroperitoneum and peritoneum nos 
11009 Malig neop oth/ill-defined sites digestive tract/peritoneum 
17559 Malignant neoplasm of intestinal tract; part unspecified 
11628 Cancer of bowel 
65460 Malignant neoplasm of spleen nec 
72224 Fibrosarcoma of spleen 
93778 Malignant neoplasm of spleen nos 
94776 Malignant neoplasm; overlapping lesion of digestive system 
56918 Malignant neoplasm other spec digestive tract and peritoneum 
51255 Malignant neoplasm of digestive tract and peritoneum nos 
34075 Malig neop of respiratory tract and intrathoracic organs 
45307 Carcinoma of respiratory tract and intrathoracic organs 
26652 Malig neop nasal cavities; middle ear and accessory sinuses 
23389 Malignant neoplasm of nasal cavities 
71204 Malignant neoplasm of cartilage of nose 
98911 Malignant neoplasm of nasal conchae 
62761 Malignant neoplasm of septum of nose 
62182 Malignant neoplasm of vestibule of nose 
42856 Malignant neoplasm of nasal cavities nos 
24456 Malig neop auditory tube; middle ear and mastoid air cells 
107916 Malignant neoplasm of auditory (eustachian) tube 
98537 Malignant neoplasm of tympanic cavity 
54613 Malignant neoplasm of tympanic antrum 
71946 Malignant neoplasm of mastoid air cells 
73537 Malig neop auditory tube; middle ear; mastoid air cells nos 
32174 Malignant neoplasm of maxillary sinus 
54636 Malignant neoplasm of ethmoid sinus 
15684 Malignant neoplasm of frontal sinus 
65215 Malignant neoplasm of sphenoidal sinus 
39590 Malignant neoplasm; overlapping lesion of accessory sinuses 
96971 Malig neop other site nasal cavity; middle ear and sinuses 
55246 Malignant neoplasm of accessory sinus nos 
319 Malignant neoplasm of larynx 
318 Malignant neoplasm of glottis 
26165 Malignant neoplasm of supraglottis 
22441 Malignant neoplasm of subglottis 
43111 Malignant neoplasm of laryngeal cartilage 
63460 Malignant neoplasm of arytenoid cartilage 
37805 Malignant neoplasm of cricoid cartilage 
107878 Malignant neoplasm of cuneiform cartilage 
47862 Malignant neoplasm of thyroid cartilage 
97332 Malignant neoplasm of laryngeal cartilage nos 
50579 Malignant neoplasm; overlapping lesion of larynx 
55374 Malignant neoplasm of epiglottis nos 





9237 Malignant neoplasm of larynx nos 
13243 Malignant neoplasm of trachea; bronchus and lung 
15221 Malignant neoplasm of trachea 
103946 Malignant neoplasm of mucosa of trachea 
37810 Malignant neoplasm of trachea nos 
12870 Malignant neoplasm of main bronchus 
17391 Malignant neoplasm of carina of bronchus 
33444 Malignant neoplasm of hilus of lung 
21698 Malignant neoplasm of main bronchus nos 
10358 Malignant neoplasm of upper lobe; bronchus or lung 
20170 Pancoast's syndrome 
31700 Malignant neoplasm of upper lobe bronchus 
25886 Malignant neoplasm of upper lobe of lung 
44169 Malignant neoplasm of upper lobe; bronchus or lung nos 
31268 Malignant neoplasm of middle lobe; bronchus or lung 
41523 Malignant neoplasm of middle lobe bronchus 
39923 Malignant neoplasm of middle lobe of lung 
54134 Malignant neoplasm of middle lobe; bronchus or lung nos 
31188 Malignant neoplasm of lower lobe; bronchus or lung 
18678 Malignant neoplasm of lower lobe bronchus 
12582 Malignant neoplasm of lower lobe of lung 
42566 Malignant neoplasm of lower lobe; bronchus or lung nos 
36371 Malignant neoplasm of overlapping lesion of bronchus & lung 
7484 Mesothelioma 
38961 Malignant neoplasm of other sites of bronchus or lung 
3903 Malignant neoplasm of bronchus or lung nos 
2587 Lung cancer 
31573 Malignant neoplasm of pleura 
67107 Malignant neoplasm of parietal pleura 
106194 Malignant neoplasm of visceral pleura 
9600 Mesothelioma of pleura 
98104 Malignant neoplasm of other specified pleura 
34742 Malignant neoplasm of pleura nos 
62556 Malignant neoplasm of thymus; heart and mediastinum 
27483 Malignant neoplasm of thymus 
95644 Malignant neoplasm of heart 
63430 Malignant neoplasm of endocardium 
65605 Malignant neoplasm of myocardium 
94975 Malignant neoplasm of pericardium 
101885 Mesothelioma of pericardium 
50289 Malignant neoplasm of heart nos 
27715 Malignant neoplasm of anterior mediastinum 
92720 Malignant neoplasm of posterior mediastinum 
61064 Malignant neoplasm of mediastinum; part unspecified 
100232 Malig neop of other site of heart; thymus and mediastinum 
66750 Malignant neoplasm of heart; thymus and mediastinum nos 
39531 Malig neo; overlapping lesion of heart; mediastinum & pleura 
66646 Malignant neoplasm; overlap lesion of resp & intrathor orgs 
44356 Malig neop other/ill-defined sites resp/intrathoracic organs 
65793 Malig neop of upper respiratory tract; part unspecified 
29283 Malignant neoplasm of other site of respiratory tract 
42569 Malignant neoplasm of respiratory tract nos 
18608 Malig neop of bone; connective tissue; skin and breast 
9902 Carcinoma of bone; connective tissue; skin and breast 
12539 Sarcoma of bone and connective tissue 





59036 Malignant neoplasm of bones of skull and face 
53594 Malignant neoplasm of ethmoid bone 
53599 Malignant neoplasm of frontal bone 
59520 Malignant neoplasm of malar bone 
95458 Malignant neoplasm of nasal bone 
55953 Malignant neoplasm of occipital bone 
50298 Malignant neoplasm of orbital bone 
54747 Malignant neoplasm of parietal bone 
55595 Malignant neoplasm of sphenoid bone 
62104 Malignant neoplasm of temporal bone 
50299 Malignant neoplasm of zygomatic bone 
17475 Malignant neoplasm of maxilla 
44452 Malignant neoplasm of vomer 
69146 Malignant neoplasm of bones of skull and face nos 
33833 Malignant neoplasm of mandible 
16704 Malignant neoplasm of vertebral column 
46939 Malignant neoplasm of cervical vertebra 
32372 Malignant neoplasm of thoracic vertebra 
54691 Malignant neoplasm of lumbar vertebra 
49701 Malignant neoplasm of vertebral column nos 
27528 Malignant neoplasm of ribs; sternum and clavicle 
37842 Malignant neoplasm of rib 
49491 Malignant neoplasm of sternum 
66639 Malignant neoplasm of clavicle 
60403 Malignant neoplasm of costal cartilage 
67763 Malignant neoplasm of costo-vertebral joint 
54493 Malignant neoplasm of xiphoid process 
51237 Malignant neoplasm of rib; sternum and clavicle nos 
71810 Malignant neoplasm of scapula and long bones of upper arm 
49054 Malignant neoplasm of scapula 
105797 Malignant neoplasm of acromion 
61741 Malignant neoplasm of humerus 
92371 Malignant neoplasm of radius 
64848 Malignant neoplasm of ulna 
65880 Malig neop of scapula and long bones of upper arm nos 
73530 Malignant neoplasm of hand bones 
106069 Malignant neoplasm of carpal bones 
72464 Malignant neoplasm of metacarpal bones 
57988 Malignant neoplasm of carpal bone - scaphoid 
69104 Malignant neoplasm of carpal bone - lunate 
94427 Malignant neoplasm of fifth metacarpal bone 
86812 Malignant neoplasm of phalanges of hand 
73556 Malignant neoplasm of hand bones nos 
54631 Malignant neoplasm of pelvic bones; sacrum and coccyx 
44609 Malignant neoplasm of ilium 
59223 Malignant neoplasm of ischium 
51921 Malignant neoplasm of pubis 
40966 Malignant neoplasm of sacral vertebra 
66908 Malignant neoplasm of coccygeal vertebra 
50152 Malignant sacral teratoma 
38938 Malignant neoplasm of pelvis; sacrum or coccyx nos 
68055 Malignant neoplasm of long bones of leg 
56513 Malignant neoplasm of femur 
50402 Malignant neoplasm of fibula 
40814 Malignant neoplasm of tibia 





105475 Malignant neoplasm of short bones of leg 
95182 Malignant neoplasm of talus 
72212 Malignant neoplasm of calcaneum 
34878 Malignant neoplasm of medial cuneiform 
69927 Malignant neoplasm of first metatarsal bone 
58949 Malignant neoplasm of phalanges of foot 
103354 Malignant neoplasm of short bones of leg nos 
67451 Malignant neoplasm/overlap lesion/bone??? Cartilage 
43614 Malignant neoplasm/bones??? Cartilage/limb;unspfd 
16075 Malignant neoplasm of bone and articular cartilage nos 
19437 Osteosarcoma 
34451 Malignant neoplasm of connective and other soft tissue 
43475 Malig neop of connective and soft tissue head; face and neck 
59382 Malignant neoplasm of soft tissue of head 
40014 Malignant neoplasm of soft tissue of face 
48517 Malignant neoplasm of soft tissue of neck 
60035 Malignant neoplasm of cartilage of ear 
49463 Malignant neoplasm of tarsus of eyelid 
108389 Malignant neoplasm soft tissues of cervical spine 
73718 Malig neop connective and soft tissue head; face; neck nos 
53989 Malig neop connective and soft tissue upper limb/shoulder 
50222 Malignant neoplasm of connective and soft tissue of shoulder 
64345 Malignant neoplasm of connective and soft tissue; upper arm 
57482 Malignant neoplasm of connective and soft tissue of fore-arm 
19321 Malignant neoplasm of connective and soft tissue of hand 
91586 Malignant neoplasm of connective and soft tissue of finger 
63988 Malignant neoplasm of connective and soft tissue of thumb 
104913 Malig neop connective soft tissue upper limb/shoulder nos 
66088 Malig neop of connective and soft tissue of hip and leg 
102949 Malignant neoplasm of connective and soft tissue of hip 
44805 Malig neop of connective and soft tissue thigh and upper leg 
54965 Malig neop connective and soft tissue of popliteal space 
30542 Malig neop of connective and soft tissue of lower leg 
54222 Malignant neoplasm of connective and soft tissue of foot 
99572 Malignant neoplasm of connective and soft tissue of toe 
90546 Malig neop connective and soft tissue hip and leg nos 
22290 Malignant neoplasm of connective and soft tissue of thorax 
29160 Malignant neoplasm of connective and soft tissue of axilla 
54186 Malignant neoplasm of diaphragm 
72522 Malignant neoplasm of great vessels 
104139 Malig neoplasm of connective and soft tissues of thor spine 
98408 Malig neop of connective and soft tissue of thorax nos 
45071 Malignant neoplasm of connective and soft tissue of abdomen 
66488 Malig neop of connective and soft tissue of abdominal wall 
94272 Malig neoplasm of connective and soft tissues of lumb spine 
60247 Malig neop of connective and soft tissue of abdomen nos 
51965 Malignant neoplasm of connective and soft tissue of pelvis 
70463 Malignant neoplasm of connective and soft tissue of buttock 
67324 Malig neop of connective and soft tissue of inguinal region 
59152 Malignant neoplasm of connective and soft tissue of perineum 
58836 Malig neop of connective and soft tissue of pelvis nos 
57471 Malig neop of connective and soft tissue trunk unspecified 
65233 Malig neop connective and soft tissue other specified site 
15182 Malignant neoplasm of connective and soft tissue; site nos 
104128 Kaposi's sarcoma of soft tissue 





70637 Malignant melanoma of lip 
54632 Malignant melanoma of eyelid including canthus 
57260 Malignant melanoma of ear and external auricular canal 
59061 Malignant melanoma of auricle (ear) 
102145 Malignant melanoma of external auditory meatus 
73744 Malignant melanoma of ear and external auricular canal nos 
47252 Malignant melanoma of other and unspecified parts of face 
41278 Malignant melanoma of external surface of cheek 
71136 Malignant melanoma of chin 
47094 Malignant melanoma of eyebrow 
68133 Malignant melanoma of forehead 
45139 Malignant melanoma of external surface of nose 
58958 Malignant melanoma of temple 
67806 Malignant melanoma of face nos 
65625 Malignant melanoma of scalp and neck 
55881 Malignant melanoma of scalp 
45306 Malignant melanoma of neck 
99257 Malignant melanoma of scalp and neck nos 
38689 Malignant melanoma of trunk (excluding scrotum) 
49814 Malignant melanoma of axilla 
32768 Malignant melanoma of breast 
53629 Malignant melanoma of buttock 
34259 Malignant melanoma of groin 
95629 Malignant melanoma of perineum 
43715 Malignant melanoma of umbilicus 
43463 Malignant melanoma of back 
51209 Malignant melanoma of chest wall 
45760 Malignant melanoma of trunk; excluding scrotum; nos 
65164 Malignant melanoma of upper limb and shoulder 
50505 Malignant melanoma of shoulder 
54685 Malignant melanoma of upper arm 
45755 Malignant melanoma of fore-arm 
62475 Malignant melanoma of hand 
25602 Malignant melanoma of finger 
63997 Malignant melanoma of thumb 
55292 Malignant melanoma of upper limb or shoulder nos 
46255 Malignant melanoma of lower limb and hip 
73536 Malignant melanoma of hip 
51873 Malignant melanoma of thigh 
54305 Malignant melanoma of knee 
39878 Malignant melanoma of popliteal fossa area 
37872 Malignant melanoma of lower leg 
42714 Malignant melanoma of ankle 
61246 Malignant melanoma of heel 
41490 Malignant melanoma of foot 
36899 Malignant melanoma of toe 
53369 Malignant melanoma of great toe 
64327 Malignant melanoma of lower limb or hip nos 
42153 Malignant melanoma of other specified skin site 
96585 Overlapping malignant melanoma of skin 
28556 Malignant melanoma of skin nos 
4632 Other malignant neoplasm of skin 
37016 Malignant neoplasm of sebaceous gland 
40443 Malignant neoplasm of sweat gland 
18245 Malignant neoplasm of skin of lip 





36731 Malignant neoplasm of canthus 
55550 Malignant neoplasm of upper eyelid 
41958 Malignant neoplasm of lower eyelid 
53515 Malignant neoplasm skin of ear and external auricular canal 
33997 Malignant neoplasm of skin of auricle (ear) 
62080 Malignant neoplasm of skin of external auditory meatus 
33271 Malignant neoplasm of pinna nec 
62399 Malig neop skin of ear and external auricular canal nos 
27370 Malignant neoplasm skin of other and unspecified parts face 
30645 Malignant neoplasm of skin of cheek; external 
49403 Malignant neoplasm of skin of chin 
55670 Malignant neoplasm of skin of eyebrow 
30576 Malignant neoplasm of skin of forehead 
16202 Malignant neoplasm of skin of nose (external) 
21327 Malignant neoplasm of skin of temple 
46008 Malignant neoplasm skin other and unspec part of face nos 
54234 Malignant neoplasm of scalp and skin of neck 
37165 Malignant neoplasm of scalp 
43619 Malignant neoplasm of skin of neck 
73760 Malignant neoplasm of scalp or skin of neck nos 
57446 Malignant neoplasm of skin of trunk; excluding scrotum 
70380 Malignant neoplasm of skin of axillary fold 
37969 Malignant neoplasm of skin of chest; excluding breast 
30543 Malignant neoplasm of skin of breast 
18618 Malignant neoplasm of skin of abdominal wall 
67748 Malignant neoplasm of skin of umbilicus 
66319 Malignant neoplasm of skin of groin 
46458 Malignant neoplasm of skin of perineum 
45077 Malignant neoplasm of skin of back 
62305 Malignant neoplasm of skin of buttock 
23480 Malignant neoplasm of perianal skin 
66447 Malignant neoplasm of skin of scapular region 
15868 Malignant neoplasm of skin of trunk; excluding scrotum; nos 
30747 Malignant neoplasm of skin of upper limb and shoulder 
43122 Malignant neoplasm of skin of shoulder 
42707 Malignant neoplasm of skin of upper arm 
30577 Malignant neoplasm of skin of fore-arm 
54352 Malignant neoplasm of skin of hand 
25245 Malignant neoplasm of skin of finger 
64406 Malignant neoplasm of skin of thumb 
60526 Malignant neoplasm of skin of upper limb or shoulder nos 
57442 Malignant neoplasm of skin of lower limb and hip 
70988 Malignant neoplasm of skin of hip 
58601 Malignant neoplasm of skin of thigh 
56954 Malignant neoplasm of skin of knee 
68197 Malignant neoplasm of skin of popliteal fossa area 
33682 Malignant neoplasm of skin of lower leg 
64270 Malignant neoplasm of skin of ankle 
104025 Malignant neoplasm of skin of heel 
70587 Malignant neoplasm of skin of foot 
65782 Malignant neoplasm of skin of toe 
67914 Malignant neoplasm of skin of great toe 
61194 Malignant neoplasm of skin of lower limb or hip nos 
24375 Dermatofibrosarcoma protuberans 
42429 Malignant neoplasm overlapping lesion of skin 





2492 Malignant neoplasm of skin nos 
27931 Kaposi's sarcoma of skin 
3968 Malignant neoplasm of female breast 
348 Ca female breast 
26853 Malignant neoplasm of nipple and areola of female breast 
23380 Malignant neoplasm of nipple of female breast 
64686 Malignant neoplasm of areola of female breast 
59831 Malignant neoplasm of nipple or areola of female breast nos 
31546 Malignant neoplasm of central part of female breast 
29826 Malignant neoplasm of upper-inner quadrant of female breast 
45222 Malignant neoplasm of lower-inner quadrant of female breast 
23399 Malignant neoplasm of upper-outer quadrant of female breast 
42070 Malignant neoplasm of lower-outer quadrant of female breast 
20685 Malignant neoplasm of axillary tail of female breast 
49148 Malignant neoplasm; overlapping lesion of breast 
56715 Malignant neoplasm of other site of female breast 
95057 Malignant neoplasm of ectopic site of female breast 
38475 Malignant neoplasm of other site of female breast nos 
9470 Malignant neoplasm of female breast nos 
19423 Malignant neoplasm of male breast 
54494 Malignant neoplasm of nipple and areola of male breast 
68480 Malignant neoplasm of nipple of male breast 
67884 Malignant neoplasm of areola of male breast 
54202 Malignant neoplasm of other site of male breast 
95323 Malignant neoplasm of ectopic site of male breast 
48809 Malignant neoplasm of male breast nos 
19389 Malig neop of bone; connective tissue; skin and breast os 
41011 Malig neop of bone; connective tissue; skin and breast nos 
13252 Malignant neoplasm of genitourinary organ 
16874 Carcinoma of genitourinary organ 
2744 Malignant neoplasm of uterus; part unspecified 
2747 Malignant neoplasm of cervix uteri 
3230 Cervical carcinoma (uterus) 
48820 Malignant neoplasm of endocervix 
57235 Malignant neoplasm of endocervical canal 
53103 Malignant neoplasm of endocervical gland 
50285 Malignant neoplasm of endocervix nos 
50297 Malignant neoplasm of exocervix 
58094 Malignant neoplasm; overlapping lesion of cervix uteri 
32955 Malignant neoplasm of other site of cervix 
95505 Malignant neoplasm of cervical stump 
57719 Malignant neoplasm of squamocolumnar junction of cervix 
43435 Malignant neoplasm of other site of cervix nos 
28311 Malignant neoplasm of cervix uteri nos 
93762 Malignant neoplasm of placenta 
28003 Choriocarcinoma 
7046 Malignant neoplasm of body of uterus 
3213 Malignant neoplasm of corpus uteri; excluding isthmus 
72723 Malignant neoplasm of cornu of corpus uteri 
68155 Malignant neoplasm of fundus of corpus uteri 
2890 Malignant neoplasm of endometrium of corpus uteri 
49400 Malignant neoplasm of endometrium 
45793 Malignant neoplasm of myometrium of corpus uteri 
45490 Malignant neoplasm of corpus uteri nos 
43940 Malignant neoplasm of isthmus of uterine body 





70729 Malignant neoplasm of isthmus of uterine body nos 
16967 Malignant neoplasm of overlapping lesion of corpus uteri 
31608 Malignant neoplasm of other site of uterine body 
33617 Malignant neoplasm of body of uterus nos 
19141 Malignant neoplasm of ovary and other uterine adnexa 
7805 Malignant neoplasm of ovary 
1986 Cancer of ovary 
49828 Malignant neoplasm of fallopian tube 
101778 Malignant neoplasm of broad ligament 
46153 Malignant neoplasm of parametrium 
97996 Malignant neoplasm of other site of uterine adnexa 
65106 Malignant neoplasm of uterine adnexa nos 
4555 Malig neop of other and unspecified female genital organs 
37328 Malignant neoplasm of vagina 
10698 Malignant neoplasm of vaginal vault 
60772 Malignant neoplasm of vagina nos 
43761 Malignant neoplasm of labia majora 
47899 Malignant neoplasm of greater vestibular (bartholin's) gland 
59362 Malignant neoplasm of labia majora nos 
58061 Malignant neoplasm of labia minora 
53910 Malignant neoplasm of clitoris 
4554 Malignant neoplasm of vulva unspecified 
11991 Primary vulval cancer 
26454 Malignant neoplasm/overlapping lesion/feml genital organs 
95421 Malignant neoplasm of other specified female genital organ 
27617 Malignant neoplasm of overlapping lesion of vulva 
20166 Malignant neoplasm of female genital organ nos 
780 Malignant neoplasm of prostate 
15148 Malignant neoplasm of testis 
64602 Malignant neoplasm of undescended testis 
7740 Seminoma of undescended testis 
96429 Malignant neoplasm of undescended testis nos 
19475 Malignant neoplasm of descended testis 
21786 Seminoma of descended testis 
38510 Malignant neoplasm of testis nos 
2961 Seminoma of testis 
3541 Malignant neoplasm of penis and other male genital organs 
50681 Malignant neoplasm of prepuce (foreskin) 
17841 Malignant neoplasm of glans penis 
48743 Malignant neoplasm of body of penis 
43392 Malignant neoplasm of penis; part unspecified 
72127 Malignant neoplasm of epididymis 
63331 Malignant neoplasm of spermatic cord 
47767 Malignant neoplasm of scrotum 
52570 Malignant neoplasm; overlapping lesion of penis 
67949 Malignant neoplasm of other male genital organ 
68161 Malignant neoplasm of seminal vesicle 
47668 Malignant neoplasm of tunica vaginalis 
68824 Malignant neoplasm; overlapping lesion male genital orgs 
92329 Malignant neoplasm of other male genital organ nos 
63224 Malignant neoplasm of penis and other male genital organ nos 
779 Malignant neoplasm of urinary bladder 
38862 Malignant neoplasm of trigone of urinary bladder 
44996 Malignant neoplasm of dome of urinary bladder 
35963 Malignant neoplasm of lateral wall of urinary bladder 





42012 Malignant neoplasm of posterior wall of urinary bladder 
41571 Malignant neoplasm of bladder neck 
28241 Malignant neoplasm of ureteric orifice 
42023 Malignant neoplasm of urachus 
36949 Malignant neoplasm of other site of urinary bladder 
47801 Malignant neoplasm; overlapping lesion of bladder 
31102 Malignant neoplasm of urinary bladder nos 
13559 Malig neop of kidney and other unspecified urinary organs 
18712 Renal malignant neoplasm 
1599 Malignant neoplasm of kidney parenchyma 
7978 Hypernephroma 
12389 Malignant neoplasm of renal pelvis 
27540 Malignant neoplasm of renal calyces 
101608 Malignant neoplasm of ureteropelvic junction 
54184 Malignant neoplasm of renal pelvis nos 
15223 Malignant neoplasm of ureter 
15644 Malignant neoplasm of urethra 
72174 Malignant neoplasm of paraurethral glands 
44884 Malignant neoplasm of other urinary organs 
59286 Malignant neoplasm of overlapping lesion of urinary organs 
29462 Malignant neoplasm of kidney or urinary organs nos 
38931 Malignant neoplasm of genitourinary organ os 
52594 Malignant neoplasm of genitourinary organ nos 
10995 Malignant neoplasm of other and unspecified sites 
8693 Carcinoma of other and unspecified sites 
20160 Malignant neoplasm of eye 
98813 Malig neop eyeball excl conjunctiva; cornea; retina; choroid 
59041 Malignant neoplasm of ciliary body 
59381 Malignant neoplasm of iris 
106569 Malignant neoplasm of crystalline lens 
56718 Malignant neoplasm of eyeball nos 
45667 Malignant neoplasm of orbit 
86996 Malignant neoplasm of connective tissue of orbit 
63104 Malignant neoplasm of orbit nos 
64817 Malignant neoplasm of lacrimal gland 
63657 Malignant neoplasm of conjunctiva 
73992 Malignant neoplasm of cornea 
28069 Malignant neoplasm of retina 
15991 Malignant neoplasm of choroid 
71584 Malignant neoplasm of lacrimal duct 
101805 Malignant neoplasm of lacrimal sac 
65357 Malignant neoplasm of nasolacrimal duct 
45922 Malignant neoplasm; overlapping lesion of eye and adnexa 
40437 Malignant neoplasm of other specified site of eye 
54956 Malignant neoplasm of eye nos 
18617 Malignant neoplasm of brain 
10851 Cerebral tumour - malignant 
15711 Malignant neoplasm cerebrum (excluding lobes and ventricles) 
48073 Malignant neoplasm of basal ganglia 
61399 Malignant neoplasm of cerebral cortex 
99913 Malignant neoplasm of globus pallidus 
70942 Malignant neoplasm of hypothalamus 
62126 Malignant neoplasm of thalamus 
54133 Malignant neoplasm of cerebrum nos 
42426 Malignant neoplasm of frontal lobe 





67236 Malignant neoplasm of hippocampus 
47556 Malignant neoplasm of temporal lobe nos 
19226 Malignant neoplasm of parietal lobe 
39088 Malignant neoplasm of occipital lobe 
52511 Malignant neoplasm of cerebral ventricles 
46789 Malignant neoplasm of choroid plexus 
45154 Malignant neoplasm of cerebellum 
44089 Malignant neoplasm of brain stem 
64557 Malignant neoplasm of cerebral peduncle 
49132 Malignant neoplasm of medulla oblongata 
93537 Malignant neoplasm of midbrain 
91240 Malignant neoplasm of pons 
68641 Malignant neoplasm of brain stem nos 
71139 Malignant neoplasm of other parts of brain 
59170 Malignant neoplasm of corpus callosum 
65241 Malignant neoplasm; overlapping lesion of brain 
100733 Malignant neoplasm of other part of brain nos 
41520 Malignant neoplasm of brain nos 
65458 Malig neop of other and unspecified parts of nervous system 
99621 Malignant neoplasm of cranial nerves 
64971 Malignant neoplasm of olfactory bulb 
70126 Malignant neoplasm of optic nerve 
65599 Malignant neoplasm of acoustic nerve 
101086 Malignant neoplasm of cranial nerves nos 
28919 Malignant neoplasm of cerebral meninges 
70104 Malignant neoplasm of cerebral meninges nos 
51115 Malignant neoplasm of spinal cord 
49714 Malignant neoplasm of spinal meninges 
67211 Malignant neoplasm of spinal meninges nos 
24235 Malig neopl peripheral nerves and autonomic nervous system 
63568 Malignant neoplasm of peripheral nerves of head; face & neck 
61716 Malignant neoplasm of peripheral nerve;upp limb;incl should 
89258 Malignant neoplasm of peripheral nerve of low limb; incl hip 
63695 Malignant neoplasm of peripheral nerve of thorax 
86046 Malignant neoplasm of peripheral nerve of abdomen 
73988 Malignant neoplasm of peripheral nerve of pelvis 
50777 Malignant neoplasm;overlap lesion periph nerve & auton ns 
106654 Mal neoplasm/periph nerves??? Nervous system;unspc 
9622 Malignant neoplasm of cauda equina 
53504 Malig neopl; overlap lesion brain & other part of cns 
49875 Malignant neoplasm of meninges; unspecified 
88144 Malignant neoplasm of other specified part of nervous system 
56490 Malignant neoplasm of nervous system nos 
5637 Malignant neoplasm of thyroid gland 
30511 Malig neop of other endocrine glands and related structures 
28148 Malignant neoplasm of adrenal gland 
61390 Malignant neoplasm of adrenal cortex 
94220 Malignant neoplasm of adrenal medulla 
70824 Malignant neoplasm of adrenal gland nos 
4218 Malignant neoplasm of parathyroid gland 
59823 Malignant neoplasm pituitary gland and craniopharyngeal duct 
8550 Malignant neoplasm of pituitary gland 
39899 Malignant neoplasm of craniopharyngeal duct 
59718 Malig neop pituitary gland or craniopharyngeal duct nos 
42460 Malignant neoplasm of pineal gland 





50035 Malignant neoplasm of aortic body and other paraganglia 
51795 Malignant neoplasm of glomus jugulare 
47840 Malignant neoplasm of aortic body 
46905 Malignant neoplasm of coccygeal body 
103995 Malignant neoplasm of aortic body or paraganglia nos 
87113 Malignant neoplasm-pluriglandular involvement;unspecified 
90659 Malignant neoplasm of other specified endocrine gland 
64195 Malig neop of endocrine gland or related structure nos 
9030 Malignant neoplasm of other and ill-defined sites 
68236 Malignant neoplasm of head; neck and face 
55098 Malignant neoplasm of head nos 
41931 Malignant neoplasm of cheek nos 
12490 Malignant neoplasm of nose nos 
51818 Malignant neoplasm of jaw nos 
16280 Malignant neoplasm of neck nos 
73510 Malignant neoplasm of supraclavicular fossa nos 
58903 Malignant neoplasm of head; neck and face nos 
47286 Malignant neoplasm of thorax 
37618 Malignant neoplasm of axilla nos 
23861 Malignant neoplasm of chest wall nos 
97547 Malignant neoplasm of intrathoracic site nos 
64810 Malignant neoplasm of thorax nos 
15976 Malignant neoplasm of abdomen 
52316 Malignant neoplasm of pelvis 
57854 Malignant neoplasm of inguinal region nos 
89916 Malignant neoplasm of presacral region 
107126 Malignant neoplasm of sacrococcygeal region 
55101 Malignant neoplasm of pelvis nos 
27449 Malignant neoplasm of upper limb nos 
31399 Malignant neoplasm of lower limb nos 
42218 Malignant neoplasm of other specified sites 
68787 Malignant neoplasm of back nos 
67217 Malignant neoplasm of trunk nos 
94355 Malignant neoplasm of flank nos 
60052 Malignant neoplasm of specified site nos 
45267 Malignant neoplasm of other and ill defined site nos 
47810 Malignant neoplasm of unspecified site 
49525 Kaposi's sarcoma; unspecified 
38736 Malignant neoplasm of other and unspecified site os 
1056 Malignant neoplasm of other and unspecified site nos 
12323 Malignant neoplasm of lymphatic and haemopoietic tissue 
37112 Malignant neoplasm of histiocytic tissue 
41369 Lymphosarcoma and reticulosarcoma 
1481 Reticulosarcoma 
60242 Reticulosarcoma of unspecified site 
71031 Reticulosarcoma of lymph nodes of head; face and neck 
70374 Reticulosarcoma of intra-abdominal lymph nodes 
95058 Reticulosarcoma of spleen 
99240 Reticulosarcoma nos 
27416 Lymphosarcoma 
71625 Lymphosarcoma of unspecified site 
71238 Lymphosarcoma of lymph nodes of head; face and neck 
62380 Lymphosarcoma of intrathoracic lymph nodes 
64670 Lymphosarcoma of intra-abdominal lymph nodes 
100352 Lymphosarcoma of lymph nodes of inguinal region and leg 





104790 Lymphosarcoma of lymph nodes of multiple sites 
63723 Lymphosarcoma nos 
21402 Burkitt's lymphoma 
59115 Burkitt's lymphoma of lymph nodes of head; face and neck 
100006 Burkitt's lymphoma of intrathoracic lymph nodes 
97577 Burkitt's lymphoma of intra-abdominal lymph nodes 
92380 Burkitt's lymphoma of lymph nodes of inguinal region and leg 
71304 Burkitt's lymphoma nos 
99887 Other specified reticulosarcoma or lymphosarcoma 
99951 Reticulosarcoma or lymphosarcoma nos 
2462 Hodgkin's disease 
65489 Hodgkin's paragranuloma 
100423 Hodgkin's paragranuloma of lymph nodes of head; face; neck 
98840 Hodgkin's paragranuloma of intra-abdominal lymph nodes 
44196 Hodgkin's granuloma 
98909 Hodgkin's granuloma of lymph nodes of head; face and neck 
64036 Hodgkin's sarcoma 
68039 Hodgkin's sarcoma of lymph nodes of axilla and upper limb 
38939 Hodgkin's disease; lymphocytic-histiocytic predominance 
71142 Hodgkin's; lymphocytic-histiocytic predominance unspec site 
68330 Hodgkin's; lymphocytic-histiocytic pred of head; face; neck 
92245 Hodgkin's; lymphocytic-histiocytic pred intrathoracic nodes 
73532 Hodgkin's; lymphocytic-histiocytic pred intra-abdominal node 
93951 Hodgkin's; lymphocytic-histiocytic pred inguinal and leg 
95338 Hodgkin's; lymphocytic-histiocytic pred intrapelvic nodes 
106911 Hodgkin's; lymphocytic-histiocytic predominance of spleen 
104743 Hodgkin's; lymphocytic-histiocytic pred of multiple sites 
29876 Hodgkin's; lymphocytic-histiocytic predominance nos 
29178 Hodgkin's disease; nodular sclerosis 
57225 Hodgkin's disease; nodular sclerosis of unspecified site 
55303 Hodgkin's nodular sclerosis of head; face and neck 
67506 Hodgkin's nodular sclerosis of intrathoracic lymph nodes 
61149 Hodgkin's nodular sclerosis of intra-abdominal lymph nodes 
65483 Hodgkin's nodular sclerosis of lymph nodes of axilla and arm 
105472 Hodgkin's disease; nodular sclerosis of spleen 
19140 Hodgkin's nodular sclerosis of lymph nodes of multiple sites 
63054 Hodgkin's disease; nodular sclerosis nos 
49605 Hodgkin's disease; mixed cellularity 
97863 Hodgkin's disease; mixed cellularity of unspecified site 
94407 Hodgkin's mixed cellularity of lymph nodes head; face; neck 
58684 Hodgkin's mixed cellularity of intrathoracic lymph nodes 
94005 Hodgkin's disease; mixed cellularity nos 
67703 Hodgkin's disease; lymphocytic depletion 
95049 Hodgkin's lymphocytic depletion of unspecified site 
63625 Hodgkin's lymphocytic depletion lymph nodes axilla and arm 
101715 Hodgkin's disease; lymphocytic depletion of spleen 
107032 Hodgkin's lymphocytic depletion lymph nodes multiple sites 
101530 Hodgkin's disease; lymphocytic depletion nos 
53397 Hodgkin's disease nos 
61662 Hodgkin's disease nos; unspecified site 
59778 Hodgkin's disease nos of lymph nodes of head; face and neck 
59755 Hodgkin's disease nos of intrathoracic lymph nodes 
107804 Hodgkin's disease nos of intra-abdominal lymph nodes 
91900 Hodgkin's disease nos of lymph nodes of axilla and arm 
99012 Hodgkin's disease nos of lymph nodes inguinal region and leg 





97746 Hodgkin's disease nos of lymph nodes of multiple sites 
42461 Hodgkin's disease nos 
33333 Other malignant neoplasm of lymphoid and histiocytic tissue 
5179 Nodular lymphoma (brill - symmers disease) 
66327 Nodular lymphoma of unspecified site 
45264 Nodular lymphoma of lymph nodes of head; face and neck 
105203 Nodular lymphoma of intrathoracic lymph nodes 
92068 Nodular lymphoma of intra-abdominal lymph nodes 
94995 Nodular lymphoma of lymph nodes of inguinal region and leg 
58082 Nodular lymphoma of lymph nodes of multiple sites 
65701 Nodular lymphoma nos 
12006 Mycosis fungoides 
95949 Mycosis fungoides of unspecified site 
91674 Mycosis fungoides of intra-abdominal lymph nodes 
96379 Mycosis fungoides of lymph nodes of axilla and upper limb 
72714 Mycosis fungoides of lymph nodes of inguinal region and leg 
95012 Mycosis fungoides of lymph nodes of multiple sites 
38005 Mycosis fungoides nos 
35014 Sezary's disease 
100532 Sezary's disease nos 
44267 Malignant histiocytosis 
69497 Malignant histiocytosis of unspecified site 
94415 Malignant histiocytosis of lymph nodes head; face and neck 
65642 Malignant histiocytosis of intra-abdominal lymph nodes 
58871 Malignant histiocytosis nos 
27330 Leukaemic reticuloendotheliosis 
5137 Leukaemic reticuloendotheliosis 
65122 Leukaemic reticuloendotheliosis of unspecified sites 
65123 Leukaemic reticuloend of intra-abdominal lymph nodes 
73777 Leukaemic reticuloendotheliosis nos 
34926 Letterer-siwe disease 
4870 Histiocytosis x (acute; progressive) 
102715 Letterer-siwe disease of unspecified sites 
102158 Letterer-siwe disease of intrathoracic lymph nodes 
54083 Letterer-siwe disease of lymph nodes of multiple sites 
47204 Letterer-siwe disease nos 
15036 Malignant mast cell tumours 
103900 Mast cell malignancy of unspecified site 
100615 Mast cell malignancy of lymph nodes inguinal region and leg 
31324 Mast cell malignancy of lymph nodes of multiple sites 
89657 Malignant mast cell tumour nos 
3604 Non - hodgkin's lymphoma 
28639 Follicular non-hodgkin's small cleaved cell lymphoma 
70842 Follicular non-hodg mixed sml cleavd & lge cell lymphoma 
49262 Follicular non-hodgkin's large cell lymphoma 
50668 Diffuse non-hodgkin's small cell (diffuse) lymphoma 
108182 Diffuse non-hodgkin's small cleaved cell (diffuse) lymphoma 
50695 Diffuse non-hodgkin mixed sml & lge cell (diffuse) lymphoma 
53551 Diffuse non-hodgkin's immunoblastic (diffuse) lymphoma 
17460 Diffuse non-hodgkin's lymphoblastic (diffuse) lymphoma 
65180 Diffuse non-hodgkin's lymphoma undifferentiated (diffuse) 
31576 Other types of follicular non-hodgkin's lymphoma 
21549 Follicular non-hodgkin's lymphoma 
17182 Follicular lymphoma nos 
70509 Diffuse non-hodgkin's centroblastic lymphoma 





39798 Diffuse non-hodgkin's lymphoma; unspecified 
17887 Malignant lymphoma otherwise specified 
90201 T-zone lymphoma 
57737 Lymphoepithelioid lymphoma 
12464 Peripheral t-cell lymphoma 
62437 Malignant reticulosis 
58962 Malignant immunoproliferative small intestinal disease 
95630 True histiocytic lymphoma 
44318 Oth and unspecif peripheral & cutaneous t-cell lymphomas 
12335 Malignant lymphoma nos 
57427 Malignant lymphoma nos of unspecified site 
50696 Malignant lymphoma nos of lymph nodes of head; face and neck 
72725 Malignant lymphoma nos of intrathoracic lymph nodes 
42579 Malignant lymphoma nos of intra-abdominal lymph nodes 
34089 Malignant lymphoma nos of lymph nodes of axilla and arm 
63105 Malignant lymphoma nos of lymph node inguinal region and leg 
71262 Malignant lymphoma nos of intrapelvic lymph nodes 
60092 Malignant lymphoma nos of spleen 
15504 Malignant lymphoma nos of lymph nodes of multiple sites 
15027 Malignant lymphoma nos 
65434 Malignant neoplasms of lymphoid and histiocytic tissue nos 
108037 Unspec malig neop lymphoid/histiocytic of unspecified site 
64427 Unspec malig neop lymphoid/histiocytic lymph node head/neck 
93384 Unspec malig neop lymphoid/histiocytic of intrathoracic node 
103353 Unspec malig neop lymphoid/histiocytic intra-abdominal nodes 
107638 Unspec malig neop lymphoid/histiocytic lymph node axilla/arm 
71609 Unspec malig neop lymphoid/histiocytic nodes inguinal/leg 
101465 Unspec malig neop lymphoid/histiocytic of multiple sites 
95792 Lymphoid and histiocytic malignancy nos 
4944 Multiple myeloma 
43552 Kahler's disease 
15211 Myelomatosis 
22158 Malignant plasma cell neoplasm; extramedullary plasmacytoma 
19028 Solitary myeloma 
21329 Plasmacytoma nos 
46042 Lambda light chain myeloma 
39187 Plasma cell leukaemia 
19372 Lymphoid leukaemia 
4222 Lymphatic leukaemia 
4251 Acute lymphoid leukaemia 
8625 Chronic lymphoid leukaemia 
27790 Chronic lymphatic leukaemia 
72774 Subacute lymphoid leukaemia 
49725 Other lymphoid leukaemia 
31586 Prolymphocytic leukaemia 
37461 Adult t-cell leukaemia 
38331 Other lymphoid leukaemia nos 
38914 Lymphoid leukaemia nos 
7176 Myeloid leukaemia 
4413 Acute myeloid leukaemia 
10726 Chronic myeloid leukaemia 
31701 Chronic granulocytic leukaemia 
100786 Chronic eosinophilic leukaemia 
102783 Chronic neutrophilic leukaemia 
27520 Chronic myeloid leukaemia nos 





70724 Myeloid sarcoma 
52327 Chloroma 
39629 Granulocytic sarcoma 
27664 Acute promyelocytic leukaemia 
66089 Other myeloid leukaemia nos 
33344 Myeloid leukaemia nos 
35875 Monocytic leukaemia 
67700 Monoblastic leukaemia 
19974 Acute monocytic leukaemia 
27458 Chronic monocytic leukaemia 
101606 Subacute monocytic leukaemia 
99015 Other monocytic leukaemia 
103645 Other monocytic leukaemia nos 
93342 Monocytic leukaemia nos 
37272 Other specified leukaemia 
42539 Acute erythraemia and erythroleukaemia 
27340 Di guglielmo's disease 
37468 Chronic erythraemia 
57671 Megakaryocytic leukaemia 
65777 Thrombocytic leukaemia 
65721 Mast cell leukaemia 
50858 Acute panmyelosis 
28276 Acute myelofibrosis 
94174 Other and unspecified leukaemia 
72197 Lymphosarcoma cell leukaemia 
99413 Other and unspecified leukaemia nos 
30632 Other specified leukaemia nos 
25191 Leukaemia of unspecified cell type 
4072 Acute leukaemia nos 
16416 Chronic leukaemia nos 
54793 Subacute leukaemia nos 
34692 Other leukaemia of unspecified cell type 
4250 Leukaemia nos 
20440 Myelomonocytic leukaemia 
61500 Acute myelomonocytic leukaemia 
22050 Chronic myelomonocytic leukaemia 
104475 Subacute myelomonocytic leukaemia 
30646 Malignant neoplasm lymphatic or haematopoietic tissue os 
49301 Malignant neoplasm lymphatic or haematopoietic tissue nos 
50290 Kaposi's sarcoma of lymph nodes 
43312 Myeloma - solitary 
38321 Plasmacytoma nos 
21868 [m]neoplasm, malignant 
8627 [m]tumour cells, malignant 
22156 [m]malignant tumour, small cell type 
24511 [m]malignant tumour, giant cell type 
32213 [m]malignant tumour, fusiform cell type 
8695 [m]carcinoma nos 
16692 [m]carcinomatosis 
57336 [m]epithelioma, malignant 
25961 [m]large cell carcinoma nos 
21609 [m]carcinoma, undifferentiated type, nos 
12609 [m]carcinoma, anaplastic type, nos 
26413 [m]pleomorphic carcinoma 
48048 [m]giant cell and spindle cell carcinoma 





6966 [m]spindle cell carcinoma 
54276 [m]pseudosarcomatous carcinoma 
69300 [m]polygonal cell carcinoma 
61984 [m]spheroidal cell carcinoma 
9291 [m]small cell carcinoma nos 
66541 [m]round cell carcinoma 
9156 [m]oat cell carcinoma 
67970 [m]small cell carcinoma, fusiform cell type 
30988 [m]small cell carcinoma, intermediate cell 
21217 [m]small cell-large cell carcinoma 
3028 [m]basal cell carcinoma nos 
59919 [m]multicentric basal cell carcinoma 
9885 [m]basal cell carcinoma, morphoea type 
29524 [m]basal cell carcinoma, fibroepithelial type 
35457 [m]basosquamous carcinoma 
13574 [m]metatypical carcinoma 
2272 [m]adenocarcinomas 
8930 [m]adenocarcinoma nos 
48223 [m]scirrhous adenocarcinoma 
27440 [m]linitis plastica 
71895 [m]superficial spreading adenocarcinoma 
28272 [m]adenocarcinoma, intestinal type 
59240 [m]carcinoma, diffuse type 
63102 [m]islet cell carcinoma 
95609 [m]insulinoma, malignant 
32294 [m]glucagonoma, malignant 
98825 [m]mixed islet cell and exocrine adenocarcinoma 
49629 [m]gastrinoma, malignant 
70516 [m]biliary tract adenomas and adenocarcinomas 
98781 [m]trabecular adenocarcinoma 
33775 [m]adenoid cystic carcinoma 
34879 [m]cylindroid adenocarcinoma 
50140 [m]cribriform carcinoma 
94083 [m]solid carcinoma nos 
34110 [m]carcinoid tumour, malignant 
23081 Carcinoid bronchial adenoma 
100625 [m]carcinoid tumour, nonargentaffin, malignant 
55468 [m]mucocarcinoid tumour, malignant 
56794 Adenocarcinoid tumour 
26253 [m]neuroendocrine carcinoma 
32641 [m]merkel cell carcinoma 
10668 [m]renal cell carcinoma 
52266 [m]grawitz tumour 
15419 [m]hypernephroma 
34096 [m]granular cell carcinoma 
60775 [m]adrenal cortical carcinoma 
16902 [m]basal cell adenocarcinoma 
49900 [m]klatskin's tumour 
71627 [m]sweat gland adenocarcinoma 
28625 [m]mucoepidermoid carcinoma 
38442 [m]serous cystadenocarcinoma, nos 
65051 [m]papillary cystadenocarcinoma, nos 
44930 [m]papillary serous cystadenocarcinoma 
95150 [m]serous surface papillary carcinoma 
51656 [m]mucinous cystadenocarcinoma nos 





54749 [m]papillary mucinous cystadenocarcinoma 
44074 [m]mucin-producing adenocarcinoma 
39038 [m]signet ring carcinoma 
61588 [m]signet ring cell carcinoma 
94438 [m]signet ring carcinoma nos 
37688 [m]acinar cell carcinoma 
12580 [m]adenosquamous carcinoma 
16146 [m]adenocarcinoma with squamous metaplasia 
8524 [m]adenoacanthoma 
42553 [m]adenocarcinoma with cartilaginous and osseous metaplasia 
94810 [m]adenocarcinoma with spindle cell metaplasia 
66000 [m]adenocarcinoma with apocrine metaplasia 
38770 [m]epithelial-myoepithelial carcinoma 
31609 [m]granulosa cell tumour, malignant 
29580 [m]sertoli cell carcinoma 
95373 [m]leydig cell tumour, malignant 
95818 [m]paraganglioma, malignant 
65047 [m]phaeochromocytoma, malignant 
50605 [m]glomangiosarcoma 
105166 [m]glomoid sarcoma 
8085 [m]sarcoma nos 
31026 [m]spindle cell sarcoma 
97463 [m]giant cell sarcoma (except of bone) 
46581 [m]pleomorphic cell sarcoma 
58837 [m]small cell sarcoma 
69844 [m]round cell sarcoma 
62396 [m]epithelioid cell sarcoma 
28599 [m]liposarcoma nos 
101923 [m]fibroliposarcoma 
28628 [m]liposarcoma, well differentiated type 
56676 [m]myxoid liposarcoma 
60127 [m]myxoliposarcoma 
103708 [m]round cell liposarcoma 
55947 [m]pleomorphic liposarcoma 
59651 [m]mixed type liposarcoma 
7856 [m]dedifferentiated liposarcoma 
31421 [m]rhabdomyosarcoma nos 
57505 [m]pleomorphic rhabdomyosarcoma 
105944 [m]mixed cell rhabdomyosarcoma 
48275 [m]embryonal rhabdomyosarcoma 
63247 [m]sarcoma botryoides 
42082 [m]alveolar rhabdomyosarcoma 
34030 [m]endometrial stromal sarcoma 
66607 [m]mixed tumour, malignant, nos 
21173 [m]mullerian mixed tumour 
21681 Nephroblastoma nos 
36870 [m]adenosarcoma 
17314 Wilms' tumour 
105862 Mesenchymal nephroblastoma 
57677 [m]hepatoblastoma 
19334 [m]carcinosarcoma nos 
67934 [m]carcinosarcoma, embryonal type 
61082 Pneumoblastoma 
98797 [m]embryonal sarcoma 
63518 [m]adenosarcoma 





17212 [m]rhabdoid sarcoma 
18771 [m]clear cell sarcoma of kidney 
48348 Pulmonary blastoma 
70383 [m]brenner tumour, malignant 
59251 [m]cystosarcoma phyllodes, malignant 
27509 [m]mesothelioma, malignant 
47734 [m]epithelioid mesothelioma, malignant 
86820 [m]mesothelioma, biphasic type, malignant 
32191 [m]dysgerminoma 
7476 [m]seminomas 
28941 [m]embryonal carcinoma nos 
37621 [m]endodermal sinus tumour 
55658 Orchioblastoma 
20350 [m]yolk sac tumour 
65861 [m]dermoid cyst with malignant transformation 
67712 [m]choriocarcinoma 
54627 [m]choriocarcinoma combined with teratoma 
29945 [m]malignant teratoma, trophoblastic 
62348 [m]haemangiosarcoma 
22650 [m]angiosarcoma 
27439 [m]kaposi's sarcoma 
38481 [m]epithelioid haemangioendothelioma, malignant 
57729 [m]lymphangiosarcoma 
99665 [m]juxtacortical osteogenic sarcoma 
63571 [m]parosteal osteosarcoma 
105275 [m]periosteal osteogenic sarcoma 
7941 [m]chondrosarcoma nos 
68220 [m]fibrochondrosarcoma 
63659 [m]juxtacortical chondrosarcoma 
98559 [m]chondroblastoma, malignant 
52684 [m]mesenchymal chondrosarcoma 
68956 [m]giant cell tumour of bone, malignant 
50859 [m]giant cell bone sarcoma 
31673 [m]osteoclastoma, malignant 
99797 [m]malignant giant cell tumour of soft parts 
4473 [m]ewing's sarcoma 
49023 [m]endothelial bone sarcoma 
38593 [m]adamantinoma of long bones 
67430 [m]tibial adamantinoma 
72443 [m]odontogenic tumour, malignant 
93175 [m]intraosseous carcinoma 
46741 [m]ameloblastic odontosarcoma 
97593 [m]ameloblastoma, malignant 
100267 [m]adamantinoma, malignant 
68730 [m]ameloblastic fibrosarcoma 
98483 [m]odontogenic fibrosarcoma 
50151 Pineoblastoma 
21758 [m]chordoma 
31574 [m]glioma, malignant 
34252 [m]gliosarcoma 
68808 Mixed glioma 
39386 Mixed glioma 
52751 [m]ependymoma, anaplastic type 
46769 [m]ependymoblastoma 
27748 Astrocytic glioma 





45531 Gemistocytic astrocytoma 
27846 Fibrillary astrocytoma 
30273 Pilocytic astrocytoma 
61783 Juvenile astrocytoma 
98800 Piloid astrocytoma 
103047 Spongioblastoma nos 
23083 [m]glioblastoma nos 
9575 [m]glioblastoma multiforme 
66064 [m]giant cell glioblastoma 
27744 Oligodendroglioma nos 
49186 [m]oligodendroglioma, anaplastic type 
46404 Oligodendroblastoma 
34763 [m]medulloblastoma nos 
65952 Desmoplastic medulloblastoma 
31767 [m]medullomyoblastoma 
37473 [m]cerebellar sarcoma nos 
41695 [m]primitive neuroectodermal tumour 
2123 Neuroblastoma nos 
67288 [m]medulloepithelioma nos 
107681 [m]teratoid medulloepithelioma 
28836 [m]retinoblastomas 
51878 [m]aesthesioneuroblastoma 
39388 [m]olfactory neuroblastoma 
62941 [m]neurofibrosarcoma 
69981 [m]neurilemmoma, malignant 
37477 [m]schwannoma, malignant 
40492 [m]triton tumour, malignant 
71869 [m]alveolar soft part sarcoma 
17178 [m]lymphomas, nos or diffuse 
36114 [m]malignant lymphoma nos 
1483 [m]lymphoma nos 
23711 [m]malignant lymphoma, diffuse nos 
16460 [m]malignant lymphoma, non hodgkin's type 
3371 [m]non hodgkins lymphoma 
71117 [m]malignant lymphoma, undifferentiated cell type nos 
46931 [m]malignant lymphoma, stem cell type 
69301 [m]malignant lymphoma, convoluted cell type nos 
99655 [m]lymphosarcoma nos 
41754 [m]malignant lymphoma, lymphoplasmacytoid type 
48253 [m]malignant lymphoma, immunoblastic type 
68964 [m]malignant lymphoma, centroblastic-centrocytic, diffuse 
41841 [m]malignant lymphoma, follicular centre cell nos 
69980 [m]malignant lymphoma, lymphocytic, well differentiated nos 
21463 [m]lymphocytic lymphoma nos 
60504 [m]lymphocytic lymphosarcoma nos 
51852 [m]malig lymphoma, lymphocytic, intermediate different nos 
39906 [m]malignant lymphoma, centrocytic 
72196 [m]malignant lymphoma, lymphocytic, poorly different nos 
67203 [m]lymphoblastic lymphosarcoma nos 
34352 [m]lymphoblastic lymphoma nos 
52591 Lymphoblastoma nos 
72241 [m]prolymphocytic lymphosarcoma 
60275 [m]malignant lymphoma, centroblastic type nos 
66603 [m]malig lymphoma, follicular centre cell, non-cleaved nos 
46877 [m]malignant lymphoma, small lymphocytic nos 





61251 [m]malign lymphoma,lymphocytic,intermediate differn, diffuse 
71652 [m]malignant lymphoma, mixed small and large cell, diffuse 
58015 [m]malignant lymphomatous polyposis 
33869 [m]malignant lymphoma, large cell, diffuse nos 
63994 [m]malignant lymphoma, large cell, cleaved, diffuse 
71619 [m]malignant lymphoma, large cell, noncleaved, diffuse 
51680 [m]malignant lymphoma, small cell, noncleaved, diffuse 
51895 [m]lymphoma, diffuse or nos 
106137 [m]reticulosarcomas 
20710 [m]hodgkin's disease 
20437 [m]lymphomas, nodular or follicular 
63699 [m]malignant lymphoma, nodular nos 
64947 [m]brill - symmers' disease 
27562 [m]follicular lymphosarcoma nos 
49253 [m]giant follicular lymphoma 
98961 [m]malignant lymphoma, centroblastic-centrocytic, follicular 
106970 [m]malig lymphoma, lymphocytic, well differentiated,nodular 
39883 [m]malig lymp, follicular centre cell, cleaved, follicular 
97852 [m]malignant lymphoma, centroblastic type, follicular 
58953 [m]malig lymp,follicular centre cell,noncleaved,follicular 
40513 [m]lymphoma, nodular or follicular nos 
46967 [m]mycosis fungoides 
63239 [m]malignant histiocytosis 
59593 [m]letterer - siwe disease 
45768 [m]acute progressive histiocytosis x 
57544 [m]true histiocytic lymphoma 
40766 [m] peripheral t-cell lymphoma nos 
31492 [m] monocytoid b-cell lymphoma 
16774 [m] cutaneous lymphoma 
18383 [m] large cell lymphoma 
9172 [m]waldenstrom's macroglobulinaemia 
31671 [m]plasma cell myeloma 
18744 [m]multiple myeloma 
3672 [m]myeloma nos 
53647 [m]myelomatosis 
39490 [m]plasmacytic myeloma 
63864 Plasmacytoma nos 
102164 [m]monostotic myeloma 
73135 [m]solitary myeloma 
99702 [m]plasma cell tumour, malignant 
94239 [m]mast cell sarcoma 
67339 [m]malignant mastocytosis 
4637 [m]leukaemias 
40420 [m]leukaemias unspecified 
41734 [m]leukaemia nos 
6316 [m]acute leukaemia nos 
22071 [m]blast cell leukaemia 
64963 [m]blastic leukaemia 
63570 [m]stem cell leukaemia 
72179 [m]subacute leukaemia nos 
31750 [m]chronic leukaemia nos 
72310 [m]aleukaemic leukaemia nos 
59929 [m]leukaemia unspecified, nos 
48155 [m]lymphoid leukaemias 
12146 [m]lymphoid leukaemia nos 





37410 [m]acute lymphoid leukaemia 
41500 [m]chronic lymphoid leukaemia 
46048 [m]prolymphocytic leukaemia 
50928 [m]burkitt's cell leukaemia 
29335 [m]adult t-cell leukaemia/lymphoma 
64618 [m]plasma cell leukaemias 
46444 [m]erythroleukaemias 
70935 [m]erythroleukaemia 
100927 [m]erythroleukaemia nos 
35697 [m]myeloid leukaemias 
71850 [m]myeloid leukaemia nos 
37723 [m]granulocytic leukaemia nos 
54585 [m]acute myeloid leukaemia 
106483 [m]subacute myeloid leukaemia 
52942 [m]chronic myeloid leukaemia 
66694 [m]naegeli-type monocytic leukaemia 
57316 [m]acute promyelocytic leukaemia 
46263 [m]acute myelomonocytic leukaemia 
48049 [m]chronic myelomonocytic leukaemia 
62330 [m]other myeloid leukaemia nos 
106197 [m]basophilic leukaemia 
57713 [m]eosinophilic leukaemias 
71377 [m]eosinophilic leukaemia 
107773 [m]eosinophilic leukaemia nos 
73088 [m]monocytic leukaemia nos 
73066 [m]miscellaneous leukaemias 
72222 [m]megakaryocytic leukaemia 
69299 [m]thrombocytic leukaemia 
93944 [m]chloroma 
5915 [m]hairy cell leukaemia 
49327 [m]acute megakaryoblastic leukaemia 
108316 [m]miscellaneous leukaemia nos 
42297 [m]leukaemia nos 
31749 [m]monocytoid b-cell lymphoma 
27965 [m]angiocentrict-cell lymphoma 
58973 [x]malignant neoplasm of lip; oral cavity and pharynx 
35180 [x]malignant neoplasm of digestive organs 
43490 [x]other specified carcinomas of liver 
45766 [x]malignant neoplasm of intestinal tract; part unspecified 
49292 [x]malignant neoplsm/ill-defin sites within digestive system 
35325 [x]malignant neoplasm of respiratory and intrathoracic orga 
40595 [x]malignant neoplasm of bronchus or lung; unspecified 
66444 [x]malignant neoplasm/overlap lesion/heart;mediastinm?? 
99096 [x]malignant neopl/overlapping les/resp???? Organs 
86997 [x]malignant neoplasm/ill-defined sites within resp system 
50292 [x]malignant neoplasm of mediastinum; part unspecified 
40749 [x]malignant neoplasm of bone and articular cartilage 
73296 [x]malignant neoplasm/bones??? Cartilage/limb;unspfd 
63300 [x]malignant neoplasm/overlap lesion/bone??? Cartilage 
43151 [x]malignant neoplasm/bone??? Cartilage; unspecified 
19144 [x]melanoma and other malignant neoplasms of skin 
56925 [x]malignant melanoma of other???? Parts of face 
19444 [x]malignant melanoma of skin; unspecified 
57184 [x]oth malignant neoplasm/skin of oth??? Parts of face 
56121 [x]malignant neoplasm of skin; unspecified 





67034 [x]mesothelioma of other sites 
21715 [x]mesothelioma of lung 
30526 [x]mesothelioma; unspecified 
93665 [x]kaposi's sarcoma; unspecified 
101668 [x]malignant neoplasm/peripheral nerves of trunk;unspecified 
105072 [x]mal neoplasm/overlap les/periph nerv??? Nerv systm 
95671 [x]malignant neoplasm of peritoneum; unspecified 
91896 [x]mal neoplasm/connective? Tissue of trunk;unspecified 
91457 [x]malignant neoplasm/connective  soft tissue;unspecified 
60162 [x]malignant neoplasm overlapping lesion of skin 
12499 [x]malignant neoplasm of breast 
40598 [x]malignant neoplasm of female genital organs 
64497 [x]malignant neoplasm of uterine adnexa; unspecified 
57756 [x]malignant neoplasm/other specified female genital organs 
55588 [x]malignant neoplasm of female genital organ; unspecified 
40671 [x]malignant neoplasm of male genital organs 
57191 [x]malignant neoplasm/other specified male genital organs 
45262 [x]malignant neoplasm of male genital organ; unspecified 
35113 [x]malignant neoplasm of urinary tract 
45260 [x]malignant neoplasm of urinary organ; unspecified 
35285 [x]malignant neoplasm of eye; brain and other parts of cent 
68027 [x]malignant neoplasm/other and unspecified cranial nerves 
41515 [x]malignant neoplasm/central nervous system; unspecified 
63925 [x]malignant neoplasm of meninges; unspecified 
47633 [x]malig neopl; overlap lesion brain & other part of cns 
39027 [x]malignant neoplasm of other specified sites 
40740 [x]malignant neoplasms of lymphoid; haematopoietic and rela 
43415 [x]other hodgkin's disease 
67518 [x]other types of follicular non-hodgkin's lymphoma 
98596 [x]other types of diffuse non-hodgkin's lymphoma 
64336 [x]other specified types of non-hodgkin's lymphoma 
102688 [x]other malignant immunoproliferative diseases 
67029 [x]other lymphoid leukaemia 
61693 [x]other myeloid leukaemia 
89762 [x]other monocytic leukaemia 
89329 [x]other specified leukaemias 
65165 [x]other leukaemia of unspecified cell type 
105025 [x]oth spcf mal neoplsm/lymphoid;haematopoietic? Tissue 
72500 [x]mal neoplasm/lymphoid,haematopoietic+related tissu,unspcf 
64515 [x]diffuse non-hodgkin's lymphoma; unspecified 
63375 [x]unspecified b-cell non-hodgkin's lymphoma 
8649 [x]non-hodgkin's lymphoma; unspecified type 
7940 [x]non-hodgkin's lymphoma nos 
63598 [x]malignant neoplasms/independent (primary) multiple sites 
64897 [x]malignant neoplasms/independent(primary)multiple sites 
10335 Cancer confirmed 
32351 Squamous cell carcinoma antigen level 
52946 Bone marrow: myeloma cells 
10178 Gleason grading of prostate cancer 
18503 Gleason prostate grade 2-4 (low) 
18612 Gleason prostate grade 5-7 (medium) 
26081 Gleason prostate grade 8-10 (high) 
37793 Figo staging of gynaecological malignancy 
104609 Clark melanoma level 2 
102116 Clark melanoma level 4 





18270 Excision malignant skin tumour 
11834 Excision biopsy of rodent ulcer 
93402 Excision biopsy of basal cell carcinoma 
26197 Administration of cancer treatment 
32411 Cancer treatment started 
54336 Cancer hospital treatment completed 
10292 Cancer diagnosis discussed 
11075 Cancer diagnosis discussed with significant other 
22382 Cancer diagnosis discussed with patient 
44952 Date cancer diagnosis received in primary care 
26076 Cancer pain and symptom management 
59054 Cancer rehabilitation and readaption 
94000 Bowel cancer detected by national screening programme 
67575 Hiv disease resulting in unspecified malignant neoplasm 
27853 Hiv disease resulting in kaposi's sarcoma 
108054 Hiv disease resulting in kaposi sarcoma 
105324 Hiv disease resulting in multiple malignant neoplasms 
51708 Hiv dis reslt/oth mal neopl/lymph,h'matopoetc+reltd tissu 
98142 Siewert type i adenocarcinoma 
97499 Siewert type ii adenocarcinoma 
96094 Siewert type iii adenocarcinoma 
101700 Hereditary nonpolyposis colon cancer 
96445 Malignant neoplasm of turbinate 
92382 Malignant neoplasm of fourth metatarsal bone 
876 Basal cell carcinoma 
1940 Rodent ulcer 
3445 Epithelioma basal cell 
93352 Squamous cell carcinoma of skin 
93490 Squamous cell carcinoma of skin nos 
105488 Local recurrence of malignant tumour of breast 
91509 Malignant neoplasm of descended testis nos 
105388 Local recurrence of malignant tumour of urinary bladder 
100083 Neuroblastoma 
26034 Other malignant neoplasm nos 
51352 Malignant neoplasms of independent (primary) multiple sites 
11035 Primary malignant neoplasm of unknown site 
104324 Malignant tumour of unknown origin 
54267 Malignant neoplasm of unspecified site nos 
104291 Hodgkin lymphoma 
104895 Nodular lymphocyte predominant hodgkin lymphoma 
105841 Nodular sclerosis classical hodgkin lymphoma 
106597 Lymphocyte-rich classical hodgkin lymphoma 
104484 Other classical hodgkin lymphoma 
106349 Hodgkin lymphoma nos 
87335 Hairy cell leukaemia 
104391 Non-hodgkin lymphoma 
95715 Mucosa-associated lymphoma 
101114 Diffuse non-hodgkin's large cell lymphoma 
102594 Diffuse large b-cell lymphoma 
105966 Extranod marg zone b-cell lymphom mucosa-assoc lymphoid tiss 
105038 Mediastinal (thymic) large b-cell lymphoma 
104152 Follicular lymphoma 
105889 Follicular lymphoma grade 1 
105095 Follicular lymphoma grade 2 
107166 Follicular lymphoma grade 3 





107973 Follicular lymphoma grade 3b 
106969 Diffuse follicle centre lymphoma 
106063 Other types of follicular lymphoma 
105335 Sarcoma of dendritic cells 
105762 Unifocal langerhans-cell histiocytosis 
105083 Histiocytic sarcoma 
105085 T/nk-cell lymphoma 
105559 Anaplastic large cell lymphoma, alk-positive 
105955 Anaplastic large cell lymphoma, alk-negative 
104862 Cutaneous t-cell lymphoma 
107949 Hepatosplenic t-cell lymphoma 
105709 Enteropathy-associated t-cell lymphoma 
105925 Subcutaneous panniculitic t-cell lymphoma 
105375 Blastic nk-cell lymphoma 
105636 Angioimmunoblastic t-cell lymphoma 
104934 Other mature t/nk-cell lymphoma 
106884 Nonfollicular lymphoma 
106867 Non-follicular lymphoma 
104386 Small cell b-cell lymphoma 
104620 Mantle cell lymphoma 
104412 Lymphoblastic (diffuse) lymphoma 
104418 Solitary plasmacytoma 
104325 B-cell acute lymphoblastic leukaemia 
104328 B-cell chronic lymphocytic leukaemia 
107017 Chronic lymphocytic leukaemia of b-cell type 
107052 Clinical stage a chronic lymphocytic leukaemia 
106924 Clinical stage b chronic lymphocytic leukaemia 
107163 Clinical stage c chronic lymphocytic leukaemia 
107643 T-cell prolymphocytic leukaemia 
104939 Adult t-cell lymphoma/leukaemia (htlv-1-associated) 
105957 Chronic myeloid leukaemia, bcr/abl positive 
107236 Atypical chronic myeloid leukaemia, bcr/abl negative 
104788 Acute myeloblastic leukaemia 
108424 Acute monoblastic leukaemia 
104273 Myelodysplastic and myeloproliferative disease 
105069 Juvenile myelomonocytic leukaemia 
104684 Multiple self-healing epithelioma of ferguson-smith 
5136 Choriocarcinoma 
50569 Neo/uncertn+unknwn behav/lymph,h'matopetc+rel tiss,unspcf 
22267 [m]neoplasm, malig, uncertain whether primary or metastatic 
10541 [m]papillary carcinoma nos 
34395 [m]verrucous carcinoma nos 
43717 [m]verrucous epidermoid carcinoma 
4852 [m]verrucous squamous cell carcinoma 
20807 [m]papillary squamous cell carcinoma 
67912 [m]papillary epidermoid carcinoma 
1624 [m]squamous cell carcinoma nos 
56600 [m]epidermoid carcinoma nos 
57680 [m]spinous cell carcinoma 
94873 [m]squamous cell carcinoma of skin nos 
29787 [m]squamous cell carcinoma, keratinising type nos 
57513 [m]epidermoid carcinoma, keratinising type 
59143 [m]squamous cell carcinoma, large cell, non-keratinising 
41816 [m]squamous cell carcinoma, small cell, non-keratinising 
45458 [m]squamous cell carcinoma, spindle cell type 





33497 [m]squamous cell carcinoma, microinvasive 
45510 [m]lymphoepithelial carcinoma 
102417 [m]superficial basal cell carcinoma 
102547 [m]basal cell carcinoma, nodular 
103440 [m]basal cell carcinoma, micronodular 
103178 [m]basal cell carcinoma, infiltrative 
103066 [m]pigmented basal cell carcinoma 
6436 [m]transitional cell carcinoma nos 
12388 [m]urothelial carcinoma 
100111 [m]schneiderian carcinoma 
58798 [m]transitional cell carcinoma, spindle cell type 
38454 [m]basaloid carcinoma 
65216 [m]cloacogenic carcinoma 
9712 [m]papillary transitional cell carcinoma 
101095 [m]grade 1 (stage pta) papillary urothelial/transit cell ca 
102244 [m]grade 2 (stage pta) papillary urothelial/transit cell ca 
101978 [m]grade 3 (stage pta) papillary urothelial/transit cell ca 
44778 [m]adenocarcinoma in tubulovillous adenoma 
8711 [m]cholangiocarcinoma 
40438 [m]bile duct carcinoma 
41313 [m]bile duct cystadenocarcinoma 
40240 [m]hepatocellular carcinoma nos 
26814 [m]hepatoma, malignant 
25641 [m]liver cell carcinoma 
107299 [m]combined hepatocellular carcinoma and cholangiocarcinoma 
46771 [m]hepatocellular carcinoma, fibrolamellar 
60756 [m]cylindroid bronchial adenoma 
52326 [m]adenocarcinoma in adenomatous polyp 
73434 [m]adenocarcinoma in multiple adenomatous polyps 
60045 [m]tubular adenocarcinoma 
73275 [m]adenocarcinoma in adenomatous polposis coli 
69210 [m]goblet cell tumour 
34015 [m]bronchiolo-alveolar adenocarcinoma 
36530 [m]alveolar cell carcinoma 
16723 [m]bronchiolar carcinoma 
57802 [m]alveolar adenocarcinoma 
35348 [m]papillary adenocarcinoma nos 
67342 [m]adenocarcinoma in villous adenoma 
27849 [m]villous adenocarcinoma 
68456 [m]chromophobe carcinoma 
36876 [m]eosinophil carcinoma 
72277 [m]basophil carcinoma 
40622 [m]mucoid cell carcinoma 
71497 [m]oxyphilic adenocarcinoma 
29008 [m]hurthle cell adenocarcinoma 
53129 [m]oncytic adenocarcinoma 
37354 [m]clear cell adenocarcinoma nos 
21741 [m]follicular adenocarcinoma nos 
21847 [m]follicular carcinoma 
59918 [m]follicular adenocarcinoma, well differentiated type 
61467 [m]follicular adenocarcinoma, trabecular type 
46761 [m]papillary and follicular adenocarcinoma 
68757 [m]nonencapsulated sclerosing carcinoma 
9447 [m]endometrioid carcinoma 






68783 [m]skin appendage carcinoma 
38575 [m]apocrine adenocarcinoma 
34269 [m]sebaceous adenocarcinoma 
34000 [m]cystadenocarcinoma nos 
69978 [m]borderline mucinous cystadenoma of the ovary 
52263 [m]serous cystadenoma, borderline malignancy 
98696 [m]papillary cystadenoma, borderline malignancy 
28396 [m]mucinous cystadenoma, borderline malignancy 
21131 [m]serous cystadenoma, borderline malignancy 
46113 [m]papillary cystadenoma, borderline malignancy 
6203 [m]papillary serous cystadenoma, borderline malignancy 
12497 [m]mucinous adenocarcinoma 
30416 [m]colloid adenocarcinoma 
95008 [m]gelatinous adenocarcinoma 
55429 [m]mucoid adenocarcionoma 
59284 [m]mucous adenocarcinoma 
8351 [m]infiltrating duct carcinoma 
21833 [m]duct carcinoma nos 
30189 [m]intraductal papillary adenocarcinoma with invasion 
39760 [m]infiltrating duct and lobular carcinoma 
58131 [m]comedocarcinoma nos 
40359 [m]juvenile breast carcinoma 
67701 [m]secretory breast carcinoma 
16677 [m]medullary carcinoma nos 
47920 [m]c cell carcinoma 
50946 [m]medullary carcinoma with amyloid stroma 
98883 [m]medullary carcinoma with lymphoid stroma 
12427 [m]lobular carcinoma nos 
7319 [m]infiltrating ductular carcinoma 
32472 [m]inflammatory carcinoma 
12300 [m]paget's disease, mammary 
60803 [m]paget's disease, breast 
42542 [m]paget's disease and infiltrating breast duct carcinoma 
12480 [m]paget's disease and intraductal carcinoma of breast 
24523 [m]paget's disease, extramammary, exc paget's disease bone 
3969 [m]intracystic carcinoma nos 
59415 [m]thymoma, malignant 
579 [m]malignant melanoma nos 
24551 [m]melanocarcinoma 
44157 [m]melanosarcoma nos 
67966 [m]naevocarcinoma 
51353 [m]malignant melanoma, regressing 
58835 [m]desmoplastic melanoma, malignant 
20982 [m]nodular melanoma 
68889 [m]balloon cell melanoma 
17232 [m]amelanotic melanoma 
63574 [m]malignant melanoma in junctional naevus 
62088 [m]malignant melanoma in hutchinson's melanotic freckle 
11922 [m]lentigo maligna melanoma 
22692 [m]acral lentiginous melanoma, malignant 
24208 [m]superficial spreading melanoma 
73251 [m]malignant melanoma in giant pigmented naevus 
23085 [m]epithelioid cell melanoma 
44061 [m]spindle cell melanoma nos 
92293 [m]spindle cell melanoma, type b 





68447 [m]blue naevus, malignant 
31323 [m]fibrosarcoma nos 
8088 [m]fibromyxosarcoma 
95024 [m]infantile fibrosarcoma 
94286 [m]congenital fibrosarcoma 
37680 [m]fibrous histiocytoma, malignant 
96231 [m]fibroxanthoma, malignant 
35034 [m]fibroxanthosarcoma 
26881 [m]dermatofibroma protuberans 
31772 [m]dermatofibrosarcoma nos 
31090 [m]pigmented dermatofibrosarcoma protuberans 
21732 [m]myxosarcoma 
10588 [m]leiomyosarcoma nos 
73916 [m]epithelioid leiomyosarcoma 
64596 [m]myxoid leiomyosarcoma 
67019 [m]angiomyosarcoma 
55268 [m]myosarcoma 
49811 [m]mesodermal mixed tumour 
106889 [m]embryonal hepatoma 
87003 [m]mesenchymoma, malignant 
50379 [m]synovial sarcoma nos 
105073 [m]synovial sarcoma, spindle cell type 
57796 [m]synovial sarcoma, biphasic type 
63286 [m]clear cell sarcoma of tendons and aponeuroses 
104720 [m]sarcomatoid mesothelioma 
21770 [m]mesothelioma, unspecified 
57084 [m]seminoma, anaplastic type 
35223 [m]spermatocytic seminoma 
9859 [m]seminoma nos 
27971 [m]germinoma 
102356 [m]polyembryoma 
33636 [m]teratoma, malignant, nos 
57087 [m]embryonal teratoma 
43865 [m]immature teratoma 
52493 [m]teratoblastoma, malignant 
37542 [m]teratocarcinoma 
61542 [m]malignant teratoma, undifferentiated type 
21682 [m]malignant teratoma, intermediate type 
71301 [m]struma ovarii, malignant 
35071 [m]mixed germ cell tumour 
98322 [m]haemangioendothelioma, malignant 
105296 [m]haemangiopericytoma, malignant 
8660 [m]osteosarcoma nos 
49862 [m]osteoblastic sarcoma 
59310 [m]osteochondrosarcoma 
5052 [m]osteogenic sarcoma nos 
24539 [m]chondroblastic osteosarcoma 
21447 [m]fibroblastic osteosarcoma 
22561 [m]telangiectatic osteosarcoma 
60631 [m]osteosarcoma in paget's disease of bone 
4118 [m]myxoid chondrosarcoma 
29337 [m] small cell osteosarcoma 
12309 [m]gliomas 
8523 [m]glioma nos 
38551 [m]gliomatosis cerebri 





8547 [m]astrocytoma nos 
50235 [m]astroblastoma 
67587 [m]pleomorphic xanthoastrocytoma 
107884 [m]peripheral neuroectodermal tumour 
27653 [m]glioma nos 
54284 [m]neuroepitheliomatous neoplasms 
39121 [m]ganglioneuroblastoma 
97961 [m]neuroepithelioma nos 
103883 [m]retinoblastoma, undifferentiated type 
48952 [m]retinoblastoma nos 
58902 [m]olfactory neurogenic tumour 
106131 [m]olfactory neuroepithelioma 
99491 [m]neuroepitheliomatous neoplasm nos 
27363 [m]meningioma, malignant 
60347 [m]leptomeningeal sarcoma 
96798 [m]meningothelial sarcoma 
106134 [m]meningeal sarcomatosis 
72433 [m]reticulosarcoma nos 
49825 [m]reticulum cell sarcoma nos 
100544 [m]reticulosarcoma, nodular 
61997 [m]hodgkin's disease nos 
101429 [m]lymphogranuloma, malignant 
56041 [m]hodgkin's disease, lymphocytic predominance 
65584 [m]hodgkin,s disease, lymphocytic predominance, diffuse 
31537 [m]hodgkin,s disease, lymphocytic predominance, nodular 
51285 [m]hodgkin's disease, mixed cellularity 
96183 [m]hodgkin's disease,lymphocytic depletion,diffuse fibrosis 
42198 [m]hodgkin's disease, nodular sclerosis nos 
40508 [m]hodgkin,s disease, nodular sclerosis, lymphocytic predom 
64343 [m]hodgkin,s disease, nodular sclerosis, mixed cellularity 
31741 [m]hodgkin,s disease, nodular sclerosis, lymphocytic deplet 
99200 [m]hodgkin's disease, nodular sclerosis, cellular phase 
89230 [m]hodgkin's granuloma 
42769 [m]hodgkin's disease nos 
95464 [m]mycosis fungoides 
97756 [m]sezary's disease 
99695 [m]mycosis fungoides nos 
63973 [m]microglioma 
70740 [m]malignant reticulosis 
47330 [m]histiocytic medullary reticulosis 
26135 [m] alpha heavy chain disease 
52593 [m] gamma heavy chain disease 
68353 [m] angioendotheliomatosis 
24317 [m]myelosis nos 
96893 [m]myeloid sarcoma 
98009 [m]granulocytic sarcoma 
102764 [m]acute panmyelosis 
37487 [m]acute myelofibrosis 
101271 [m]acute panmyelosis 
107281 [m]neuroendocrine neoplasm 
98361 [x]kaposi's sarcoma of other sites 
40608 [x]malignant neoplasm of thyroid and other endocrine glands 
64309 [x]malignant neoplasm of endocrine gland, unspecified 
96226 [x]malignant neoplasm/overlap lesion/other+ill-defined sites 
52029 [x]malignant neoplasm without specification of site 





10411 Waldenstrom's macroglobulinaemia 
108235 Waldenstrom macroglobulinaemia 
101350 Alpha heavy chain disease 
99067 Gamma heavy chain disease 
48145 Anaemia in ovarian carcinoma 
30537 Polyneuropathy in malignant disease 
57551 Myasthenic syndrome due to other malignancy 
49482 Myopathy due to malignant disease 
60433 Osteoporosis in multiple myelomatosis 
5069 Meckel's diverticulum 
33781 Meckel's diverticulum nos 
51029 Mast cell disease 
17521 Mastocytosis 
31561 [v]follow-up examination aft surgery for malignant neoplasm 
42509 [v]follow-up exam aft combined treatment for malig neoplasm 
44421 [v]folow-up exam aft other treatment for malignant neoplasm 
36321 [v]folow-up exam aft unspec treatment for malignant neoplasm 
 
Moderate or severe renal disease 
Medcode Description 
103532 [X]Heredtry nephrpthy NEC difus mesangiocapilry glomneph 
56893 Chron neph syn difus mesangial prolifrtiv glomerulonephritis 
57168 Chron nephritic syndrom difuse membranous glomerulonephritis 
65400 Chronic diffuse glomerulonephritis 
4669 Chronic focal glomerulonephritis 
97758 Chronic glomerulonephritis  diseases EC 
15097 Chronic glomerulonephritis NOS 
29013 Chronic kidney disease stage 1 
12586 Chronic kidney disease stage 2 
12566 Chronic kidney disease stage 3 
12479 Chronic kidney disease stage 4 
12585 Chronic kidney disease stage 5 
61494 Chronic membranoproliferative glomerulonephritis 
10809 Chronic membranous glomerulonephritis 
73026 Chronic neph syn difus mesangiocapillary glomerulonephritis 
60857 Chronic nephritic syn diffuse crescentic glomerulonephritis 
57568 Chronic pyelonephritis with medullary necrosis 
99631 Chronic pyelonephritis without medullary necrosis 
65064 Chronic rapidly progressive glomerulonephritis 
67995 Focal membranoproliferative glomerulonephritis 
8828 H/O: nephritis 
41881 Mesangiocapillary glomerulonephritis NEC 
36342 Mesangioproliferative glomerulonephritis NEC 
67193 Nephritis unsp membranoprolif glomerulonephritis lesion 
94350 Nephritis unsp????? glomerulonephritis lesion NOS 
2773 Nephritis; nephrosis and nephrotic syndrome 
21989 Nephrotic syn;diffuse mesangiocapillary glomerulonephritis 
99644 Nephrotic syndrome??????? glomerulonephritis 
63615 Other chronic glomerulonephritis NOS 
34648 Renal dwarfism 
50728 Renal infantilism 
66062 Renal rickets 





61930 [X]Renal failure 
7804 Chronic glomerulonephritis 
512 Chronic renal failure 
6712 End stage renal failure 
56939 Hypokalaemic nephropathy 
6842 Impaired renal function 
25980 Impaired renal function disorder NOS 
12465 Membranoproliferative nephritis unspecified 
10647 Nephritis - chronic 
4850 Nephritis and nephropathy unspecified 
33580 Nephritis and nephropathy unspecified 
30310 Nephrogenic diabetes insipidus 
11875 Nephropathy - chronic 
50804 Other impaired renal function disorder NOS 
68114 Phosphate-losing tubular disorders 
41676 Renal cortical necrosis unspecified 
350 Renal failure unspecified 
45867 Renal medullary necrosis unspecified 
29638 Renal osteodystrophy 
34637 Renal osteodystrophy NOS 
101453 [X]Other chronic tubulo-interstitial nephritis 
96819 [X]Other disorders resulting/impaired renal tubular function 
94842 [X]Renal tubulo-interstitial diseases 
100693 [X]Renal tubulo-interstitial disorders/transplant rejection 
63000 Benign hypertensive heart and renal disease 
10081 Chronic uraemia 
64636 Compensation for renal failure NOS 
11773 Dialysis for renal failure 
24736 Drug/heavy-metal-induced tubulo-interstitial and tub conditn 
53852 End stage renal failure 
8330 End-stage renal disease 
112094 Failed attempted abortion with renal failure 
8668 Glomerular disease 
7190 Glomerulosclerosis 
2996 Haemodialysis NEC 
57987 Hyperten heart&renal dis+both(congestv)heart and renal fail 
63466 Hypertensive heart and renal disease 
68659 Hypertensive heart and renal disease NOS 
28684 Hypertensive heart and renal disease with renal failure 
21837 Hypertensive heart&renal dis wth (congestive) heart failure 
4668 Hypertensive renal disease 
32423 Hypertensive renal disease with renal failure 
8919 Impaired renal function disorder 
8037 Insertion of ambulatory peritoneal dialysis catheter 
30709 Insertion of temporary peritoneal dialysis catheter 
28158 Kidney dialysis with complication, without blame 
39598 Kidney failure as a complication of care 
54990 Kidney transplant with complication, without blame 
67232 Malignant hypertensive heart and renal disease 
39649 Malignant hypertensive renal disease 
5291 Membranous nephritis unspecified 
31402 Necrotising renal papillitis 
15780 Nephritis, nephrosis and nephrotic syndrome NOS 
11873 Nephropathy, unspecified 
2999 Nephrotic syndrome 





48022 Other specified compensation for renal failure 
49150 Other specified nephritis, nephrosis or nephrotic syndrome 
2994 Peritoneal dialysis 
59194 Placement ambulatory apparatus- compensate renal failure OS 
56760 Placement ambulatory apparatus compensation renal failure 
36442 Placement ambulatory dialysis apparatus - compens renal fail 
65089 Placement other apparatus- compensate for renal failure NOS 
107901 Placement other apparatus- compensate for renal failure OS 
83513 Placement other apparatus for compensation for renal failure 
23960 Potter's syndrome 
16008 Proliferative nephritis unspecified 
58164 Rapidly progressive nephritis unspecified 
67261 Ren tub-interstitl disordr/systemc connectv tiss disorder 
20073 Renal dialysis 
66714 Renal dialysis with complication, without blame 
63760 Renal failure after crushing 
11554 Renal failure as a complication of care 
41013 Renal function impairment with growth failure 
11787 Renal impairment 
18774 Renal transplant with complication, without blame 
41148 Renal tubulo-interstitial disorder in SLE 
64622 Renal tubulo-interstitial disorder/ neoplastic diseases 
45523 Renal tubulo-interstitial disorders in diseases EC 
48057 Renal tubulo-interstitial disordrs in transplant rejectn 
20516 Salt-losing nephritis 
101756 Thomas intravascular shunt for dialysis 
62520 Unsp nephrit synd, diff endocap prolif glomerulonephritis 
30301 Unsp nephrit synd, diff mesang prolif glomerulonephritis 
36125 Unspecif nephr synd, diff concentric glomerulonephritis 
101666 Unspecified abortion with renal failure 
5182 Unspecified glomerulonephritis NOS 
60128 Unspecified nephritic syndrome, dense deposit disease 




97091 [X]2ndry malignant neoplasm/bladder??? urinary organs 
68332 [X]2ndry malignant neoplasm/oth?? parts/nervous system 
66163 [X]2ndry?? malignant neoplasm lymph nodes/multi regions 
6170 Carcinomatosis 
13569 Disseminated malignancy NOS 
65466 Kaposi's sarcoma of multiple organs 
35186 [X]Malignant neoplasm of ill-defined; secondary and unspeci 
54253 [X]Secondary malignant neoplasm of other specified sites 
57481 [X]Secondary malignant neoplasm/oth? respiratory organs 
88022 [X]Secondary malignant neoplasm/oth?? digestive organs 
5199 Cerebral metastasis 
4403 Liver metastases 
7830 Lymph node metastases 
6471 Metastases of respiratory and/or digestive systems 
18676 Pathological fracture due to metastatic bone disease 
25366 Secondary and unspec malig neop ant mediastinal lymph nodes 





50199 Secondary and unspec malig neop axilla and upper limb LN 
73538 Secondary and unspec malig neop axilla and upper limb LN NOS 
37540 Secondary and unspec malig neop axillary lymph nodes 
62124 Secondary and unspec malig neop bronchopulmonary lymph nodes 
101662 Secondary and unspec malig neop circumflex iliac LN 
41691 Secondary and unspec malig neop coeliac lymph nodes 
18658 Secondary and unspec malig neop common iliac lymph nodes 
68611 Secondary and unspec malig neop deep cervical LN 
61289 Secondary and unspec malig neop deep inguinal lymph nodes 
92703 Secondary and unspec malig neop deep parotid lymph nodes 
95378 Secondary and unspec malig neop diaphragmatic lymph nodes 
69132 Secondary and unspec malig neop external iliac lymph nodes 
61677 Secondary and unspec malig neop inferior mesenteric LN 
69392 Secondary and unspec malig neop inferior tracheobronchial LN 
50904 Secondary and unspec malig neop infraclavicular lymph nodes 
63915 Secondary and unspec malig neop inguinal and lower limb LN 
105953 Secondary and unspec malig neop intercostal lymph nodes 
84368 Secondary and unspec malig neop internal iliac lymph nodes 
37919 Secondary and unspec malig neop internal mammary lymph nodes 
44931 Secondary and unspec malig neop intra-abdominal LN NOS 
52736 Secondary and unspec malig neop intra-abdominal lymph nodes 
72803 Secondary and unspec malig neop intrapelvic LN NOS 
6701 Secondary and unspec malig neop intrapelvic lymph nodes 
93716 Secondary and unspec malig neop intrathoracic LN NOS 
64116 Secondary and unspec malig neop intrathoracic lymph nodes 
49214 Secondary and unspec malig neop lymph nodes head/face/neck 
20159 Secondary and unspec malig neop lymph nodes multiple sites 
15507 Secondary and unspec malig neop lymph nodes NOS 
28059 Secondary and unspec malig neop of facial lymph nodes 
70747 Secondary and unspec malig neop of inguinal and leg LN NOS 
64918 Secondary and unspec malig neop of superficial parotid LN 
58692 Secondary and unspec malig neop paratracheal lymph nodes 
46409 Secondary and unspec malig neop pectoral lymph nodes 
55463 Secondary and unspec malig neop post mediastinal lymph nodes 
52190 Secondary and unspec malig neop pulmonary lymph nodes 
47366 Secondary and unspec malig neop sacral lymph nodes 
39433 Secondary and unspec malig neop submandibular lymph nodes 
38343 Secondary and unspec malig neop submental lymph nodes 
67797 Secondary and unspec malig neop superfic tracheobronchial LN 
33395 Secondary and unspec malig neop superficial cervical LN 
54278 Secondary and unspec malig neop superficial inguinal LN 
72713 Secondary and unspec malig neop superficial mesenteric LN 
98626 Secondary and unspec malig neop supratrochlear lymph nodes 
66775 Secondary and unspec malignant neoplasm mastoid lymph nodes 
65253 Secondary and unspec malignant neoplasm occipital lymph node 
9618 Secondary and unspecified malignant neoplasm of lymph nodes 
97832 Secondary cancer of the cervix 
65490 Secondary cancer of the vulva 
27651 Secondary carcinoma of other specified sites 
24301 Secondary carcinoma of respiratory and/or digestive systems 
36200 Secondary malig neop of large intestine or rectum NOS 
35053 Secondary malig neop of respiratory and digestive systems 
66083 Secondary malig neop of respiratory or digestive system NOS 
67396 Secondary malig neop of retroperitoneum and peritoneum 
97672 Secondary malig neop of retroperitoneum or peritoneum NOS 





36401 Secondary malignant neoplasm of adrenal gland 
22146 Secondary malignant neoplasm of bladder 
7654 Secondary malignant neoplasm of bone and bone marrow 
5198 Secondary malignant neoplasm of brain 
33843 Secondary malignant neoplasm of brain and spinal cord 
59375 Secondary malignant neoplasm of brain or spinal cord NOS 
16760 Secondary malignant neoplasm of breast 
73616 Secondary malignant neoplasm of cervix uteri 
28727 Secondary malignant neoplasm of colon 
55946 Secondary malignant neoplasm of duodenum 
104480 Secondary malignant neoplasm of epididymis and vas deferens 
99511 Secondary malignant neoplasm of ileum 
110433 Secondary malignant neoplasm of jejunum 
1952 Secondary malignant neoplasm of kidney 
44529 Secondary malignant neoplasm of large intestine and rectum 
36147 Secondary malignant neoplasm of liver 
15103 Secondary malignant neoplasm of liver 
4137 Secondary malignant neoplasm of lung 
51551 Secondary malignant neoplasm of mediastinum 
56345 Secondary malignant neoplasm of other digestive organ 
54120 Secondary malignant neoplasm of other part of nervous system 
62584 Secondary malignant neoplasm of other respiratory organs 
22524 Secondary malignant neoplasm of other specified site NOS 
16500 Secondary malignant neoplasm of other specified site NOS 
5842 Secondary malignant neoplasm of other specified sites 
18616 Secondary malignant neoplasm of other specified sites 
62828 Secondary malignant neoplasm of other urinary organ NOS 
73213 Secondary malignant neoplasm of other urinary organs 
44615 Secondary malignant neoplasm of ovary 
49145 Secondary malignant neoplasm of penis 
27391 Secondary malignant neoplasm of peritoneum 
16213 Secondary malignant neoplasm of pleura 
21590 Secondary malignant neoplasm of prostate 
62909 Secondary malignant neoplasm of rectum 
35364 Secondary malignant neoplasm of retroperitoneum 
19945 Secondary malignant neoplasm of skin 
55096 Secondary malignant neoplasm of skin NOS 
9505 Secondary malignant neoplasm of skin of breast 
100296 Secondary malignant neoplasm of skin of face 
43930 Secondary malignant neoplasm of skin of head 
48828 Secondary malignant neoplasm of skin of hip and leg 
35999 Secondary malignant neoplasm of skin of neck 
63896 Secondary malignant neoplasm of skin of shoulder and arm 
41144 Secondary malignant neoplasm of skin of trunk 
64680 Secondary malignant neoplasm of small intestine and duodenum 
38918 Secondary malignant neoplasm of spinal cord 
34145 Secondary malignant neoplasm of testis 
45824 Secondary malignant neoplasm of tongue 
54679 Secondary malignant neoplasm of unknown site 
60134 Secondary malignant neoplasm of ureter 
53528 Secondary malignant neoplasm of urethra 
55090 Secondary malignant neoplasm of uterus 
70736 Secondary malignant neoplasm of vagina 
60335 Secondary malignant neoplasm of vulva 
67129 Secondary unspec malig neop lymph nodes head/face/neck NOS 





3152 [M]Carcinoma, metastatic, NOS 
54874 [M]Metastatic signet ring cell carcinoma 
22267 [M]Neoplasm, malig, uncertain whether primary or metastatic 
3197 [M]Neoplasm, metastatic 
9366 [M]Secondary carcinoma 
6985 [M]Secondary neoplasm 
24293 [M]Squamous cell carcinoma, metastatic NOS 
8600 Pain from metastases 
112718 secondary malignant neoplasm of liver intrahepatic bile duct 




44288 [D]Laboratory evidence of human immunodefiency virus [HIV] 
41185 [X]Dementia in human immunodef virus [HIV] disease 
112034 [X]HIV dis reslt/oth mal neopl/lymph;h'matopoetc? tissu 
96751 [X]HIV disease result/haematological???? abnorms;NEC 
112037 [X]HIV disease resulting in multiple diseases CE 
102117 [X]HIV disease resulting in multiple infections 
112030 [X]HIV disease resulting in other bacterial infections 
112035 [X]HIV disease resulting in other malignant neoplasms 
112031 [X]HIV disease resulting in other mycoses 
112033 [x]hiv disease resulting in other non-hodgkin lymphoma 
69767 [X]HIV disease resulting in other non-Hodgkin's lymphoma 
102252 [X]HIV disease resulting in other specified conditions 
107807 [X]HIV disease resulting in other viral infections 
112036 [X]HIV disease resulting in unspecified malignant neoplasm 
104134 [X]HIV disease resulting/other infectious??? diseases 
112032 [X]HIV disease resulting/unspcf infectious??? disease 
62854 [X]Human immunodeficiency virus disease 
100769 [X]Unspecified human immunodeficiency virus [HIV] disease 
36294 Acquired human immunodeficiency virus infection syndrome NOS 
23770 Acquired immune deficiency syndrome 
58857 Acute human immunodeficiency virus infection 
23763 AIDS carrier 
58859 Asymptomatic human immunodeficiency virus infection 
51708 HIV dis reslt/oth mal neopl/lymph;h'matopoetc? tissu 
66367 HIV dis resulting oth types of non-Hodgkin's lymphoma 
104466 hiv disease complicating pregnancy childbirth puerperium 
47632 HIV disease result/haematological???? abnorms;NEC 
111980 hiv disease resulting in burkitt lymphoma 
44617 HIV disease resulting in Burkitt's lymphoma 
23951 HIV disease resulting in candidiasis 
66368 HIV disease resulting in cytomegaloviral disease 
108054 hiv disease resulting in kaposi sarcoma 
27853 HIV disease resulting in Kaposi's sarcoma 
65117 HIV disease resulting in lymphoid interstitial pneumonitis 
111979 HIV disease resulting in multiple diseases CE 
50076 HIV disease resulting in multiple infections 
105324 HIV disease resulting in multiple malignant neoplasms 
37006 HIV disease resulting in mycobacterial infection 
111981 hiv disease resulting in other types of non-hodgkin lymphoma 





104717 hiv disease resulting in pneumocystis jirovecii pneumonia 
67575 HIV disease resulting in unspecified malignant neoplasm 
8281 HIV disease resulting in wasting syndrome 
71450 HIV disease resulting/unspcf infectious disease 
111972 hiv infection monitoring first telephone invitation 
111973 hiv infection monitoring second telephone invitation 
109327 hiv infection monitoring telephone invitation 
111974 hiv infection monitoring third telephone invitation 
69766 HIV infection with persistent generalised lymphadenopathy 
105040 hiv pos gen health check serv declind - enhanc service admin 
2835 HIV positive 
111971 hiv positive general health check service declined 
44303 Human immunodef virus resulting in other disease 
101191 human immunodeficiency virus annual review 
9130 human immunodeficiency virus infection 
108385 human immunodeficiency virus infection monitoring invitation 
98966 human immunodeficiency virus monitoring 
70869 Human immunodeficiency virus with constitutional disease 
53636 Human immunodeficiency virus with neurological disease 
62891 Human immunodeficiency virus with other clinical findings 
101836 Human immunodeficiency virus with secondary cancers 
70528 Human immunodeficiency virus with secondary infection 
33943 Notification of AIDS 
109513 human immunodeficiency virus drug resistance test 
110374 human immunodeficiency virus type 1 subtype identification 




Medcode Description Smoking status 
11788 Non-smoker Never 
33 Never smoked tobacco Never 
12957 Ex-light smoker (1-9/day) Ex 
72706 Tobacco dependence in remission Ex 
12961 Ex-trivial smoker (<1/day) Ex 
12956 Ex-heavy smoker (20-39/day) Ex 
776 Stopped smoking Ex 
97210 Ex-cigarette smoker Ex 
26470 Ex pipe smoker Ex 
90 Ex smoker Ex 
12955 Ex-moderate smoker (10-19/day) Ex 
100963 Ex-smoker annual review Ex 
12959 Ex-very heavy smoker (40+/day) Ex 
19488 Ex cigar smoker Ex 
12946 Ex-smoker - amount unknown Ex 
98447 Ex-smoker annual review - enhanced services administration Ex 
100495 Ex roll-up cigarette smoker Ex 
106359 Referral to smoking cessation service Current 
40417 Stop smoking monitor default Current 
63666 Fagerstrom test for nicotine dependence Current 
59866 Reasons for smoking scale Current 
63299 Ftnd - fagerstrom test for nicotine dependence Current 
12941 Occasional smoker Current 





47273 Motives for smoking scale Current 
12964 Keeps trying to stop smoking Current 
74907 Smoking cessation therapy Current 
104310 Current smoker annual review Current 
11527 Dna - did not attend smoking cessation clinic Current 
10211 Smoking cessation milestones Current 
62686 Minutes from waking to first tobacco consumption Current 
94958 Smoking cessation drug therapy Current 
9045 Advice on smoking Current 
49418 Rfs - reasons for smoking scale Current 
56144 [X]mental and behav dis due to use of tobacco: harmful use Current 
100099 Smoking cessation advice declined Current 
98493 Smoking cessatn monitor template complet - enhanc serv admin Current 
30762 Not interested in stopping smoking Current 
31114 Ready to stop smoking Current 
103507 Stop smoking service opportunity signposted Current 
7622 Smoking cessation advice Current 
35055 [V]tobacco abuse counselling Current 
60720 Stop smoking monitor 2nd lettr Current 
85247 Nicotine replacement therapy using nicotine inhalator Current 
90522 Smoking cessation therapy nos Current 
41042 Smoking cessation advice provided by community pharmacist Current 
1822 Very heavy smoker - 40+cigs/d Current 
12952 Smoking started Current 
98347 Current smoker annual review - enhanced services admin Current 
106391 Referral to smoking cessation service declined Current 
46321 Reason for restarting smoking Current 
104230 Smoking cessation programme declined Current 
41979 Smoking restarted Current 
12944 Light smoker - 1-9 cigs/day Current 
98154 Referral to nhs stop smoking service Current 
11356 Seen by smoking cessation advisor Current 
32572 Over the counter nicotine replacement therapy Current 
68658 Tobacco dependence nos Current 
70746 Tobacco dependence, continuous Current 
81440 Nicotine replacement therapy using nicotine patches Current 
12942 Smoker - amount smoked Current 
12947 Pipe smoker Current 
107504 Mfs - motives for smoking scale Current 
63717 Bupropion contraindicated Current 
98137 Brief intervention for smoking cessation Current 
53101 Stop smoking monitor verb.inv. Current 
89464 Nicotine replacement therapy using nicotine lozenges Current 
10742 Referral to stop-smoking clinic Current 
7130 Stop smoking monitoring admin. Current 
104185 Smoking cessation drug therapy declined Current 
12945 Rolls own cigarettes Current 
25106 Nicotine replacement therapy provided free Current 
12966 Smoking reduced Current 
108835 Tobacco dependence, episodic Current 
3568 Heavy smoker - 20-39 cigs/day Current 
61905 [X]mental and behavioural disorder due to use of tobacco Current 
42722 Stop smoking monitor 1st lettr Current 
91708 Other specified smoking cessation therapy Current 
66387 Stop smoking monitor 3rd lettr Current 





24529 Nicotine replacement therapy refused Current 
32687 Tobacco dependence Current 
10184 Pregnancy smoking advice Current 
95610 Tobacco dependence, unspecified Current 
58597 Stop smoking monitor phone inv Current 
91513 Occasions for smoking scale Current 
112529 [X]mental & behav dis due to use tobacco: psychotic disorder Current 
111853 [X]mental & behav dis due to use tobacco: acute intoxication Current 
40418 Refuses stop smoking monitor Current 
18573 Referral to smoking cessation advisor Current 
102361 Referral for smoking cessation service offered Current 
12951 Smoking restarted Current 
12958 Trivial smoker - < 1 cig/day Current 
93 Cigarette smoker Current 
12240 Trying to give up smoking Current 
57639 Bupropion refused Current 
85975 Nicotine replacement therapy using nicotine gum Current 
1878 Moderate smoker - 10-19 cigs/d Current 
1823 Smoker Current 
6359 Nicotine withdrawal Current 
18926 Lifestyle advice regarding smoking Current 
32083 Stop smoking clinic admin. Current 
101338 Failed attempt to stop smoking Current 
34126 Negotiated date for cessation of smoking Current 
98245 Stop smoking face to face follow-up Current 
97643 Fagerstrom test for nicotine dependence Current 
66409 Nicotine replacement therapy contraindicated Current 
9833 Nicotine replacement therapy Current 
30423 Thinking about stopping smoking Current 
12943 Cigar smoker Current 
110692 Varenicline smoking cessation therapy offered Current 




Medcode Readcode Description Alcohol status 
12949 1361.00 Teetotaller Non-drinker 
12970 1361.11 Non drinker alcohol Non-drinker 
4447 1361.12 Non-drinker alcohol Non-drinker 
12979 136m.00 Current non drinker Non-drinker 
967 1367.00 Stopped drinking alcohol Former drinker 
22933 136a.00 Ex-trivial drinker (<1u/day) Former drinker 
26471 136b.00 Ex-light drinker - (1-2u/day) Former drinker 
19495 136c.00 Ex-moderate drinker - (3-6u/d) Former drinker 
19493 136d.00 Ex-heavy drinker - (7-9u/day) Former drinker 
12983 136e.00 Ex-very heavy drinker-(>9u/d) Former drinker 
385 1362.11 Drinks rarely Occasional drinker 
749 1362.12 Drinks occasionally Occasional drinker 
12971 136f.00 Spirit drinker Moderate drinker 
2689 136g.00 Beer drinker Moderate drinker 
12968 136h.00 Drinks beer and spirits Moderate drinker 





956 136j.00 Social drinker Moderate drinker 
26472 136l.00 Alcohol intake within recommended sensible limits Moderate drinker 
12980 136n.00 Light drinker Moderate drinker 
12985 136o.00 Moderate drinker Moderate drinker 
44783 1d19.00 Pain in lymph nodes after alcohol consumption Moderate drinker 
24735 2577.00 O/e - breath - alcohol smell Moderate drinker 
10161 2577.11 O/e - alcoholic breath Moderate drinker 
12982 136k.00 Alcohol intake above recommended sensible limits Heavy drinker 
8999 136p.00 Heavy drinker Heavy drinker 
12984 136q.00 Very heavy drinker Heavy drinker 
19401 136r.00 Binge drinker Heavy drinker 
19494 136s.00 Hazardous alcohol use Heavy drinker 
30695 136t.00 Harmful alcohol use Heavy drinker 
94670 136w.00 Alcohol misuse Heavy drinker 
101718 136y.00 Drinks in morning to get rid of hangover Heavy drinker 
84218 13zy.00 Disqualified from driving due to excess alcohol Heavy drinker 
1399 E23..12 Alcohol problem drinking Heavy drinker 
7746 E250.00 Nondependent alcohol abuse Heavy drinker 
12271 E250.11 Drunkenness nos Heavy drinker 
27518 E250.12 Hangover (alcohol) Heavy drinker 
17777 E250.13 Inebriety nos Heavy drinker 
3782 E250.14 Intoxication - alcohol Heavy drinker 
669 E250000 Nondependent alcohol abuse, unspecified Heavy drinker 
23610 E250100 Nondependent alcohol abuse, continuous Heavy drinker 
12974 E250200 Nondependent alcohol abuse, episodic Heavy drinker 
31569 E250300 Nondependent alcohol abuse in remission Heavy drinker 
28150 E250z00 Nondependent alcohol abuse nos Heavy drinker 
9169 R103.00 [d]alcohol blood level excessive Heavy drinker 
23978 U81..00 [x]evidence of alcohol involvement determined by 
level of intoxication 
Heavy drinker 
16587 Zv11311 [v]problems related to lifestyle alcohol use Heavy drinker 
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Please complete all mandatory fields below (marked with an asterisk *) and as many of the 
non-mandatory fields as you can then click Submit to submit your registration. You don't 
need to complete everything in one go, this record will appear in your My PROSPERO 
section of the web site and you can continue to edit it until you are ready to submit. Click 
Show help below or click on the icon 
to see guidance on completing each section. 
This record cannot be edited because it has been rejected 
 
 
1. * Review title. 
Give the working title of the review, for example the one used for obtaining funding. Ideally 
the title should state succinctly the interventions or exposures being reviewed and the 
associated health or social problems. Where appropriate, the title should use the PI(E)COS 
structure to contain information on the Participants, Intervention (or Exposure) and 
Comparison groups, the Outcomes to be measured and Study designs to be included. 
Cardiac Complications Following Community Acquired Pneumonia: A Systematic Review and 
Meta-analysis 
 
2. Original language title. 
For reviews in languages other than English, this field should be used to enter the title in 
the language of the review. This will be displayed together with the English language title. 
English 
 
3. * Anticipated or actual start date. 
Give the date when the systematic review commenced, or is 
expected to commence. 24/09/2018 
 
4. * Anticipated completion date. 
Give the date by which the review is expected 
to be completed. 31/07/2019 
 
5. * Stage of review at time of this submission. 
Indicate the stage of progress of the review by ticking the relevant Started and Completed 
boxes. Additional information may be added in the free text box provided. 
Please note: Reviews that have progressed beyond the point of completing data extraction 
at the time of initial registration are not eligible for inclusion in PROSPERO. Should 
evidence of incorrect status and/or completion date being supplied at the time of 
submission come to light, the content of the PROSPERO record will be removed leaving 
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only the title and named contact details and a statement that inaccuracies in the stage of 
the review date had been identified. 
This field should be updated when any amendments are made to a published record and 
on completion and publication of the review. If this field was pre-populated from the initial 
screening questions then you are not able to edit it until the record is published. 
 
The review has not yet started: No 
 
Review stage Started           Completed 
Preliminary searches Yes  No 
Piloting of the study selection process Yes  No 
Formal screening of search results against eligibility criteria Yes  No 
Data extraction No No 
Risk of bias (quality) assessment No No 
Data analysis No No 
Provide any other relevant information about the stage of the review here (e.g. Funded 
proposal, protocol not yet finalised). 
 
6. * Named contact. 
The named contact acts as the guarantor for the accuracy of the information presented in 
the register record. Vadsala Baskaran 
 
Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: 
Dr Baskaran 
 
7. * Named contact email. 
Give the electronic mail address of 
the named contact. 
vadsala.baskaran@nhs.net 
8. Named contact address 
Give the full postal address for the named contact. 
Room B02, Clinical Sciences Building, Nottingham City Hospital, Hucknall Rd, Nottingham, 
NG5 1PB 
 
9. Named contact phone number. 
Give the telephone number for the named contact, including 
international dialling code. 07515533617 
10. * Organisational affiliation of the review. 
Full title of the organisational affiliations for this review and website address if available. 
PROSPERO 





This field may be completed as 'None' if the review is not affiliated to any organisation. 
University of Nottingham 
 
Organisation web address: 
https://www.nottingham.ac.uk/ 
 
11. * Review team members and their organisational affiliations. 
Give the title, first name, last name and the organisational affiliations of each member of 
the review team. Affiliation refers to groups or organisations to which review team 
members belong. 
Dr Vadsala Baskaran. University of Nottingham  
Professor Tricia McKeever. University of Nottingham 
Professor Wei Shen Lim. Nottingham University Hospitals NHS Trust 
 
12. * Funding sources/sponsors. 
Give details of the individuals, organizations, groups or other legal entities who take 
responsibility for initiating, managing, sponsoring and/or financing the review. Include 
any unique identification numbers assigned to the review by the individuals or bodies 
listed. 
 
13. * Conflicts of interest. 
List any conditions that could lead to actual or perceived undue influence on 




Give the name and affiliation of any individuals or organisations who are working on the 
review but who are not listed as review team members. 
 
15. * Review question. 
State the question(s) to be addressed by the review, clearly and precisely. Review 
questions may be specific or broad. It may be appropriate to break very broad questions 
down into a series of related more specific questions. Questions may be framed or refined 
using PI(E)COS where relevant. 
1. What is the incidence of and risk factors for cardiac complications in patients with CAP? 
2. What is the mortality associated with cardiac complications in patients with CAP? 
3. What are the relevant biomarkers? 
 
16. * Searches. 
Give details of the sources to be searched, search dates (from and to), and any restrictions 
(e.g. language or publication period). The full search strategy is not required, but may be 
supplied as a link or attachment. 
An initial limited search of MEDLINE has been undertaken followed by analysis of the text 
words contained in the title and abstract, and of the index terms used to describe article. 
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The sources to be searched would include MEDLINE and Embase from inception to Dec 
2018. There will be no language or publication period restrictions.The reference list of all 
studies selected for critical appraisal will be screened for additional studies. 
17. URL to search strategy. 
Give a link to a published pdf/word document detailing either the search strategy or an 
example of a search strategy for a specific database if available (including the keywords that 
will be used in the search strategies), or upload your search strategy.Do NOT provide links to 
your search results. 
 
https://www.crd.york.ac.uk/PROSPEROFILES/123996_STRATEGY_20190131.pdf 
Alternatively, upload your search strategy to CRD in pdf format. Please note that by 
doing so you are consenting to the file being made publicly accessible. 
Do not make this file publicly available until the review is complete 
 
18. * Condition or domain being studied. 
Give a short description of the disease, condition or healthcare domain being studied. 
This could include health and wellbeing outcomes. 
Cardiac complications, including acute coronary syndrome, heart failure and arrhythmia 
following community acquired pneumonia. 
19. * Participants/population. 
Give summary criteria for the participants or populations being studied by the review. The 
preferred format includes details of both inclusion and exclusion criteria. 
The current review will consider studies that enrol adult participants (18 years and 
above) and report cardiovascular complications associated with a clinical and 
radiological diagnosis of CAP. Studies which included hospital acquired pneumonia 
(i.e. hospital admission within the last 10 days) will be excluded. 
20. * Intervention(s), exposure(s). 
Give full and clear descriptions or definitions of the nature of the interventions or the 
exposures to be reviewed. 
Exposure would be those with a clinical and radiological diagnosis of CAP (defined as 
symptoms and signs consistent with an acute lower respiratory tract infection associated 
with acute consolidation on plain radiography with no alternative diagnoses). 
21. * Comparator(s)/control. 
Where relevant, give details of the alternatives against which the main subject/topic of the 
review will be compared (e.g. another intervention or a non-exposed control group). The 
preferred format includes details of both inclusion and exclusion criteria. 
N/A 
 
22. * Types of study to be included. 
Give details of the types of study (study designs) eligible for inclusion in the review. If there 
are no restrictions on the types of study design eligible for inclusion, or certain study types 
are excluded, this should be stated. The preferred format includes details of both inclusion 
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and exclusion criteria. 
Observational studies including prospective and retrospective cohort studies and case-
control studies. Cross- sectional studies will be excluded. 
23. Context. 
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Give summary details of the setting and other relevant characteristics which help 
define the inclusion or exclusion criteria. 
 
24. * Main outcome(s). 
Give the pre-specified main (most important) outcomes of the review, including details 
of how the outcome is defined and measured and when these measurement are 
made, if these are part of the review inclusion criteria. 
• What is the short-term (30-day) and long-term (1 year) effect of CAP on 
developing incident cardiac complications? 
• What are the risk factors for developing incident cardiac complications in patients 
with CAP? 
 
Timing and effect measures 
The main outcomes will be measured at different time-points;30 days, 90 days and 1 
year Pooled relative risks will be estimated using risk ratios and odds ratios, with 
95% confidence intervals. Measures of effect adjusted for confounders will be used 
in preference to crude measures of effect. Rate ratios and hazard ratios will not be 
combined with risk ratios and odds ratios. 
25. * Additional outcome(s). 
List the pre-specified additional outcomes of the review, with a similar level of detail to 
that required for main outcomes. Where there are no additional outcomes please 
state ‘None’ or ‘Not applicable’ as appropriate 
to the review 
What are the relevant biomarkers? 
 
Timing and effect measures 
N/A 
 
26. * Data extraction (selection and coding). 
Give the procedure for selecting studies for the review and extracting data, 
including the number of researchers involved and how discrepancies will be 
resolved. List the data to be extracted. 
Data will be extracted from papers included in the review using the standardized data 
extraction form by two independent reviewers. Any disagreements that arise between 
the reviewers will be resolved through discussion, or with a third reviewer. Authors of 
papers will be contacted to request missing or additional data where required. 
27. * Risk of bias (quality) assessment. 
State whether and how risk of bias will be assessed (including the number of 
researchers involved and how discrepancies will be resolved), how the quality of 
individual studies will be assessed, and whether and how this will influence the 
planned synthesis. 
Selected studies will be critically appraised by two independent reviewers at the study 
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level for methodological quality in the review using quality assessment/ risk of bias tool 
created for the purpose of this study. The Newcastle-Ottawa Scale (NOS) will be used 
for assessing the quality of non-randomised studies in meta-analysis. Any 
disagreements that arise will be resolved through discussion, or with a third reviewer. 
All studies, regardless of their methodological quality, will undergo data 
extraction and synthesis (where possible). 
28. * Strategy for data synthesis. 
Give the planned general approach to synthesis, e.g. whether aggregate or individual 
participant data will be used and whether a quantitative or narrative (descriptive) 
synthesis is planned. It is acceptable to state that a quantitative synthesis will be used 
if the included studies are sufficiently homogenous. 
Narrative synthesis of evidence will be conducted for all included studies. Papers will, 
where possible be pooled in statistical meta-analysis. A funnel plot will be generated to 
assess publication bias if there are 10 or more studies included in a meta-analysis. A 
'summary of findings' table will be used to outline the best available evidence, highlight 
similarities and inconsistencies within the evidence, and subsequently formulate 
summary statements to describe the body of evidence. 
 
 
29. * Analysis of subgroups or subsets. 
Give details of any plans for the separate presentation, exploration or analysis of 
different types of participants (e.g. by age, disease status, ethnicity, socioeconomic 
status, presence or absence or co- morbidities); different types of intervention (e.g. 
drug dose, presence or absence of particular components of intervention); different 
settings (e.g. country, acute or primary care sector, professional or family care); or 
different types of study (e.g. randomised or non-randomised). 
Subgroup analyses will be conducted where there are sufficient data to investigate 
the association of CAP and the different cardiac complications that are identified. 
 
30. * Type and method of review. 
Select the type of review and the review method from the lists below. Select the 
health area(s) of interest for your review. 
 
 
Type of review  
Cost effectiveness No 
Diagnostic No 
Epidemiologic No 
Individual patient data (IPD) meta-analysis No 
Intervention No 
PROSPERO 







Narrative synthesis No 




Prospective meta-analysis (PMA) Yes 
Review of reviews No 
Service delivery No 
Synthesis of qualitative studies No 




Health area of the review  
Alcohol/substance misuse/abuse No 
Blood and immune system No 
Cancer No 
Cardiovascular Yes 
Care of the elderly No 
Child health No 
Complementary therapies No 
Crime and justice No 
Dental No 
Digestive system No 
Ear, nose and throat No 
Education No 
Endocrine and metabolic disorders No 
Eye disorders No 
General interest No 
Genetics No 
Health inequalities/health equity No 
Infections and infestations No 
International development No 




Obstetrics and gynaecology No 
PROSPERO 





Oral health No 
Palliative care No 
Perioperative care No 
Physiotherapy No 
Pregnancy and childbirth No 
Public health (including social determinants of health) No 
Rehabilitation No 
Respiratory disorders Yes 
Service delivery No 
Skin disorders No 
Social care No 
Surgery No 
Tropical Medicine No 
Urological No 
Wounds, injuries and accidents No 




Select each language individually to add it to the list below, use the bin icon to remove 
any added in error. English 
There is not an English language summary 
 
32. Country. 
Select the country in which the review is being carried out from the drop down 
list. For multi-national collaborations select all the countries involved. 
England 
 
33. Other registration details. 
Give the name of any organisation where the systematic review title or protocol is 
registered (such as with The Campbell Collaboration, or The Joanna Briggs Institute) 
together with any unique identification number assigned. (N.B. Registration details 
for Cochrane protocols will be automatically entered). If extracted data will be stored 
and made available through a repository such as the Systematic Review Data 
Repository (SRDR), details and a link should be included here. If none, leave blank. 
N/A 
 
34. Reference and/or URL for published protocol. 
Give the citation and link for the published 
protocol, if there is one Give the link to the 
published protocol. 
Alternatively, upload your published protocol to CRD in pdf format. Please note 
PROSPERO 





that by doing so you are consenting to the file being made publicly accessible. 
No I do not make this file publicly available until the review is complete 
Please note that the information required in the PROSPERO registration form must be 
completed in full even if access to a protocol is given. 
 
35. Dissemination plans. 
Give brief details of plans for communicating essential messages from the 
review to the appropriate audiences. 
 




Give words or phrases that best describe the review. Separate keywords with a 
semicolon or new line. Keywords will help users find the review in the Register (the 
words do not appear in the public record but are included in searches). Be as specific 
and precise as possible. Avoid acronyms and abbreviations unless these are in wide 
use. 
Community acquired pneumonia; cardiac complications; systematic review; meta-
analysis; acute coronary syndrome; heart failure; arrhythmia 
37. Details of any existing review of the same topic by the same authors. 
Give details of earlier versions of the systematic review if an update of an existing 
review is being registered, including full bibliographic reference if possible. 
N/A 
 
38. * Current review status. 
Review status should be updated when the review is completed and 





39. Any additional information. 
Provide any other information the review team feel is relevant to the registration of the 
review. 
 
40. Details of final report/publication(s). 
This field should be left empty until details of the 






Appendix 4: SR Search terms (Chapter 4) 
1. community-acquired infections/ 
2. Community acquired.tw. 
3. 1 or 2 
4. Exp pneumonia/ or pneumon*.tw. 
5. 3 and 4 
6. Community acquired pneumonia.mp 
7. 5 or 6 
•  
8. Observational study.mp. or exp observational study/ or exp epidemiologic 
methods/ 
9. Prospective study.mp. or exp prospective studies/ 
10. Cohort study.mp or exp cohort studies/ 
11. Case-control study.mp. or exp case-control studies/ 
12. Or/ 8-11 
13. 7 and 12 
 
14. Exp Morbidity/ 
15. Exp Mortality/ or "hospital mortality"/  
16. Exp prognosis/ 
17. patient readmission/ 
18. survival/ 
19. survival analysis/ 




21. (morbidity or mortality or inpatient mortality or death* or treatment outcome or 
prognosis or length of stay or complication* or readmission* or re-admission* or 
rehospitali* or re-hospitali* or survival).mp. 
 
22. Exp cardiovascular diseases/  
23. exp coronary disease/ 
24. exp heart failure/ 
25. exp arrhythmias, cardiac/ 
26. Exp acute coronary syndrome/  
27. exp unstable angina/  
28. exp myocardial infarction/ 
29. exp myocardial ischemia/ 
30. exp coronary thrombosis/ 
31. exp pericarditis/  
32. (cardiovascular or cardiac or heart or coronary or arrhythmia* or arhythmia* or 
acute coronary syndrome or unstable angina or heart attack or heart failure or 
myocardial infarct* or myocardial isch* or pericarditis or shock*).mp.  
33. or/ 14-32 
34. 13 and 33 
 
35. remove duplicates from 34  
36. animals/ not humans/  





Appendix 5: Data extraction form (Chapter 4) 
























Abstract only     ☐                                       Full paper                   ☐ 
English          ☐                     Other language     ☐  
 
Study Details 
Type of study 
Prospective     ☐                                Retrospective ☐ 
 
 Cohort              ☐                                Other               ☐ 
Country  
Number of centres 
 
 
Type of centres  
Enrolment period  








 Participant Details 
Inclusion criteria  
CAP definition: 
 
Exclusion criteria  




























Results                                                                                                                                                                                  




☐ Incidence of cardiac complication(s); new/ worsening of existing symptoms/ 
new and worsening symptoms 
☐ Mortality  
☐ Risk factors for cardiac complication(s) 
☐ Biomarkers 
 
Time frame Type of cardiac complication Proportion (%) Denominator 
    
    
 
Time frame Mortality rate (95% CI) Proportion (%) Denominator 
    




Risk factors for 
cardiac 
complications 
































Quality: Modified Newcastle Ottawa Scale (Cohort studies) 
Note: A study can be given a maximum of one star for each numbered item within the 
Selection and Outcome categories. A maximum of two stars can be given for 
Comparability. 
Selection Representativeness of the exposed cohort (1) 
a) Truly representative of the average CAP in the community (1) 
b) Somewhat representative of the average CAP in the community 
(1)  
c) Selected group e.g. nurses, volunteers 
d) No description of the derivation of the cohort 
 
Selection Ascertainment of exposure (1) 
a) Secure record (e.g. medical records, chest radiograph) (1)  
b) Structured interview (1)  
c) Written self-report  
d) No description  
e) Other 
 
Selection Demonstration that outcome of interest (i.e. cardiac complication/ 
worsening of existing cardiac symptom) was not present at start of 
study (1) 
a) Yes (1)  
b) No or not explicitly stated 
 
*Comparability Individuals in different outcome groups are comparable, based on 
the study design or confounders are adjusted for in the analysis (2) 
a) The study controls for age (1)  
b) Study controls for other factors; sex (1)  
c) Outcome groups are not comparable on the basis of the design 
and analysis are not controlled for confounders 
 
Note: Statements of no differences between groups or that 
differences were not statistically significant are not sufficient for 
establishing comparability. 
 
Outcome Assessment of outcome (i.e. cardiac complication) (1) 
a) Independent or blind assessment or confirmation of the outcome 
by reference to secure records (medical records, ECG, chest 
radiograph, blood test, etc.) (1)  
b) Record linkage (e.g. ICD codes) (1)  
c) Self report (i.e. no reference to original medical records or x-rays 
to confirm the outcome) 
d) Other/ No description  
 
Outcome Adequacy of follow-up of cohorts (1) 
a) Complete follow up; all subject accounted for (1)  
b) Subjects lost to follow up unlikely to introduce bias; number lost 
≤ 20%, or description provided of those lost (1)  





d) No statement 
Total  / 5 or 
/ 7 
 
*Used for studies which adjust for confounders 
Quality: Modified Newcastle Ottawa Scale (Case-control studies) 
Note: A study can be given a maximum of one star for each numbered item within the 
Selection and Outcome categories. A maximum of two stars can be given for 
Comparability. 
 
Selection Is the case definition adequate? (1) i.e. with cardiac complication 
a) yes, with independent validation (e.g.  >1 person/ record/ time/ 
process to extract information or reference to primary record source 
such as chest radiograph, ECG, blood test or medical records) (1)  
b) yes, e.g., record linkage (ICD codes) or self-report with no 
reference to primary record  
c) no description 
 
 
Selection Representativeness of the cases (1)  
a) consecutive or obviously representative series of cases (1)   
b) potential for selection biases or not stated 
 
 
Selection Selection of Controls (1)  
a) community controls (1)   
b) hospital controls  
c) no description 
 
 
Selection Definition of Controls (1)  
a) no history of disease (endpoint) (1)   
b) no description of source  
 
 
Comparability Comparability of cases and controls on the basis of the design or 
analysis (2)  
a) study controls for age (1)   
b) study controls for any additional factor; sex (1)  
 
 
Exposure Ascertainment of exposure i.e. CAP (1)  
a) secure record (e.g. medical records, chest radiograph) (1)   
b) structured interview where blind to case/control status (1)   
c) interview not blinded to case/control status  
d) written self-report or medical record only  
e) no description 
 
 




a) yes (1)   
b) no 
 
Exposure Non-Response rate (1)  
a) same rate for both groups (1)  
b) non respondents described  
c) rate different and no designation  
 
 
Total  / 9 
 





References reviewed for relevant associated articles        Yes    ☐ 






Appendix 6: Codes for Chapter 5 
Acute coronary syndrome 
ICD-10  Description 
I21   Acute myocardial infarction 
I21.0   Acute transmural myocardial infarction of anterior wall 
I21.1   Acute transmural myocardial infarction of inferior wall 
I21.2  Acute transmural myocardial infarction of other sites 
I21.3  Acute transmural myocardial infarction of unspecified site  
I21.4 Acute subendocardial myocardial infarction 
I21.9  Acute myocardial infarction; unspecified 
I22  subsequent myocardial infarction 
I22.0  Subsequent myocardial infarction of anterior wall  
I22.1 Subsequent myocardial infarction of inferior wall 
I22.8  Subsequent myocardial infarction of other sites 
I22.9  Subsequent myocardial infarction of unspecified site 
I23  Certain current complications following acute myocardial infarction 
I23.0  haemopericardium as current complication following acute myocardial infarction 
I23.1  Atrial septal defect as current complication following acute myocardial infarction 
I23.2  Ventricular septal defect as current complication following acute myocardial infarction 
I23.3  Rupture of cardiac wall without haemopericardium as current complication following 
acute myocardial  
I23.4  Rupture of chordae tendineae as current complication following acute myocardial 
infarction 
I23.5  Rupture of papillary muscle as current complication following acute myocardial infarction  
I23.6  Thrombosis of atrium; auricular appendage; and ventricle as current complications 
following acute myocardial infarction 
I23.8  Other current complications following acute myocardial infarction 
I24.9 Acute ischemic heart disease, unspecified 




I50 Heart failure 
I50.1 Left ventricular failure, unspecified 
I50.2 Systolic (congestive) heart failure 
I50.20 Unspecified systolic (congestive) heart failure  
I50.21 Acute systolic (congestive) heart failure 
I50.23 Acute on chronic systolic (congestive) heart 
I50.3 Diastolic (congestive) heart failure 
I50.30 Unspecified diastolic (congestive) heart failure 
I50.31 Acute diastolic (congestive) heart failure 
I50.33 Acute on chronic diastolic (congestive) heart failure 




I50.40 Unspecified combined systolic (congestive) and diastolic (congestive) heart failure 
I50.41 Acute combined systolic (congestive) and diastolic (congestive) heart failure 
I50.43 Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure 
I50.8 Other heart failure 
I50.81 Right heart failure 
I50.810 …… unspecified 
I50.811 Acute right heart failure 
I50.813 Acute on chronic right heart failure 
I50.814 …… due to left heart failure 
I50.82 Biventricular heart failure 
I50.83 High output heart failure 
I50.84 End stage heart failure 
I50.89 Other heart failure 




I47 Paroxysmal tachycardia 
I47.0 Re-entry ventricular arrhythmia 
I47.1 Supraventricular tachycardia 
I47.2 Ventricular tachycardia 
I47.9 Paroxysmal tachycardia; unspecified 
I48 Atrial fibrillation and flutter 
I48.0 Paroxysmal atrial fibrillation 
I48.1 Persistent atrial fibrillation 
I48.19 Other persistent atrial fibrillation 
I48.3 Typical atrial flutter 
I48.4 Atypical atrial flutter 
I48.9 Unspecified atrial fibrillation and atrial flutter 
I48.91 Unspecified atrial fibrillation 
I48.92 Unspecified atrial flutter 
I49 Other cardiac arrhythmias 
I49.0 Ventricular fibrillation and flutter 
I49.01 Ventricular fibrillation 
I49.02 Ventricular flutter 
I49.1 Atrial premature depolarization 
I49.2 Junctional premature depolarization 
I49.3 Ventricular premature depolarization 
I49.4 Other and unspecified premature depolarization 
I49.40 Unspecified premature depolarization 
I49.49 Other premature depolarization 
I49.5 Sick sinus syndrome 
149.8 Other specific cardiac arrhythmias 







96838 [X]Acute transmural myocardial infarction of unspecif site 
109035 [X]Subsequent myocardial infarction of other sites 
99991 [X]Subsequent myocardial infarction of unspecified site 
40429 Acute anteroapical infarction 
12139 Acute anterolateral infarction 
17872 Acute anteroseptal infarction 
28736 Acute atrial infarction 
9276 Acute coronary insufficiency 
11983 Acute coronary syndrome 
8935 Acute inferolateral infarction 
29643 Acute inferoposterior infarction 
241 Acute myocardial infarction 
14658 Acute myocardial infarction NOS 
9507 Acute non-Q wave infarction 
10562 Acute non-ST segment elevation myocardial infarction 
62626 Acute papillary muscle infarction 
32854 Acute posterolateral myocardial infarction 
30330 Acute Q-wave infarct 
41221 Acute septal infarction 
12229 Acute ST segment elevation myocardial infarction 
3704 Acute subendocardial infarction 
29758 Acute transmural myocardial infarction of unspecif site 
19655 Angina at rest 
14897 Anterior myocardial infarction NOS 
23708 Atrial septal defect/curr comp folow acut myocardal infarct 
13566 Attack - heart 
30421 Cardiac rupture following myocardial infarction (MI) 
36423 Certain current complication follow acute myocardial infarct 
2491 Coronary thrombosis 
26975 ECG: antero-septal infarct. 
52705 ECG: lateral infarction 
59032 ECG: myocardial infarct NOS 
7783 ECG: myocardial infarction 
8246 ECG: myocardial ischaemia 
55401 ECG: subendocardial infarct 
26972 ECG:posterior/inferior infarct 
24126 Haemopericardium/current comp folow acut myocard infarct 
16408 Healed myocardial infarction 
1204 Heart attack 
39655 Impending infarction 
1678 Inferior myocardial infarction NOS 
14898 Lateral myocardial infarction NOS 
1677 MI - acute myocardial infarction 
68357 Microinfarction of heart 
4017 Old myocardial infarction 
34803 Other acute myocardial infarction 
46017 Other acute myocardial infarction NOS 
5387 Other specified anterior myocardial infarction 
17464 Personal history of myocardial infarction 
9555 Post infarct angina 




23892 Posterior myocardial infarction NOS 
23579 Postmyocardial infarction syndrome 
46112 Postoperative transmural myocardial infarction anterior wall 
59189 Ruptur cardiac wall w'out haemopericard/cur comp fol ac MI 
59940 Ruptur chordae tendinae/curr comp fol acute myocard infarct 
49735 Rupture of papillary muscle 
69474 Rupture papillary muscle/curr comp fol acute myocard infarct 
17689 Silent myocardial infarction 
18842 Subsequent myocardial infarction 
45809 Subsequent myocardial infarction of anterior wall 
38609 Subsequent myocardial infarction of inferior wall 
72562 Subsequent myocardial infarction of other sites 
46166 Subsequent myocardial infarction of unspecified site 
13571 Thrombosis - coronary 
29553 Thrombosis atrium,auric append&vent/curr comp foll acute MI 
63467 True posterior myocardial infarction 
7347 Unstable angina 
1431 Unstable angina 




21235 Suspected heart failure 
9913 Heart failure confirmed 
5155 O/E - pulmonary oedema 
46672 New York Heart Assoc classification heart failure symptoms 
18853 New York Heart Association classification - class I 
13189 New York Heart Association classification - class II 
19066 New York Heart Association classification - class III 
51214 New York Heart Association classification - class IV 
24503 Cardiac failure therapy 
32898 Admit heart failure emergency 
8464 Acute cor pulmonale 
5141 Congestive cardiomyopathy 
2062 Heart failure 
1223 Cardiac failure 
398 Congestive heart failure 
2906 Congestive cardiac failure 
10079 Right heart failure 
10154 Right ventricular failure 
9524 Biventricular failure 
23707 Acute congestive heart failure 
27884 Decompensated cardiac failure 
11424 Compensated cardiac failure 
884 Left ventricular failure 
43618 Pulmonary oedema - acute 
5942 Impaired left ventricular function 
5255 Acute left ventricular failure 
27964 Acute heart failure 
4024 Heart failure NOS 
17278 Cardiac failure NOS 
7321 Pulmonary oedema NOS 




48466 Acute oedema of lung, unspecified 
5293 Acute pulmonary oedema NOS 
66306 Heart failure as a complication of care 




53893 [x]other specified cardiac arrhythmias 
6503 Cardiac arrhythmias 
1535 Cardiac dysrhythmia nos 
4044 Cardiac dysrhythmias 
17597 Ecg: supraventricular arrhythmia 
19707 Ecg: ventricular arrhythmia 
29371 Ecg: ventricular arrhythmia nos 
8651 Nodal rhythm disorder 
31133 Other cardiac dysrhythmia nos 
7827 Other cardiac dysrhythmias 
31690 Re-entry ventricular arrhythmia 
3757 Ecg: atrial fibrillation 
31286 Ecg: ventricular fibrillation 
9479 Implant intravenous pacemaker for atrial fibrillation 
31077 Defibrillation 
99338 External ventricular defibrillation 
2212 Atrial fibrillation and flutter 
1664 Atrial fibrillation 
1268 Paroxysmal atrial fibrillation 
35127 Non-rheumatic atrial fibrillation 
96277 Permanent atrial fibrillation 
96076 Persistent atrial fibrillation 
23437 Atrial fibrillation and flutter nos 
4374 Ventricular fibrillation and flutter 
4827 Ventricular fibrillation 
25583 Cardiac arrest-ventricular fibrillation 
41916 Ventricular fibrillation and flutter nos 
1757 Atrial flutter 
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Appendix 7: PROSPERO Registration (Chapter 6) 
The effect of smoking on the risk of developing community 
acquired pneumonia in adults 
 





Abby Hunter, Wei Shen Lim, Tricia McKeever, Rachael Murray, Vadsala 
Baskaran. The effect of smoking on the risk of developing community 





2. Review question 
The objective of this systematic review is to synthesise the best available research 
evidence to determine the risk of developing community acquired pneumonia in 
adults who currently or have ever smoked. Specifically, the review question is: what 
is the effect of smoking on the risk of developing community acquired pneumonia in 
adults? If possible we will also explore what effect stopping smoking has on risk of 
developing community acquired pneumonia in adults. 
 
3. Searches 
The search keywords were determined based on the Cochrane Tobacco 
Addiction review group terms for smoking and the BMJ Clinical Evidence study 
design search filters. 
 
- Smoking, smoking cessation, tobacco, tobacco cessation, tobacco dependency, 
passive smoking, second hand smoke, quit smoking, cease smoking, stop smoking, 
give up smoking, community acquired pneumonia, CAP, cohort study, case-control 
study, longitudinal study, prospective study, epidemiologic methods. 
 
The following databases will be searched: 
 







- Web of Science 
 
We will hand search reference lists of included articles. Databases will be 
searched from inception to present, with no language restriction. 
4. Types of study to be included 
This review will consider observational studies including prospective and 
PROSPERO 




retrospective cohort studies and case-control studies for inclusion. Cross-
sectional studies will be excluded. 
 
5. Condition or domain being studied 
The condition of interest is community acquired pneumonia. Cases of 
pneumonia contracted outside of healthcare settings (community-acquired 
pneumonia) will be considered 
. 
6. Participants/population 
The review will consider studies that include adults aged 18 years and above. 
Studies including participants with pre-existing medical conditions will be included. 
 
7. Intervention(s), exposure(s) 




The exposure is tobacco smoking. We will consider current smokers and ex-smokers. 
The control, i.e. non-exposed group will be non-smokers. 
 
9. Main outcome(s) 
Risk (reported as odds ratio, risk ratio or hazard ratio) of community acquired 
pneumonia in smokers and non-smokers. 
 
10. Additional outcome(s) 
None. 
 
11. Data extraction (selection and coding) 
Two reviewers will independently screen titles and abstracts as well as full text 
selection against the inclusion and exclusion criteria. Any disagreements will be 
resolved by discussion. 
 
Covidence will be used to manage references. 
 
A data extraction form will be developed, piloted and modified as necessary. Two 
reviewers will carry out the data extraction independently. Study authors will be 
contacted if the required information is unclear or not included in the paper where 
studies are published within the past 10 years. 
 
Excel will be used for collating information on (but not limited to) the following: 
publication details, study characteristics (setting, study design, time frame), 
population characteristics (age, gender, co-morbidities), details of smoking status, 
estimates of effects, length of follow up, included covariates. Where multiple 
publications exist for the same study, the one with the most relevant outcomes will 
be included. 
12. Risk of bias (quality) assessment 
Two review authors will independently assess the risk of bias in included studies. 
Risk of bias for included observational studies will be assessed using the Newcastle-
Ottawa scale, as recommended by the Cochrane Non-Randomized Studies Methods 
Working Group. Disagreements between the review authors over the risk of bias in 
PROSPERO 




particular studies will be resolved by discussion. 
 
13. Strategy for data synthesis 
Narrative synthesis of evidence will be conducted for all included studies. Meta-
analysis using random effects models will be conducted where possible. Pooled 
relative risks will be estimated using risk ratios and odds ratios, with 95% 
confidence intervals. Measures of effect adjusted for confounders will be used in 
preference to crude measures of effect. Heterogeneity between studies will be 
reported using visual inspection and quantified using I². 
 
Subgroup analyses will be conducted where there are sufficient data to investigate 
different diagnostic categories of community acquired pneumonia, and also to 
compare ex-smokers with current and never smokers. Subgroup analysis will also 
be conducted to explore reasons for heterogeneity based on methodological 
quality (?6 vs <6), study design, and country (high versus low/middle income 
countries). Where statistical pooling is not possible the findings will be presented in 
narrative form including tables and figures to aid in data presentation where 
appropriate. 
 
A funnel plot will be generated to assess publication bias if there are 10 or more 
studies included in a meta- analysis. Statistical tests for funnel plot asymmetry 
(Egger test, Begg test, Harbord test) will be performed where appropriate. Analyses 
will be conducted using Review Manager 5. 
 
We will adhere to the Meta-analysis Of Observational Studies in Epidemiology 
(MOOSE) (Stroup et al, 2000) and Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines (Moher et al, 2010) throughout the review 
process. 
 
14. Analysis of subgroups or subsets 
Subgroup analyses will be conducted where there are sufficient data to 
investigate different diagnostic categories of community acquired pneumonia, 
and also to compare ex-smokers with current and never smokers. Subgroup 
analysis will also be conducted to explore reasons for heterogeneity based on 
methodological quality (?6 vs <6), study design, and country (high versus 
low/middle income countries). 
 
15. Contact details for further information  
Abby Hunter abby.hunter@nottingham.ac.uk 
 
16. Organisational affiliation of the review 
University of Nottingham 
17. Review team members and their organisational affiliations 
Dr Abby Hunter. 
University of Nottingham 
Professor Wei Shen Lim. 
University of Nottingham 
Professor Tricia McKeever. 
University of Nottingham Dr 
Rachael Murray. University 
of Nottingham 
Miss Vadsala Baskaran. University of Nottingham 
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18. Type and method of review 
Meta-analysis, Systematic review 
 
19. Anticipated or actual start date 
01 November 2017 
 
20. Anticipated completion date 
01 November 2018 
 
21. Funding sources/sponsors 
This work was supported by core funding to the UK Centre for Tobacco and 
Alcohol Studies (www.ukctas.net) from the British Heart Foundation, Cancer 
Research UK, Economic and Social Research Council, Medical Research Council 
and the Department of Health, under the auspices of the UK Clinical Research 
Collaboration. 
 
22. Conflicts of interest Language 





24. Stage of review 
Review Ongoing 
 
25. Subject index terms status 
Subject indexing assigned by CRD 
 
26. Subject index terms 
Adult; Community-Acquired Infections; Humans; Pneumonia; Risk; Smoking 
 
27. Date of registration in PROSPERO 
19 April 2018 
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19 April 2018 
28. Date of first submission 
16 April 2018 
 
29. Stage of review at time of this submission 
 
 
Stage Started Completed 
Preliminary searches Yes Yes 
Piloting of the study selection process Yes Yes 
Formal screening of search results against eligibility criteria Yes Yes 
Data extraction Yes No 
Risk of bias (quality) assessment Yes No 
Data analysis No No 
 
 
The record owner confirms that the information they have supplied for this 
submission is accurate and complete and they understand that deliberate provision 
of inaccurate information or omission of data may be construed as scientific 
misconduct. 
 
The record owner confirms that they will update the status of the review when it is 





This information has been provided by the named contact for this review. CRD has accepted 
this information in good faith and registered the review in PROSPERO. The registrant 
confirms that the information supplied for this submission is accurate and complete. CRD 
bears no responsibility or liability for the content of this registration record, any associated 




Appendix 8: SR Search terms (Chapter 6) 
MEDLINE (Ovid) 
1. exp smoking/ or smok*.mp. 
2. exp smoking cessation/ or smoking cessation.mp. 
3. exp “tobacco use”/ or exp Tobacco/ or exp tobacco products/ or exp “tobacco use 
disorder”/ of tobacco.mp. 
4. exp tobacco smoke pollution/ or passive smok*.mp. or second?hand smok*.mp. 
5. (nicotine* or cigar*).mp. 
6. cotinine*.mp. 
7. 1 or 2 or 3 or 4 or 5 or 6  
8. exp Community-Acquired Infections/  
9. exp pneumonia/ or pneumon.mp. 
10. 8 OR 9 
11. community acquired pneumonia.mp.  
12. 10 OR 11 
13. observational study.mp. or exp observational study/ or exp epidemiologic methods/ 
14. prospective study.mp. or exp prospective studies/ 
15. exp cohort studies/ 
16. case-control study.mp. or exp case-control studies/ 
17. 13 OR 14 OR 15 OR 16  
18. 7 AND 12 AND 17 






1. exp Smoking/ or smok*.mp. 
2. exp Smoking Cessation/ or smoking cessation.mp. 
3. exp “Tobacco Use”/ or exp Tobacco/ or exp “Tobacco Use Disorder”/ or tobacco.mp. 
4. exp Tobacco Smoke Pollution/ or passive smok*.mp. or second?hand smok*.mp. 
5. (nicotine* or cigar*).mp. 
6. cotinine*.mp. 
7. 1 or 2 or 3 or 4 or 5 or 6 
8. exp Community-Acquired Infections/ 
9. exp pneumonia/ or pneumon*.mp. 
10. 8 and 9 
11. community acquired pneumonia.mp. 
12. 10 or 11 
13. observational study.mp. or exp Observational Study/ or exp Epidemiologic Methods/ 
14. prospective study.mp. or exp Prospective Studies/ 
15. exp Cohort Studies/ 
16. case-control study.mp. or exp Case-Control Studies 
17. 13 or 14 or 15 or 16 
18. 7 and 12 and 17 





1. exp SMOKING CESSATION/ or smoking.mp. or exp PASSIVE SMOKING/ or exp 
TOBACCO SMOKING/ 
2. tobacco.mp. 
3. second?hand smoke.mp. 
4. exp NICOTINE/ or nicotine.mp. 
5. cigar.mp. 
6. cotinine.mp. 
7. 1 or 2 or 3 or 4 or 5 or 6 
8. community acquired infections.mp. 
9. pneumonia.mp. or exp PNEUMONIA/ 
10. community acquired pneumonia.mp. 
11. 8 or 9 or 10 
12. exp observation methods/ or observational stud*.mp. 
13. epidemiolog*.mp. or exp EPIDEMIOLOGY/ 
14. epidemiologic methods.mp. 
15. exp Prospective Studies/ or prospective stud*.mp. 
16. cohort stud*.mp. 
17. case-control study.mp. 
18. 12 or 13 or 14 or 15 or 16 or 17 




Web of Science 
1. smoking 
2. smoking cessation 
3. tobacco 
4. tobacco products 
5. tobacco cessation 
6. passive smoking 




11. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 
12. observational study 
13. epidemiology 
14. prospective study 
15. cohort study 
16. case control study 
17. 12 OR 13 OR 14 OR 15 OR 16 
18. community acquired infection 
19. pneumonia 
20. community acquired pneumonia 
21. 18 AND 19 
22. 20 OR 21 
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How is smoking 












































Comments, e.g. risk 
for light smokers, 
heavy smokers etc 
Odds/Hazard/risk/rate 




























Quality: Newcastle Ottawa Scale (Cohort studies) 
Note: A study can be given a maximum of one star for each numbered item within the 
Selection and Outcome categories. A maximum of two stars can be given for 
Comparability. 
Selection Representativeness of the exposed cohort  
a) Truly representative (1)  
b) Somewhat representative (1)  
c) Selected group  
d) No description of the derivation of the cohort 
 
Selection Selection of the non-exposed cohort (1) 
a) Drawn from the same community as the exposed cohort 
(1)  
b) Drawn from a different source  
c) No description of the derivation of the non-exposed 
cohort 
 
Selection Ascertainment of exposure (1) 
a) Secure record (e.g., surgical record) (1)  
b) Structured interview (1)  
c) Written self-report  
d) No description e) Other 
 
Selection Demonstration that outcome of interest was not present at 
start of study (1) 
a) Yes (1)  
b) No 
 
Comparability Comparability of cohorts on the basis of the design or 
analysis controlled for confounders (2) 
a) The study controls for age, sex and marital status (1)  
b) Study controls for other factors (list) 
_________________________________ (1)  
c) Cohorts are not comparable on the basis of the design or 
analysis controlled for confounders 
 
Outcome Assessment of outcome (1) 
a) Independent blind assessment (1)  
b) Record linkage (1)  
c) Self report  
d) No description  
e) Other 
 
Outcome Was follow-up long enough for outcomes to occur (1) 
a) Yes (1)  
b) No 
 
Outcome Adequacy of follow-up of cohorts (1) 
a) Complete follow up- all subject accounted for (1)  
b) Subjects lost to follow up unlikely to introduce bias- 
number lost less than or equal to 20% or description of those 
lost suggested no different from those followed. (1)  
c) Follow up rate less than 80% and no description of those 
lost  





Total   
 
Quality: Newcastle Ottawa Scale (Case-control studies) 
Note: A study can be given a maximum of one star for each numbered item within the 
Selection and Outcome categories. A maximum of two stars can be given for 
Comparability. 
Selection 1) Is the case definition adequate?  
a) yes, with independent validation *  
b) yes, e.g., record linkage or based on self reports  
c) no description 
 
Selection 2) Representativeness of the cases  
a) consecutive or obviously representative series of cases *  
b) potential for selection biases or not stated 
 
Selection 3) Selection of Controls  
a) community controls *  
b) hospital controls  
c) no description 
 
Selection 4) Definition of Controls  
a) no history of disease (endpoint) *  
b) no description of source  
 
Comparability 1) Comparability of cases and controls on the basis of the 
design or analysis  
a) study controls for _______________ (Select the most 
important factor.) *  
b) study controls for any additional factor * (This criteria 
could be modified to indicate specific control for a second 
important factor.)  
 
Outcome 1) Ascertainment of exposure  
a) secure record (eg surgical records) *  
b) structured interview where blind to case/control status *  
c) interview not blinded to case/control status  
d) written self-report or medical record only  
e) no description 
 
Outcome 2) Same method of ascertainment for cases and controls  
a) yes *  
b) no 
 
Outcome 3) Non-Response rate  
a) same rate for both groups *  
b) non respondents described  
c) rate different and no designation 
 












References reviewed for relevant associated articles        Yes 
 










Appendix 10: Read codes for Chapter 7 
Stop smoking interventions 
Medical Readcodes 
Medcode Description 
89464 Nicotine replacement therapy using nicotine lozenges 
85975 Nicotine replacement therapy using nicotine gum 
85247 Nicotine replacement therapy using nicotine inhalator 
81440 Nicotine replacement therapy using nicotine patches 
74907 Smoking cessation therapy 
67178 Nicotine replacement therapy provided by community pharmacis 
66387 Stop smoking monitor 3rd lettr 
60720 Stop smoking monitor 2nd lettr 
58597 Stop smoking monitor phone inv 
53101 Stop smoking monitor verb.inv. 
49418 RFS - Reasons for smoking scale 
47273 Motives for smoking scale 
42722 Stop smoking monitor 1st lettr 
41042 Smoking cessation advice provided by community pharmacist 
40418 Refuses stop smoking monitor 
40417 Stop smoking monitor default 
38112 Smoking cessation programme start date 
34127 Smoking status at 4 weeks 
34126 Negotiated date for cessation of smoking 
32572 Over the counter nicotine replacement therapy 
32083 Stop smoking clinic admin. 
28834 Anti-smoking monitoring admin. 
25106 Nicotine replacement therapy provided free 
19485 Stop smoking monitor.chck done 
18926 Lifestyle advice regarding smoking 
18573 Referral to smoking cessation advisor 
12953 Attends stop smoking monitor. 
11527 DNA - Did not attend smoking cessation clinic 
11356 Seen by smoking cessation advisor 
10898 Smoking free weeks 
10742 Referral to stop-smoking clinic 
10211 Smoking cessation milestones 
10184 Pregnancy smoking advice 
9833 Nicotine replacement therapy 
9045 Advice on smoking 
7622 Smoking cessation advice 
7130 Stop smoking monitoring admin. 
110692 varenicline smoking cessation therapy offered 
109716 issue of nicotine replacement therapy voucher 
108966 smoking cessation esa monitoring template completed 
106391 referral to smoking cessation service declined 
106385 stop smoking invitation third sms text message 
106384 stop smoking invitation second sms text message 
106359 referral to smoking cessation service 
105710 smoking cessation 12 week follow-up 
105572 stop smoking invitation short message service text message 
104310 current smoker annual review 




104185 smoking cessation drug therapy declined 
104086 stop smoking invitation first sms text message 
103760 copd structured smoking assessment declined 
103507 stop smoking service opportunity signposted 
103400 referred for copd structured smoking assessment 
103208 smoking status at 12 weeks 
102951 lost to smoking cessation follow-up 
102361 referral for smoking cessation service offered 
101854 declined consent for smoking cessation data sharing 
101851 declined consent for follow-up by smoking cessation team 
101764 practice based smoking cessation programme start date 
101634 consent given follow-up after smoking cessation intervention 
101385 consent given for follow-up by smoking cessation team 
101338 failed attempt to stop smoking 
101325 declin cons follow-up evaluation after smoking cess interven 
101210 consent given for smoking cessation data sharing 
100099 smoking cessation advice declined 
99838 recently stopped smoking 
98493 smoking cessatn monitor template complet - enhanc serv admin 
98347 current smoker annual review - enhanced services admin 
98284 refer copd structured smoking assessment - enhanc serv admin 
98283 copd structured smoking assessment declined - enh serv admin 
98245 stop smoking face to face follow-up 
98154 referral to nhs stop smoking service 
98137 brief intervention for smoking cessation 
96992 smoking cessation - enhanced services administration 
94958 smoking cessation drug therapy 
91708 other specified smoking cessation therapy 
90522 smoking cessation therapy nos 
66409 nicotine replacement therapy contraindicated 
63717 bupropion contraindicated 
63016 [x]bupropion causing adverse effects in therapeutic use 
59866 reasons for smoking scale 
57639 bupropion refused 
53031 adverse reaction to nicotine 
31114 ready to stop smoking 
30762 not interested in stopping smoking 
30423 thinking about stopping smoking 
24529 nicotine replacement therapy refused 
21637 stop smoking monitor admin.nos 
12964 keeps trying to stop smoking 
12240 trying to give up smoking 




467 Zyban 150mg modified-release tablets (glaxosmithkline uk ltd) 
1248 Nicorette 10mg/ml nasal spray (pharmacia ltd) 
1703 Nicorette 15mg transdermal patch (pharmacia ltd) 
2876 Nicorette citrus 2mg medicated chewing gum (pfizer ltd) 
3404 Niquitin 21mg transdermal patch (glaxosmithkline consumer healthcare) 
3818 Nicotinell tts 30 sq cm transdermal patch (novartis consumer health uk ltd) 
4166 Nicorette citrus 4mg medicated chewing gum (pfizer ltd) 
4704 Niquitin 7mg transdermal patch (glaxosmithkline consumer healthcare) 




5115 Bupropion 150mg modified-release tablets 
5320 Nicorette 10mg inhalator (mcneil products ltd) 
5440 Nicorette 10mg transdermal patch (pharmacia ltd) 
5457 Nicotine 5mg/16hours transdermal patches 
5479 Nicotine 10mg/16hours transdermal patches 
5502 Nicotine 15mg/16hours transdermal patches 
5515 Nicotine 1mg lozenge 
5531 Nicotinell 1mg lozenge (novartis consumer health uk ltd) 
5606 Nicotinell tts 20 sq cm transdermal patch (novartis consumer health uk ltd) 
5659 Niquitin 4mg lozenges original menthol mint (omega pharma ltd) 
5700 Niquitin 2mg lozenges original menthol mint (omega pharma ltd) 
5758 Nicotine 4mg medicated chewing gum sugar free 
5784 Nicotine 4mg lozenges sugar free 
5877 Nicorette 2mg microtab (pharmacia ltd) 
5944 Nicotine 10mg inhalation cartridges with device 
5946 Nicotinell 2mg medicated chewing-gum (novartis consumer health uk ltd) 
6018 Nicorette 5mg transdermal patch (pharmacia ltd) 
6323 Nicotine 2mg medicated chewing gum sugar free 
6448 Nicotine 21mg/24hours transdermal patches 
6565 Niquitin fresh mint 2mg medicated chewing gum (omega pharma ltd) 
6593 Niquitin mint 4mg lozenges (omega pharma ltd) 
6630 Niquitin mint 2mg lozenges (omega pharma ltd) 
6642 Niquitin fresh mint 4mg medicated chewing gum (omega pharma ltd) 
6698 Nicotinell 2mg lozenges (glaxosmithkline consumer healthcare) 
7303 Nicotinell tts 10 sq cm transdermal patch (novartis consumer health uk ltd) 
7644 Nicabate 21mg transdermal patch (marion merrell dow ltd) 
8571 Nicotine 500micrograms/dose nasal spray 
9591 Nicotine 14mg/24hours transdermal patches 
9804 Nicotine 7mg/24hours transdermal patches 
9806 Nicotine 2mg lozenges sugar free 
10527 Nicabate 14mg transdermal patch (marion merrell dow ltd) 
10623 Nicabate 7mg transdermal patch (marion merrell dow ltd) 
11718 Nicotine 2mg sublingual tablets sugar free 
13048 Nicotinell 4mg medicated chewing-gum (novartis consumer health uk ltd) 
25510 Nicotine 2mg mint flavour chewing-gum 
25516 Nicotine 4mg mint flavour chewing-gum 
25523 Nicorette 2mg mint flavour chewing-gum (pharmacia ltd) 
27311 Niconil 22mg/24 hr transdermal patch (elan pharma) 
27410 Champix 0.5mg/1mg 2 week treatment initiation pack (pfizer ltd) 
27411 Champix 1mg tablets (pfizer ltd) 
27412 Varenicline 1mg tablets and varenicline 500microgram tablets 
27414 Varenicline 1mg tablets 
29680 Niconil 11mg/24 hr transdermal patch (elan pharma) 
31939 Nicorette 4mg mint flavour chewing-gum (pharmacia ltd) 
33392 Nicotine 22mg/24 hr transdermal patch 
35035 Champix 0.5mg tablets (pfizer ltd) 
35089 Varenicline 500microgram tablets 
36457 Nicopatch 21mg/24hours transdermal patches (pierre fabre ltd) 
36618 Nicopatch 7mg/24hours transdermal patches (pierre fabre ltd) 
36635 Nicopatch 14mg/24hours transdermal patches (pierre fabre ltd) 
37646 Nicotine 1.5mg lozenges sugar free 
37716 Nicopass 1.5mg lozenge (wockhardt uk ltd) 
38958 Nicotinell 1mg lozenges (glaxosmithkline consumer healthcare) 
39046 Nicorette invisi 25mg/16hours patches (mcneil products ltd) 
39123 Nicotine 25mg/16hours transdermal patches 




39521 Niquitin pre-quit mint 4mg lozenges (omega pharma ltd) 
39572 Nicorette invisi 10mg/16hours patches (mcneil products ltd) 
40617 Nicotinell tts 20 patches (glaxosmithkline consumer healthcare) 
40620 Nicotinell tts 30 patches (glaxosmithkline consumer healthcare) 
40683 Nicotinell tts 10 patches (glaxosmithkline consumer healthcare) 
40730 Niquitin minis mint 1.5mg lozenges (omega pharma ltd) 
40865 Niquitin minis mint 4mg lozenges (omega pharma ltd) 
41040 Nicorette lemon 2mg microtab (mcneil products ltd) 
41356 Nicorette microtab 2mg sublingual tablets (mcneil products ltd) 
41368 Niquitin 21mg patches (omega pharma ltd) 
41372 Niquitin clear 21mg patches (omega pharma ltd) 
41376 Nicorette 15mg patches (mcneil products ltd) 
41377 Nicorette original 2mg medicated chewing gum (mcneil products ltd) 
41425 Nicorette freshmint 4mg medicated chewing gum (mcneil products ltd) 
41426 Niquitin 7mg patches (omega pharma ltd) 
41474 Nicorette 10mg patches (mcneil products ltd) 
41485 Niquitin 14mg patches (omega pharma ltd) 
41493 Nicorette icy white 4mg medicated chewing gum (mcneil products ltd) 
41496 Nicorette 500micrograms/dose nasal spray (mcneil products ltd) 
41505 Niquitin clear 14mg patches (omega pharma ltd) 
41507 Niquitin clear 7mg patches (omega pharma ltd) 
41753 Nicorette original 4mg medicated chewing gum (mcneil products ltd) 
41765 Nicotinell mint 2mg medicated chewing gum (glaxosmithkline consumer healthcare) 
41778 Nicorette fruitfusion 4mg medicated chewing gum (mcneil products ltd) 
41779 Nicorette icy white 2mg medicated chewing gum (mcneil products ltd) 
41801 Nicorette freshmint 2mg medicated chewing gum (mcneil products ltd) 
41802 Nicorette 5mg patches (mcneil products ltd) 
41808 Nicotinell fruit 4mg medicated chewing gum (glaxosmithkline consumer healthcare) 
41809 Nicorette mint 4mg medicated chewing gum (mcneil products ltd) 
41860 Nicotine bitartrate 2mg sublingual tablet 
41864 Nicorette fruitfusion 2mg medicated chewing gum (mcneil products ltd) 
41879 Nicotinell liquorice 2mg medicated chewing gum (glaxosmithkline consumer healthcare) 
41881 Nicotinell classic 2mg medicated chewing gum (novartis consumer health uk ltd) 
41909 Nicotinell mint 4mg medicated chewing gum (glaxosmithkline consumer healthcare) 
41931 Nicotinell fruit 2mg medicated chewing gum (glaxosmithkline consumer healthcare) 
42011 Nicotinell classic 4mg medicated chewing gum (novartis consumer health uk ltd) 
42016 Nicorette mint 2mg medicated chewing gum (mcneil products ltd) 
42047 Nicotinell liquorice 4mg medicated chewing gum (glaxosmithkline consumer healthcare) 
42048 Nicotine bitartrate 1mg lozenges sugar free 
42221 Nicotine 4mg lozenges sugar free (teva uk ltd) 
42286 Nicotine bitartrate 2mg lozenges sugar free 
44106 Niquitin minis cherry 1.5mg lozenges (omega pharma ltd) 
45429 Nicorette quickmist 1mg/dose mouthspray freshmint (mcneil products ltd) 
45504 Nicotine 1mg/dose oromucosal spray sugar free 
45603 Nicorette freshmint 2mg lozenges (mcneil products ltd) 
46588 Nicotinell icemint 2mg medicated chewing gum (novartis consumer health uk ltd) 
46592 Nicorette 15mg inhalator (mcneil products ltd) 
46701 Nicotinell icemint 4mg medicated chewing gum (novartis consumer health uk ltd) 
46717 Nicotine 15mg inhalation cartridges with device 
48620 Boots nicassist 10mg inhalator (the boots company plc) 
49088 Niquitin clear 21mg patches (waymade healthcare plc) 
49204 Champix 0.5mg/1mg 2 week treatment initiation pack (mawdsley-brooks & company 
ltd) 
49305 Nicorette cools 2mg lozenges (mcneil products ltd) 
49319 Nicorette cools 4mg lozenges (mcneil products ltd) 
49607 Boots nicassist 15mg patches (the boots company plc) 




50487 Niquitin clear 14mg patches (waymade healthcare plc) 
50541 Champix 0.5mg/1mg 2 week treatment initiation pack (sigma pharmaceuticals plc) 
54102 Niquitin pre-quit clear 21mg patches (omega pharma ltd) 
54574 Boots nicassist minty fresh 4mg medicated chewing gum (the boots company plc) 
55417 Zyban 150mg modified-release tablets (lexon (uk) ltd) 
55590 Nicotine 11mg/24 hr transdermal patch 
56552 Boots nicassist minty fresh 2mg medicated chewing gum (the boots company plc) 
57417 Nicorette 5mg patches (waymade healthcare plc) 
57731 Nicobloc liquid (nicobloc plc) 
57829 Niquitin strips mint 2.5mg oral films (omega pharma ltd) 
58034 Nicotine 2.5mg orodispersible films sugar free 
58410 Niquitin minis orange 1.5mg lozenges (omega pharma ltd) 
58675 Boots nicassist 5mg patches (the boots company plc) 
60236 Boots nicassist 10mg patches (the boots company plc) 
61777 Nicotinell support icemint 4mg medicated chewing gum (glaxosmithkline consumer 
healthcare) 
62246 Nicotinell support icemint 2mg medicated chewing gum (glaxosmithkline consumer 
healthcare) 
65406 Nicorette fruitfusion 6mg medicated chewing gum (mcneil products ltd) 
65765 Nicotine 6mg medicated chewing gum sugar free 
65968 Boots nicassist 15mg inhalator (the boots company plc) 
66101 Boots nicassist translucent 10mg/16hours patches (the boots company plc) 
66285 Boots nicassist 21mg/24hours transdermal patches (the boots company plc) 
66376 Nicotine 0.35mg lozenge 
66460 Boots nicassist microtab 2mg sublingual tablets (the boots company plc) 
66614 Boots nicassist 14mg/24hours transdermal patches (the boots company plc) 
66778 Champix 0.5mg/1mg 4 week treatment initiation pack (pfizer ltd) 
67143 Boots nicassist 2mg lozenges (the boots company plc) 
67802 Nicorette 10mg patches (waymade healthcare plc) 
68621 Boots nicassist 1mg lozenges (the boots company plc) 
68879 Boots nicassist 10mg/ml nasal spray (the boots company plc) 
71101 Nicorette 15mg patches (waymade healthcare plc) 
71238 Niquitin extra fresh mint 2mg medicated chewing gum (omega pharma ltd) 
71539 Niquitin extra fresh mint 4mg medicated chewing gum (omega pharma ltd) 
72553 Boots nicassist translucent 25mg/16hours patches (the boots company plc) 
72740 Boots nicassist fruit fresh 4mg medicated chewing gum (the boots company plc) 
72950 Nicotine 7mg/24hours transdermal patches (ennogen healthcare ltd) 
73322 Boots nicassist 7mg/24hours transdermal patches (the boots company plc) 
73595 Nicorette quickmist 1mg/dose mouthspray cool berry (mcneil products ltd) 







Appendix 11: Results and classification as likely pathogen or contaminant among 
positive cultures taken from patients (Chapter 8) 
Blood culture 
Likely pathogen n N Likely contaminant n N 
Coagulase negative Staphylococcus 13 6 Coagulase negative Staphylococcus 47 36 
Enterococcus spp. 8 5 Propionibacterium sp. 2 2 
Klebsiella spp. 3 2 Streptococcus oralis 1 1 
Citrobacter koseri 3 2 Micrococcus luteus 1 1 
Candida parapsilosis 1 1 Diphteroid bacilli 1 1 
Escherichia coli 1 1 Anaerobic streptococci 1 1 
Pseudomonas spp. 1 1 Streptococcus species (Facklamia Languida) 1 1 
Staphylococcus aureus  1 1 Streptococcus parasanguinis 1 1 
Haemophilus influenzae 1 1 Granulicatella adiacens 1 1 
 32 20 Saccharomyces cerevisiae 1 1 
   Actinomyces sp. 1 1 
   Corynebacterium striatum 1 1 
   Lysinbacillus sphaericus 1 1 
    60 49 
 
Legend: 
n= Number of times an organism was cultured from a test sample 





Likely pathogen n N Likely contaminant n N 
Klebsiella spp. 17 14 Candida spp 21 15 
Escherichia coli 7 5 Enterococcus spp 2 2 
Pseudomonas spp. 5 4 Yeast 2 2 
Enterobacter spp. 4 3 Upper respiratory tract flora 1 1 
MRSA 4 2 Streptococcus anginosus 1 1 
Serratia marcesens 3 2  27 21 
Staphylococcus aureus  3 3    
Pluralibacter gergoviae 2 1    
Proteus mirabilis 2 2    
Citrobacter koseri 2 2    
Raoultella sp. 1 1    
Morganella morganii 1 1    
Stenotrophomonas maltophilia 1 1    
Haemophilus influenzae 1 1    




n= Number of times an organism was cultured from a test sample 






Likely pathogen n N Likely contaminant n N 
Serratia marcesens 10 5 Candida spp 10 6 
Enterobacter spp. 7 3 Yeast 6 4 
Escherichia coli 6 2 Mixed growth of Coliform & Candida 4 2 
Klebsiella spp. 4 3 Respiratory commensals 2 1 
Raoultella sp. 4 1 Corynebacterium sp 1 1 
Pseudomonas spp. 3 2  23 14 
Proteus mirabilis 2 2    
Staphylococcus aureus  2 2    
Haemophilus influenzae 2 1    
Aspergillus fumigatus 2 1    
Citrobacter koseri 1 1    
Acinetobacter baumanii 1 1    
 44 24    
 
Legend: 
n= Number of times an organism was cultured from a test sample 






Likely pathogen n N Likely contaminant n N 
Pseudomonas spp. 19 11 Candida spp 13 10 
Stenotrophomonas maltophilia 7 3 Enterococcus sp 2 2 
Escherichia coli 6 5 Respiratory commensals 41 32 
Klebsiella spp. 8 6  56 44 
Citrobacter koseri 6 5    
Enterobacter spp. 6 6    
Staphylococcus aureus  7 6    
Proteus mirabilis 2 2    
Serratia marcesens 2 2    
Burkholderia multivorans 2 1    
Haemophilus influenzae 2 1    
Pluralibacter gergoviae 1 1    
Delftia acidovorans 1 1    
Yersinia enterocolitica 1 1    
Acinetobacter baumanii 1 1    
 71 52    
 
Legend: 
n= Number of times an organism was cultured from a test sample 
N= Number of patients from whom the organism was cultured in that test sample 
